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PRODUCTION OF ET-1 AND BIG ET-1 BY HUMAN CELL LINES 
C Arun1, RFL James1, KE Porter1, NJM London1, DM Hemingway3,
1Dept of Surgery, University of Leicester, 2Dept of Oncology, 3Dept of
Surgery, Leicester Royal Infirmary, Leicester LE1 5WW, UK 
Aims Endothelin, the most potent vasoconstrictor known has been implicated in the
development and spread of malignancy. In this study, we assessed the production of
endothelin-1 (ET-1) and its precursor big endothelin (big ET-1) by human cancer cell lines. 
Methods Ten human cancer cell lines were cultured (lung n = 4, colorectal n = 3,
gastro-oesophageal n = 2, pancreatic n = 1). The culture media were replaced with
fresh media after the cells attained confluence. After 48 hours, the conditioned media
were batch analysed for ET-1 and big ET-1 by using a sandwich enzyme linked
immunoassay (ELISA) (Biomedica, Austria). To elucidate the action of endothelin
converting enzyme (ECE), big ET-1 was added to one of the oesophageal cancer cell
lines after they attained confluence. Similarly, the media were analysed for the
presence of ET-1 and big ET-1 
Results All the ten cancer cell lines produced ET-1 and nine of ten cancer cell lines
produced big ET-1. ET-1 and big ET-1 were not produced in equimolar amounts. The
ratio of ET-1 to big ET-1 was 0.56–11.88 (range). All three colorectal cancer cell lines
and four of the lung cancer cell lines produced both ET-1 and Big Et-1. Interestingly,
the oesophageal cancer cell line that produced high concentrations of ET-1 did not
produce any measurable big ET-1. Addition of Big ET-1 into this cell line medium to
assess the action of ECE, measuring ET-1 and big ET-1 after 48 hours resulted in
complete cleavage of big ET-1 and there was no measurable big ET-1 in the medium. 
Human Cancer ET-1 Big ET-1 
Cell lines (pg/ml per 106 cells)* (pg/ml per 106 cells)* 
1 Lung 13.9 (0.46–73.1) 7.9 (2.3–22.2) 
2 Colorectal 9.2 (2.61–126.6) 13.2 (4.1–51.1) 
3 Gastro-oesophageal 70.7 (48.8–92.6) 5.95 (0–11.9) 
4 Pancreas 10.36 (9.3–11.3) 18.6 (16.4–20.1) 
* Expressed as median (range). 
Conclusions Human cancer cell lines produce both ET-1 and Big ET-1. The
difference in ET-1 and big ET-1 production suggests that the ECE activity is variable
in different human cancer cell lines. 
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PLASMA BIG ET-1 – A TUMOUR MARKER AND SURROGATE
MARKER FOR ANGIOGENESIS IN LUNG CANCER C Arun1, 
KE Porter1, G McMahon3, NJM London1, KO’Byrne2, DM Hemingway3, 1Dept
of Surgery, University of Leicester, 2Dept of Oncology, 3Dept of Surgery,
Leicester Royal Infirmary, Leicester, UK 
Introduction Endothelin-1 (ET-1), a potent vasoactive peptide, is a hypoxia
inducible angiogenic growth factor associated with the development and growth of
solid tumours. This study was performed to assess whether plasma big endothelin
levels (big ET-1), a stable precursor of ET-1, could be used as a tumour marker in lung
cancer. 
Patients and methods The plasma concentration of big ET-1 was measured in 31
patients with proven lung cancers prior to any treatment from February 2000 to
December 2000 and in 20 age/sex matched controls. Twenty-three patients had non-
small cell lung cancer (NSCLC) and 8, small cell lung cancer (SCLC). EDTA plasma
samples were analysed within 2 months of collection using a sandwich enzyme linked
immunoassay (Biomedica, Austria). 
Results Median big ET-1 plasma levels in patients with lung cancer were 
4.4 pg/ml, range 0–22.7 pg/ml. These were significantly elevated compared to
median big ET-1 plasma levels in controls and were 2.1 pg/ml, range 1.2–13.4 pg/ml
(Mann-Whitney test P = 0.0001). No significant difference was seen between median
plasma levels of big ET-1 in patients with NSCLC 5.0 pg/ml, range 0–22.4 compared
to those in patients with SCLC 4.3, range 0–8.8 pg/ml. 
Groups Median plasma  Range (pg/ml) Mann–Whitney 
levels (pg/ml)
1 Controls 2.1 1.2–13.4 
(n = 20)
2 Lung Cancer  4.4 0.0–22.7 P = 0.0001 
(n = 31)
Conclusion Plasma big ET-1 levels were significantly elevated in lung cancer
patients. This study indicates that plasma big ET-1 levels should be evaluated as a
tumour marker and potential surrogate marker of angiogenesis in this disease. 
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PRODUCTION OF ET-1 AND BIG ET-1 BY HUMAN CELL LINES C
Arun*1, RFL James1, KE Porter1, NJM London1, DM Hemingway3,
1Dept of Surgery, University of Leicester, 2Dept of Oncology, 3Dept of
Surgery, Leicester Royal Infirmary, Leicester LE1 5WW, UK 
Aims Endothelin, the most potent vasoconstrictor known has been implicated in the
development and spread of malignancy. In this study, we assessed the production of
endothelin-1 (ET-1) and its precursor big endothelin (big ET-1) by human cancer cell
lines. 
Methods Ten human cancer cell lines were cultured (lung n = 4, colorectal n = 3,
gastrooesophageal n = 2, pancreatic n = 1). The culture media were replaced with
fresh media after the cells attained confluence. After 48 hours, the conditioned media
were batch analysed for ET-1 and big ET-1 by using a sandwich enzyme linked
immunoassay (ELISA) (Biomedica, Austria). To elucidate the action of endothelin
converting enzyme (ECE), big ET-1 was added to one of the oesophageal cancer cell
lines after they attained confluence. Similarly, the media were analysed for the pres-
ence of ET-1 and big ET-1 
Results All the ten cancer cell lines produced ET-1 and nine of ten cancer cell lines
produced big ET-1. ET-1 and big ET-1 were not produced in equimolar amounts. The
ratio of ET-1 to big ET-1 was 0.56–11.88 (range). All three colorectal cancer cell lines
and four of the lung cancer cell lines produced both ET-1 and Big ET-1. Interestingly,
the oesophageal cancer cell line that produced high concentrations of ET-1 did not
produce any measurable big ET-1. Addition of Big ET-1 into this cell line medium to
assess the action of ECE, measuring ET-1 and big ET-1 after 48 hours resulted in
complete cleavage of big ET-1 and there was no measurable big ET-1 in the medium. 
Human Cancer  ET-1  Big ET-1 
Cell lines (pg/ml per 106 cells)* (pg/ml per 106 cells)*
1 Lung 13.9 (0.46–73.1) 7.9 (2.3–22.2) 
2 Colorectal 9.2 (2.61–126.6) 13.2 (4.1–51.1) 
3 Gastro-oesophageal 70.7 (48.8–92.6) 5.95 (0–11.9) 
4 Pancreas 10.36 (9.3–11.3) 18.6 (16.4–20.1) 
*Expressed as median (range) 
Conclusions Human cancer cell lines produce both ET-1 and Big ET-1. The
difference in ET-1 and big ET-1 production suggests that the ECE activity is variable
in different human cancer cell lines. 
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MODIFICATIONS TO ENDOTHELIAL TUBULIN BY NITRIC OXIDE
(NO) – RESPONSE TO MICROTUBULE-DEPOLYMERISING
AGENT, COMBRETASTATIN A-4-PCS Parkins*, IH Cook, GM Tozer. Tumour
Microcirculation Group, Gray Laboratory Cancer Research Trust, Northwood,
Middx, UK 
Combretastatin A-4-P (CA-4-P) is a novel vascular-targeting agent showing tumour
cytotoxicity due to its significant reduction in tumour blood flow. Its mechanism of
action is due to its potent microtubule-depolymerising activity, showing selective
action against proliferating endothelial cells that occur in tumour vasculature. We
have previously reported that NO protects against the anti-vascular actions of CA-4-P
in solid tumours (Tozer et al., Cancer Res, 1999; 59: 1626–1634. Parkins et al., Br J
Cancer, 2000; 83: 811–6). 
Post-translational addition of tyrosine to tubulin, performed by the enzyme tubulin
tyrosine ligase (TTL), is a common modification to tubulin conferring changes in
protein stability. However, it has been shown that NO-dependent nitration of free tyro-
sine yields 3-nitrotyrosine (3-NT) which is also a substrate of TTL and becomes irre-
versibly incorporated into tubulin. 
We therefore hypothesise that NO increases the generation of 3-NT, thereby gener-
ating an isotype of tubulin with increased resistance to the microtubule-
depolymerising agent CA-4-P. 
In vitro studies of tyrosine-and 3-NT-modifications to tubulin structure were
performed in murine SVEC4-10 endothelial or two tumour cell lines, isolated from
tumours showing widely different response to CA-4-P in vivo. Cells were cultured in
the absence of tyrosine or 3-NT for 24 h. Subsequent addition of either tyrosine or 
3-NT to the media allowed for incorporation into tubulin, which was detected using
western blot analysis. Results indicate that tyrosine and 3-NT were incorporated into
tubulin protein only, although the incorporation of 3-NT was strongly inhibited by low
concentrations of tyrosine. TTL enzyme was detected in all three cell lines. 
To model the in vivo situation, cultured endothelial cells were exposed to tumour-
conditioned medium, obtained from cloned tumour cell lines isolated from the CA-
4-P-responsive tumour. Exposure to this tumour-conditioned medium resulted in
significantly reduced incorporation of 3-NT into endothelial tubulin and may account
for the relatively greater vascular damage induced by CA-4-P in this tumour type. 
Further studies are underway to test the hypothesis that incorporation of 3-NT into
tubulin of endothelial cells confers resistance to the microtubule-depolymerising and
anti-vascular actions of CA-4-P. 
This work is funded by the Cancer Research Campaign. 
British Journal of Cancer (2001) 85(Suppl 1), 33–109
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1918, available online at http://www.idealibrary.com on 34 Poster presentations
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COMBRETASTATIN A-4-PHOSPHATE PREVENTS NEUTROPHIL
RECRUITMENT TO TNF-a ACTIVATED ENDOTHELIUM UNDER
FLOW AC Brooksa, GE Nashb, CS Parkinsa, GM Tozera, aTumour
Microcirculation Group, Gray Laboratory Cancer Research Trust, Mt Vernon
Hospital, Northwood, Middx, bDept. of Physiology, Medical School, University
of Birmingham, Birmingham, UK 
Combretastatin A-4-phosphate (CA-4-P) is a potent tubulin-binding agent at or near
the colchicine-binding site. In vivo it causes vascular shutdown at relatively nontoxic
doses in a range of murine and human tumours [Chaplin et al., 1999], and significant
infiltration of neutrophils in murine tumours [Parkins et al., 2000]. Adherence of
neutrophils to endothelium may be regarded as a stepwise process, characterized by
rolling, adhesion and migration. Previously we have found that CA-4-P directly
induces neutrophil recruitment to HUVECs [Unpublished data]. In the present study
we have examined the effects of CA-4-P upon the recruitment of neutrophils to 
TNF-  a stimulated endothelium. 
HUVECs were seeded into glass capillaries (microslides) and grown under condi-
tions of flow as previously described [Luu et al., 1999]. HUVECs were treated with
TNF-a for 4 hours at 37˚C, and for the final 30 minutes of this incubation either 
CA-4-P or colchicine were added. Slides were incorporated in a flow system mounted
on a video microscope, and isolated human neutrophils were perfused through the
microslides, and images captured in real time. From the video recording, the number
of neutrophils falling into each of the 3 categories of adhesion, per field of view was
calculated. 
Pre-treatment of HUVECs with TNF-a or CA-4-P alone resulted in a dose-
dependent increase in neutrophil recruitment compared to control, as previously
described. Incubation with colchicine alone also resulted in an increase in neutrophil
recruitment. However, incubation of TNF-a stimulated endothelium with CA-4-P or
colchicine prior to neutrophil perfusion resulted in an attenuation of neutrophil
recruitment compared to TNF-a treated controls. 
The data presented demonstrate that under certain circumstances CA-4-P is able to
attenuate the recruitment of neutrophils to endothelium. This may therefore have an
effect upon neutrophil-related vascular damage following CA-4-P treatment in vivo. 
Chaplin DJ, Pettit GR, Hill SA (1999). Anticancer Res 19: 189–95 
Luu NT, Rainger GE, Nash GB (1999 J Vasc Res 36: 477–85 
Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM (2000) Br J Cancer 83:
811–816 
The author is a recipient of a grant from the Association for International Cancer
Research. 
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INDOLE-ETHER QUINAZOLINES: A NOVEL SERIES OF
SELECTIVE AND POTENT VEGF RECEPTOR TYROSINE KINASE
INHIBITORS SR Wedge1, LF Hennequin2, DJ Ogilvie1, J Kendrew1, 
M Dukes1, ESE Stokes1, D McKerrecher1, P Plé2, B Curry1, 1Cancer and
Infection Research, AstraZeneca, Alderley Park, SK10 4TG, UK, and
2AstraZeneca Pharma, Centre de Recherches, Z.I. Parc Industriel Pompelle,
BP1050, 51689 Reims Cedex 2, France
Inhibition of VEGF-signalling is an attractive anti-tumour target given the apparent
pivotal role of VEGF in the regulation of tumour angiogenesis and vascular perme-
ability. Two high-affinity receptors for VEGF with associated tyrosine kinase activity
have been identified on human vascular endothelium: VEGF-R1 (Flt-1) and 
VEGF-R2 (KDR). We are developing inhibitors of VEGF-receptor tyrosine kinase
activity which are orally bioavailable and therefore compatible with chronic adminis-
tration for continual constraint of tumour angiogenesis. 
Novel indole ether quinazolines have been identified which are potent inhibitors of
Flt-1 and KDR tyrosine kinase activity in isolated enzyme assays in vitro. Subsequent
inhibition of VEGF-stimulated proliferation of human umbilical vein endothelial cells
(HUVECs) was demonstrated at subnanomolar concentrations (IC50 values) with
these compounds. Data indicate that the indole ether quinazolines are extremely selec-
tive molecules. Selectivity ratios of greater than 1000-fold have been achieved in
kinase enzyme assays (e.g. versus EGFR, FGFR and CDK2) and in cell proliferation
assays stimulated by different growth factors (e.g. EGF, and FGF). This class of
compound demonstrates significant antitumor activity in established Calu-6 lung
tumor xenografts following chronic oral once-daily dosing at doses of 1–10
mg/kg/day. These compounds are also known to have broad-spectrum antitumour
activity in a range of human tumour xenograft models, which is consistent with the
inhibition of VEGF-signalling. 
P7
A MECHANISTIC EXAMINATION OF ZD6474, A VEGF RECEPTOR
TYROSINE KINASE INHIBITOR, IN VIVO J Kendrew1, SR Wedge1,
DJ Ogilvie1, M Dukes1, JO Curwen1, LF Hennequin4, ESE Stokes1, B Curry1,
PF Wadsworth2, GHP Richmond2, D Checkley3 and JC Waterton3,
Departments of 1Cancer and Infection, 2Safety Assessment and 3Enabling
Science and Technology, AstraZeneca, Alderley Park, SK10 4TG, UK, and
4AstraZeneca Pharma, Centre de Recherches, Z.I. Parc Industriel Pompelle,
BP1050, 51689 Reims Cedex 2, France 
ZD6474 is a low molecular weight inhibitor of KDR tyrosine kinase which demon-
strates significant broad-spectrum oral activity in histologically diverse human tumor
xenograft models (12.5–100 mg/kg/day, p.o.). ZD6474 can also produce tumor
regression in well-established PC-3 prostate tumours (Wedge et al Proc AACR 2000
41: Abstract 3610). 
For confirmation of inhibition of VEGF-signalling and angiogenesis in vivo, a
number of pharmacodynamic endpoints were examined. VEGF has been shown to
induce a profound hypotension in anaesthetised rats when administered as a large
bolus dose, an effect attributed to a specific signaling response through the growth
factor’s cognate receptor. ZD6474 (50 mg/kg, p.o.), 2 h prior to VEGF (8 ug, i.v.),
inhibited VEGF-induced hypotension by 67% when compared to vehicle-treated
controls (P < 0.002 by Anova). Measurement of tumor vascular permeability by
dynamic GdDTPA contrast-enhanced MRI was also examined as VEGF is known to
have a permeabilising effect on the endothelium. Human prostate tumor xenografts
(PC-3, 0.6–1.4 cm3 volume) were established in athymic mice and the tumor vascular
permeability surface area product K(trans) determined by GdDTPA-MRI using the
kinetic model of Tofts and Kermode (Magn. Res. Med., 17: 357, 1991). ZD6474
(12.5–100 mg/kg, p.o.), or vehicle, was then administered to mice 24 h and 2 h prior
to a second measurement of K(trans). Comparison of pre- and post-treatment K(trans)
values showed a 28% reduction with 100 and 50 mg/kg ZD6474 and a 14 and 15%
reduction with 25 and 12.5 mg/kg respectively. VEGF-driven angiogenesis is also a
prerequisite for ossification during long-bone extension. The effect of ZD6474 on
growth plate morphology was therefore examined. ZD6474 produced a dose-
dependent hypertrophy of the femoro-tibial growth plates of young growing rats,
when administered once-daily (p.o.) for 14 days. A dose of 50 mg/kg/day increased
the combined growth plate area by 57% (P < 0.001, one-tailed t-test). Similar effects
have also been reported with agents which specifically sequester VEGF (e.g. Gerber
et al Nat Med 1999 5: 623). These studies support the inhibition of VEGF-signalling
in vivo by ZD6474. 
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ACTIVITY OF COMBRETASTATIN A1 PHOSPHATE IN MURINE
MODELS OF LIVER METASTASIS, SE Holwell, MC Bibby, Cancer
Research Unit, University of Bradford, Richmond Rd, Bradford, West
Yorkshire, BD7 1DP, UK 
The combretastatins are a group of novel antitumour agents derived from the African
shrub Combretum caffrum. Combretastatin A4 phosphate has previously been shown
to demonstrate significant antitumour and antivascular effects in pre-clinical trials and
more recently has shown promising results in clinical trials. Combretastatin A1 phos-
phate, a prodrug of a close structural analogue of combretastatin A4 phosphate, has
recently been developed. In order to assess the potential clinical activity of this novel
agent, clinically relevant models were required. In this study, syngeneic (MAC 15A)
and human xenograft (DLD-1, HT29) models of liver secondaries of colon cancer in
mice were developed by direct injection of cells into the liver. These models have
been used to compare combretastatin A4 phosphate with the novel analogue combre-
tastatin A1 phosphate. The A1 analogue showed antitumour activity in all three
tumours in the subcutaneous site (P<0.01) but the A4 analogue, although active
against MAC 15A and DLD-1 (P<0.01), was less active against HT29 (P<0.05).
Responses in the more clinically relevant hepatic tumour models were varied. MAC
15A tumours showed no treatment-associated necrosis with either compound at doses
that were effective against subcutaneous tumours whereas treatment-associated
necrosis was seen in both DLD-1 and HT29. Image analysis indicated that combretas-
tatin A1 phosphate (83% necrosis in HT29, 91% in DLD-1) was more effective in the
liver deposits than A4 (18% necrosis in HT29, 22% in DLD-1). MAC 15A failed to
vascularised in the liver despite growing to >5 mm in diameter whereas the other two
tumours indicate clear vascularisation even when <3mm in diameter. These studies
suggest that combretastatins work by an anti-vascular mechanism against colon carci-
noma in the murine liver. In addition, the antitumour activity of the compounds was
found to differ depending upon tumour site. Perhaps most significantly, results
suggest that combretastatin A1 phosphate may have greater potential than A4 for
treating metastatic disease. 
This work has been funded by War on Cancer and the Cancer Research Campaign. Poster presentations 35
P9
HAEM OXYGENASE AND COMBRETASTATIN A4-PHOSPHATE
VASCULAR DAMAGE AF Khelifi1, VE Prise1, C Kanthou1, 
JE Clark2, R Foresti2, R. Motterlini2 and GM Tozer1, 1Tumour Microcirculation
Group, Gray Laboratory Cancer Research Trust, Mt Vernon Hospital,
Middlesex HA6 2JR, 2Vascular Biology Unit, Department of Surgical
Research, Northwick Park Institute for Medical Research, Middlesex 
HA1 3UJ, UK 
Combretastatin A4-Phosphate (CA-4-P) is a tubulin binding agent which causes
prolonged and extensive shut down in tumour blood flow leading to secondary tumour
cell death. Phase I clinical trials with this tumour vascular targeting compound have
now been completed. Haem oxygenase (HO) catalyses the degradation of haem
producing iron, bilirubin and carbon monoxide. HO-1, the inducible form of the
enzyme, is thought to play a protective role against various cellular stresses possibly
including the vascular injury induced by CA-4-P. In the present study, the effects of
CA-4-P on HO activity and protein levels were investigated in vivo, in subcutaneous
transplants of the P22 rat carcinosarcoma tumour, and in vitro using the P22 tumour
cell line. 
Treatment with CA-4-P produced a decrease in total HO activity and HO-I protein
levels in P22 tumours in vivo and in P22 tumour cells in culture. This was in contrast
to the liver, where CA-4-P stimulated HO-1 production and the kidney where there
was no effect. This suggests that HO-1 might play a protective role against CA-4-P
induced vascular injury in the liver but not in the tumour. 
These preliminary results indicate that there may be a differential in HO-1 produc-
tion in response to CA-4-P treatment between tumours and normal tissues. It may be
possible to exploit this differential and the protective role of HO-1 to improve the
therapeutic ratio of this drug. 
P10
REDUCTION IN IMMUNOHISTOCHEMICAL STAINING OF
THROMBOSPONDIN-1 PREDICTS PROGRESSION IN
SUPERFICIAL BLADDER CANCER JC Goddard1, CD Sutton2, JL Jones3, KJ
O’Byrne4, RC Kockelbergh1, Dept. of Urology1 Surgery2, Pathology3 &
Oncology4, University Hospitals of Leicester NHS Trust, UK 
Introduction Thrombospondin-1 (TSP-1) is a large multifunctional glycoprotein
which has been shown to have antiangiogenic functions. Reduced expression has been
associated previously with poor outcome in invasive bladder cancer. The purpose of
this study was to investigate the relationship of TSP-1 expression and outcome in a
series of superficial bladder cancers. 
Methods A series of 231 cases of superficial bladder cancer were stained with
antibody against TSP-1. We assessed the location and percentage of TSP-1 staining. A
scoring system based on location and percentage staining was developed and applied
to all cases. 
Results Of the 231 cases, 143 presented as pTa and 88 as pT1. Fifty cases
progressed to muscle invasive disease and 181 did not. Immunostaining of TSP-1 was
discrete and confined to four distinct areas: Epithelial-Stromal junction, Perivascular,
Tumour cell and Stromal. Perivascular staining was present in 26% of cases that
progressed compared to 60% that did not (P = 0.00002), epithelial-stromal staining
was seen in 44% of cases that progressed versus 50% (P = 0.4), stromal staining was
present in 10% of cases that progressed versus 11% (P = 0.8) and tumour cell staining
was in 4% of cases that progressed versus 2% of cases that did (P = 0.5). The perivas-
cular TSP-1 staining score was significantly lower in cases which progressed to
muscle invasive disease (P = 0.00006). In a univariate binary logistic regression
analysis decreasing perivascular TSP-1 staining was significantly associated with risk
of progression (Hazard Ratio 1.74, 95% Cl 1.50–2.03 P = < 0.000001). In a multi-
variate binary logistic regression model, independent predictors of progression were,
decreasing perivascular TSP-1 staining (P = 0.011) and stage pT1 at presentation 
(P < 0.000001) 
Conclusion In this series of superficial bladder cancer, a reduction in the
immunohistochemical expression of TSP-1 was significantly associated with disease
progression to muscle invasion. This is consistent with the hypothesis that TSP-1 is
antiangiogenic. 
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GLUCOSE TRANSPORTER GLUT-1 EXPRESSION
CORRELATES WITH TUMOUR HYPOXIA AND PREDICTS
METASTASIS FREE SURVIVAL IN ADVANCED CARCINOMA OF THE
CERVIX R Airley1,2, J Loncaster1, M Bromley1, S Roberts1, C West1 & 
I Stratford2, 1CRC Experimental Radiation Oncology Group, Paterson
Institute for Cancer Research, 2Experimental Oncology Group, School of
Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford
Road, Manchester M13 9PL, UK 
Hypoxic tumours are known to be more malignant, more likely to metastasise and to
have a poor prognosis. They are also radio- and chemoresistant. For this reason, it is
desirable that a clinically useful marker of hypoxia is found, so that treatment with
radiotherapy and bioreductive chemotherapy can be rationally applied to individual
patients. Eppendorf histography, by virtue of its proven predictive qualities, has been
used in our laboratory to validate markers of hypoxia that can be detected using
immunohistochemistry. These markers include antibodies to pimonidazole adducts
and intrinsic markers such as the enzyme carbonic anhydrase IX and the glucose
transporter GLUT-1. The latter is a facilitative glucose transporter that is ubiquitously
expressed in normal tissue and expressed at higher levels in a number of tumours. Its
potential as an intrinsic hypoxia marker arises from its dual control in hypoxic condi-
tions by reduced oxidative phosphorylation and the hypoxia-inducible factor (HIF-1)
oxygen sensing pathway. 
GLUT-1 protein expression has been assessed in individual biopsy sections taken
from 54 patients with locally advanced cervical carcinoma, who prior to treatment
with radiotherapy were assessed for tumour oxygenation status with the Eppendorf
oxygen electrode. By utilising a low-tech scoring system, the intensity of GLUT-1
expression was found to correlate weakly with pO2 (r = 0.28, P = 0.04). In order to
extrapolate this correlation to the known adverse effects of tumour hypoxia on
outcome, we examined the prognostic significance of Glut-1 staining in a retrospec-
tive series of 121 advanced stage cervical carcinoma treated with radiotherapy, and we
found that patients with an absence of Glut-1 significantly increased the likelihood of
metastasis-free survival (P = 0.022). These findings suggest that Glut-1 may be an
intrinsic marker of hypoxia, with prognostic significance, that can easily be applied in
a clinical setting. 
P12
EXPRESSION OF HYPOXIA-INDUCIBLE FACTOR 1 IN
PRIMARY AND SECONDARY HUMAN OVARIAN CARCINOMAS
C Baluch, B Burke, K Corke, M Wells, CE Lewis, Tumour Targeting Group,
Division of Genomic Medicine, University of Sheffield Medical School
Sheffield S10 2RX, UK 
Patients with epithelial ovarian cancer (EOC) have a survival rate over 5 years of only
about 30%. Such a poor prognosis is due to the majority already having local (pelvic
and/or peritoneal) or distant metastases at diagnosis. This means that effective treat-
ments need to be developed to halt or slow the development of both the primary and
the secondary tumours in EOC. Multiple areas of hypoxia (low oxygen) are common
in most forms of malignant tumour and hypoxic tumour cells are relatively resistant to
radio-and chemotherapy. Hypoxia stimulates gene expression in mammalian cells via
the induction of various transcription factors, including hypoxia-inducible factor-1
(HIF-1) which transactivates cognate binding sites (hypoxia response elements,
HRE’s) in or near the promoters of oxygen-sensitive genes. Recently, HRE-driven
therapeutic DNA constructs have been used to target gene therapy to hypoxic sites
(i.e. HIF-1 expressing cells) in human tumour xenografts in mice. This approach may
hold particular promise in the selective targeting of secondary tumours in EOC as
these have been postulated to be severely hypoxic. Here, we have used immunohisto-
chemistry to demonstrate HIF-1 alpha expression in 22/28 (79%) serous EOC and in
virtually all omental deposits examined. Where matched primary/secondary tumour
samples were available, secondary tumours expressed similar or more HIF-1 than
corresponding primary tumours. Both malignant cells and stromal cells expressed
HIF-1, the proportion/extent of which varied between different areas of a given
tumour as well as between different tumours. HIF-1 expression was usually maximal
in peri-necrotic tumour cells and in areas of rapid growth near to the invasive margin
of tumours. In sum, this study demonstrates abundant expression of HIF-1 in both
primary and secondary ovarian tumours, suggesting that both may be suitable targets
for HRE-regulated gene therapy. 36 Poster presentations
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TUMOUR HYPOXIA AND VASCULARITY IN LYMPHOMA 
A Sibtain1, GD Wilson2, PJ Hoskin1, Marie Curie Research Wing,
Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK 
Introduction Tumour hypoxia has been shown to occur in a variety of solid tumours
and is a factor in limiting treatment outcome. This study examines hypoxia in
lymphoma using the Eppendorf microelectrode and the 2-nitroimidazole compound,
pimonidazole. The use of pimonidazole with immunohistochemical staining of tissue
biopsy specimens for hypoxia demonstrates microregional of hypoxia from which
hypoxic fraction can be calculated. Dual staining with CD34 enables analysis of
hypoxia in relation to blood vessels. 
Methods and Materials Twelve patients with accessible lymphoma masses were
recruited (five high grade). Five underwent intratumoural oxygen measurements using
the Eppendorf probe and tumour biopsy 12–24 hours after intravenous pimonidazole.
Adequate biopsies were only obtained in three. Seven patients underwent post
pimonidazole biopsy only. Immunohistochemical staining for both pimonidazole and
blood vessels was performed on sections of the tissue biopsy samples. A dichromic
staining technique was used to demonstrate these characteristics on the same section.
Light and dark pimonidazole staining, vessel density and vessel to hypoxia distance
were quantified with the aid of an image analysis software package. 
Results The median pO2 measured by the Eppendorf probe for each mass ranged
from 11.2 to 40.4 mmHg. The median hypoxic fraction, defined as the number of
readings less than 5mmHg (HF5), was 26 mmHg (range from 0–36%). The median
hypoxic fraction, estimated by the proportion of pimonidazole staining, was 0%
(range for light staining 0–5%, range for dark staining 0–1.6%). Three of the ten
biopsy samples exhibited pimonidazole staining and four of the five tumours that
under went Eppendorf measurements showed hypoxia. The median vascular density
was 77 vessels per mm2 (range 36–131 vessels/mm2). The median vessel to light
staining distance was 87 microns (range 12–203 microns), and to dark staining was
104 microns (range 21–250 microns). 
A negative correlation emerged between vascular density and hypoxic fraction
measured by pimonidazole (r = –0.9). No correlation emerged between HF5 and
hypoxic fraction measured by dark or light pimonidazole, when staining was present
(r = 0.13). 
Conclusion This cohort of lymphomas exhibited little hypoxia when estimated by
pimonidazole staining. However a significant hypoxic fraction was seen on Eppendorf
probe measurements, although mean p02 was relatively high compared to data in
epithelial solid tumours. Vascular density is inversely proportional to the degree of
pimonidazole staining seen.
P14
ROLE OF NOS IN THE METABOLISM OF PIMONIDAZOLE, 
A HYPOXIC MARKER EC Chinje, KJ Williams, SL Lockyer, BA
Telfer IJ Stratford, Experimental Oncology Group, School of Pharmacy &
Pharmaceutical Sciences, University of Manchester, Oxford Road,
Manchester, M13 9PL, UK 
Nitric oxide synthase (NOS) represents a relatively unexplored example of an endoge-
nously up-regulated enzyme that could provide tumour selective metabolism of
chemotherapeutic prodrugs. Two main features of the enzyme make it a very attrac-
tive target to improve cancer therapy. Firstly, it generates nitric oxide (NO), which is
important in tumour angiogenesis and maintenance of vascular homeostasis. Of
significant importance, elevated levels have been found in several neoplastic tissues.
Secondly, its dimeric nature provides two distinct catalytic domains (a reductase and
an oxidase) that will bioactivate a broad repertoire of established and novel
chemotherapeutic agents. The enzymes are haem-based proteins similar to members
of the cytochrome P450 family. In addition, the reductase domain of NOS shares a
high degree of sequence homology with cytochrome P450 reductase (P450R), known
to be important for the bioactivation of many bioreductive drugs under low oxygen
tension (hypoxia). This requirement for a reductive environment refines the speci-
ficity of the prodrug target, since hypoxia is a unique characteristic of solid tumours. 
We have successfully employed an optimised expression vector in which the
human elongation factor 1a promoter produces a bicistronic message containing 
the genes for human iNOS and puromycin resistance. Following transfection of the
human breast cell line, MDA231, clones have been selected that have been demon-
strated by immunoblotting and enzyme activity to stably express NOS at levels that
have been reported for clinical samples. A 40-fold increase in NOS activity was
mirrored by a 4–5 fold increase in reductase activity using cytochrome c as substrate.
In this study, we have examined the role of NOS in contributing to the extent of
pimonidazole-adducts formation under hypoxia. Parental cells, sense and empty-
vector clones were rendered hypoxic for 2 hours prior to addition of the drug and
followed by further 3 hour incubation under hypoxia. FACS analysis was then
performed with appropriate antibodies to determine the extent of adducts formation. 
Preliminary results do indicate that NOS activity may contribute to the overall
extent of pimonidazole-adduct formation in these tumour cells under hypoxia. Hence,
development and evaluation of our model in vivo will be very useful in evaluating the
use of NOS-activated hypoxia-mediated prodrugs as probes in selected patient popu-
lations and could represent a gain in the rational application of prodrug chemotherapy. 
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NUCLEAR TRANSLOCATION OF THE p65 SUBUNIT OF NFkB 
IS REGULATED BY WILD-TYPE p53 IN MCF-7 CELLS IN
RESPONSE TO HYPOXIA AND REOXYGENATION CA Parker, CE Lewis,
JA Royds, Section of Oncology and Cellular Pathology, Division of Genomic
Medicine, University of Sheffield Medical School, Beech Hill Road, Sheffield,
S10 2RX, UK 
The presence of chronic or transient hypoxia within solid tumours contributes to
tumour progression and resistance to therapy. p53 and NFkB transcription factors
both respond to multiple stress stimuli, including hypoxia. NFkB has an anti-
apoptotic function and promotes proliferation, whereas p53 can induce cell cycle
arrest and apoptosis. 
This study aimed to identify any interactions between these two transcription
factors during the response of MCF-7 cells to hypoxia and reoxygenation. 
MCF-7 breast carcinoma cell lines were incubated with control or antisense
oligonucleotides directed against wild-type p53 for 24 hours and then exposed to
normoxia (21% O2), hypoxia (0.5% O2) or reoxygenation following a 6 hour period of
hypoxia. Levels of cellular proliferation and viability were assessed and nuclear
extracts assayed for p53 and p65 protein levels by western blotting. 
In normoxic conditions, control and antisense treated cells showed very similar
growth and protein levels, with no nuclear expression of p53 and p65. Hypoxic anti-
sense treated cells showed increased growth and viability compared to controls.
Control cells in hypoxia showed p53 upregulation from 1–24 hours and a window of
nuclear p65 at 4 hours. In contrast, antisense treated hypoxic cells lacked p53 expres-
sion and exhibited constitutive nuclear p65 expression. During reoxygenation, anti-
sense treated cells had enhanced growth and viability compared to controls. Control
and antisense treated cells showed identical protein expression during reoxygenation,
with a lack of p53 but with nuclear p65 expressed during 1–24 hours of reoxygena-
tion. 
This data demonstrates that antisense inhibition of wild-type p53 leads to constitu-
tive nuclear translocation of p65 in response to hypoxia. When p53 is absent from
tumour cells, hypoxia may be able to further promote tumour progression via a
prolonged activation of NFkB. 
This work is supported by Yorkshire Cancer Research. 
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MODIFYING LOW-DOSE HYPER-RADIOSENSITIVITY BY
RIBOZYME MEDIATED DOWN-REGULATION OF POLY
(ADP-RIBOSE) POLYMERASE, A Chalmers, S Scott, B Marples, M Joiner,
Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK 
Aim To elucidate the role of the DNA damage-sensing protein poly(ADP-ribose)
polymerase (PARP) in mediating the hypersensitive response of human glioma cell
lines to low doses of ionising radiation. 
Background In many mammalian cell systems, small acute doses of radiation
below ~50 cGy are more lethal per unit dose than higher doses, at which radioresistance
increases. These dual phenomena have been termed low-dose hyper-radiosensitivity
(HRS) and increased radioresistance (IRR). There is evidence that IRR reflects dose-
dependent changes in DNA repair mechanisms but the details remain unclear. PARP is
a highly-conserved nuclear enzyme activated by binding to DNA strand breaks that
has been shown to modulate the activity of key components of the DNA repair
system, including p53 and DNA-dependent protein kinase. Abrogation of the IRR
response in tumour cell lines by chemical inhibitors of PARP provides evidence that
this enzyme plays a key role in the HRS/IRR phenomenon. 
Procedures To study the role of PARP more specifically, we have generated a
dual-expression plasmid vector encoding a ribozyme (short, catalytic RNA species
with site-specific cleavage activity) targeted against PARP mRNA, and a green fluo-
rescent protein which allows selection and sorting of transfected cells. The 38 base
ribozyme RNA molecule binds to PARP mRNA at a site immediately downstream
from the start codon; it is anticipated that cleavage at this site will substantially down-
regulate expression of the PARP protein. Negative control vectors encoding the
reverse ribozyme sequence and a scrambled version have also been cloned. Using a
liposomal transfection agent, vectors were introduced in to T98G human glioma cell
lines. After a 48 hour incubation, transfected cells were selected using a fluorescence-
activated cell sorter (FACS). Established low-dose cell survival assays of FACS-
sorted cells will be used to generate low-dose survival curves. The effect of the
ribozyme on PARP protein and activity levels will be assessed by Western blotting
and NAD+ incorporation assays respectively. 
Findings Introduction of active and control vectors in to T98G glioma cells has
been achieved, with transfection rates of ~30%. Western blots and cell-survival assays
are in progress, and a PARP activity assay is in development. Any changes in the low-
dose survival characteristics of the ribozyme-transfected cells, compared with
untransfected and negative control-transfected cells, will be examined in relation to
changes in levels of PARP expression and activity. Future studies will address the
effect of PARP down-regulation in cell lines with similar radiosensitivity but which
express varying degrees of the HRS phenomenon. The results will allow elucidation
of the role of PARP in mediating low-dose HRS in gliomas. Poster presentations 37
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EVALUATION OF RH1 AS AN INNOVATIVE BIOREDUCTIVE
AGENT AND A POTENTIAL RADIOSENSITIZER IN THE
TREATMENT OF SOLID TUMORS J Kim, DP Wilks, CML West, 
JY Kim1, H Valentine1, DP Wilks, CML West1, AV Patterson2, IJ Stratford2, 
JH Hendry1, CRC Group of Experimental Radiation Oncology, PICR, Christie
Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX1, Dept. of
Pharmacy & Pharmaceutical Sciences, University of Manchester, Oxford
Road, Manchester M13 9PL, UK2
One of the most important causes of radiotherapy failure in solid tumor is the presence
of hypoxic cells. Bioreductive drugs, which are designed to target radioresistant
hypoxic tumor cells has clear rationale to be used in conjunction with radiotherapy.
RH1 is an innovative bioreductive agent that was developed in the Paterson Insti-
tute as a water-soluble analogue of MeDZQ (2,5-diaziridinyl-3,6-dimethyl-1,4-
benzoquinone) and is currently under phase I trials as a joint collaboration between
the CRC and the NCI. RH1 cytotoxicity to cancer cells is mainly via bioreductive
metabolites that alkylate DNA and lead to the production of inter-strand cross-links2.
The aim of this study is to investigate the drug’s ability to interact with radiation either
additively or by a radiosensitizing effect. In order to understand the types and extent
of enzymes involved in drug metabolism, several cloned MDA231 breast cancer cell
lines have been obtained. These are MDA231 D7, R4 and wild type (WT); the first
two of which were infected with DT-diaphorase and P-450 reductase, respectively. In
order to determine the radiosensitizing effect of RH1, radiation and drug response are
assessed alone and in combination. Cells in an actively metabolizing and proliferating
status were used. Radiation survival curves were obtained for the three cell lines and
their radiosensitivity assessed as SF2 yielding similar values of 0.38, 0.37 and 0.35 for
D7, R4 and WT, respectively. RH1 dose response curves were established for each
line by exposing cells to graded doses of RH1 (0–30 nM). RH1 was cytotoxic towards
all three cell lines studied with greatest toxicity in D7 cells that have the highest level
of DT-diaphorase. The sensitivity of the three cell lines to the drug was shown to be
significantly different with IC40–50% values of 1 nM for D7, 4–6 nM for R4 and WT,
respectively. But the magnitude of these differences between lines did not mirror
differences in DT-diaphorase (450-fold higher in D7 Vs WT). These results suggest
that there should be the roles of other unknown enzymes or individual host factors
such as cellular repair. Drug-radiation interaction study was done under aerobic condi-
tion for the three cell lines. Radiation and RH1 interaction was investigated in oxic
condition using IC90% drug dose. Regardless of the extent of cell killing by its own,
addition of RH1 before irradiation shifted cell survival curve down in parallel way by
the amount of the drug effect which suggesting an additive cell killing effect of RH1
with radiation. Future work includes hypoxic cell drug sensitivity and radiation-drug
interaction under hypoxic condition. In addition, a clinical study will determine the 
P17 Cont’d
levels of relevant bioreductive enzymes in tumor and normal tissues taken from
patients with tumors. Studies about series of repair protein that is relevant to the
damage caused by the drug and radiation will be carried out in parallel. This will
provide information on inter-patient heterogeneity in terms of the cytotoxic effect
caused by the drug and radiation and so examine the feasibility of using an individu-
alised cancer treatment using RH1. 
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THE P53 FUNCTIONAL YEAST ASSAY PREDICTS RADIATION
SENSITIVITY IN GASTRO-OESOPHAGEAL CELL LINES 
SD Oglesby1, E Warbrick1, DA Johnston2, JF Dillon2, AJ Munro1, TR Hupp2,
AM Thompson1, 1Dept. Surgery & Mol. Oncology, University of Dundee,
2Dept. Molecular and Cellular Pathology, University of Dundee, UK 
Introduction p53 is known to play a key role in determining the cellular response to
chemotherapy and radiotherapy, with tumours containing mutant p53 tending to be
resistant to treatment. Traditional methods for determining p53 status are either labo-
rious and expensive (sequencing), or correlate poorly with true p53 function
(immunohistochemistry). In addition, both methods suffer when tumour material is
contaminated with normal tissue as is the case with endoscopic biopsies. 
The functional yeast assay (FYA) is a relatively new technique which is simple,
and has inherent properties which allow it’s use even on biopsy material containing
normal tissue. The assay allows for the rapid screening of large numbers of samples.
We have used the FYA to assess a number of gastro-oesophageal cell lines and
oesophageal cancers, and attempted to correlate the p53 status of the cell lines with
their response to clinical doses of radiation. 
Materials and Methods Cell lines: OE21 (oesophageal squamous carcinoma),
OE33 (oesophageal adenocarcinoma), AGS (gastric adenocarcinoma). 
Each cell line was irradiated with 2–5 Gy of gamma irradiation, this dosage being
similar to that used in many radiotherapy regimes. Evidence of apoptosis or growth
arrest were then sought for 24 hours post treatment using flow cytometry. 
The p53 status of the cell lines and also of 6 sequentially presenting oesophageal
cancers was assessed using FYA. 
Results The OE21 and OE33 cell lines score as mutant p53 with the FYA, and are
resistant to radiation. The AGS cell line contains wild type p53, and apoptoses
following 2Gy irradiation. The p53 status of the oesophageal cell lines has not previ-
ously been reported. Four of the 6 oesophageal cancers scored as mutant with the
FYA. 
Discussion Chemo-radiotherapy plays an important part in the management of
gastro-oesophageal malignancy. Predicting those patients likely to respond would be
advantageous. The functional yeast assay is a powerful tool for assessing p53 status in
human tumours, we have shown that it can be applied to biopsy material from gastro-
oesophageal tumours. FYA predicts response in-vitro, further studies are required to
determine whether it predicts response in-vivo. 
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RADIOSENSITIZATION BY NOVEL INHIBITORS OF PARP, PI,
AND DNA-PK, NU7026, IN VITRO. S Veuger*1, BW Durkacz1, 
BT Golding1, RJ Griffin1, N Martin1, DR Newell1, L Rigoreau1, M Stockley1, 
SE Webber2, Z Hostomsky2 and NJ Curtin1, University of Newcastle upon
Tyne UK1, Agouron Pharmaceuticals, San Diego, USA2
Cell lines deficient in poly(ADP-ribose) polymerase (PARP) or DNA dependent
protein kinase (DNA-PK) are unable to carry out DNA single strand break (SSB) and
double strand break (DSB) repair, respectively, making them highly radio- and
chemo-sensitive. Inhibitors of these enzymes should therefore have potential as radio-
and chemo-sensitizers for cancer therapy. Radiosensitization by the novel PARP and
DNA-PK inhibitors, PI and NU7026, respectively, was investigated in Chinese
hamster ovary cells: DNA-PK deficient V3 cells and their DNA-PK proficient coun-
terpart, V3 YAC (transfected with a yeast artificial chromosome containing human
DNA-PKcs). NU7026 was neither growth inhibitory (sulphorhodamine B (SRB)
assay) nor cytotoxic (clonogenic assay) per se at concentrations ≤ 20 mM in either cell
line. Exponentially growing V3 YAC cells were sensitized to IR by 0.4 mM PI and 
10 mM NU7026 (1.4 and 1.5-fold, respectively) with greater than additive effects 
(2.8-fold sensitization) of the drugs in combination, being observed. In the V3 cells,
PI caused a 1.4-fold sensitization whilst no radiosensitization was observed with
NU7026, confirming that the primary intracellular target of NU7026 is DNA-PK.
Recovery from potentially lethal damage (PLDR) was investigated in growth arrested
V3 and V3 YAC cells. G1 arrest in plateau phase cells was confirmed by flow cyto-
metric analysis. V3-Yac and V3 cells were exposed to equitoxic doses of g-IR (6Gy
and 1.4GY respectively) and following a 24 hr delay in cloning, which allows quies-
cent cells to repair PLD, the surviving fraction of V3 YAC cells increased 8–10 fold
but survival of V3 cells only increased 1–2 fold. In the V3 YAC cells this PLD
recovery was reduced by approx. 70% by inclusion of PI during the recovery period
whilst NU7026 abolished this recovery. Co-incubation with both inhibitors reduced
survival to below that of cells that had not been allowed to recover. The modest
recovery seen in V3 cells was not inhibited by NU7026 but was fully inhibited by PI.
The mechanism underlying the effects of PI and NU7026 were investigated by
measuring DNA DSB levels by neutral elution. Following exposure of V3 YAC cells
to 75 GYg IR the majority of DNA strand break rejoining (~90%) occurred within 60
min. Repair was inhibited by 35% by PI and 55% by NU7026, and the two drugs in
combination completely inhibited rejoining. In DNA-PK deficient V3 cells only about
50% of the DNA DSB had rejoined by 60 min in the absence of drug, As expected,
NU7026 had no effect on rejoining but PI (alone or in combination with NU7026)
inhibited rejoining by 50–60%. These studies are consistent with PARP and DNA-PK
activity being required for the repair of and recovery from radiation induced DNA
damage and that radiosensitization can be achieved by inhibition of these enzymes. 38 Poster presentations
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A RAPID DUAL-FLUORESCENCE DNA MISREPAIR ASSAY
FOR PREDICTING RADIOSENSITIVITY IN UROLOGICAL
CANCER CELL LINES Sangar VK1,3, Collis SJ1, Cowan R2, Roberts SA1,
Hendry JH1, Margison GP1, Clarke NW2,3, CRC/Paterson Institute for Cancer
Research1, Christie Hospital2, Manchester, M20 4BX & Hope Hospital3,
Salford, M6 8HD, UK 
Introduction Radiotherapy is an important treatment modality for bladder and
prostate cancer. Cellular radiosensitivity is related to incorrect repair (misrepair) of
DNA double-strand breaks. This study reports the use of a novel Rapid Dual-
Fluorescence (RDF) Assay for DNA misrepair in urological cancers. 
Methods A circular DNA plasmid, pREVY, containing the genes encoding
enhanced green fluorescent protein (EGFP) and enhanced yellow fluorescent protein
(EYFP) was linearised using a restriction endonuclease that cleaves between the
enhancer and promoter regions controlling EGFP expression. The circular (control)
and linear plasmids were individually transfected into tumour cell lines of differing
radiosensitivity: prostate (LNCaP) and bladder (MGHU-1 and S40b). The DNA
misrepair was quantified using flow cytometry and computer analysis of the shift in
the intensities of the two fluorescent proteins. The colony-forming assay was used to
produce radiation survival curves from which a measure of radiosensitivity, the alpha
parameter, was recorded. 
Results The alpha values for LNCaP, MGHU-1 and S40b were 0.35, 0.025 and
0.17 respectively. The corresponding DNA misrepair values as measured by the above
assay were 83.4%, 48.2% and 39.9%. A trend between percentage misrepair and the
alpha value was observed (R = 0.72, P = 0.02), with the more radiosensitive cells
showing greater misrepair. 
Conclusion The RDF assay, which takes only three days to perform, is a
promising new technique for measuring DNA misrepair and may enable assessment
of radiosensitivity in prostate and bladder cancers prior to treatment. (Supported in
part by The CRC) 
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DIFFERENTIAL RADIOSENSITISATION OF INTRA-TUMOUR
CELL POPULATIONS BY GEMCITABINE Sangar VK1,3, Ramani
VAC2, Cowan R2, Roberts SA1, Hendry JH1, Margison GP1, Clarke NW2,3,
CRC/Paterson Institute for Cancer Research1, Christie Hospital2,
Manchester, M204BX & Hope Hospital3, Salford, M6 8HD, UK 
Introduction Gemcitabine is a nucleoside analogue which has known radiosensi-
tising properties in certain tumours. Its effect is highly cell type and schedule depen-
dent. Here we highlight its radiosensitising effects in bladder cancer cells in vitro and
assess the differential intra-tumour activity by studying two related bladder tumour
cell lines with different radiosensitivities. 
Methods & materials Two invasive bladder tumour cell lines were studied, the
radioresistant line MGHU-1 (parent) and its radiosensitive clone S40b. Standard
clonogenic assays were undertaken to establish the radiosenistivities of both cell lines.
In order to screen these cell lines for the radiosensitising effects of Gemcitabine the
MTT assay was utilised. Each cell line was treated with three different doses of
Gemcitabine (0.01, 0.25 and 0.5 umol for MGHU-1 and 0.01, 0.35 and 0.5 umol for
S40b) at three different time points prior to radiotherapy (48, 24 and 12 hours; 0–6
Gy). After approximately six doublings viable fractions were calculated and survival
curves were fitted to the LQ model. Using unwieghted non-linear least-squares regres-
sion those time points where there was possible synergy between Gemcitabine and
radiation were highlighted. 
Results The clonogenic survival curves confirmed the radiosensitivities of both
cell lines with SF2s of 0.90 and 0.64; and alpha values of 0.025 and 0.18 for MGHU-
1 and S40b respectively. Synergy between Gemcitabine and radiation was achieved
with 0.01 umol of Gemcitabine given at 48 and 12 hours prior to radiation in the S40b
cell line (P < 0.001 at 48 hrs, P = 0.021 at 12 hrs). Further evidence of radiosensitisa-
tion was noted at 0.35 umol (S40b) Gemcitabine given 12 hrs prior to radiation 
(P = 0.021). No significant synergy was evident in MGHU-1. 
Conclusion Gemcitabine radiosensitises bladder tumour cell lines. The results
suggest that its effects are greater in those tumour cell populations which are more
radiosensitive. 
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DO OXIDATIVE DNA LESIONS ACCUMULATE IN BRAIN  
TISSUE IN XERODERMA PIGMENTOSUM? AE Kiltie1, 
JL Ravanat,3 SW Wijnhoven2, H Vrieling2, J Cadet3, T Lindahl1, 1Department
of Mutagenesis, ICRF Clare Hall Laboratories, EN6 3LD, UK, 2Leiden
University Medical Centre, 2333 AL, Netherlands, 3CEA Grenoble, F-38054,
France
Some xeroderma pigmentosum (XP) patients (20%) suffer from neurodegeneration,
which may be caused by free-radical induced DNA damage produced during endoge-
nous cellular metabolism. XP patients are deficient in nucleotide excision repair
(NER). Forms of DNA damage such as those causing major helix distortion, are
repaired by NER rather than by the base excision repair (BER) pathway, which
corrects most endogenous DNA damage. Cyclopurine deoxynucleoside lesions are
formed by free-radicals in hypoxic conditions. Lesions are produced in which the base
and 2¢deoxyribose are joined by an extra covalent bond, and this prevents DNA glyco-
sylases from releasing such adducts. These lesions are highly efficient blocking
lesions to DNA polymerases and to 3¢ exonucleases and are therefore cytotoxic. 
As cyclopurine lesions are repaired by NER but not BER, it is hypothesised that
cyclopurines may accumulate in XP brains to cause neurodegeneration. 
Organs have been obtained from old (1–2 years old) and young mice with XPA-and
XPC-deficiencies. Preliminary work has been carried out using tissue from normal
mice. Genomic DNA was extracted from tissues (brain, liver, kidney, skin, spleen,
heart, lung, testes) using a sodium iodide method to minimise oxidative damage
during DNA processing. DNA was then digested to nucleosides, using nuclease P1,
phosphodiesterases I and II, and alkaline phosphatase. Preliminary (non-XP) brain
tissue samples spiked with a 22mer oligonucleotide containing a single 5¢,
8-cyclo-2¢deoxyadenosine lesion (5¢R diastereoisomer; 5¢cyclodAdo) have been
analysed using hypersensitive HPLC and tandem mass spectrometry (HPLC MS/MS).
No cyclopurine lesions were detected in brain tissue from normal mice, but
5¢cyclodAdo was detected in the spiked samples in expected amounts. 
Once the sensitivity of the HPLC MS/MS technique has been optimised, tissue
from old and young XPA-and XPC-deficient mice and normal young and old controls
will be analysed for the presence of cyclopurine deoxynucleotides. 
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HYPOFRACTIONATED PALLIATIVE RADIOTHERAPY IN ADULT
GLIOBLASTOMA MULTIFORME VR Bulusu, SG Russell, K
Burton, G Robinson, NG Burnet, Oncology centre, Addenbrooke’s Hospital,
Hill’s road, Cambridge, CB2 2QQ, UK
Introduction Glioblastoma multiforme (GBM) in adults carries a poor prognosis. In
elderly or poor performance status patients (pts), a short course of radiotherapy may
be appropriate for palliation. 
Aim To assess the overall survival and subjective response to a hypofractionated 
2 weeks course of palliative radiotherapy (RT) in adult GBM pts treated at
Addenbrooke’s hospital from 1998–2000. 
Materials and Methods 40 adult pts with a histologically proven GBM have been
irradiated with 30 Gy in six fractions over 2 weeks using 6MV photons (27 Gy if 260 kV)
using a parallel pair cut down whole brain radiotherapy technique. Age, WHO perfor-
mance status, duration of symptoms, presence or absence of fits, site of tumour, details of
neurosurgical procedure (NSP), subjective response, overall survival (from the date
of neurosurgical procedure) and post radiotherapy survival were recorded. The mean,
median, 95% CI and p values for significance in difference in means were calculated. 
Results N = 40, Males = 20, Females = 20, WHO PS ≤ 1 = 15 and ³ 2 = 25. Mean
age 64.3 yrs (Range 41–76 years). 83% had no history of fits at presentation. Partial
debulking was carried out in 50% pts. Symptoms were stable or improved after RT in
75% of pts. RT was tolerated with minimal side effects in the majority of patients. The
mean overall survival (OS) from NSP for the whole group was 22.3 weeks (17–27.6,
95% CI). The mean OS for the good and poor PS groups was 35.7 weeks (25.7–45.7,
95%CI) and 14 weeks (11–17, 95%CI) respectively (P < 0.05). In poor PS (WHO ³ 2),
the mean post RT survival was only 9.5 weeks (6.5 –12.5, 95% CI). 
Duration Mean (weeks) 95%CI Median (weeks) 
Symptoms 5.8 4.7–6.9 5 
NSP to Consult 1.6 1.2–2 1.1 
Consult to RT 1.8 1.5–2.1 1.5 
End of RT-death 17.4 12.1–22.7 17.1 
Conclusions Hypofractionated RT in adult pts with GBM is well tolerated and offers
either stabilization or improvement of symptoms in 75% of the patients. WHO PS is a strong
prognostic factor for survival. No significant correlation between other clinical variables and
survival was seen. For poor PS adult pts with GBM best supportive care might be a suitable
alternative to RT though this may have to be evaluated in a randomized clinical trial. Poster presentations 39
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ZD1839 (‘IRESSA’), AN EGFR-TKI, ENHANCES THE
ANTITUMOUR EFFECT OF RADIOTHERAPY IN A HUMAN
COLORECTAL CARCINOMA XENOGRAFT MODEL KJ Williams1, 
BA Telfer1, IJ Stratford1, SR Wedge2, 1School of Pharmacy, The University of
Manchester, Manchester, M13 9PL, UK, 2Cancer and Infection Bioscience,
AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK 
ZD1839 is an orally active epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) that has been demonstrated to block EGFR-mediated mitogenic
signaling pathways that promote the proliferation and survival of cancer cells.
ZD1839 has demonstrated promising efficacy and tolerability in Phase I clinical
studies. Recently, ionising radiation has been implicated as a potential stimulus for
EGFR signaling. Hence, we have evaluated the possible therapeutic benefit of
ZD1839 in combination with radiotherapy. The effect ZD1839 in combination with
single and fractionated dose radiotherapy was analysed in two separate experiments.
In each case, nude mice (8 weeks old) bearing subcutaneous LoVo colon carcinoma
xenografts (200–250 mm3) were randomly assigned into the designated treatment
groups. In Protocol 1, mice received vehicle or ZD1839 (100 mg kg–1) for 14 days,
either alone or combined with a single 5 Gy dose of X-irradiation. In Protocol 2, mice
received vehicle or ZD1839 (100 mg kg–1) for 14 days, either alone or combined with
3 ´ 2 Gy fractions at 24-h intervals. ZD1839 or vehicle was administered 2 h before
radiotherapy. Experiments were terminated when a relative tumour volume four times
that at the initiation of treatment was obtained (7.4 ± 0.4 and 9.8 ± 0.6 days for vehicle
controls in Protocols 1 and 2, respectively). Protocol 1 revealed comparable growth
delays (GD) for vehicle plus 5 Gy or ZD1839 alone treated tumours (7.6 ± 0.6 and 
7.8 ± 0.6 days, respectively). ZD1839 plus 5 Gy produced tumour regression and a
GD of 14.1 (±1) days, a radiation dose modification of 1.6. In Protocol 2, ZD1839
alone induced a GD of 5.1 (± 0.9) days and 3 ´ 2 Gy plus vehicle a GD of 7.4 (±1.2)
days. Combining ZD1839 with 3 ´ 2 Gy enhanced the therapeutic effect of radiation
alone, and a GD of 18.7 (± 2.8) was achieved. The GD obtained with the combined
therapy exceeded that seen with 5 ´ 2 Gy (11.6 ± 1.3 days). These data support a
clinical evaluation of ZD1839 and radiotherapy. 
‘Iressa’ is a trade mark of the AstraZeneca group of companies. 
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ASSESSMENT OF PRECLINICAL MODELS FOR COLORECTAL
CANCER RW Wilkinson1, D Ellison2, R Poulsom3, J Staub4, 
M Ilyas4, WF Bodmer4, D Snary1, SJ Mather2, EL Ross1, 1Imperial Cancer
Research Technology, Dominion House, 59 Bartholomew Close, London EC1A
7BE, UK, 2ICRF Nuclear Medicine Group, Dominion House, 
59 Bartholomew Close, London EC1A 7BE,3 ICRF Histopathology Dept., 
44 Lincoln Inns Field, London,4 ICRF Cancer and Immunogenetics Lab,
Institute of Molecular Medicine, University of Oxford, UK
In this study a human carcinoembryonic antigen transgenic (CEA.Tg) mouse model
was validated for the pre-clinical assessment of anti-CEA-directed agents. CEA.Tg
mice were derived from a colony which express the complete human CEA gene and
flanking regulatory sequences which results in cell-type and organ specific expression
of CEA. As with humans, the mice had low serum levels of CEA and cell surface
CEA expression was localised in the gastrointestinal (GI) tract. Pharmacokinetic
studies in wildtype and CEA.Tg mice were performed after intravenous injection of
I125-labelled murine monoclonal antibodies (mAbs) [either an anti-human CEA mAb,
PR1A3, or an isotype control (IC)] and tissues were sampled at 4, 24 and 48 hours
after the injection. Both mAbs showed similar biodistribution patterns in the wildtype
mice while in the CEA.Tg, PR1A3 specifically localised to the CEA expressing
tissues. In the GI tract the percentage injected dose (%ID) for PR1A3 was signifi-
cantly higher than the IC mAb at all the time points sampled. In CEA.Tg mice bearing
a murine tumour transfected with human CEA, PR1A3 targeted and was retained at
the tumour site at high levels. When CEA.Tg mice were backcrossed with the natural
mutant Min (multiple intestinal neoplasia) mouse offspring developed spontaneous
CEA positive intestinal polyps that were bound by I125 labelled PR1A3. These results
demonstrate the therapeutic potential of the anti CEA antibody, PR1A3, and emphases
the validity of using relevant models in preclinical studies. 
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DEVELOPMENT OF A MURINE CEA TUMOUR MODEL 
JJ Irlam, DE Gilham, RE Hawkins, CRC Department of Medical
Oncology, University of Manchester, Paterson Institute for Cancer Research,
Manchester, M20 4BX, UK 
The primary aim of this study was to develop a murine tumour model expressing the
human tumour associated antigen, Carcinoembryonic antigen (CEA). CEA expression
has been linked with colorectal / breast and ovarian tumours. The development of this
model will then be used to test targeted adoptive immunotherapy technology and
primarily the targeting of modified T-lymphocytes to CEA expressing tumours. 
The murine Lewis Lung (LL-2) carcinoma cell line is of C57/bl-6 background, are
negative by flow cytometry and Western blot analysis for CEA. A 900 base pair
domain of the 5¢ end of human CEA cDNA was engineered to be expressed on the cell
surface by a coupling with a murine MHC class I transmembrane anchor domain
(CEAdo.MTM). This domain is specifically targeted by the single chain antibody
C23, derived from the monoclonal antibody MFE23. The CEA fragment was cloned
into a retroviral vector, and the LL-2 cells were transduced. The transduced cells were
then quickly cloned by limiting dilution. The expanded clones were analysed for the
expression of CEAdo.mtm on their surface, using the single chain antibody C23hufc
(kindly provided by Chris Allinson, Department of Med. Onc.). A clone expressing
high level was identified; Clone 28. This initial clone was further sub-cloned through
3 rounds of limiting dilution, in an attempt to collect a pure population of high
CEAdo.mtm expressing cells. These sub-clones were chosen due to their varying
levels of CEAdo.mtm surface expression, ranging from low to high. These clones
were used in in vitro assays with modified T-lymphocytes. Effector T-cells were modi-
fied to specifically target the CEA domain using the C23 single chain antibody
coupled to CD3. After co-culture with targetted lymphocytes the remaining target cell
population was found to be CEA negative by flow cytometry and western blot
analysis. This infers that the CEA positive target cells had been successfully targeted
by the modified lymphocytes. The target population exposed to non-specific modified
T-cells showed no change in the cell viability and no loss in CEA domain expression
when analysed by Flow cytometry and western blot analysis. 
The highest expressor of the CEAdo.mtm, clone 28–7–12 was used to establish an
In vivo mouse model, to investigate the maintainence of expression and the growth
kinetics of the LL-2 cells transduced with CEAdo.mtm. Preliminary growth curves
indicated that there was no difference in the growth kinetics between the transduced
cell line and the parent LL-2 cell line. Immunostaining using cryostat sections clearly
demonstrated a maintainance of CEAdo.mtm expression throughout the 3 week
growth period of the tumour. 
It is anticipated that these cells will provide a basis of a stringent model to further
investigate the effectiveness of gene modified cellular adoptive immunotherapy. 
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A RAPID METHOD FOR THE ANALYSIS OF CELL
PROLIFERATION AND SURVIVAL IN INTESTINAL ADENOMA
FROM THE APCMIN MOUSE, JL Burns, JA Howell, and AB Hassan*, Cell
and Development Group, Department of Zoology, University of Oxford, South
Parks Road, Oxford OX1 3PS, UK basshassan@zoo.ox.ac.uk
Mutation of the murine gene coding for Apc has provided a model of human familial
adenomatous polyposis coli (ApcMin1+). The number and size of small intestinal polyps
depends on age, strain dependent genetic modifiers, dietary fat and gut organisms.
Combination of ApcMin1+ with disruption of genes implicated in colorectal carcinoma
(e.g. Msh2, Egf, Igf2, p53, Dnmt) has extended the utility of this model to the analysis
of the genetic pathways relevant to human cancer. Insights into the mechanistic effects
of genetic modification have been limited, partly because of the difficulty in devel-
oping reliable and reproducible assays using intestinal tissue. 
We describe a rapid method which may help in the analysis of cell survival and
proliferation in intestinal adenoma. Small and large intestines from C57B1/6J wild
type and ApcMin1+ adult mice were removed into ice-cold PBS. Rapid processing of
intestines, with removal of intestinal contents and exposure of the lumen, was
performed using a jig and blade designed (by us) for this purpose. Segments of tissue
or intestinal adenoma were incubated in ice-cold PBS (Ca2+ and Mg2+ free)/EDTA and
gently filtered (70 mm filter). Single cell suspensions of epithelial cells free from
smooth muscle were generated. Cell processed in this way are amenable to either
culture, antibody labelling (for analysis of chimeras) or flow cytometric analysis. To
investigate cell proliferation, we utilised antibodies to Mcm2 and BrdU incorporation.
We present new information following pulse and pulse-chase BrdU incorporation of
normal and adenomatous epithelium which reveal aspects of cell turnover within
adenoma. We have analysed normal intestinal tissue and adenoma cell death using
sub-G1 analysis of flow cytometric profiles and FAM-VAD-FMK to detect caspase
activity (1–9). Finally, we present the results of analysis following combination of
ApcMin1+ with genetic modification of Igf2 and Msh2. Experiments were performed
following approval of the Home office and Departmental ethics committee and
following the guidelines of the UKCCR. 
*Supported by Senior Clinical Research Fellowship of the Cancer Research Campaign. 40 Poster presentations
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CYCLOOXYGENASE-2 (COX-2) EXPRESSION IN ApcMin/+
MOUSE INTESTINAL MACROPHAGES OO Faluyi, 
J Henwood, C Bonifer, MA Hull, PL Coletta, Molecular Medicine Unit,
University of Leeds, St James’s University Hospital, Leeds, LS9 7TF, UK
There is compelling genetic and pharmacological evidence to suggest that the
inducible isoform of the cyclooxygenase gene, Cyclooxygenase-2 (Cox-2) plays an
important role in intestinal tumorigenesis. Elevated levels of Cox-2 expression have
been demonstrated in colorectal cancers and adenomas in humans as well as in
intestinal tumours in animal models. Previously, we have shown by immunohisto-
chemistry that Cox-2 expression is up-regulated and localised to interstitial
macrophages in ApcMin/+ mouse intestine as well as in human sporadic colorectal
adenomas. To further define the Cox-2 expressing cell population, intestinal lamina
propria mononuclear cells (LPMNCs) have been isolated from ApcMin/+ mice and wild-
type littermates. Isolated LPMNCs were subjected to semi-quantitative reverse tran-
scription-polymerase chain reaction (RT-PCR) analysis. Higher levels of Cox-2
expression were detected in LPMNCs isolated from ApcMin/+ mouse intestine as
compared with wild-type littermates. 
In order to isolate the Cox-2 expressing macrophage population, the ApcMin/+
mouse has been crossed with the EGFP-lysozyme mouse in which green fluorescent
protein (GFP) is expressed specifically in cells of the myelomonocytic lineage. Using
these mice and the macrophage specific monoclonal antibodies ER-HR3, F4/80 and
MOMA-1, interstitial macrophages have been separated from other LPMNCs by flow
cytometry and fluorescence-activated cell sorting techniques. 
Utilizing semi-quantitative RT-PCR, we have shown that there is increased Cox-2
expression in ApcMin/+ mouse LPMNCs. Further studies on ApcMin/+ mice expressing
GFP in their macrophages will allow prostaglandin and cytokine secretion profiles of
interstitial macrophages in ApcMin/+ mice to be determined which will help in clari-
fying the role of Cox-2 in intestinal tumorigenesis as well as in revealing potential
therapeutic targets for colon cancer prevention. 
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ELEVATED PYRIMIDOPURINONE-DEOXYGUANOSINE
ADDUCTS IN ADENOMAS OF APCMIN MICE AND
SUPPRESSION BY DIETARY CURCUMIN Ricky A Sharma, Sarah Perkins,
Raj Singh, Will P Steward, Andy Gescher, Oncology Department & MRC
Toxicology Unit, University of Leicester, LE1 9HN, UK
Pyrimidopurinone adducts of deoxyguanosine (M1G) reflect oxidative damage of
DNA  via base propenals, and production of malondialdehyde (MDA) by endogenous
lipid peroxidation and by catalysis via cyclooxygenase (COX). COX-2 is upregulated
at early stages of adenoma formation in Min mice, a model of intestinal carcinogen-
esis characterized by an Apc gene defect1. Curcumin, a polyphenolic antioxidant
derived from the spice turmeric, has been shown to inhibit lipid peroxidation and
COX-2 expression in vitro. Dietary curcumin diminishes rat colon mucosal M1G
levels2, and suppresses adenoma formation in Min mice3. We tested two hypotheses:
MDA and M1G levels are elevated in intestinal adenomas of Apc mutant Min mice;
and M1G levels are modified by dietary curcumin in a manner favourable to cancer
chemoprevention. Mice were fed a standard AIN-76A diet from 4 to 18 weeks of age,
containing 0.1% or 0.2% curcumin. MDA concentration was measured by colori-
metric assay, and M1G adduct levels by immunoslot blot. Curcumin and its metabo-
lites were analyzed by HPLC. In control animals, although MDA levels did not differ
significantly between intestinal mucosa and adenoma tissue (0.9–2.1 nmol/mg
protein), M1G levels were 3-fold higher in adenomas than mucosa (12.0 ± 3.8 versus
3.7 ± 1.3 adducts per 107 nucleotides, P < 0.001 by ANOVA). The 0.1% and 0.2%
curcumin diets did not alter M1G levels in normal mucosa, but both diets decreased
adenoma M1G by approximately 43% when compared to control animals (P = 0.006
by ANOVA). In mice fed the 0.2% diet, the concentrations of curcumin in intestinal
and colonic mucosa were 507 ± 86 and 111 ± 23 nmol/g tissue respectively. The
results demonstrate for the first time that levels of M1G adducts are elevated in prema-
lignant lesions in this genetic mouse model, and that the discrepancy with normal
mucosal M1G is not accounted for by MDA concentration. The dietary antioxidant
curcumin can attenuate this elevation, and merits evaluation in patients with colorectal
polyposis. 
1. Oshima M et al 1996 Cell 87: 803–809 
2. Sharma RA et al 2001 Clin Cancer Res: in press
3. Mahmoud NN et al 2000 Carcinogenesis 21: 921–927
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PILOT STUDY OF CURCUMA EXTRACT IN PATIENTS: SAFETY
AND BIOLOGICAL ACTIVITY RA Sharma, HR McLelland, CR
Ireson, DJL Jones, KA Hill, SA Euden, ML Williams, M Pirmohamed2, SM
Plummer, MM Manson, AJ Gescher, WP Steward, Oncology Department &
MRC Toxicology Unit, University of Leicester, LE1 9HN, UK2, Department of
Pharmacology, University of Liverpool, L69. 3GE, UK 
Curcuma spp. extracts, particularly curcumin, prevent colon cancer in rodents, and
may be therapeutic against established malignancy. Information on the pharmacody-
namics and pharmacokinetics of curcumin in humans is lacking. A dose-escalation
study of standardized Curcuma extract in capsule form (P54FP, Phytopharm plc.) was
conducted at doses between 440 and 2200 mg per day, containing 36 to 180 mg
curcumin and 400 to 2000 mg essential oils. Fifteen patients with advanced progres-
sive colorectal cancer, refractory to standard chemotherapy, received Curcuma extract
daily for up to 4 months. In addition to chemotherapeutic parameters, 3 potential
markers of systemic biological activity were measured in blood: Lymphocytic
glutathione S-transferase (GST) activity; leukocytic levels of a DNA adduct (M1G)
formed by malondialdehyde, a product of lipid peroxidation and prostaglandin (PG)
biosynthesis; and PGE2 concentrations, both basal and those induced in vitro by
lipopolysaccharide. Patients were also genotyped for GSTM1, GSTP1 and GSTT1
polymorphisms. Pretreatment levels of leukocytic M1G in patients with GSTM1 null
genotype were 74% higher than those in GSTM1 expressers (P < 0.001 by ANOVA).
Oral Curcuma extract was well tolerated, and dose-limiting toxicity was not observed.
Neither curcumin nor its metabolites were detected in blood or urine (limit of detec-
tion 5 pmol/ml). Curcumin was recovered from the faeces of all patients and curcumin
sulphate was identified in one, confirmed by mass spectrometry. Ingestion of 440 mg
Curcuma extract for 28 days was accompanied by a 59% decrease in lymphocytic
GST activity (P < 0.001 by ANOVA). Lymphocytic GST activity in patients at higher
doses and leukocytic M1G levels in all patients were constant within each patient and
unaffected by treatment with Curcuma extract. Basal and induced PGE2 values hinted
at dose-dependent inhibition. Five patients exhibited stable disease on CT scan for
2–4 months of treatment. The results suggest that i) Curcuma extract can be adminis-
tered to patients at doses of up to 2.2 g daily without significant toxicity, ii) curcumin
has low oral bioavailability in humans, and iii) whole blood PGE2 concentration and
lymphocytic GST activity may be useful as systemic pharmacodynamic biomarkers in
trials incorporating larger patient numbers. 
Supported by the Medical Research Council, Phytopharm plc., and the University
Hospitals of Leicester. 
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THE METABOLISM OF THE CHEMOPREVENTIVE AGENT
CURCUMIN BY HUMAN GUT CR Ireson1, S Orr3, D Jones1, 
ML Williams2, CK Lim1, RD Verschoyle1, WP Steward2, AJ Gescher1, 1MRC
Toxicology Unit, 2Department of Oncology, University of Leicester LE1 9HN, and
3UK Human Tissue Bank, De Montfort University, Leicester, UK
Curcumin (diferuloylmethane) is the major active ingredient in the spice turmeric, a
yellow pigment that can be isolated from the rhizome of the Curcuma longa plant.
Whilst there is substantial evidence for the chemopreventive activity of curcumin in
animal models and in cell lines, little is understood regarding the role of metabolism
in its efficacy. Recently we characterised curcumin metabolites in rats in vivo and in
suspensions of human and rat hepatocytes (1). These studies and evidence presented
earlier suggest the possibility that curcumin is conjugated in the gut. Therefore we
compared metabolism of curcumin to its sulphate and glucuronide conjugates and
products of its reduction by subcellular fractions prepared from human small intestine
and liver. Curcumin (0.1 mM) was incubated with cytosol or microsomes for 1 hour.
Putative metabolites were identified by liquid chromatography-electrospray mass
spectrometry in the selected ion-monitoring mode. Curcumin sulphate (m/z = 447)
was identified in cytosol of gut (103 ± 23 nmol/mg protein) and liver (39±8 nmol/mg
protein). Microsomes metabolised curcumin to its glucuronide conjugate (m/z = 543)
at 255 ± 229 nmol/mg of protein in gut and 94 ± 30 nmol/mg in liver. The reduction
products of curcumin, tetrahydrocurcumin (m/z = 371) and hexahydrocurcumin (m/z
= 373) were found in the cytosol of both tissues. These results demonstrate that reduc-
tion of curcumin occurs in both liver and gut cytosol and are consistent with the notion
that glucuronidation and sulphation are important routes of curcumin metabolism in
human gut. As these metabolites are less capable of interfering with cyclooxygenase-
2 expression than parent curcumin1, gut seems to play a deactivating role in curcumin
disposition. 
1. Ireson et al, Cancer Research, in press Poster presentations 41
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GLYCINE-EXTENDED GASTRIN PROMOTES COLON
CARCINOGENESIS A Aly, GS Baldwin, A Shulkes, University of
Melbourne, Department of Surgery, Austin Campus, ARMC, Studley Rd.,
Heidelberg, Victoria 3084, Australia 
Recent interest has focussed on the role of gastrin precursors as potential promoters of
carcinogenesis in colorectal carcinoma.1 A useful model for the identification of
potential promoters of carcinogenesis is the formation of aberrant crypt foci (ACF) in
the colons of rats exposed to colon-specific carcinogens such as azoxymethane.2 The
risk of malignancy is related to the total number and nature of ACF formed. The aim
of this project was to investigate the short term effect of continuous systemic infusion
of the gastrin precursor glycine-extended gastrin (G-gly) on the development of ACF
in rat colon. 
Methods G-gly was delivered systemically via Alzet miniosmotic pumps at a dose
of 2.5 nmol/kg/hr over a four week experimental period. Rats were injected with
azoxymethane (15 mg/kg) subcutaneously in two doses one week apart at the begin-
ning of the experiment. Colons were harvested, fixed in formalin and stained with
0.1% methylene blue to allow visualisation of ACF. The number and nature of ACF
were counted and compared to controls not exposed to G-gly. 
Results Azoxymethane reliably produced aberrant crypts in both control and G-
gly-treated rats. The number of ACF per centimeter of colon in the G-gly-treated
group was increased by 56% compared to controls (P = 0.006). There was an increase
in all ACF subtypes (with one, two, three or more crypts per focus) in the G-gly-
treated rats, and the relative proportions of each subtype were similar to
azoxymethane-treated controls. There was no significant change in the distribution of
ACF throughout the colon after G-gly treatment. 
Conclusion The observation that G-gly increased the overall number of all types
of ACF induced in azoxymethane-treated rats suggests that G-gly may act as a
promoter of carcinogenesis. 
1. Baldwin GS, Shulkes A (1998) Gastrin, gastrin receptors and colorectal
carcinoma. Gut 42: 581–584 
2. McLellan EA, Bird RP (1988) Aberrant crypts: Potential preneoplastic lesions in
the murine colon. Cancer Res 48: 6187–6192 
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LOSS OF EXPRESSION OF ESTROGEN RECEPTOR BETA IN
COLON CANCER N Jassam1, SM Bell1, S Gray1, L Harkin1, 
G Skliris2, V Speirs2, P Quirke1, 1Academic Unit of Pathology, Algernon Firth
Building and 2Molecular Medicine Unit, Clinical Sciences Building, University
of Leeds, Leeds, West Yorkshire, LS2 9JT, UK 
Gender differences in the incidence and behaviour of colon cancer suggest a hormonal
influence. The age-adjusted incidence rates for colon cancer are lower in women than
men and furthermore epidemiological data suggest a protective effect for hormone
replacement therapy (HRT) on this disease. However the biological mechanism by
which estrogen influences the pathogenesis of colorectal cancer is unknown. Evidence
exist for the expression of estrogen receptors (ER) in human colon tissue, recently it
has been shown that the predominant ER is ERb. The aim of the present study is to
investigate ERb expression in normal and colorectal cancer samples, at both the
protein and mRNA level in a large well-defined patient cohort. 
We have performed immunohistochemistry using a monoclonal antibody directed
against the C-terminus of ERb on 91 archival formalin-fixed paraffin embedded
samples from consecutive patients diagnosed with colorectal cancer at Leeds General
Infirmary during 1998 (53 males, 38 females, age range = 48–92). Strong nuclear
immunoreactivity was observed in epithelial cells lining the colonic crypts and in
tumour cell nuclei. Occasional positivity was observed in fibroblasts. Loss of ERb
expression was found in 21% of the colon cancer samples irrespective of the gender,
age, or tumour stage of the patients. High levels of ERb expression were identified in
the adjacent normal colon mucosa. Interestingly loss of ERb expression was higher in
left colon and rectal cancers (27%) than right colon cancers (8%). Currently the
immunohistochemistry results are being confirmed by Western analysis of 20 paired
normal and colonic tumours. 
Our results support epidemiological studies, which suggest that hormone replace-
ment therapy and or dietary estrogen influence the course of colon cancer and that
these effects are mediated by ERb. 
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THE PATTERN OF EXPRESSION OF CDC25B INVERSELY
COMPLEMENTS THAT OF CYCLIN B1 IN NORMAL COLUMNAR
INTESTINAL EPITHELIUM AND NEOPLASTIC OESOPHAGEAL TISSUE
CM Pring1, AGK Li1, C Verbecke2, PJ Guillou1, GWB Clark1, PA Robinson2,
Department Surgery1/ Molecular Medicine2, Clinical Sciences Building, 
St. James’s University Hospital, Leeds, UK 
Aims Increased levels of transcripts encoding the G2/M cell cycle checkpoint phos-
phatase, CDC25B, have been reported in oesophageal adenocarcinoma as well as
many other carcinomas including breast, gastric and head and neck cancers, compared
to matched normal tissues. Our aim was to compare the protein expression of
CDC25B with the G2/M cyclin, Cyclin B1, and the cell proliferation marker Ki-67, in
both normal columnar mucosa from the small intestine and neoplastic oesophageal
tissue. 
Procedures CDC25B, Ki-67 and Cyclin B1 were detected by standard immuno-
histochemical techniques and their expression was compared in parallel tissue
sections. Immunoreactivity was scored by two independent assessors and graded; –, +,
++ or +++ (– = no expression; +++ = strong expression). Six sections of normal
columnar epithelium and twenty one sections of oesophageal adenocarcinoma were
compared. 
Major findings Cells in the basal layer of normal columnar intestinal mucosa and
in crypts stained (+++) for Ki-67 and (++) for Cyclin B1 but were negative for
CDC25B in all six sections. In marked contrast, the more differentiated cells of the
villi were negative (–) for Ki-67 and Cyclin B1 but stained (++/+++) for CDC25B.
Furthermore, whereas strong expression of CDC25B was observed in 6/7 well differ-
entiated tumours (positive predictive value 75%) and in 2/8 moderately differentiated
tumours, only weak staining (–/+) was noted in the majority (5/6) of poorly differenti-
ated tumours. This pattern correlates inversely with the expression of Cyclin B1. 
Significance of research As increased levels of CDC25B transcripts have been
reported previously in oesophageal adenocarcinomas, our results infer that the
apparent absence of CDC25B expression is likely to be due to its rapid turnover. 
Conclusion We have determined an inverse relationship between the levels of
expression of CDC25B and Cyclin B1 in cells of normal intestinal mucosa and
oesophageal adenocarcinomas. This finding was surprising, as the established func-
tion of active CDC25B in cells is to promote G2/M transition. We propose that its
apparent absence in proliferating cells is due to its rapid turnover and its stabilisation
in more differentiated cells. Its role in the more differentiated phenotype is not clear at
the present time.
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c-erbB-2 PROTEIN EXPRESSION AND GENE POLYMORPHISM
IN COLORECTAL CANCER JA McKay1, JF Loane2, VG Ross2,
MM Ameyaw1, GI Murray2, J Cassidy1, HL McLeod1. Departments of
1Medicine and Therapeutics, and 2Pathology, University of Aberdeen,
Aberdeen, Scotland, AB25 2ZD, UK 
The c-erbB-2 oncogene is frequently activated in epithelial tumours, and amplification
and/or overexpression is clinically associated with poor prognosis, and a reduced
response to chemotherapy and endocrine therapy, in breast cancer. In addition, a Val655
Ile polymorphism in the transmembrane domain of the c-erbB-2 gene has been associ-
ated with an increased risk of breast cancer in a Chinese population1. The prognostic
utility of c-erbB-2 in colorectal cancer remains equivocal, while the relevance of the
Val655Ile polymorphism is unknown in this disease. We have investigated the protein
expression of c-erbB-2 in a large cohort of 248 well-characterised colorectal tumours,
and in a subset of 42 lymph node metastases. c-erbB-2 protein was assessed using
immunohistochemistry, and staining was evaluated according to the US FDA-approved
scoring system2, which classifies complete membrane staining of >10% of tumour cells
as positive c-erbB-2 expression. Furthermore, we have evaluated the Val655Ile polymor-
phism by PCR-RFLP in 151 colorectal cancer patients and 257 healthy control
subjects. Immunohistochemical studies revealed that 203/248 (81.8%) tumours
expressed c-erbB-2, although only 8/248 (3.2%) showed strong positive immunoreac-
tivity. Colon tumours were significantly more likely to express c-erbB-2 protein than
rectal tumours (P = 0.005), however there was no correlation with Dukes’ stage, differ-
entiation grade, age or sex of the patient. Moreover, no association was seen with
patient survival (P = 0.56), which suggests that c-erbB-2 is not a prognostic factor in
colorectal cancer. Only 22/42 (52.4%) lymph node metastases displayed staining
patterns concordant with their corresponding primary tumour, with the majority of
divergent cases showing higher staining of primary tumours (18/42 cases, 42.9%). This
indicates that c-erbB-2 immuno-histochemistry of primary colorectal tumours cannot
be used to predict the status of lymph node metastases. PCR-RFLP analysis of the 
c-erbB-2 Val655Ile polymorphism in colorectal cancer patients and a control group of
Caucasian subjects demonstrated that allele frequencies were identical between cases
and controls (Ile = 0.80 and Val = 0.20 in each case), indicating that this polymorphism
is not related to the risk of developing colorectal cancer in this population. In addition,
there was no relationship between c-erbB-2 protein expression and the Val655Ile poly-
morphism (P = 0.58). In conclusion, it would appear that c-erbB-2 is not a major factor
involved in the development or progression of colorectal cancer, and that novel thera-
pies targeting this molecule may be of little benefit in this disease. 
1. Xie D, Shu X-O, Deng Z et al 2000 J Natl Cancer Inst 92: 412 
2. Jacobs TW, Gown AM, Yaziji H 1999 J Clin Oncol 17: 1983 42 Poster presentations
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THE PROGNOSTIC VALUE OF HER-2 IN DUKES’ B
COLORECTAL CANCER S Essapen1*, M Green2, C de Vries1, 
C Shotton1, C Topham2, C Marks2, M Cook2, H Modjtahedi1, H Thomas1
1Cancer Study Group, University of Surrey, Guildford, Surrey GU2 7XH, UK,
2Royal Surrey County Hospital, Guildford, Surrey GU2 5XX, UK 
Introduction Human Epidermal Growth Factor Receptor-2 (HER-2) is a transmem-
brane glycoprotein, which is overexpressed in a number of epithelial cancers. The
prognostic role of HER-2 has been established in breast cancer but remains controver-
sial in colorectal cancer. 
Aim and methods In the present study, the prognostic significance of HER-2/neu
(c-erbB-2), was investigated in fifty patients with Dukes’ B colorectal cancer who
underwent radical surgery between 1990 and 1995, using an anti-HER-2 mAb
HM64.13 (developed by Dr Modjtahedi) and a standard avidin-biotin horseradish
peroxidase immunohistochemistry method. 
Four categories were defined for the percentage of tumour cells showing cyto-
plasmic and/or membranous immunostaining (CMI) (≤10%, > 10–30%, >30–50%,
>50%). The percentage of tumour cells exhibiting membranous immunostaining (MI)
was similarly categorised. The intensity of the immunostaining was categorised as
negative, weak, moderate, and strong. The association between these scores and
cancer death or time to progression was estimated using Cox regression. Covariates
included in the model were age, sex, tumour site, size, stage, grade, and lymphovas-
cular invasion. Correlation between variables was tested using c2 tests. The mean age
of the study population was 72.5. Of the 50 patients, 19 had a tumour size of >5 cm; 8
had a T4N0 cancer; and 4 patients had lymphovascular invasion. 
Major findings Six (12%) patients had negative (≤10%) HER-2 immunostaining.
Of those tumours showing HER-2 overexpression, 29 (58%) cases had >50% CMI,
and 7 (14%) cases showed MI in >50% of the tumour. The intensity of the MI and
CMI was moderate to strong in 28 (56%) and 26 (52%) cases respectively. A signifi-
cant correlation was found between T4N0 cancers and the percentage of tumour cells
showing MI (P = 0.05). Furthermore, there was a suggestion of a correlation between
the percentage of tumour cells with CMI and lymphovascular invasion (P = 0.15). No
correlation with clinical outcome was seen which might be explained by the lack of
events in this small cohort of patients. 
Conclusion HER-2 overexpression is seen in a significant number of colorectal
cancers. This data suggests that there may be a correlation between HER-2 over-
expression and T4N0 cancers and lymphovascular invasion. This needs to be explored
in a larger cohort of patients, as it may aid the selection of Dukes’ B patients at higher
risk of recurrence, and for whom adjuvant chemotherapy is indicated. 
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UP-REGULATION OF HEPARIN-BINDING EPIDERMAL GROWTH
FACTOR-LIKE GROWTH FACTOR BY GASTRIN IN COLORECTAL
CANCER CELLS DF McWilliams, PA Clarke, SA Watson Academic Unit of
Cancer Studies, University Hospital, Nottingham, NG7 2UH, UK 
Introduction Gastrin is a central, autocrine growth factor in colorectal tumours.
Gastrin also modulates expression of the epidermal growth factor family in the
stomach. At least three gastrin peptide species are secreted by colorectal tumours and
may act to promote growth via different receptor isoforms. In this study we used anti-
sense gastrin mRNA technology to investigate the effects of this hormone upon
colorectal tumour proliferation and downstream gene activation. 
Materials and methods Total RNA was extracted from 20 paired colorectal tumour
and resection margin tissue removed at Nottingham University Hospital. Reverse tran-
scription real-time PCR was performed for gastrin, epidermal growth factor (EGF),
amphiregulin (AR), heparin binding EGF-like growth factor (HB-EGF) and transforming
growth factor-a (TGF-a). Quantification of relative gene expression levels (the ∆∆ ct
value) was obtained by comparison to the housekeeping gene, GAPDH. Antisense gastrin
transfections were performed on HCT116, Pan l, MGLVA1 acites and ST16 cell lines,
which were selected for stability with G418. RNA extraction and RT-real time PCR for the
above cDNA’s were then performed. A tetrazolium based proliferation assay (MTT assay)
was performed to determine growth rates of antisense cell lines. Immunohistochemistry
staining for HB-EGF, AR and CD31 were performed on 6 tumour and resection margin
paraffin-embedded tissue sections. Image analysis software was used to quantify staining
intensity from 8 observations per section (HB-EGF and AR). 
Results Gastrin was detected in 80% (16/20) of colorectal tumour cDNA’s. Members
of the EGF family were almost ubiquitously detected in all cDNA’s At the mRNA level, a
highly significant correlation between gastrin and HB-EGF was observed (P < 0.01,
Durban-Watson). All other EGF family members showed non-significant positive correla-
tions to gastrin mRNA levels. Antisense gastrin significantly reduced proliferation and
HB-EGF mRNA levels in the four tumour cell lines examined. In the colorectal tumour
cell line (HCT116), gastrin antisense reduced the MTT uptake (P < 0.05, Student’s t-test)
and median ∆∆ ct value of HB-EGF, from 0.00298 to 0.00024 (P < 0.01, Mann-Whitney).
The HB-EGF staining intensity was significantly higher in 5/6 colorectal tumours over
paired resection margins (P < 0.05, T-test). Blood vessels from consecutive sections of
tumour and resection margin stained positively for CD31 and HB-EGF. 
Conclusions Autocrine gastrin up-regulates proliferation rates and HB-EGF
mRNA in tumour cell lines. The HB-EGF protein is over expressed in colorectal
tumour tissue compared to resection margin mucosa. Gastrin may increase prolifera-
tion directly in colorectal tumours and also modulate HB-EGF levels. The HB-EGF
levels in colorectal cancer may also influence the proliferation of epithelial cells and,
possibly, tumour vasculature. 
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EXPRESSION OF EGFR and HER-2/neu IN GASTRIC
CARCINOMA AND THEIR PROGNOSTIC SIGNIFICANCE 
H Modjtahedi1, B Gharesi-Fard2, M Vasei2, A Malekhosseini2, A Ghaderi*2
1Cancer Study Group, University of Surrey, Guildford GU2 7XH, UK, 2Dept
Immunology, Pathology and Surgery, Shiraz University of Med. Sciences,
Shiraz, Iran 
Overexpression of the members of the type-I growth factor receptor family, in partic-
ular EGFR and HER-2/neu, has been reported in a number of epithelial malignancies
and this in turn has been associated with a poor prognosis in many such patients. 
In this study 124 specimens of known cases of gastric carcinoma in Iranian patients
were examined immunocytochemically for the expression of the EGFR and HER-2
molecules and results were compared with clinicopathological data. Indirect
immunoperoxidase method using specific mAbs was applied on paraffin-embedded
tissues. 
Results indicated that 47 (37.9%) and 19 (15.3%) of tumors showed positive
(either membrane or cytoplasmic) staining with anti EGFR mAb ICR16 and anti-
HER-2 mAb ICR12 respectively. Expression of the EGFR was significantly associ-
ated with lymph node involvement (P < 0.02), locally invasive (P < 0.002), large
tumor size (P < 0.02), and high-stage (III/IV) tumors (P < 0.0004), but no correlation
was observed between nuclear grade and the location of the tumor. Expression of
HER-2 was significantly correlated to low stage tumors (I/II). Although, HER-2 posi-
tive tumors were more likely to be associated with serosal invasion and lymph node
metastasis, these correlations were not significant. 
The results of this study support the hypothesis that overexpression of the EGFR
may be a predictor for poor prognosis in patients with gastric carcinoma. 
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CHANGES IN THE EXPRESSION OF COMPONENTS OF THE IGF
SYSTEM IN ADENOCARCINOMA OF THE COLON AND RECTUM
M Davies1, S Coe1, S Gupta1, D Adeyemo1, G Goldspink2 , M Winslet1
Department of Surgery1, Department of Anatomy2, Royal Free Hospital &
University College Medical School, Pond Street, London. NW3 2QG, UK 
Aims The mitogenic and anti-apoptotic signals of the IGF-I and -II are mediated via
the insulin-like growth factor type-I receptor (IGF-IR). Insulin-like binding protein-4
(IGFBP-4) has been shown to be solely inhibitory to the actions of IGF-I and -II. Our
aim was to compare the expression and distribution of IGF-IR and the inhibitory
IGFBP-4 in malignant and non-malignant human colorectal tissue. 
Materials Samples were removed from resected colorectal tissue (30 patients) and
were frozen immediately. RNA was extracted and fragments of IGF-IR and IGFBP-4
were cloned using RT-PCR. Protein was extracted and separated using SDS PAGE
and probed using a polyclonal antibody to IGFBP-4. Frozen sections were cut and
immuno-histochemistry was used to determine the distribution of IGF-IR and IGFBP-
4 in the tissue, using an avidin-biotin immuno-staining complex. This was carried out
in five fields in both superficial and deep portions of samples. The staining was
repeated with immuno-fluorescence and quantified using an image analyser. 
Results We detected mRNA for both IGFBP-4 and IGF-IR in all samples. Using
western immuno-blotting a band corresponding to 28 kDa, (representing IGFBP-4)
was detected in all samples. Densitometric analysis of the radiographs confirmed that
the expression of IGFBP-4 was significantly less (P < 0.05) in the malignant tissue.
Immuno-staining for IGF-IR was greatest in the crypts, lamina propria and the base-
ment membrane. This expression was quantified using immuno-florescence and
shown to be similar in both groups. There was no correlation between strong IGF-IR
positivity and either grade or staging of tumours. IGFBP-4 stained most strongly in
the muscle layers and stronger in the non-malignant tissue. 
Conclusion Though the IGF-IR receptor is still abundantly expressed we did not
find increased expression in malignant tissue – contrary to recent publications1.
Therefore, the potential exists for IGF-I and -II, both of which are expressed in
colorectal cancer2, to exert anti-apoptotic and mitogenic effects via the IGF-IR. The
expression of inhibitory growth factor IGFBP-4 was less in malignant colorectal
tissue and so there may be increased bio-availability of IGFs in colorectal cancer. The
Roche light-cycler is currently being used to quantify the IGFBP-4 mRNA to establish
whether the reduced expression occurs at the gene level. 
1. Hakam A, Yeatman T, Lu L, Mara L, Marcet G, Nicosa S, Karl N and Coppola D
(1999) Expression of insulin-like growth factor type-I receptor in human
colorectal cancer. Human Pathology 30 (10): 1128–1133 
2. Freier S, Weiss O, Eran M, Flyvberg R, Dahan R, Nepesh I, Safra T, Shilani E and
Raz I (1999) Expression of insulin growth factor in adenocarcinoma of the colon
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PRIMARY TUMOUR EXCISION REVERSES THE REDUCTION
OF CIRCULATING DENDRITIC CELLS IN COLORECTAL
CANCER A Huang1, J Gilmour2, P Amjadi2, DC Henderson2, 
TG Allen-Mersh1, Depts. of Surgery1 & Immunology2, ICSM, Chelsea &
Westminster Hospital, London, UK 
Aims Antigen-presenting dendritic cells (DCs) are important in the anti-cancer
response and their deficiency may predispose to the escape of cancer from immune
control. We hypothesized that circulating DCs are quantitatively reduced in colorectal
cancer and that this is reversed by curative cancer excision, as well as being qualita-
tively deficient in expressing costimulatory molecules (CD86) that are required for
effective antigen presentation. 
Methods Flow cytometric analyses were performed on blood samples taken pre-
operatively and 8 weeks post-operatively. DCs defined as negative for surface expres-
sion of CD3, CD14, CD16, CD19, CD20 & CD56 and positive for HLA-DR were
measured as a percentage of the mononuclear cell population. The prevalence and
intensity of CD86 expression in DCs were also measured. 
Results 67 colorectal cancer patients, 51 healthy controls and 25 patients with
inflammatory bowel diseases were studied. Pre-operatively there was a significant
reduction in the percentage of circulating DCs in colorectal cancer patients (median =
0.25%) compared with controls (0.41%; Mann–Whitney U test, P < 0.0001) and
patients with colonic inflammation (0.39%, P = 0.005). There was no significant
increase in the other mononuclear cells indicating an absolute decrease in the number
of DCs. The extent of DC reduction did not relate to cancer stage. Post-operatively
DCs increased significantly in patients who underwent curative cancer resection
(Wilcoxon signed rank test, (P = 0.0001) but not in those with residual cancer 
(P = 0.33), control subjects (P = 0.07), or inflammatory cases (P = 0.18). The pre-
operative prevalence of CD86+ DCs was increased above controls (41%) in inflamma-
tory cases (60%; P = 0.003) but not in colorectal cancer patients (38%; P = 0.53).
There was no difference in the immunofluorescent intensity of CD86+ DCs between
the three groups before and after surgery. 
Conclusion In colorectal cancer there is a reduction in circulating DCs that is
reversed by tumour excision. The lack of rise in CD86 molecule expression in DCs
suggests that antigen presentation is impaired in colorectal cancer. This quantitative
and qualitative DC deficiency may be one mechanism by which colorectal cancer
escapes from immune destruction. 
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FLOW CYTOMETRY CORRELATES WITH RT-PCR FOR 
IN VITRO BUT NOT IN VIVO DETECTION OF CIRCULATING
COLORECTAL CANCER CELLS. G Tsavellas, H Patel, A Huang, R Araia, 
C Glover, TG Allen-Mersh, Department of Academic Surgery, ICSM, Chelsea
and Westminster Hospital, London, UK 
Aims Circulating tumour cells (CTCs) may predict survival in colorectal cancer, but
methods for their detection require validation. We developed a flow cytometric assay
for CTC detection and compared its sensitivity with the reverse transcription poly-
merase-chain reaction (RT-PCR) as a clinically validated gold standard. 
Methods Peripheral venous blood from healthy ‘no-cancer’ patients was spiked
with HT29 colon cancer cells and analysed using flow cytometry (FACS). Cancer
cells were defined as positive for pan-cytokeratin and negative for CD45 pan-leuco-
cyte antigen. Blood (3 ´ 28 ml) from primary colorectal cancer patients (n = 15) and
‘no cancer’ controls (n = 22) was equally divided for FACS analysis as above, and 
RT-PCR for CEA and CK20 cDNA. 
Results In non-spiked control blood, the median number of cytokeratin
positive/CD45 negative events detected by FACS was 0 (upper 95 percentile = 13). In
spiking experiments using FACS, there was a significant correlation between the
number of spiked cells and their recovery (r2 = 0.89, P <0.05), with a mean cell
recovery of 78%. With an upper normal threshold of 13 events, the lowest detectable
abnormal concentration was 20 spiked cells in 14 ml blood (median recovery = 14
cells). An abnormal spiked cell result on FACS (> 13 cells) concurred significantly
with a positive RT-PCR result (P < 0.05, Fisher’s Exact test). FACS detection of
tumour cells was significantly higher in spiked blood (at the lower sensitivity limit of
20 cells in 14 ml) compared with blood from cancer patients (Mann-Whitney U test, 
P < 0.05). No difference was identified by FACS, between blood taken from healthy
controls (median 0 events, iqr = 0–3) and colorectal cancer patients (median 2 events,
iqr = 0–3). There was no concordance in CTC detection between FACS and RT-PCR
in cancer patient blood (P = 0.8, Fisher’s Exact test). 
Conclusion FACS detection of tumour cells is feasible in-vitro and correlates well
with RT-PCR. Its sensitivity in-vivo is poor and does not correlate with RT-PCR
detection of CTC’s. Reasons for this might include in-vivo cell aggregation, hetero-
geneity of cytokeratin expression or fragility of CTC’s, compared with cultured
tumour cells. 
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IDENTIFICATION OF DIFFERENTIALLY EXPRESSED
PROTEINS IN COLORECTAL CANCER LC Lawrie1,2, 
GI Murray2, Departments of 1Molecular & Cell Biology, 2Dept. of Pathology,
University of Aberdeen, Aberdeen, UK 
Colorectal cancer is one of the most common malignancies in the UK with 30,000
new cases and 20,000 deaths from the disease each year. Improving prognosis requires
a greater understanding of the biology of colorectal cancer (CRC) and the identifica-
tion of molecular markers of CRC which may be useful as novel therapeutic targets or
as diagnostic aids. Proteomics is a powerful analytical tool which can help elucidate
mechanisms of disease development and progression by comparing differences in
protein expression profiles from normal or colonic tumour tissues. 
We have examined fresh frozen paired samples of normal and tumour tissue from
patients with Duke’s stage C adenocarcinomas located in the sigmoid colon, which
were selected from the Aberdeen Colorectal Cancer Database. Two-dimensional gel
electrophoresis was performed to produce protein expression maps from samples of
normal and tumour tissue. Image analysis of the gel maps identified proteins which
showed altered expression. These proteins were excised from the gel and subject to
mass spectrometric analysis then identified through database searching. As well as
proteomic examination of bulk normal and tumour tissue, we have also used immuno-
magnetic beads to obtain distinct populations of tumour or normal colonic epithelial
cells for proteome analysis. 
Initial results have shown that there are a significant number of differences in
protein expression in colon cancer compared with normal colonic epithelium. Proteins
which have shown increased expression in tumours include; peptidylprolyl cis-trans
isomerase, calgranulin B and triosephosphate isomerase. Proteins which have been
identified as showing decreased expression in colon tumours include; smooth muscle
protein 22-alpha, heat shock 27 kDa protein, tropomyosin alpha chain and epithelial
muscle type, alpha-1-antitrypsin precursor, myosin and desmin. Proteomic analysis of
normal and colonic tumour tissues can be expected to provide a further insight into the
molecular mechanisms of colorectal cancer tumour development and progression. 
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A PILOT STUDY OF THE USE OF OXALIPLATIN IN METASTATIC
COLORECTAL CANCER AT VELINDRE  SS Mitra, AE Brewster. 
T Crosby, TS Maughan Velindre Hospital, Cardiff, CF4 7XL, UK 
Aims Metastatic colo-rectal cancer has a median survival of 12–18 months. Newer
drugs like Irinotecan and Oxaliplatin could improve survival.(1) (2) Is Oxaliplatin a
safe and effective drug in metastatic colorectal cancer? 
Procedures and methods We studied 31 patients with metastatic colorectal cancer
who were treated with Oxaliplatin chemotherapy between September 1998 and April
2000. Out of the 31 patients, 3 patients had Oxaliplatin with 5FU chemotherapy as 1st
line treatment while 28 had the drug as 2nd or 3rd line. The age of the patients ranged
from 27 to 72 years with a median age of 60 years. Out of the 31 patients. 20 had
metastases in the liver. 9 had recurrent disease in the abdomen, 4 had metastases in the
lungs. 2 had skeletal metastases and I had mediastinal lymphadenopathy. 
Results 2 of the 3 patients on 1st line Oxaliplatin had partial responses while the third
patient has just completed 3 cycles and is unassessable.26 patients had 5FU as first line
chemotherapy and 11 had a partial response to 5FU while 12 had progressive disease
while on the 5FU.3 patients had stable disease on the 5FU. 1 patient had Tomudex and
another had CPT-11 with Tomudex as first line treatment. 21 of the 28 patients had
Oxaliplatin as 2nd line chemotherapy while 7 had it as 3rd line chemotherapy. There were
no complete responses, 8 partial responses and 8 patients had stable disease. The dura-
tion of response varied from 0-11 months with a median of 4 months. 6 patients
progressed on chemotherapy while 2 were not assessable because they are still on
chemotherapy. Of the 7 patients who had Oxaliplatin as 3rd line chemotherapy, 3 had
progression. 3 had stable disease while I patient had a partial response. Among the 28
patients, 22 had Oxaliplatin with 5FU while 6 had Oxaliplatin alone. Of the 6 patients
who had Oxaliplatin as a single agent, 2 had a partial response. 2 progressed while 2 had
stable disease. I patient died from renal failure on chemotherapy, 10 out of 31 patients
had grade 1–2 peripheral sensory neuropathy aggravated by cold and particularly
affecting the larynx in 3 patients. 6 patients had grade 2 nausea and vomiting, 2 had
acute diarrhoea and 4 patients had neutropenic sepsis. 
Conclusions Oxaliplatin used in combination with 5FU is a highly effective and
safe drug in metastatic colorectal cancer with a partial response rate of 33% and stable
disease rate of 28.5%. The duration of response is short with a median response of 4
months. It is effective even in 5FU refractory disease. The data suggests it should be
used early on in the natural history of metastatic colorectal cancer. 
1. Cunningham D et al A phase III multicentre randomized study of CPT-II versus
supportive care (SC) alone in patients (Pts) with 5 FU – resistant metastatic
colorectal cancer (MCRC). Proc.ASCO 17:A–1. Ia. 1998 
2. Andre T, et al: Multicentre phase II study. JCO 17(11): 3560–3568. 1999 44 Poster presentations
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LOW DOSE FOLINIC ACID WITH INFUSIONAL AND BOLUS
5FLUOROURACIL IN ADVANCED COLORECTAL CARCINOMA
M Osborne, N Shah, PJ Hoskin, MG Powell, R Anthony-Pillau, R Glynne-
Jones, A Makris. Mount Vernon Hospital, Northwood HA6 2RN, UK 
Aim The de Gramont schedule incorporates bolus and infusional 5 fluorouracil (5FU)
with high dose folinic acid (FA) and is widely used in the treatment of advanced
colorectal carcinoma. However the benefit of high dose FA is uncertain. This study
assesses the activity of low dose FA in the de Gramont schedule in metastatic
colorectal carcinoma. 
Patients and Methods 82 patients (49 male, 33 female), median age 68 years
(range 35–79) were treated with a modified de Gramont schedule consisting on days 1
and 2 of FA at a dose of 20 mg/m2 administered intravenously over 30 minutes,
followed by 5FU bolus at 400 mg/m2, then 5FU infusion 400 mg/m2 (65 patients) or
600 mg/m2 (17 patients) over 22 hours. Chemotherapy was given every two weeks to
a total of six courses. Sites of metastatic disease were: liver 66 patients, lung 10, peri-
toneum 18, local recurrence 12, nodes 12 with 54 patients presenting at original diag-
nosis with metastatic disease. 14 patients were previously treated with adjuvant 5FU.
Response assessment was radiological (37), with tumour markers (33) and clinical
(12). 
Results Median follow up 4.3 months (range 1–16). 27/82 (33%) failed to
complete 6 courses, 25 due to uncontrolled disease, 1 due to toxicity. 7 patients
required a delay, 4 due to neutropenia. Grade 3 neutropenia was recorded in 4/82(5%),
Grade 3 diarrhoea in 4/82(5%), Grade 3 nausea in 1/82(1%). Overall response
achieved: CR 2/82(2%), PR 32/82(39%), SD 16/82(20%), PD 32/82(39%). 
Conclusion Low dose FA in combination with bolus and infusional 5FU is compa-
rable to the standard de Gramont schedule with high dose FA in terms of toxicity and
response rates. Further follow up is required to fully evaluate duration of response but
potential cost benefit with the reduced dose of FA is important. 
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AN UPDATE ON THE MRC FOCUS/CR08 TRIAL: THE FIRST
300 PATIENTS Matt Seymour on behalf of the MRC Colorectal
Cancer Group and all the participants, Cancer Division, MRC Clinical Trials
Unit, 222 Euston Road, London, UK 
FOCUS is a large multi-centred randomised trial designed to assess the role of
irinotecan and oxaliplatin in advanced colorectal cancer. Compared with the best
evidence-based regimen – a Modified de Gramont 5FU/FA schedule (MdG), followed
on progression by single agent irinotecan – FOCUS investigates each of the new
agents in combination with MdG, as either first-line or second-line treatment. 
Because of the relatively new status of both irinotecan and oxaliplatin, and the
specialised demands of the new regimens on doctors, nurses and pharmacists, general
minimum requirements, along with specific staff experience, are required before an
Oncology Centre/Unit can be registered for participation in FOCUS. 
A total of 2100 patients are required, and the first patient was entered in May 2000.
After a slow start, accrual is now close to the target rate, and 300 patients had been
entered from 36 centres by the end of January 2001. The pre-treatment characteristics
of the patients were: median age 62 years (range 27–83 years); male 70%; WHO
performance status 0–41%, 1–51%, 2–8%; colon cancer 55%; stoma 30%; objective
measurable evaluability of disease 93%; resected primary 70%, unresected/unre-
sectable 26%, local recurrence 4%; metastases 98% (liver mets 80%, nodes 32%, lung
mets 30%, peritoneum 10%). 
Data is available on 90 patients who have reached their 12-week re-assessment
point. All patients received their allocated regimen, 80% receiving 6 cycles. Response
was reported as complete 5%, partial 26%, stable (or no evidence of progression)
46%, progressed 11%, died 12%. 
19 serious adverse events considered to be related to treatment have been reported.
These were mainly related to prolonging hospitalisation (9) and venous access prob-
lems (7). None were fatal or life threatening. 16 patients have died (all disease-related
except 1 who died following surgery for bowel obstruction). 
The trial is accruing extremely well, and the increased emphasis on Quality
Assurance appears to be resulting in a low level of serious adverse events, excellent
compliance to treatment plans and good clinical form return and QL completion. 
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A COMPARISON OF DOSE AND SCHEDULING EFFECT OF 
5-FU CHEMOTHERAPY IN ADVANCED COLORECTAL CANCER
PA O’Neill, DB Smith, E Marshall, PI Clark, SM O’Reilly, Department of
Medical Oncology, Clatterbridge Centre of Oncology, Bebington, Wirral,
Merseyside, CH63 4JY, UK 
We conducted a single centre randomised trial to investigate the schedule and dose
effect of 5 fluorouracil and folinic acid (5FU/FA) in advanced colorectal cancer. 
We compared the maximum tolerated dose (650 mg/m2) of 5FU/FA given as a
bolus injection with the same dose by continuous intravenous infusion (CI) and with a
third group given 50% higher dose (975 mg/m2) of 5FU/FA by CI. All patients
received FA at the same dose of 20 mg/m2. 
103 patients were randomised. The mean age for all patients was 63.1 years.
Chemotherapy was completed as planned in 59% patients and 8% stopped early due to
progressive disease. Delays occurred in 21% patients and dose reductions in 11%.
Hand-foot syndrome was more common in the 975 mg/m2 group (P = 0.08), as was
mucositis (P = 0.001) whereas diarrhoea more frequent in the bolus group (P = 0.02).
There was a higher incidence of cardiac events in the 975 mg/m2 group (P = 0.035).
Response rate was highest in the 975 mg/m2 CI group at 21% Vs 8% in the bolus
group. Median PFS was 4.6 months (bolus), 5.9 months (650 mg/m2 CI) and 8.1
months (975 mg/m2 CI) for the three groups (NS). There was a trend towards a longer
median OS for the 975 mg/m2 CI group at 10.7 months Vs 8.1 months for bolus and
8.5 months for 650 mg/m2 CI group (P = 0.3). 
These results suggest a dose intensity effect rather than a scheduling effect for the
increased efficacy of CI schedules over bolus and highlight the potential for signifi-
cant cardiac toxicity including sudden death in higher dose regimens given by contin-
uous infusion. 
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RESECTION OF COLORECTAL LIVER METASTASES: 
A SYSTEMATIC REVIEW J Colquitt1, P Simmonds1, J Primrose1, 
M Rees2, G Poston3, 1Cancer Sciences Division, Southampton University
School of Medicine, 2Dept. of Surgery, Basingstoke Hospital, RG24 9NA,
3Dept. of Surgery, Royal Liverpool Hospital, L7 8XP, UK 
Hepatic resection for colorectal metastases is increasingly being undertaken, although
the efficacy has never been evaluated in a randomised controlled trial. Case series
demonstrate 5 year survival up to 40% following curative resection, whereas 5 year
survival in unresected patients is rare. However, patients undergoing resection may be
a highly selected group with a better prognosis. Aim: to determine morbidity and
survival following liver resection for colorectal metastases and to identify potential
prognostic factors. Methods: A systematic review of published and unpublished
studies was conducted. Studies were identified by computerised searches of databases
and specialist registers, handsearching, scanning references and contacting investiga-
tors. Eligibility and quality of studies were assessed independently by 2 reviewers and
data were extracted using a standard form. To be eligible for inclusion studies must
have included at least 100 patients and had a median follow up of 24 months for
surviving patients. Investigators were contacted where information was insufficient to
determine eligibility. Preliminary results: of 517 identified publications, 48 (including
multiple publications of the same study) met inclusion criteria, providing 28 eligible
studies. Most common reasons for exclusion: 409 (79%) reported less than 100
patients, 379 (66%) had a follow-up of less than 24 months median or not reported.
Six eligible (21%) studies were multicentre, 20 (71%) were single centre and 2 (7%)
were from two centres. Seven (25%) studies were prospective, 19 (68%) were retro-
spective and 2 were unclear. The quality of studies varied. Eligibility criteria for
surgery or inclusion in the study were not reported by 8 (29%) studies, and principal
confounders (e.g. synchronous metastases, curative intent) were not reported by 7
(25%) studies. Primary end points such as postoperative mortality and survival were
not clearly defined in 12 (43%) and 22 (79%) studies respectively. Operative mortality
was excluded from survival analysis in 6 (21%) studies. Surgery was the only inter-
vention received by a defined group of patients in just 5 (18%). In 12 (43%) studies
additional therapies were received by all patients or by a subgroup who were not
analysed separately, and use of additional therapies was not reported in 11 (39%)
studies. Overall 5 year survival ranged from 25% to 58% although patient characteris-
tics varied enormously. Conclusions: Although the many published studies, in
general. suggest a substantial benefit from surgical resection, the identification of
patients most likely to benefit is limited due to methodological weaknesses and incon-
sistencies between studies. Further summary information on the outcomes from these
studies and potential prognostic factors will be presented. Poster presentations 45
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CULTURED PURIFIED NORMAL BREAST EPITHELIAL CELLS
RAPIDLY LOSE OESTROGEN RECEPTOR ALPHA (ER)
EXPRESSION, WHEREAS PURIFIED MALIGNANT BREAST CELLS
STABLY MAINTAIN THEIR ER STATUS MS Kothari, M Slade*, S Ali*, 
HD Sinnett*, S Shousha*, N Livni*, L Buluwela*, R Vashisht+, P Thorpe+, 
RC Coombes*, *Imperial College School of Medicine and +West Middlesex
Hospital, London, UK 
The aim of this study was to purify malignant cells from primary breast cancers, char-
acterise and culture them for a time length sufficient to be able to perform functional
studies on them. Fresh pathological discard tissue was enzymatically digested and
after appropriate filtration malignant epithelial cells were isolated using Ber-Ep4
immunolabelled beads (Dynal). Cells were maintained in short-term culture and char-
acterised by cytology, fluorescent in situ hybridisation (FISH) (using centromere
specific DNA probes to chromosomes 6,7,11,12,17 and 18) and immunostaining for
oestrogen receptor alpha (ERa), progesterone receptor (PR) and cytokeratins 8 and
18. Normal epithelial cells were purified from reduction mammoplasty tissue
and cultured and immunostaining done using the above markers. In addition these and
MCF-7 cells served as controls. Cytological examination confirmed >95% purity of
malignant cells in all 15 tumor samples stained for Haematoxylin and Eosin. A high
rate (>90%) of aneusomy was observed by FISH on cells from all 6 tumours studied.
These were also confirmed to be pure epithelial cultures using cytokeratin staining. In
all 10 tumor samples studied for ER and PR it was found that these were retained
in malignant cultures for the entire time length studied (7–14 days) but completely lost
within 24 hrs (ER) to 60 hrs (PR) in the 6 benign cultures studied. Furthermore puri-
fied normal breast cells proliferate in culture, whereas malignant cells do not,
although they can be maintained in culture for 3–4 weeks. We conclude that (a) it is
possible to purify and maintain breast cancer cells for a sufficient period to permit
functional studies and (b) ER is retained enabling us to use these cells for studies of
endocrine resistance in vitro. 
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ATTENUATED OESTROGEN RECEPTOR ALPHA EXPRESSION
FOLLOWING PURIFICATION OF NORMAL MAMMARY
EPITHELIAL CELLS CAN BE RESTORED BY ADENOVIRUS MEDIATED
GENE TRANSDUCTION MS Kothari, RS Tolhurst, H Yahaya, 
MJ Slade, S Shousha, S Ali, L Buluwela, RC Coombes, Cancer Cell Biology
Section, Division of Medicine, Imperial College School of Medicine, London,
UK 
Over half of all breast cancers overexpress oestrogen receptor alpha (ERa) and
around 70% of these respond to anti-oestrogen therapy, clearly demonstrating the
importance of oestrogen receptor in breast cancer. However, there is little data
regarding the importance of ERa overexpression in breast cancer initiation. In this
regard, there has been little success in the production of cultured luminal epithelial
cells that express steroid receptors and respond to ovarian steroids. In the present
study we have evaluated the expression of ERa in normal human mammary epithelial
cells seeded in culture following immunomagnetic purification. To do this, luminal
epithelial cells were isolated from normal reduction mammoplasty tissue using Ber-
Ep4 immunolabelled beads (Dynal) and seeded in culture. Cytokeratin 8 and 18
immunostaining confirmed that these preparations were of a very high purity (>97%).
Further, immunostaining analysis showed that ERa expression was restricted to
between 15–30% of the cells immediately following purification. However, on subse-
quent culturing, we found that ERa expression was rapidly attenuated, resulting in
loss of expression within the first 24–36 hours. There is a similar reduction in proges-
terone receptor expression, although very low levels can be detected for up to 60 hrs
following culture. RT PCR experiments have further confirmed these findings.
Together our results suggest that endogenous ERa expression is unstable in normal
primary luminal cells in culture. However, in further experiments, we have gone on to
show that purified primary luminal epithelial cells can be efficiently transduced with a
recombinant adenovirus encoding the human oestrogen receptor. By doing this, we
have found that it is possible to maintain ERa expression in luminal epithelial cells
for the lifetime of primary cultures, thereby facilitating further studies to address the
consequence of ERa overexpression in normal human mammary epithelial cells. 
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DIFFERENTIAL PROTEIN TYROSINE PHOSPHATASE
EXPRESSION IN BREAST CANCER, M Rafferty, L McArdle, 
P Dervan, D Easty, Pathology Department, University College Dublin,
Belfield Dublin 4, Ireland 
In breast cancer, proliferation and differentiation is governed by protein phosphoryla-
tion. Tyrosine phosphorylation is particularly important and is regulated by the
opposing actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases
(PTPs). Many PTKs encode oncogenes involved in initiation and progression of
breast cancer. PTPs may act as tumour suppressor genes by antagonizing the effects of
PTK. Alternatively they may augment the oncogenic effect by repriming substrates
for PTKs. 
In this study, PTP expression in mammary epithelial cells (HMEC) was compared
to that in malignant breast cell lines. Degenerate RT-PCR was carried out and resultant
products were cloned and sequenced. 107 and 108 clones were isolated from ZR75-1
and from HMEC respectively. Seventeen PTPs were isolated and used as probes for
northern blotting. Northern blot analysis showed a down regulation of four genes,
PTP-KAPPA, PTP-EPSILON, PTP-GAMMA and PTP-BAS, in malignant cell lines
compared to HMEC. PTP-PEST, TC-PTP, PTP-1B, PTP-ALPHA, LAR and DEP-1
were up-regulated in cell lines. Further analysis for PTP-BAS at the protein level is
currently being carried out using western blotting and immunohistochemistry tech-
niques. 
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AKT2 IS DIFFERENTIALLY REGULATED IN HUMAN BREAST
CANCER CELL LINES KM Nicholson, CH Streuli, NG Anderson,
School of Medicine, University of Manchester, Oxford Road, Manchester,
M13 9PT, UK 
Akt (protein kinase B) is a family of serine/threonine kinases consisting of three
isoforms (Akt1/PKBa, Akt2/PKBb and Akt3/PKBg) with an important role in
protecting cells from the induction of apoptosis by various stresses such as growth
factor depletion and detachment of cells from their growth matrix. Activation of Akt
in response to hormonal or growth factor stimulation is via the lipid products of phos-
phatidylinositol-3-kinase. Once activated Akt can phosphorylate and negatively regu-
late various pro-apoptotic targets within the cell such as BAD and members of the
forkhead family of transcription factors including FKHR, FKHRL1 and AFX.
Consistent with the role of Akt in cell growth and survival, Akt is known to be over-
expressed and/or amplified in various human cancers (Akt1 in gastric, Akt2 in ovarian
and pancreatic, Akt3 in breast). To date there is little information regarding the role of
the individual isoforms in the processes involved in tumorigenesis, therefore this
study aimed to determine the expression, activation and regulation of the individual
isoforms of Akt in breast cancer. Nine breast cell lines were used in this study – 2
normal (MTSV1-7 and MCF10F), 2 estrogen receptor (ER) positive cancer cell lines
(T47D and MCF7) and 5 ER negative cancer cell lines (MDAMB231, SKBR3,
BT474, HS578T and CAL51). The expression and activity of each isoform was
assessed using isoform-and phospho-specific antibodies. In addition, the expression
of PTEN, a negative regulator of Akt often deleted or mutated in human cancers
resulting in a high constitutive activation of Akt, and the expression and phosphoryla-
tion of FKHR, a downstream target of Akt were determined. Results showed that Akt1
activation in the presence of serum (steady-state) was similar across the cell line
panel. Akt3 was active in only one breast cancer cell line (HS578T) at steady state.
More interestingly, Akt2 activation at steady state was increased in 6/7 breast cancer
cell lines relative to the normal breast cell lines (range 9–23 fold). Phosphorylation of
FKHR did not correlate with Akt activation in these cell lines. Loss of PTEN expres-
sion correlated with a high level of Akt activation but not with phosphorylation of
FKHR. Cell lines with all three isoforms activated at steady state were chosen to
investigate the effects of EGF, IGF-I or heregulin a on the activation of each isoform
of Akt. In each cell line Akt2 was activated to a greater extent than either Akt1 or
Akt3 following growth factor stimulation, indicating a differential regulation of Akt2. 
Collectively these results suggest an involvement of Akt2 in breast cancer growth
and survival. Overexpression studies are ongoing to further elucidate the involvement
of Akt2 in tumorigenesis. 
This work was funded by the Breast Cancer Campaign, registered charity no
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SERUM OESTROGEN MODULATES THE IN VIVO LEVEL OF
P53 EXPRESSION IN BREAST CANCER XENOGRAFTS 
D Ziyaie1, D Dornan2, TR Hupp2, NM Kernohan2, AM Thompson1, 1Dept. of
Surgery, Molecular Oncology, 2Dept. of Molecular, Cellular Pathology,
Ninewells Hospital, Dundee DD1 9SY, UK 
Background Breast cancers, unlike most other epithelial malignancies often acquire
abnormalities in p53 protein activity rather than p53 gene mutations. It is therefore
postulated that these functional abnormalities in p53 activation may be influenced
by specific cellular/environmental changes rather than genetic mutations. In breast
cancer, activation of oestrogen receptor proteins is one of the most important regula-
tory events involved in the pathogenesis of these tumours. Although functional links
between p53 and an individual’s serum hormone levels have been explored previ-
ously the results have been inconclusive and a consistent relationship between p53
protein expression and circulating serum oestrogen hormone levels has not been
defined. 
Methods We have investigated p53 expression in response to serum oestrogen
concentrations along with its two key gene products p21 WAF1 and MDM-2 which
are known to be transcriptionally induced by p53 in a xenograft model established
from an MCF-7 breast cancer cell line. Protein expression in relation to the varying
oestrogen serum concentrations was determined by western blot analysis and further
confirmed on histological sections using highly sensitive human specific p53 mono-
clonal antibodies. 
Results Though immediately prior to the injection of oestrogen, the p53 protein
levels exhibited strong immuno-reactivity, within hours following the injection,
protein levels were sharply reduced and continued to be repressed in the presence of
high serum oestrogen concentration. Following the natural reduction in hormone
levels however, p53 protein levels rose coincident with the lowering levels of the
serum oestrogen prior to a repeat bolus injection. Similar trends were observed with
p21WAF1 whose expression also correlated inversely with serum oestrogen concen-
trations. However another key effector, MDM2 protein, did not change significantly
under the same conditions highlighting the striking specificity that hormone levels
have on the p53-p21WAF1 axis. 
Discussion An inverse relationship between p53 protein and p21WAF1 protein
expression compared with serum oestrogen concentration highlights a potential link
between hormone level and the regulation of p53 activity rather than p53 degradation
since MDM-2 protein levels remain constant under conditions where p53 protein and
p21WAF1 levels respond to hormone changes. MDM2 protein levels are often uncou-
pled from p53 activity, and the fact that MDM2 protein levels are unperturbed during
these hormone fluctuations provided, with hindsight, an excellent internal control for
hormone specificity. 
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Conclusion A functional correlation between oestrogen and p53 protein levels
introduces novel practical implications in terms of the timing of drug delivery partic-
ularly in pre-menopausal women where the anti-cancer treatments are directed
towards inducing cell death or apoptosis, which is one of the key properties that
defines p53 as a tumour suppressor gene. 
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BIOCHEMICAL AND MOLECULAR MECHANISMS OF GROWTH
INHIBITION IN HUMAN BREAST CANCER CELLS BY
SULFAMOYLATED ESTRONE DERIVATIVES L Wood,1 LW Woo2, 
A Purohit2, BVL Potter2, MJ Reed3, G Packham1, 1CRC Wessex Medical
Oncology Unit, Cancer Sciences Division, University of Southampton, SO16
6YD, 2Wolfson Laboratory of Medicinal Chemistry and Sterix Ltd, University
of Bath, BA2 7AY, 3Endocrinology and Metabolic Medicine and Sterix Ltd,
Imperial College, London W2 1NY, UK 
We have previously shown that the sulfamoylated estrone derivatives, 
2-Methoxyestrone-3-O-Sulfamate (2-MeOEMATE) and 2-Ethylestrone-3-O-
Sulfamate (2-EtEMATE), potently inhibited cell growth, caused mitotic arrest and
induced apoptosis in a panel of estrogen receptor positive and negative breast cancer
cell lines (MacCarthy-Morrogh et al., 2000, Cancer Res 60:5441). The sulfamoylated
estrone derivatives inhibited tubulin polymerisation in vitro, and induced BCL-2
phosphorylation and p53 expression in intact cells. The sulfamoylated compounds
were significantly more active in all of these assays relative to their parental
compounds or the endogenous estradiol metabolite 2-Methoxyestradiol (2-MeOE2).
The aim of our present study is to discover the molecular basis for this enhanced
activity. 
We have used competitive binding assays to further investigate the interactions of
the compounds with the colchicine binding site of tubulin. Although 2-MeOEMATE
and 2-EtEMATE inhibited the ability of paclitaxel to induce in vitro polymerisation of
tubulin more potently than 2-MeOE2, 2-MeOEMATE and 2-EtEMATE bind directly
to the colchicine binding site with similar affinities to that of 2-MeOE2. This suggests
that the sulfamoylated compounds may interact at multiple sites on the tubulin mole-
cule, or that their interaction with the colchine binding site results in more potent
effects on tubulin dynamics. Although, 2-MeOE2 has recently been shown to inhibit
superoxide dismutase (SOD) activity, it is not known whether this activity is also
enhanced by sulfamoylation and might contribute to the enhanced biological actions
of 2-MeOEMATE and 2-EtEMATE. We have determined the effects of a series of
estrone and estradiol derivatives on SOD activity. Most importantly, sulfamoylation
completely destroys SOD inhibitory activity. Therefore, the enhanced activity of the
sulfamoylated compounds correlates with increased tubulin polymerisation inhibitory
actions (but not higher affinity binding) rather than increased SOD inhibitory activity. 
Finally, we have shown that 2-MeOEMATE and 2-EtEMATE upregulate expres-
sion of the DR5 (TRAIL Receptor 2) death receptor in CAL51 breast cancer cells, and
sensitised these cells to TRAIL induced apoptosis. Upregulation of DR5 by 
2-MeOEMATE and 2-EtEMATE and their co-operation with TRAIL to induce apop-
tosis in breast cancer cells may have important implications for anti-cancer therapies.
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CYP24 ACTION IN BREAST CANCER CELLS AE Miles, 
JS Moore, FL Ng*, KW Colston*, MJ Campbell, Division of Medical
Sciences, University of Birmingham, B15 2TH, *St. Georges Hospital Medical
School, London 
Breast cancer cell lines display a wide range of sensitivities to the induction of growth
arrest by 1a,25dihydroxyvitamin D3 (1a,25(OH)2D3) despite comparable expression
of the vitamin D receptor (VDR). 1a,25(OH)2D3 induces its own metabolism by
induction of CYP24, (25(OH)D3-24-hydroxylase), which generates sequentially
1a,24,25(OH)3D3, 1a,25(OH)2-24-oxo-D3, 1a,23,25(OH)3-24-oxo-D3 and ultimately
calcitroic acid. This gene has recently been described as a putative oncogene in breast
cancer although the mechanism remains unclear. 
Using an in-house antibody to CYP24 we have examined expression levels in a
panel of breast cancer cell lines (MCF-7, ZR-75-1, T47-D, MDA-MB-231). In all
these cell lines we have found higher protein expression in exponentially proliferating
than confluent cells, correlating with elevated cyclin E and increased numbers of cells
in S and G2M phases of the cell cycle. Screening of proliferative responses to each
CYP24 metabolite in soft agar and liquid culture revealed that in both the estrogen
responsive MCF-7 and estrogen insensitive MDA-MB-231 cells the 1a,24,25(OH)3D3
metabolite demonstrated significantly reduced antiproliferative effects compared to
1a,25(OH)2D3 and 1a,25(OH)2-24-oxo-D3, and, in the case of MDA-MB-231, signif-
icant growth stimulation at physiological doses (10-10 M, (P< 0.01) ). 1a,25(OH)2-
24-oxo-D3 and 1a,23,25(OH)3-24-oxo-D3 were potent inducers of apoptosis and
differentiation of MCF-7 cells but were ineffective in MDA-MB-231 cells. 
We have also screened cell lines and primary breast tumour material to test for
CYP24 amplification. Using a PCR-based analysis we have found CYP24 gene
amplification in MCF-7 and ZR-75-1 cell lines and 1 out of 24 primary samples. 
These studies indicate that breast cancer cells express CYP24 and that highest
basal expression is associated with exponential proliferation. CYP24 metabolism
modulates the antiproliferative effects of 1a,25(OH)2D3 by giving rise to ligands with
divergent biological effects; we hypothesise that the balance of these actions normally
integrates proliferation and differentiation. Malignant transformation may involve
suppression of the antiproliferative and pro-apoptotic signals of 1a,25(OH)2D3 and its
metabolites thereby deriving a clonal advantage. Poster presentations 47
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INHIBITORY EFFECTS OF BISPHOSPHONATES ON GROWTH
OF BREAST AND LUNG CARCINOMA CELLS CD Macdonald,
SG Jayasundara, JL Mansi, KW Colston, Department of OGEM St George’s
Hospital Medical School, London SW17 0RE, UK 
Breast and lung cancer commonly metastasize to bone, causing pain and impaired
mobility in addition to hypercalcaemia. Bisphosphonates (BP) are a group of drugs
which are commonly used in the treatment of certain bone diseases due to their
inhibitory effects on osteoclasts. 
In patients with advanced breast cancer and bone metastases, BPs have been used
to reduce the incidence of hypercalcaemia and skeletal morbidity. As yet few studies
have addressed their effectiveness in lung cancer patients. We are studying the
problem in a new way to determine if BPs may have direct effects on breast and lung
cancer cells. This study investigated the in vitro effects of the BPs, zoledronic acid,
pamidronate and clodronate on the growth, viability and induction of apoptosis in
three lung cancer cell lines: NCI H292 (mucoepithelial) NCI H69 and NCI H510
(small cell carcinomas). Cells were cultured in multiwell plates for up to 3 days in the
presence or absence of BPs (0–2000 mM). Results were compared with MDA-MB231
breast cancer cells. 
Cell growth was monitored by Crystal Violet dye assay and Sulphorhodamine B,
while cell viability was quantitated by MTS dye reduction. Changes in apoptosis
related protein were determined by assessing bcl-2/bax ratio and cleavage of pro-
caspase-3 into 17 kD & 11 kD fragments by immuno blotting. All three BPs induced
inhibition of growth and viability in MDA-MB-231 breast cancer cells. This was
accompanied by a decrease in bcl-2/bax ratio and pro-caspase-3 cleavage. BPs also
reduced cell number in the 3 lung cancer cell lines by day 3 of treatment. NCI H292
cells were the most sensitive, displaying a significant dose related inhibition of cell
growth and viability. A Time related decrease in bcl-2/bax ratio was seen in zole-
dronic acid treated NCI H292 cells. In contrast NCI H510 and NCI H69 both showed
an increase in bcl-2/bax ratio suggesting that reduction in cell number may be due to
inhibition of cell growth but not apoptosis. Taken together our results suggest that BPs
have direct inhibitory effects on both lung and breast carcinoma cells in vitro. Both
NCI H69 and NCI H510 cells grow as suspension cultures while NCI H292 cells 
are adherent. An integrin dependent pathway may be associated with BP induced
apoptosis. 
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ZOLEDRONIC ACID AND PACLITAXEL HAVE SYNERGISTIC
EFFECTS ON BREAST CANCER CELL APOPTOSIS IN VITRO
EVIDENCE FROM ISOBOLGRAM AND GRAFIT SOFTWARE ANALYSIS. 
S Jagdev1, P Croucher2, A Rostami-H2, R Coleman1, 1YCR Dept of Clinical
Oncology, 2Human Metabolism and Clinical. Biochemistry, University of
Sheffield, UK 
Bisphosphonates are becoming increasingly important in the management of bone
metastases from breast cancer. Recent clinical data suggest that the adjuvant use of
bisphosphonates alongside anti-neoplastic agents may influence the development of
extra-skeletal as well as skeletal metastases and confer a survival benefit. These
observations raise the intriguing possibility that bisphosphonates may act in synergy
with anti-neoplastic therapy. We have previously shown that the potent third genera-
tion bisphosphonate zoledronic acid reduces breast cancer cell number and induces
apoptosis after long-and short-term exposure in vitro. The aim of this study was to
investigate the effects of combining zoledronic acid with paclitaxel on MCF-7 cell
number and apoptosis. 
MCF-7 cells were treated with increasing concentrations of zoledronic acid
(0.01–100 mM) alone and in combination with increasing concentrations of
paclitaxel (0.01–10 nM). Cell number was determined and the proportion of apoptotic
cells assessed by analysis of nuclear morphology. Dose response curves were plotted
for the effect of each combination of drugs on cell number and apoptosis. These were
used construct isobolgrams that revealed evidence of synergistic effects on MCF-7
cell number and apoptosis when zoledronic acid and paclitaxel were combined.
However, quantifying the magnitude and assessing statistical significance of syner-
gism required more rigorous non-linear 3D analysis. The latter was carried out by
fitting user-defined models of synergism to data using the GraFit software (Ver 3). 
The general interaction model (Greco WR et al., 1995) contained a non-additivity
term, a, and sigmoidicity function for curve shape, g. If a = 0 then an additive effect
could be assumed; higher values indicated synergy. Using the GraFit software, the
calculated a and g for the combined effects of zoledronic acid and paclitaxel on cell
numbers were 3.31 (±2.33) and 0.90 (±0.13), respectively. 
These data suggest that, when combined, zoledronic acid and paclitaxel have
synergistic effects on breast cancer cells in vitro. The mechanisms require further in
vitro and in vivo study. 
1. Greco WR, Bravo G and Parsons J (1995). The search for synergy: A critical
review from a response surface perspective. Pharmacol Rev 47: 331–385 
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EFFECT OF NITRIC OXIDE ON MMP-9 SECRETION IN MCF-7
ADR AND MDA-MB 231 HUMAN BREAST CANCER CELL LINES
M Lahiri, A Martin, J Martin, School of Health Sciences, University of
Wolverhampton, Wolverhampton WV1 1DJ, UK 
The aim of the present study was to detect whether endogenously and/or exogenously
produced nitric oxide (NO) had an effect on MMP-9 secretion in MCF-7, MCF-7
ADR, T47D and MDA-MB 231 human breast cancer cell lines. 
Gelatin zymography analysis was used to detect MMP-9 secretion from the cell
lines. MMP-9 secretion was detected in MCF-7 ADR and MDA-MB 231 cells but not
in MCF-7 and T47D cell lines under quiescent conditions. The addition of TNF-a or
exogenous NO via the NO donor, sodium nitroprusside (SNP) increased MMP-9
secretion in both MCF-7 ADR and MDA-MB 231 cells. 
TNF-a treatment of MCF-7, MCF-7 ADR, T47D and MDA-MB 231 cell lines
caused an increase in NO production. A decrease in NO production was observed
upon the addition of either a general nitric oxide synthase (NOS) inhibitor 
(L-NAME), an inducible NOS (iNOS) specific inhibitor (AMT) or an endothelial
NOS (eNOS) specific inhibitor (L-NIO). However, these inhibitors had no effect on
TNF-a stimulated MMP-9 secretion in MCF-7 ADR and MDA-MB 231 cell lines. 
In conclusion, our results indicated that the addition of an exogenous NO donor
increased MMP-9 secretion but endogenously produced NO, following TNF-a treat-
ment, had no effect on MMP-9 secretion. 
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ANTI-PROLIFERATIVE EFFECTS OF THE EGF RECEPTOR
TYROSINE KINASE INHIBITOR ZD1839 IN MDA-MB231
BREAST CANCER CELLS T Ahmad, KC Chan, NJ Bundred, NG Anderson
School of Medicine, University of Manchester, Oxford Road, Manchester 
M13 9PT 
Overexpression of the EGF receptor (EGFR) occurs frequently in a number of human
cancers and correlates with aggressive tumour behaviour and poor patient prognosis.
We studied the effects of a novel orally active EGF receptor tyrosine kinase inhibitor,
ZD1839 (IressaTM), on the proliferation and signalling in the EGFR overexpressing
MDA-MB231 breast cancer cell line. 
ZD1839 dose-dependently inhibited the proliferation of MDA-MB231 cells
cultured in serum-containing medium. Proliferation was inhibited by 59±2% at 1 mM
ZD1839. The proliferation of MDA-MB231 cells in serum-free medium is maintained
by autocrine growth factors secreted as a result of a mutant active K-Ras in these cells.
ZD1839 (1 mM) inhibited the proliferation of MDA-MB231 cells in serum free
medium by 32±7%. 
ZD1839 dose dependently inhibited EGF-induced EGFR tyrosine phosphorylation
in MDA-MB231 cells with an estimated IC50 of 2 nM. Similarly, ZD1839 inhibited
EGF-induced activation of protein kinase B (PKB)/Akt and ERK MAP kinases.
However ZD1839 treatment did not reduce the constitutive high basal level of ERK
activation due to the presence of mutant K-Ras suggesting that ERK inhibition is not
essential for the anti-proliferative effects of ZD1839. The importance of the ERK
pathway in mediating proliferation in MDA-MB231 cells was tested using PD098059,
an inhibitor of MEK activation. Treatment of cells with PD98059 (100 mM)
completely blocked ERK activation and inhibited proliferation by ≈ 93%. At doses of
PD098059 that led to an inhibition of proliferation similar to that achieved by 1 mM
ZD1839 (59%) there was a significant reduction in the level of activated ERK.
Together, these results confirm that the ERK pathway is required for the maximal
proliferation of MDA-MB231 cells. However ERK inhibition is not necessary for
ZD1839-induced inhibition of proliferation, suggesting that EGFR utilises ERK-inde-
pendent pathways to promote proliferation in these cells. 
We investigated the role of the phosphoinositide 3-kinase (PI3-K) pathway in the
proliferation of MDA-MB231 cells. LY294002 (50 mM), an inhibitor of PI3-K inhib-
ited prolferation by 17%, a result which rules out any major contribution to prolifera-
tion by the PI3-K signalling pathway in this cell line. We are currently investigating
the roles of other signalling pathways in the proliferation of MDA-MB231 cells. 
In conclusion ZD1839 potently inhibits both serum-induced and autocrine regu-
lated proliferation in EGFR overexpressing MDA-MB231 cells via mechanisms that
do not involve reduced activation of ERK MAP kinases. 48 Poster presentations
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ANGIOGENESIS IN DUCTAL CARCINOMA IN SITU OF THE
BREAST IS ASSOCIATED WITH THE DEVELOPMENT OF 
AN INVASIVE RECURRENCE NB Teo1,2, BS Shoker1, MC Jarvis1, 
C Holcombe2, L Martin2, JP Sloane1, UK, 1Pathology Department, University
of Liverpool, 2Breast Unit, Royal University Hospital, Liverpool L7 8XP, UK 
Background Up to 50% of recurrences of ductal carcinoma in situ (DCIS) of the
breast are associated with invasive carcinoma but to date no pathological or molecular
features have been found to predict for the development of invasive disease. For a
tumour to invade, it requires the formation of new blood vessels. Previous studies
have described a vascular rim around ducts involved by DCIS raising the possibility
that the characteristics of periductal vascularisation may be important in determining
transformation from in situ to invasive disease. 
Methods  Periductal vascular density and phenotype were determined using
morphometry and a panel of anti-endothelial antibodies (von Willebrand factor
[vWF], CD31, CD141 and CD34) and related to a) the presence of invasive carcinoma
b) other histological features and c) the risk of either invasive or in situ recurrence. For
each section, the entire number of stained vessels within 100 micrometer of foci of
DCIS were counted. Up to 50 foci of DCIS on a single slide were scored and the
microvessel density (MVD) was calculated for each focus. Normal lobules at least 2
mm away were used as controls. 
Results Pure DCIS in comparison to normal lobules exhibited a greater density of
CD34+ vessels (P = 0.004) but a decrease in those immunopositive for vWF 
(P = 0.001), indicating a change in phenotype as well as density. DCIS associated
with invasive carcinoma showed a profile similar to that of pure DCIS but with statis-
tically significantly greater numbers of CD34+ (P = 0.003) vessels and fewer staining
for vWF (P = 0.030). There was a significant negative correlation between vascular
density and both the ductal cross-sectional areas (highest P<0.001 except CD31 with
P = 0.300) and the extent of the necrosis (highest P = 0.002). A correlation between
vascular density and nuclear grade was also noted, being highest in the intermediate
grade. In addition when cases of DCIS that subsequently recurred were compared
with those that did not, the former cases of DCIS had a higher CD34 MVD (P<0.001).
Furthermore the highest MVD was seen in cases of DCIS that subsequently developed
invasive cancer. 
Conclusions  Blood vessels surrounding DCIS appear to have a different
immunophenotype when compared with blood vessels surrounding normal breast
lobules. Furthermore increases in vascular density, as detected with the CD34 anti-
body, correlates with recurrence and the development of invasive carcinoma. 
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PERIDUCTAL AND STROMAL ANGIOGENESIS IN DUCTAL
CARCINOMA IN SITU (DCIS): ITS RELATIONSHIP TO
RECURRENCE AND THYMIDINE PHOSPHORYLASE EXPRESSION 
NB Teo1,2*, BS Shoker1, CM Jarvis1, C Holcombe2, JP Sloane1,1Pathology
Department, University of Liverpool, 2Breast Unit, Royal University Hospital,
Liverpool L7 8XP, UK 
Background Angiogenesis is though to be important in invasive cancer and may also
have a role in preinvasive disease. We have previously shown that periductal angio-
genesis in DCIS is associated with an increased risk of subsequently developing a
recurrence. The aims of the present study were a) to identify the relationship between
periductal and stromal vascularity and its association with recurrence and b) to deter-
mine whether thymidine phosphorylase (TP) is associated with angiogenesis or recur-
rence in DCIS. 
Methods Cases of DCIS which did not subsequently recur (n = 20), which devel-
oped a subsequent in situ recurrence (n = 20) and which developed a subsequent inva-
sive recurrence (n = 12) were investigated. Periductal and stromal (hotspot)
microvessel density (MVD) was determined quantitatively using CD34 and vWF anti-
bodies. TP expression by DCIS was semiquantitatively assessed using the H-score
method. 
Results Using vWF the stromal and periductal MVD showed a strong positive
correlation (P < 0.001) with both methods giving similar mean values. In contrast,
when angiogenesis was assessed with CD34 this relationship was lost. Not only were
the mean values for both stromal and periductal MVD higher than those obtained with
vWF, but also the periductal MVD was significantly greater than the stromal MVD
(highest P = 0.037). Furthermore, a relationship between recurrence and stromal
MVD was not seen. For TP, although relationships were seen between the H-score
and MVD, a relationship with recurrence was not identified. 
Conclusions Periductal MVD appears to be more important than stromal MVD in
predicting for recurrence after DCIS. However, recurrent disease does not appear to
be related to TP expression by DCIS. Periductal vascularity as assessed by CD34 is a
better predictor of recurrence than stromal assessment. 
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ASSESSMENT OF MICROREGIONAL BLOOD FLOW IN HUMAN
BREAST CARCINOMAS AFTER ADMINISTRATION OF
ANTHRACYCLINE CHEMOTHERAPY K Goodchild1, SA Hill2, A Sibtain1, 
DJ Chaplin2, A Makris1, 1Marie Curie Research Wing, Mount Vernon Hospital,
Northwood, HA6 2RN, UK, 2Gray Laboratory Research Trust, Mount Vernon
Hospital, Northwood, HA6 2RN, UK 
Introduction Anthracyclines are effective anti cancer agents in the treatment of breast
cancer. Delivery of systemic therapy requires an adequate blood supply. After admin-
istration of doxorubicin, mice bearing human tumour cell lines consistently show a
sustained reduction in microregional blood flow for up to 60 minutes. Similar results
in human tumours might compromise the delivery of multi-agent drug regimens. The
use of neoadjuvant chemotherapy provides a useful in vivo model for studying the
effects of anthracyclines on microregional blood flow in primary breast carcinoma. 
Aim To investigate the effect of anthracycline administration on microregional
human tumour blood flow using laser Doppler flowmetry. 
Methods Microregional blood flow was measured in 24 consecutive females
receiving primary medical therapy for biopsy proven invasive breast cancer. TNM
staging T2–4, N0-1, M0. Age range 33–78 years. Fifteen patients received FEC 
(5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2)
and eight patients MM (methotrexate 35 mg/m2 and mitoxantrone 11 mg/m2). Up to
6 laser Doppler probes were inserted into the primary tumour. Blood flow was
recorded for 10 minutes pre and up to 60 minutes post epirubicin or mitoxantrone
administration prior to the administration of other drugs. 
Results Results are available from 23 patients. Overall no change in tumour
microregional perfusion was seen after anthracycline administration. However
marked intra – and inter-tumour heterogeneity in blood flow was noted. 
Conclusions Microregional perfusion has been measured in the context of primary
medical therapy for breast cancer. Anthracyclines do not appear to reduce human
tumour blood flow and should not therefore compromise the delivery of multi-agent
systemic therapy. 
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PPROGNOSTIC VALUE OF ESTROGEN-PROGESTRONE
RECEPTORS (ER, PR), EGFR and HER-2 IN BREAST CANCER,
A Ghaderi1, B Gharesi-Fard1, A Talei1, M Vasei1, H Modjtahedi2, 
Dept. Immunology, Pathology and Surgery, Shiraz University of Med.
Sciences. Shiraz-Iran, 2Cancer Study Group, University of Surrey, 
Guildford GU2 7XH UK 
Overexpression of the members of the type-I growth factor receptor family, in partic-
ular EGFR and HER-2/neu, has been reported in a number of epithelial malignancies
and this in turn has been associated with a poor prognosis in many such patients. The
anti-HER-2 monoclonal antibody trastuzumab (Herceptin®) has recently been
approved for the treatment of HER-2 overexpressing metastatic breast cancer. 
In the present study, the prognostic significance of estrogen receptor (ER), proges-
terone receptor (PR), and two members of the epidermal growth factor receptor
(EGFR) family namely, EGFR (c-erbB-1) and HER-2/neu (c-erbB-2), were investi-
gated in a series of breast tumor by comparing with the pathological data and
Nottingham index. Indirect Immunoperoxidase method was used for determination of
these receptors on formalin fixed paraffin-embedded sections of 112 breast carcinoma
tissues from Iranian patients in Shiraz. 
Results indicated that 51 (45.5%), 25 (22.3%), 51 (45.5%), 55 (49.1%), of tumors
showed positive immunoreactivity with anti EGFR, HER-2, ER, or PR monoclonal
antibodies respectively. Strong correlation between HER-2 staining and size 
(P <0.002), histological grade (P < 0.02) and Nottingham index of tumors (P < 0.007)
was observed but no significance association was found with the EGFR. In cases of
ER, PR, strong relationship between lack of expression of these two receptors and size
(P < 0.008, P < 0.04), histological grade (P < 0.0005, P < 0.008) and Nottingham
index of tumors (P < 0.04, P < 0.05) was observed. 
Strong correlation between HER-2 staining and negative staining for ER 
(P < 0.03), suggested that there is a reverse correlation between HER-2 and ER ex-
pression in patients with breast cancer in Iran. Poster presentations 49
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HEAT SHOCK PROTEIN 27 PREDICTS SURVIVAL IN EARLY
BREAST CANCER Penny O’Neill1, Abeer Shabaan2, Andrew
Dodson2, Christopher S Foster2, 1Clatterbridge Centre for Oncology,
Bebington, Wirral, CH 63 4JY, 2Dept. Of Pathology, University of Liverpool,
Merseyside, L69 3GA, UK 
Heat shock proteins (hsps) occupy a central role in the regulation of intracellular
homeostasis and have been shown to correlate with aggressive biological behaviour in
prostate cancer. In previous studies hsp27 has shown conflicting associations with
outcome in breast cancer. 
Eighty-seven cases of primary invasive breast cancer diagnosed 1993/94 were
retrieved from the archives of The Royal Liverpool University Hospital along with 
40 cases of normal breast tissue for use as controls. All cases underwent histopatho-
logical review. The majority (80/87) of cases were invasive ductal carcinoma, 5 were
invasive lobular, 1 tubular and 1 medullary. 8% were grade 1, 46% grade 2 and 46%
grade 3. Chemotherapy was given to 19% cases and 56% received adjuvant hormone
treatment. There have been 38 relapses and 27 deaths. Immunohistochemistry for
hsp27 was performed using heat treatment antigen retrieval and a murine monoclonal
antibody (Novocastra Laboratories Ltd). Positive staining was cytoplasmic and quan-
tified by measuring the mean optical density (OD) and mean area of staining for each
case using a morphometric image analysis system. hsp27 mean OD was quantified
using 5 random fields per case. In addition the % of positive stained cells was esti-
mated manually. In normal breast the expression was significantly lower than the
expression in the malignant cases (P < 0.001). In cancers, higher hsp27 expression
was significantly associated with positive ER status (P < 0.001) and ER% (r = 0.44, 
P = 0.01). Those patients who had died showed a significantly lower expression of
hsp27 (P = 0.04). In normal breast the mean OD was 0.34 whereas in cancers it was
0.57. In cancers a higher hsp27 mean OD was significantly associated with hsp 27% 
(r = 0.63, P = 0.01), ER% (r = 0.28, P = 0.01), and positive ER status (P < 0.001).
Those patients still alive had a significantly higher hsp27 mean OD compared with
those who had died (P = 0.004). 
In this cohort of primary breast cancer patients hsp27 expression was associated
with a better outcome. In addition we have shown that quantitative analysis of positive
staining using a morphometric image analysis system is feasible and provides objec-
tive data that are more strongly associated with outcome than manual interpretation. 
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FUNCTIONAL ACTIVITY OF ABC-TRANSPOR-TERS CAN BE
AN ADDITIONAL PROGNOSTIC FACTOR OF HORMONE
THERAPY EFFICACY IN BREAST CANCER PATIENTS E Koldaeva, 
T Bogush, E Bogush, G Tchemeris, N Kushlinsky, E Gerstain, G Smirnova, 
I Shubina, Russian Blokhin Cancer Research Center, Moscow, Russia 
Estrogen receptors (ER) are determinants of sensitivity to antiestrogen hormone
therapy of breast cancer but the treatment is not effective enough in all the patients
(pts) with ER-positive tumor status. We have supposed that among the various reasons
of this situation activity of ABC-transporter(s)’ can be an important one because
antiestrogens can inhibit transporter activity binding to them and thereby decreasing
an active (free) intracellular concentration of antiestrogens bound to ER and as a result
– hormone therapy efficacy. The aim of the study was to evaluate ABC-transporters’
functional activity in ER-positive primary breast cancer. Activity of both P-gp and
other ABC-transporter(s) was assayed in 59 pts by a new methodology described by
us previously using two transporter inhibitors – verapamil (for P-gp) and sodium azide
(for all energy-dependent transporters). RESULTS. 1. No expression of both P-gp and
non-P-gp transporter(s)’ activity was shown in 38% of the ER-positive tumors. We
believe that according to the index investigated these pts can have the best prognosis
in terms of successful anticancer hormone therapy. 2. Expression of ABC-
transporter(s)’ functional activity (both P-gp and non-P-gp or non-P-gp only) was
shown in about 62% of the ER-positive tumors. We believe that these pts (especially
with tumor expression of both P-gp and non-P-gp transporters) can have worse prog-
nosis in terms of successful anticancer’ hormone therapy as compared to those with
no tumor ABC-transporters’ activity. We believe also that influence of expression 
of both types of ABC-transporters’ functional activity (both P-gp and non-P-gp 
transporters) on antiestrogen therapy of breast cancer with low level of ER has to be
the most pronounced. Clinical confirmation of the conclusion is under way. 
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CLINICAL, RADIOLOGICAL AND PATHOLOGICAL
ASSESSMENT OF RESPONSE TO NEOADJUVANT
CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED 
BREAST CANCER A Srivastava1, NK Bosu1, O Coshic1, A Kumar1, 
R Dawar2, S Bandhu3, A Goyal1*, 1Dept. of Surgery, 2Dept of Pathology, 
3Dept of Radiology, All India Institute of Medical Sciences, 
New Delhi-110029, India 
Clinical assessment is inaccurate for assessment of chemotherapeutic response.
Mammography and ultrasonography of the breast may provide useful additional infor-
mation. Histological assessment however remains the gold standard. 
Objectives To evaluate the association between clinical, radiological (mammo-
graphic and ultrasonographic) and pathological response after neo-adjuvant
chemotherapy in patients with locally advanced breast cancer. 
Material and Methods Forty one patients of cytologically/histopathologically
proven locally advanced breast cancer(stageIII) were studied for assessment of
response of neoadjuvant chemotherapy. All patients received three cycles of neoadju-
vant chemotherapy (CAF/CMF) at three weeks interval. Clinical, mammographic,
ultrasonographic examination was done before starting the chemotherapy and 3 weeks
after the 3rd cycle of chemotherapy to assess the response to neoadjuvant
chemotherapy. Twenty five patients were operated 3 weeks after the 3rd cycle of
neoadjuvant chemotherapy. Macroscopic and microscopic pathology review was used
to assess the degree of tumor reduction. Clinical and radiological response was
compared with the gold standard i.e-histological response. 
Results  Clinically 17(41.5%) patients had complete response(CR), 22(53.7%)
patients had partial response(PR) and 2(4.9%) patients had no response(NR) or stable
disease. Diagnostic indices compared to histological finding were-sensitivity = 100%,
specificity = 55%, positive predictive value (PPV) = 35.7%, negative predictive value
(NPV) = 55%, positive predictive value (PPV) = 35.7%, negative predictive
value(NPV) = 100%. Mammographic examination was done for 34 patients(7 were
lost to follow up). Six (17.6%) patients had CR, 25(73.5%) patients had PR and
3(8.8%) patients had NR or stable disease. Diagnostic indices compared to histolog-
ical finding were-senstivity = 80%, specificity = 90%, PPV = 66.6%, NPV = 94.7%.
Ultrasonographic examination was done for 33 patients (8 were lost to follow up). Six
(18.2%) patients had CR, 23(69.7%) patients had PR and 4(12.1%) patients had NR or
stable disease. Diagnostic indices compared to histological finding were-sensitivity =
60%, specificity = 90%, PPV = 60%, NPV = 90%. 14 of the 25 patients operated were
clinically complete responders, 10 were clinical partial responders and 1 was non
responder. In most cases the pathological response of chemotherapy correlated
with clinical response. The greatest discordance was found in patients with clinical
complete response. Of those operated 18(72%) patients had macroscopic and 
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microscopic residual tumor. Seven patients had no macroscopic tumor. Of these five
had no microscopic evidence of disease while 2 had microscopic residual tumor. 
Conclusions Clinical assessment alone is inaccurate for assessment of chemo-
therapeutic response. The accurate assessment of tumor response to neoadjuvant
chemotherapy in locally advanced breast cancer should be a reflection of clinical
examination, mammographic and ultrasonographic evaluation and finally histopatho-
logical evaluation. 50 Poster presentations
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A COMBINATION OF VINORELBINE AND CARBOPLATIN AS
FIRST LINE TREATMENT FOR PATIENTS WITH METASTATIC
BREAST CANCER – A PHASE II STUDY. AS Protheroe, S Rodwell, H Aram,
D Dodwell, M Crawford, C Bradley, TJ Perren, S Hill, JK Joffe1, On behalf of
the Yorkshire Breast Cancer Research Group, 1Huddersfield Royal Infirmary,
Huddersfield, ICRF Cancer Medicine Research Unit, St James’s University
Hospital, Leeds UK LS9 7TF, UK 
The combination of vinorelbine and carboplatin has been investigated as a first line
treatment in the setting of metastatic breast cancer, within the Yorkshire region. The
aim of the study is to identify the activity of this new regimen with potential for non-
cross resistance with anthracycline and taxane containing treatments. The scheduling
of this combination comprises day one and day eight vinorelbine 25 mg/m2 and day
one carboplatin AUC5, repeated on a three weekly cycle. Between October 1998 and
February 2001 29 patients have been enrolled on this study from five centres within
Yorkshire. Further patients continue to be entered. Of the 29 patients enrolled 23 have
received 3 or more cycles of treatment, 2 of these are still ongoing and 21 are evalu-
able for response. 27 patients are evaluable for toxicity. One patient died from
neutropenic sepsis and 7 (26%) patients withdrew because of toxicity. 19 out of 27
(70%) patients experienced a grade 3/4 neutropenia, 10/27 (37%) developed a grade
3/4 neutropenic infection. 2/27 (7%) developed grade 3 anaemia, 2/27 (7%) grade 3
thrombocytopenia, 2/27 (7%) grade 3 nausea, 1/27 (4%) grade 3 vomiting, 1/27 (4%)
grade 3 diarrhoea and 1/27 (4%) grade 3 hyponatraemia. 11 out of 21 (52.4%) patients
have achieved a partial response, 5/21 (23.8%) stable disease and 5/21 (23.8%) have
had progressive disease. Data will be presented on response rates and progression free
survival with up dated information on toxicity and tolerability. 
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TANGO – A PHASE III, RANDOMISED TRIAL OF GEMCITABINE
IN PACLITAXEL-CONTAINING, EPIRUBICIN-BASED, ADJUVANT
CHEMOTHERAPY FOR HIGHER RISK, EARLY STAGE, BREAST CANCER
CJ Poole1, J Carmichael, RE Coleman, HM Earl, D Dodwell, M Verrill, 
RCF Leonard, J Mansi, D Cameron, C Twelves, P Canney, JA Dunn1, 
HC Howard1, S Bathers1, 1CRC Trials Unit, Institute for Cancer Studies,
University of Birmingham, B15 2TT, UK 
Despite recent advances, many women still succumb to the metastatic complications of
breast cancer and more effective adjuvant treatment is required. The 1998 Oxford
Overview confirmed that combination chemotherapy provides significantly improved
relapse-free (RFS) and overall survival (OS), and that the substitution of anthracyclines
confers further modest advantage. More recently, the 3000-patient CALGB 9344 trial
has shown that the sequential addition of four cycles of paclitaxel to standard therapy
with four cycles of AC offers additional survival advantage (HR = 0.86. However,
retrospective subgroup analysis suggests that the improvement in RFS (901 events) is
limited to the 1055 ER-negative patients randomised (HR = 0.75; P = 0.02). A similar
trend is seen in the less mature (551 events) NSABP-B28 study (HR = 0.75; n.s.). 
Since the Overview itself shows little effect from single agent adjuvant therapy, it
seems plausible that consolidation with a paclitaxel-based combination may be superior
to paclitaxel alone. Arguably, gemcitabine seems the best candidate for incorporation
into such a regimen; not only does its use avoid the more difficult non-myelosuppressive
toxicity exhibited by other agents such as capecitabine or vinorelbine in combination
with paclitaxel, but three trials show encouraging activity for the gemcitabine-paclitaxel
combination in advanced breast cancer, particularly in respect of CR rates (16–21%). 
The aim of the tAnGo trial is to examine whether the addition of gemcitabine (1250
mg/m2 days 1 and 8, q 3 weeks) to paclitaxel (175 mg/m2/3 hours, day 1, q 3 weeks)
following four cycles of epirubicin (90 mg/m2 day 1, q 3 weeks) and cyclophos-
phamide (600 mg/m2 day 1, q 3 weeks) improves RFS in relation to epirubicin and
cyclophosphamide followed by paclitaxel alone. At present, the available data from
CALGB 9344 and NSABP-B28 would perhaps support this approach most strongly in
ER-negative and/or PGR-negative patients. 
The primary endpoint of the study is RFS at 5 years. RFS at 10 years and OS at 5 and
10 years will be addressed as secondary endpoints. A safety study of pulmonary and
cardiac function will involve 130 patients and provide a sensitive measure of any sub-
clinical problems associated with the gemcitabine/paclitaxel/radiotherapy combination.
Quality of life data will also be collected from a subset of 500 women. The accrual target
is 3000 patients recruited within 3 to 4 years from centres within the UK, North
America, and continental Europe. There are three planned interim analyses, the first at
440 events, the second at 800, and the final analysis after 1570. Log-rank analysis on
intention to treat will be carried out on all causes of mortality and relapse. 
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EVALUATION OF CLINICAL COMPLETE RESPONSE TO
NEOADJUVANT CHEMOTHERAPY IN PRIMARY BREAST
CANCER USING (18F)-FLUORODEOXYGLUCOSE POSITRON EMISSION
TOMOGRAPHY RJ Burcombe1, A Makris1, M Pittam1, J Lowe2, J Emett2, 
W L Wong2, 1Marie Curie Research Wing, 2The Paul Strickland Scanner
Centre, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK 
Aim To determine whether (18F)-fluorodeoxyglucose (FDG) positron emission
tomography (PET) can predict complete pathological response (pCR) in patients
achieving a good clinical response to neoadjuvant chemotherapy for primary breast
cancer. 
Patients and methods Ten patients who achieved a good clinical response –
complete clinical response (cCR) or minimal residual disease (MRD) – to six cycles
of neoadjuvant FEC chemotherapy (5 fluorouracil 600 mg/m2) epirubucin 60 mg/m2
and cyclophosphamide 600 mg/m2 underwent FDG PET scanning prior to definitive
breast surgery. PET scan reports were correlated with subsequent histopathological
findings. 
Results No FDG uptake was visualised at the primary tumour site on PET scan in
any patient. Nine patients had residual invasive carcinoma at operation, ranging from
2–20 mm in maximum dimension. Histology is awaited in one case. Of the five
patients who underwent axillary surgery, no axillary FDG uptake was seen pre-opera-
tively although 3 of the 5 were node positive at operation. 
Conclusions FDG PET scans failed to detect residual invasive carcinoma pre-
operatively at both the primary site and involved axillary lymph nodes in this series of
good clinical responders. Consequently, its sensitivity as a tool to identify complete
pathological response to neoadjuvant chemotherapy is inadequate for clinical use. 
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EVALUATION OF ER, PgR, HER2 AND Ki67 AS PREDICTORS
OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR
OPERABLE BREAST CANCER RJ Burcombe1, A Makris1, PI Richman1, 
M Pittam1, F Daley2, S Noble2, GD Wilson2, 1Marie Curie Research Wing,
2The Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, HA6
2RN, UK 
The increasing use of neoadjuvant chemotherapy for operable breast cancer provides an
opportunity to identify biological markers that predict clinical response to treatment. 
96 women (mean age 57 years, range 27–78) received 6 cycles of FEC
chemotherapy (5-Fluouracil 600 mg/m2, Epirubicin 60 mg/m2, Cyclophosphamide
600 mg/m2) prior to surgery and / or radical radiotherapy. Tamoxifen was commenced
post-operatively in patients with ER positive tumours. Clinical response was assessed
using conventional UICC criteria and categorised as ‘responders’ (complete or partial
response) or ‘non-responders’ (stable or progressive disease). Immunohistochemical
analysis was performed on all diagnostic core biopsies and 50 subsequent surgical
specimens using monoclonal mouse antibodies for anti-HER2 (Zymed laboratories),
ER and PgR (Novocastra) and Ki67 (Dako). 
80% of patients were clinical responders, including 23 (24%) achieving complete
clinical response. 68% of core biopsies were ER+, 60% PgR + and 15% HER2+. Ki67
proliferation index ranged from 1.5–58.5% (median 24.4%). Clinical response rates
by marker status and Ki67 index (above and below median) are shown below: 
ER+  ER–  PgR+  PgR–  HER2+  HER2–  Low   High  
Ki67 Ki67
Responders (%)  82  77  84  74  64  82  83  76 
Neither ER nor PgR status at diagnosis predicted clinical response. There was a trend
towards poor response in HER2+ patients (P = 0.11). All HER2 overexpressors
remained HER2+ after neoadjuvant chemotherapy. A reduction in Ki67 index before
and after treatment was seen (median change –37%) but no significant difference was
found between responders (median change –41%) and non-responders (–14%). Poster presentations 51
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A PHASE II PILOT STUDY OF VINORELBINE AND CISPLATIN
IN PATIENTS WITH METASTATIC BREAST CANCER (MBC), 
J Abraham, K McAdam1,2, C B Wilson1, H M Earl1, 1Addenbrookes Hospital
NHS Trust, Cambridge CB2 2QQ, 2Peterborough District Hospital NHS Trust
Purpose Vinorelbine is a novel vinca alkaloid which has shown excellent response
rates (RR) in patients with MBC – 40–60% first-line and 60–70% second-line in
combination with anthracyclines, paclitaxel and 5fluorouracil. In addition there
appears to be a lack of cross-resistance with anthracyclines. There have been few
previous phase II studies using vinorelbine in combination with cisplatin involving a
small number of patients (17–26) with sparse quality of life (QoL) data. RR were
reported between 60–70% and median progression free survival (PFS) of 7.3 months
(11.3 months for responders). The main dose-limiting toxicity was myelosuppression
(10% CTC grade II/IV) with 5–43% grade (G) II/III nausea/vomiting and 11% grade
II neuropathy. The aim of this study is to evaluate the activity and feasability of this
combination in patients with MBC undergoing second or third-line therapy. Primary
endpoints are PFS and RR and secondary endpoints are QoL and toxicity. 
Methods All patients had MBC and had received at least one previous
chemotherapy regimen for metastatic disease. WHO performance status was 0–2,
with a treatment-free interval of > 3 months and a life expectancy of > 3 months with
adequate renal, liver and haematological function. Patients were given Vinorelbine 25
mg/m2 on day 1/day 8 and Cisplatin 80 mg/m2 on day 1, repeated every 21 days up to
a maximum of 6 cycles. Toxicity, QoL, renal, liver and hasematological function were
assessed prior to each cycle and disease assessment was made after the 3rd and 6th
cycle. 
Results 8 patients have been recruited to date (mean age 55 years). 5 patients had
previously received an anthracycline and 2 patients a taxane. The majority of patients
(5) had only received one chemotherapy regimen previously and 1 patient had had 3
previous combinations. 4 patients had disease at a single site, 3 at 2 sites and 1 at 3
sites and these included liver (1 patient), lung (4), bone (2), nodal (3) and soft tissue
(2). 3 patients received all 6 cycles, 1 patient each received 5, 4 and 1 cycle and 2
patients received 3 cycles. There were dose reductions in 4 patients (2 -neutropenia
and 2 ototoxicity). Toxicity was generally mild: Nausea G I/II – 44% and G III 2%;
neutropenia G1/II 11% and G III/IV 11%, constipation G I/II 14%, ototoxicity GIII
2%, nephrotoxicity G I 2% and neuropathy G I/II 14%. RR was 50% (1 CR, 3PR, 1SD
and 3PD). The mean duration of response was 2.5 months (1–5 months). 
Conclusion Vinorelbine and Cisplatin is an active combination in patients with
MBC even in those pre-treated with anthracyclines. Toxicity was generally mild. This
trial is still actively recruiting and full results together with the quality of life evalua-
tion will be available later this year. 
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PROTEIN TYROSINE PHOSPHATASES DOWN-REGULATED IN
MELANOMA L McArdle1, M Rafferty1, O Bergin1, 
PA Dervan2, D Easty1, 1Pathology Department, University College Dublin,
2Mater Misercordiae Hospital, Dublin 
Protein-tyrosyl phosphorylation is a key control mechanism for growth and differenti-
ation. Phosphotyrosine levels are controlled by the co-ordinated actions of protein
tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). A number of PTKs
are encoded by proto-oncogenes or viral oncogenes, and are implicated in carcinogen-
esis. Excessive expression of PTKs can contribute to melanoma formation; previously
we found over-expression of PTKs in late stage melanoma (Easty et al., 1995). It was
hypothesized but remains unproven that PTPs function as tumour suppressors. Here
we survey PTP expression in pigment cells. PTP genes were cloned from a melanoma
cell line and normal human melanocytes by RT-PCR, using degenerate primers based
upon conserved sequences within the catalytic domain of published PTPs. Northern
blotting was used to test for quantitative differences in PTP expression in normal and
malignant cells. Fifteen genes were tested and two sequences, PTP-KAPPA and 
PTP-PI were selected for further study. Expression of these genes was decreased or
lost in melanoma cell lines compared to normal melanocytes, and in some unmanipu-
lated melanoma biopsies. This was confirmed at the protein level for PTP-KAPPA in
lysates from unmanipulated melanoma biopsies. PTP-KAPPA was detected in
compound nevi. Interestingly, both genes are members of the type 2 receptor PTPs
and their structures suggest a role in cell adhesion. PTP-KAPPA is upregulated by
TGFb (a negative regulator of cell growth) and has been implicated in contact inhibi-
tion. Loss of PTP expression may contribute to the abnormal tyrosine phosphorylation
seen in melanoma; these genes are candidate tumour suppressors. 
Easty et al., Cancer Research, 55, 2528–2532, (1995) 
Sponsored by the Health Research Board 
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17b ESTRADIOL AND THE FEMALE SURVIVAL ADVANTAGE IN
MELANOMA R Molife1,2, C Layton2, P Lorigan1, 
S MacNeil2, 1Dept of Oncology, Weston Park Hospital, Sheffield, S10 2SJ,
UK, 2University Section of Medicine, Northern General Hospital, S5 7AU, UK 
Epidemiological data shows that female patients with primary melanoma have a
significant survival advantage over males (1); this female survival benefit can also be
demonstrated in immuno-deficient animals (2). In investigating a possible mechanism
for this benefit, we have previously reported that the female steroid 17b estradiol
significantly reduces invasion of a human melanoma cell line (A375SM) through
fibronectin in vitro (3). Our aim was to extend this work into a preclinical model of
melanoma using a reconstructed human skin model which allows the investigation of
melanoma/cell/extracellular matrix (ECM) interactions. Three human cutaneous cell
lines A375SM, HBL and C8161 were compared in this model. Human skin was ster-
ilised and made acellular to form de-epidermalised dermis (DED) with retained base-
ment membrane antigens. Dermal fibroblasts (Fib), epidermal keratinocytes (K) and
human melanoma cells were added to the DED. The resultant composites were
cultured in 17b estradiol (10–11 to 10–7) at an air-liquid interface for 14–18 days prior
to histology and immunohistochemistry. A quantitative blind scoring system was used
to assess the effect of 17b estradiol on skin morphology and melanoma invasion. 
All three melanoma lines showed marked invasion into the dermis in this model. 17b
estradiol slightly reduced the invasion of HBL cells (P > 0.05) and significantly reduced
the invasion of A375SM (P < 0.005 at 10–9) and C8161 cells (P < 0.005 at 10–8) (n = 3).
In contrast, estradiol had no significant effect on the morphology of the epithelial
layer in the absence of melanoma cells (n = 6). The introduction of melanoma cells in
general had relatively little effect on the morphology of the epidermal layer until
steroids were added. For one cell type (A375SM) estradiol improved the quality of the
K layer whilst for HBLs, estradiol decreased the quality; there was no effect when
C8161 cells were present. Thus, estradiol was consistent in reducing invasiveness of
melanoma but did not appear to directly affect the epidermal layer. 
These preliminary findings confirm that this model allows one to ask whether 17b
estradiol may act directly on melanoma cells or indirectly via effects on the epidermal
keratinocytes (which may act as a barrier to melanoma invasion). The simplest inter-
pretation of our current data in this model is that it is the melanoma cells, rather than
the keratinocytes, which respond directly to steroids with a modest reduction in their
invasion. 
1. Miller JG and MacNeil S, 1997 Br J Derm 136:657 
2. Ladanyi A, Timar J, Bocsi J et al. 1995 Melanoma Res 5:83 
3. Richardson B, Price A, Wagner M et al. 1999 Br J Canc 80 (12): 2025 
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A PHASE I STUDY OF TEMOZOLOMIDE AND CARBOPLATIN IN
PATIENTS WITH METASTATIC MELANOMA SJ Strauss, M Marples,
T Meyer, M Napier, J Boxall, GJS Rustin, Dept of Medical Oncology, Mount Vernon
Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
Purpose Temozolomide is an oral alkylating agent with equivalent response rates to
DTIC in the treatment of metastatic melanoma, and carboplatin has a reported
response rate of 16%. Both drugs have favourable toxicity profiles and can be admin-
istered as an outpatient. We conducted a Phase I trial to establish the maximum toler-
ated dose (MTD) of this combination. 
Patients and Methods Thirty patients with metastatic melanoma were treated with
escalating doses of both drugs. In phase I, patients were treated with temozolomide at
750 mg/m2 divided over 5 days, and carboplatin administered on day 1. Cycles were
repeated 4 weekly for a maximum of 6 cycles. Patients were treated in 4 cohorts of 3 at
carboplatin doses escalating from AUC 3 to AUC 4, AUC 5 and AUC 6. In phase II the
dose of temozolomide was increased to 1000 mg/m2 and escalation of carboplatin
dose repeated. 
Results In Phase I, 12 patients, aged 39–67 years (median 55) received 35 cycles
of treatment. Toxicity was primarily haematological (Table). There was one dose
delay due to neutropenia. Nine patients progressed on treatment and 3 had stable
disease. In phase II, 18 patients aged 40–81 years (median 55) received 49 cycles of
treatment. There were 8 delays, 4 for thrombocytopenia, and 4 for neutropenia. There
were 2 dose reductions for thrombocytopenia. The dose limiting toxicity was haema-
tological with 2 patients experiencing grade III/IV neutropenia and 1 patient grade IV
thrombocytopenia at a carboplatin dose of AUC 5. The MTD was carboplatin AUC 4.
In both phases, only 4 patients had ³ grade 2 nausea. Two patients achieved partial
responses, 4 had stable disease, and 12 progressed on treatment. 
No. Patients with Haematological Toxicity ³ Grade 2 / No. Patients Treated 
Temozolomide dose  Carboplatin dose 
AUC 3  AUC 4  AUC 5  AUC 6 
*750 mg/m2 1/3  1/3 1/3 1/3 
100 mg/m2 2/3 5/11  2/4  – 
*No patients experienced grade III/IV toxicity 
Conclusion The combination of carboplatin and temozolomide is well tolerated
with acceptable toxicity at doses of temozolomide 1000 mg/m2 and carboplatin
AUC4. Preliminary response information is encouraging and further phase II trials
should be considered. 52 Poster presentations
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A PHASE I/II STUDY OF TREOSULFAN(T) AND DACARBAZINE
(D)IN CHEMONAIVE PATIENTS WITH MALIGNANT MELANOMA
CV Eswar1, T Murdoch1, M Sheddon2, A McMurray2, E Marshall1,
Clatterbridge Centre for Oncology, Bebington, Wirral, L63 4JY, 2Medac,
Glasgow, G3 6EQ, UK 
Treosulphan (T) is a bifunctional alkylating agent, which has recently been reported to
have activity in melanoma both in vitro against choroidal melanoma (Neale et al, BJC
1999) and chemoresistant melanoma cell lines. In vivo at relapse it has also shown
activity in metastatic melanoma (MM) patients (Neuber et al, Melan Res 1999).
Furthermore T appears to have enhanced in vitro activity when used in combination
(Myatt et al, Anticancer Drugs 1997). In view of these findings, we have embarked on
a phase I/II study on T in combination with DTIC (D) in chemotherapy naive patients
with MM. D was administered at a set dose (850 mg/m2) at 21 day intervals upto a
maximum of 6 cycles. In addition patients received a short IV infusion of T immedi-
ately preceding D at one of 4 dose levels (4 gm/m2, 6 gm/m2, 7 gm/m2, 8 gm/m2) with
a 3 day granisetron and dexamethasone antiemetic regimen. Eligibility criteria
included; ECOG performance status ≤2, no prior chemotherapy (excluding limb
perfusion and immunotherapy), anticipated survival >3 months, adequate hepatic/
renal function and normal haemotological indices. Exclusion criteria were sympto-
matic CNS metastases. To date 15 patients (4 ocular, 11 cutaneous) have received 49
cycles. Cohorts 1&2 have completed treatment and 3&4 are continuing
chemotherapy. So far the combination has been very well tolerated with mild non
haemotological toxicity consisting of grade (G) 1–2 lethargy, G 1–2 nausea and
vomiting, G 1 alopecia & G1 skin rashes. 3 patients developed G3 thrombocytopenia
& G 3 neutropenia (one each in cohorts 1/2/3). There has been cumulative thrombo-
cytopenia and neutropenia over successive cycles of chemotherapy, but there has been
no dose relationship. Out of 10 patients who have completed treatment 3 have stable
disease (SD)and seven patients had progressive disease (PD) of which 4 had PD in the
CNS. Recruitment continues for the final cohort, which has now been expanded to
determine the response rate to the combination. 
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PREDICTING PROGRESSION AND SURVIVAL IN BLADDER
CANCER: USE OF P27K1P1 (P27) AND EPIDERMAL GROWTH
FACTOR RECEPTOR (EGFR) A Valentine, JL Ritchie, GB Nevin, 
SR McKeown, School of Biomedical Sciences, University of Ulster,
Jordanstown, N. Ireland 
At initial presentation, 70% of bladder tumours are superficial while the remaining
30% are invasive. A minority of patients (around 30%) who present with superficial
disease remain disease-free for life after tumour removal. The majority will have
multiple recurrences, at some time in their lifetime and 10–20% of these will become
invasive. The identification of prognostic markers which could predict disease
progression, as early as possible, is vital and would allow for the establishment of
appropriate treatment regimens. Absent or decreased expression of the cyclin depen-
dent kinase inhibitor, p27kip1 (p27) and over-expression of Epidermal Growth Factor
Receptor (EGFR) have been found in many tumour types including breast, lung and
prostate. The purpose of this study was to determine whether p27 and EGFR could be
used individually, or in combination, as reliable prognostic markers in bladder cancer.
Immunohistochemistry was used to assess bladder tumours for p27 (58 samples),
nuclear EGFR (69 samples) and 53 biopsies for both markers. To assess p27
status, samples were divided into p27 negative (< 30%) and p27 positive (> 30%).
P27 status in bladder tumours was associated with tumour stage (p < 0.0001), disease
recurrence (P = 0.0448) and disease progression (P = 0.0020). Patients with p27 posi-
tive tumours had a longer disease-free survival, progression-free survival and overall
survival than those patients with p27 negative tumours (log-rank analysis: P = 0.0015,
0.0006 and 0.0283 respectively). To assess nuclear EGFR status, samples were
divided into EGFR positive (> 5%) and EGFR negative (< 5%). Nuclear EGFR
expression was associated with disease progression (P = 0.0044) and progression-free
survival (log-rank analysis: P = 0.0129). When p27 and nuclear EGFR expression
were combined, a superior prognostic indicator to either p27 or nuclear EGFR status
alone was created (P = 0.0002). 
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A PHASE II TRIAL OF CISPLATIN, METHOTREXATE AND
VINBLASTINE CHEMOTHERAPY FOR PURE SQUAMOUS
CELL CARCINOMA OF THE URINARY TRAC JM Russell, GO Griffiths, 
BM Uscinska, RA Cowan, KM Grigor on behalf of the MRC Bladder Cancer
Group, MRC Clinical Trials Unit, 222 Euston Road, London, UK 
A UK multi-centre phase II trial was carried out to make an assessment of the
response rate to cisplatin, methotrexate and vinblastine (CMV) chemotherapy in
patients with pure squamous cell carcinoma of the urinary tract. Eligible patients had
initial presentation with T3-T4 disease, pelvic relapse after radiotherapy or surgery, or
nodal or metastatic disease, with at least one site of disease assessable for response.
All patients were to receive 3 cycles of CMV over 3 weeks (30 mg/m2 methotrexate
and 4 mg/m2 vinblastine on days 1 and 8, 100 mg/m2 cisplatin on day 2 and 15 mg 
6h r´ 4 folinic acid on days 2 and 9). The primary endpoint was response assessed 9
weeks after commencement of treatment, the secondary endpoint was survival. From
October 1993 to February 1999 a total of 38 patients were entered by 13 centres. 55%
of patients were male, 58% less than 60 years old and 76% WHO performance status
0/1, 58% of patients (n = 22) received all 3 cycles. The review pathologist reported
76% (n = 29) to be pure squamous cell carcinoma, 16% (n = 6) to be transitional cell
carcinoma with squamous differentiation and 8% (n = 3) to be other. Using all 38
patients at 9 weeks 13% (n = 5) had a CR, 26% (n =10) a PR, 24% (n = 9) SD, 16% 
(n = 6) progression and 21% (n = 8) were not assessable. Using the 29 patients with
pure squamous cell carcinoma only, at 9 weeks 14% (n = 4) had a CR, 28% (n = 8) a
PR, 24% (n = 7) SD, 14% (n = 4) progression and 21% (n = 6) were not assessable. A
total of 29 patients have died; 76% (n=22) were due to squamous cell carcinoma
disease, 3% (n = 1) was treatment related and 21% (n = 6) were due to other reasons.
CMV chemotherapy is active in squamous cell carcinoma of the bladder, of the same
order as in transitional cell carcinoma. 
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A PHASE II TRIAL OF CONTINUOUS 5-FLUOROURACIL (5-FU)
IN RECURRENT LOCALLY ADVANCED OR METASTATIC
TRANSITIONAL CELL CARCINOMA OF THE URINARY TRACT 
M Highley, G Griffiths, B Uscinska, P Harper, R Huddart J Barber on behalf of
the MRC Bladder Cancer Working Party, MRC Clinical Trials Unit, 222
Euston Road, London NW1 2DA, UK
A UK multi-centre phase II trial was carried out to make an assessment of the
response rate at 8, 16 and 24 weeks and toxicity to continuous infusion of 5-FU in
patients with recurrent locally advanced or metastatic transitional cell carcinoma of
the urinary tract. Eligible patients were those with either pelvic relapse after radio-
therapy or surgery, or nodal or metastatic disease. Patients were not to have received
previous systemic chemotherapy. All patients were to receive 24 weeks of continu-
ously infused 5-FU at a dose of 300 mg/m2/day via a Hickman line. A total of 50
patients were entered by 8 centres, 64% of patients were over 65 years old, 70% were
male and 78% had a WHO performance status of 0/1. We currently have data on
response at 8 weeks for 43 of the patients; none had a complete response, 16% (n = 7)
had a partial response, 16% (n = 7) had stable disease, 53% (n = 23) progression and
14% (n = 6) were not assessable. A total of 34 patients have died, 88% (n = 30) of
deaths were due to transitional cell carcinoma and 12% (n = 4) were due to other
causes, there were no treatment related deaths. More detailed data, in particular
response at 16 & 24 weeks, will be available for time of presentation. Poster presentations 53
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ZD1839 (‘IRESSA’) INHIBITS THE GROWTH RESPONSE OF
BLADDER TUMOUR CELL LINES TO EPIDERMAL GROWTH
FACTOR AND THE INDUCTION OF TIMP1 JE Nutt1, JKMellon2, J Lunec1,
1Cancer Research Unit, 2Dept of Surgery, University of Newcastle, Newcastle
upon Tyne, NE2 4HH 
The Epidermal Growth Factor Receptor (EGF-R) in bladder cancer is associated with
high tumour stage and grade, and has been found to be a strong independent predictor
of invasive tumour progression and poor long term survival. ZD1839 (‘Iressa’) is an
orally active, selective EGF-R tyrosine kinase inhibitor which blocks signal transduc-
tion pathways implicated in cancer cell proliferation. The effect of both EGF stimula-
tion and its inhibition with ZD1839 has been investigated in 2 EGF-R positive human
bladder tumour cell lines, RT112 and RT4. Cells grown in serum free RPMI medium
showed increased growth over 4 days when treated with 10 or 50 ng ml–1 EGF as
measured by the SulfurRhodamine B assay. 1mM ZD1839 alone had no effect on cell
growth, but the rate was decreased with 5mM ZD1839. However, the proliferative
effect of EGF stimulation in both cell lines was inhibited in the presence of 1mM
ZD1839, demonstrating its effect on EGF-R signaling. 
Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are implicated in
tumour invasion and metastasis. Conditioned medium from both cell lines treated with
a combination of 10 ng ml–1 EGF and 1 and 5mM ZD1839 for 48 h showed no change
in MMP2 concentrations using zymograms. However, using Western blot analysis,
TIMP1 was shown to increase in conditioned medium from RT112 cells treated with
50ng ml–1 EGF. This was partially inhibited with both 1 and 5mM ZD1839, suggesting
alterations in the balance of MMPs and their inhibitors in EGF stimulated cells, which
may be important in the treatment of bladder tumours. The effects of ZD1839 on
MMPs found in the urine of bladder cancer patients will be investigated. 
‘Iressa’ is a trade mark of the AstraZeneca group of companies 
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META-ANALYSIS OF INTRAVESICAL THERAPY FOR
SUPERFICIAL BLADDER CANCER: SUPERIORITY OF
BACILLUS CALMETTE-GUERIN MAY BE CONFINED TO HIGH RISK
PATIENTS MD Shelley1, J Court1, K Burgon1, B Coles1, H Kynaston2, T Wilt3
and MD Mason1, Cochrane Unit, Velindre Hospital, Cardiff CF14 2TL, 2 Dept.
of Urology, UWCM, Heath Park, Cardiff CF4 4XW, 3 Dept. of Veterans Affairs,
MN 55417, USA
Background Tumour recurrence following transurethral resection (TUR) for Ta and
T1 bladder cancer is a major clinical problem. Intravesical administration of mito-
mycin C (MMC) or Bacillus Calmette-Guerin (BCG) has proven prophylactic activity
but both are associated with local and systemic side effects. A systematic review and
meta-analysis was carried out to compare the efficacy of these two agents. 
Methods  A comprehensive search of MEDLINE, CANCERLIT, EMBASE,
Healthstar, BIDS, Cochrane Controlled Trials Register and DARE was performed,
and hand searching of relevant journals undertaken. Trials in any language were
included in the meta-analysis if they were properly randomised, included medium to
high risk patients with Ta or T1 bladder cancer and compared intravesical MMC
versus BCG. Time to event analyses of tumour recurrence with a sensitivity analysis
for subgroups according to patients’s risk of recurrence, were performed. 
Results Twenty-seven articles were identified but only 6 were considered appro-
priate for analysis. This represented 1527 patients in total, 693 randomised to MMC
and 834 to BCG. Both MMC and BCG were effective in delaying tumour recurrence
following TUR. Statistical analysis indicated evidence of significant heterogeneity
between trials (P = 0.0009). The weighted mean (reciprocal of the variance) log
hazard ratio (variance) for recurrence for the six trials was –0.016 (0.005). This indi-
cated no significant difference between MMC or BCG (P = 0.83). A subgroup
analysis of three trials that included only high risk Ta and T1 patients, indicated no
heterogeneity (P = 0.25) and a log hazard ratio (variance) for recurrence of -0.371
(0.012). With MMC used as the control in the meta-analysis, a negative ratio is in
favour of BCG and in this case it is highly significant (P = 0.0079). Local toxicities
(dysurea, cystitis, frequency and haematurea) were associated with both MMC (34%)
and BCG (27%). Systemic toxicities, such as chills fever and malaise were observed
with both agents although skin rash was more common with MMC. 
Conclusion The data from the present meta-analysis indicates that recurrence-free
survival was significantly prolonged with intravesical BCG compared to MMC in
patients with a high risk of tumour recurrence. 
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PHOTODYNAMIC THERAPY FOR SUPERFICIAL BLADDER
CANCER UNDER LOCAL ANAESTHETIC C Briggs1,2,
DCShackley1,2, A Gilhooley1, C Whitehurst2, JV Moore2, CD Betts1, 
K O’Flynn1, NW Clarke1, 1Paterson Institute for Cancer Research, Christie
Hospital, Manchester M20 9BX, 2Hope Hospital Department of Urology,
Salford M6 8HD
Introduction Photodynamic therapy (PDT) using 5-aminolaevulinic acid (ALA) is a
novel technique used in the treatment of certain skin cancers. We report a phase 1 trial
evaluating ALA PDT in the treatment of superficial bladder cancer under local anaes-
thetic (LA). 
Methods 18 patients with recurrent superficial transitional cell carcinoma (stage
Ta/CIS; grades 1–3) were treated using escalating doses of ALA (3–6%) and light
(25–50 Jcm-2). The following intravesical LA techniques were used: (i) no LA (ii)
passive diffusion of 40 ml 2% lignocaine (iii) electromotive drug administration
(EMDA) of salt-free 2% lignocaine. Pain was assessed using a linear analogue score
on a scale of 0–10. Tolerability and toxicity was assessed using the different LA, light
and ALA regimes. 
Results Patients (n=2) undergoing 3% ALA PDT without LA experienced
pain/spasm and the procedure was abandoned. Using lignocaine all patients (n=8)
tolerated the procedure well [median pain score 1(range 0–2)]. On increasing the
ALA dose to 6%, 6 patients reported pain with a median pain score of 8 (range 5–10)
with 3 failing to tolerate the intended light dose. Using the most potent LA technique
(EMDA of lignocaine) with maximum light and ALA dose, 2 patients were success-
fully treated (pain score 2). 
All patients had short-lived bladder irritability following the procedure (resolving
within 3 weeks) though this was substantially reduced with intravesical dexametha-
sone. There was no subjective/objective effect on long-term bladder function and no
reported photosensitivity. Serum lignocaine levels in all patients were minimal. Of the
12 patients tolerating the procedure, 9 had significant tumour response, 6% ALA
being most efficacious. 
Conclusion Bladder ALA PDT is safe and with appropriate LA is well-tolerated.
It is effective in a proportion of cases and with further refinement it may be possible
for use on an out-patient basis under LA. 54 Poster presentations
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COULD CONFORMAL (CFRT) OR INTENSITY MODULATED
RADIOTHERAPY (IMRT) REDUCE TOXICITY IN THE
RADIOTHERAPY (RT) OF BLADDER CANCER? RA Huddart1,2, 
JN Staffurth2, EJ Adams1, VN Hansen1, The Royal Marsden Hospital1, 
The Institute of Cancer Research2, Sutton, Surrey, SM2 5PT. UK
Trials of CFRT have demonstrated that reducing the volume of irradiated normal
tissue can reduce incidence of late toxicity. The main organ at risk of toxicity in radio-
therapy for bladder cancer is the bladder itself. This toxicity limits dose and hence
efficacy of treatment. Our previous pilot data suggested that reducing the high dose
volume may reduce bladder toxicity. This thesis is to be tested in a multicenter phase
III study commencing 2001 (BC2000). 
Aims To investigate the potential of different treatment strategies to reduce normal
tissue irradiation while treating localised bladder cancer. 
Method A patient with localised bladder carcinoma was planned using a conven-
tional RT (CvRT) plan to cover whole bladder & extravesical disease with a 2 cm
margin (WB). This was compared to a CFRT plan and to 2-phase treatment plans
(PB)(50Gy to whole bladder and 14Gy to tumour with 2 cm margin) with CvRT and
CFRT and a novel concomitant boost technique (ComRT) using 2 segments per beam.
These plans were further compared to 3-field (3F) & 5F IMRT plan (generated on
©HELAX-TMS) and 3F, 5F & 9F IMRT plans (©CORVUS). Dose volume
histograms (DVHs) were produced for non-target bladder (outside gross tumour),
rectum and bowel. 
Results Summarised in table below: 
STRUCTURE Non-target bladder Rectum* Bowel* 
PLAN %>55 Gy %>60 Gy %>50 Gy  %>40 Gy %>50 Gy 
3F CvRT WB 100 100 33 80 56 
3F CFRT WB 100 100 29 69 47 
3F CvRT PB 45 41 15 70 49 
3F CFRT PB 38 31 15 61 38 
3F Cv ComRT PB 42 37 20 62 52 
3F CF Com RT PB 35 30 22 56 39 
3F HELAX IMRT 36 24 5 36 25 
5F HELAX IMRT 39 23 11 35 25 
3F CORVUS IMRT 50 20 15 53 29 
5F CORVUS IMRT 37 22 4 39 25 
9F CORVUS IMRT 36 23 5 43 21 
*Proportion of small bowel or rectum in CT-scanned volume 
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Conclusion The benefit of CFRT over CvRT is small. 2-phase bladder and boost
plans can reduce the volume of non-target bladder, rectum and bowel irradiated.
IMRT can achieve further gains in normal tissue avoidance over CFRT plans. On this
preliminary data a 5F CORVUS IMRT plan or 3F HELAX plan would seem to be
optimum. Data on additional patients is under evaluation and will be presented. 
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SCREENING PANCREATIC JUICE FOR P53 MUTATIONS 
USING A YEAST FUNCTIONAL ASSAY JThreadgold1, 
N Howes1, I Ellis2, I Gilmore1, H Smart1, M Lombard1, W Greenhalf1 & 
JP Neoptolemos1, 1Dept of Surgery, Univ of Liverpool, Liverpool, L69 3GA,
2Dept of Clinical Genetics, Alder Hey Children’s Hospital, Liverpool, L12 2AP 
Despite only representing 2–3% of total cancer cases, pancreatic cancer is the 4th
biggest cancer killer. The most common form of pancreatic cancer is Pancreatic
Ductal Adenocarcinoma (PDAC). This disease is characterised by rapid metastasis
and high mortality. Early surgery dramatically increases survival but differentiating
malignancy from benign conditions, such as pancreatitis, is often impossible at this
stage. The molecular pathogenesis of PDAC is thought to involve mutations in k-ras,
p16, SMAD4 and p53 genes. Over 700 p53 mutations (>90% of which are found in
exons 5–8) can be detected in cancer. A functional assay is required to detect and iden-
tify low copy numbers of mutant p53 in a background of wild type sequences. 
The aim is to develop and test a novel screening approach for PDAC based on
identification of p53 mutations in pancreatic juice. The European Registry of
Hereditary Pancreatitis (HP) and Familial Pancreatic Cancer (FPC) (EUROPAC) has
identified patients with a predisposition for pancreatic cancer. DNA was extracted
from pancreatic juice collected from patients undergoing endoscopic examination
(ERCP) and also from tumour tissue removed from cancer patients. A yeast functional
assay of p53, based on the system developed by Dr. Iggo (ISREC) has been devel-
oped. p53 exons 5–8 are amplified and linked by polymerase chain reaction (PCR).
The PCR product is then transformed along with a plasmid containing the coding
sequence of human p53 into a yeast strain carrying a reporter gene, ADE2, under p53
transcriptional control. Wild type p53 will result in ADE2 activation and the produc-
tion of white yeast, while recombination between plasmid p53 and mutant p53 PCR
product prevents ADE2 activation and the resultant yeast are red in colour. DNA is
extracted from selected red colonies and screened for the presence of a plasmid by
PCR. Positive colonies are then transformed into E. coli or sequenced directly. 
The viability of the screening technique has been confirmed with controls: 
5 pancreatic cancer cell lines, 30 matched pancreatic juice and tissue samples from
PDAC patients, 20 matched juice and tissue samples from chronic pancreatitis
patients and 10 normal controls. We have found that this system of p53 mutation
analysis is both sensitive and specific and may be a viable strategy for screening of
high-risk patients. 
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THE ROLE OF HSP90 IN REGULATION OF APOPTOSIS IN 
PANCREATIC CANCER AB Mason, M Burkitt, CJ Magee, 
D O’Connor and W Greenhalf, Department of Surgery, 5th Floor UCD,
Duncan Building, Royal Liverpool University Hospital, Daulby Street,
Liverpool, L69 3GA 
Hsp90 is a molecular chaperone that binds and maintains proteins in a stable inactive
state. Inhibition of Hsp90 results in cell cycle arrest and apoptosis. Targets of Hsp90
directly involved in cell cycle progression are well known (e.g. Cdk4, Raf-1), the role
of Hsp90 in apoptosis regulation is unclear. 
We have selected genes on the basis of their ability to overcome the toxicity in
yeast. One of these was the human gene BASS2. We have shown by Northern blot that
BASS2 is highly expressed in pancreas compared to other organs (skeletal muscle,
heart, lung, liver and brain). In addition we identified the yeast mitochondrial import
protein, MAS70 gene as a Bax antagonist. In a screen of a 2-hybrid cDNA library
BASS2 was found to bind to Hsp90. MAS70 has previously been shown to also bind
to Hsp90. We have shown by Immunohistochemistry that Hsp90 localises predomi-
nantly to the nucleus in pancreatic ductal adenocarcinoma (PDAC) whereas in normal
pancreatic ductal cells it is predominantly cytoplasmic. We are at present using
immunofluorescence to further characterise the localisation of Hsp90 and to study the
affect of co-expression of BASS2 on this localisation. 
To further characterise Hsp90 binding to BASS2, full length Hsp90 and the N- and
C-terminal fragments of Hsp90 and MAS70 were amplified from cDNA. MAS70 and
BASS2 were cloned into the yeast 2-hybrid vector pAS2-1, in frame with the Gal4
DNA binding domain, and the Hsp90 inserts were cloned into the complementary
vector pGAD424, in frame with the Gal4 transcriptional activation domain. The plas-
mids were then co-transformed into the yeast strain CG1985 (Clontech), and the inter-
actions between these proteins was assessed by the production of b-galactosidase
assayed using X-gal. BASS2 binds to the C-terminal of Hsp90; co-expression of the
Hsp90 co-chaperone Cdc37 was shown not to influence this binding. Poster presentations 55
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EFFECT OF STABLE TRANSFECTION WITH GASTRIN 
ANTISENSE ON THE GROWTH OF AN ORTHOTOPICALLY
TRANSPLANTED HUMAN PANCREATIC TUMOUR AD Gilliam, 
DF McWilliams, TM Morris, PA Clarke SA Watson, Academic Unit of Cancer
Studies, University Hospital, Nottingham, NG7 2UH
Background There is increasing evidence to suggest that human pancreatic carci-
nomas produce gastrin and express the CCK-2 receptor, contributing to their malig-
nant potential. 
Aim To assess the effect of transfection of the gastrin antisense gene on tumour
progression of a xenografted human pancreatic tumour cell line, thereby investigating
the role of gastrin as an autocrine growth factor. 
Methods Lysates of the human pancreatic tumour cell line Pan 1 were assayed for
CCKBR isoforms by Western blotting using rabbit polyclonal antibodies raised
against an N-terminal epitope sequence of the classical CCK-2 receptor. RNA isolated
from PAN-1 was reverse transcribed, amplified by polymerase chain reaction, and
hybridised with gastrin and CCK-2 primers. Reverse Transcriptional real-time PCR
was performed on the cDNA using the DNA binding fluorescent dye SYBR green.
Quantification of relative gene expression levels (the ∆∆ ct value) was obtained by
comparison to the housekeeping gene, GAPDH. Panl was stably transfected with
gastrin antisense and vector control genes. The liposome-mediated method, Tfx-20
(Promega, UK), was used and the plasmid and reagent were mixed and added to the
culture medium. Successful transfection was confirmed by Southern blotting with a
relevant oligoprobe. In vitro cell proliferation was assessed using the colorimetric
MTT assay. An in vivo study was performed according to UKCCCR guidelines. 1e6
transfected cells were injected in 20 ml of PBS into the tail of the pancreas of nude
mice. There were 10 mice in each group. Mice were terminated at 30 days and the
cross sectional area and weights of the pancreatic tumours were assessed. 
Results Western blotting confirmed the presence of the CCK-2 receptor and real
time PCR confirmed gastrin and CCK-2 expression in the Pan 1 cell line. The Pan1
gastrin antisense cell line had a significantly reduced basal growth in serum-free
medium when compared to the vector control (43–50% inhibition, P = 0.01, Student’s
t-test). In addition, there was a reduction in the size (P = 0.051, paired t-test) and
weight (P = 0.033, paired t-test) of the Pan 1 tumours transfected with the antisense
gene vs control vector in vivo. 
Conclusion Gastrin may play an important role in the progression of pancreatic
carcinoma by means of an autocrine and paracrine pathway, supporting the use of
anti-gastrin agents for treatment of the disease. 
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THE REGULATION OF EXPRESSION OF S100A4 IN 
PANCREATIC DUCTAL ADENOCARCINOMA BY THE ZINC
FINGER BKLF CW Herbert1, BR Barraclough2 and W Greenhalf1,
1Department of Surgery, 5th Floor UCD, Duncan Building, Royal Liverpool
University Hospital, Daulby Street, Liverpool, L69 3GA, 2School of Biological
Sciences, University of Liverpool, L69 3BX
Pancreatic Ductal Adenocarcinoma has the highest incidence to mortality rate of any
human cancer with a 5 year survival rate of just 0.4% worldwide. Of the 37220 cases
diagnosed in Britain between 1986 and 1993, only 938 patients survived for 5 years 
or more. The prognosis for sufferers of this disease is bleak because of the high
frequency of metastases. The use of chemotherapeutics and radiotherapeutics has only
produced a marginal survival benefit. Surgical resection is the main treatment for this
disease but in most cases the cancer has progressed to a stage where it has become
inoperable. S100A4(p9Ka, mts1), a Calcium-binding protein, has been shown to be
overexpressed in the advanced stages of many cancers and increased expression levels
have been associated with the metastatic phenotype. 
Using immunohistochemical staining and real-time PCR, we have shown that
S100A4 is highly expressed in Pancreatic cancers, especially in the hepatic metas-
tases, compared to normal tissue. Using a yeast one-hybrid system and DNA foot-
printing, we have shown that BKLF (Basic Kruppel-Like Factor), a Zinc Finger
protein which acts as a repressor of transcription, binds to specific CACCC sequences
in the minimal S100A4 promoter. BKLF has been shown to associate with the co-
repressor CtBP (C-terminal Binding Protein), a short range repressor which acts 
on the core promoter region and can indirectly interact with Rb protein, in vivo and 
in vitro. The binding to CtBP has been shown to be essential for the repression activity
of BKLF. Using real-time PCR we have studied the expression levels of these genes in
normal and cancerous pancreas tissue samples, as well as in Pancreatic cell lines. 
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REAL-TIME KRAS MUTATIONAL ANALYSIS IN THE DIAGNOSIS 
OF EARLY PANCREATIC DUCTAL ADENOCARCINOMA 
T Wong, N Howes, MG Lombard, HL Smart, I Gilmore, R Sutton, 
F Campbell, Y Kang, I Ellis, W Greenhalf, JP Neoptolemos, Dept. of Surgery,
University of Liverpool, Liverpool L69 3GA
KRAS mutations occur in 75–80% of pancreatic ductal adenocarcinoma (PDAC).
Conventional screening modalities are limited in detecting early, potentially curable
lesions and in this study, we investigate the role of real-time mutational analysis as a
tool for the diagnosis of early pancreatic ductal adenocarcinoma (PDAC). 
DNA was prepared from tissue, or from pancreatic juice/bile extracted from
patients during ERCP. This was analysed by real-time ARMS, involving DNA ampli-
fication using primers, which have a 3¢ base corresponding to the relevant KRAS
mutations. The appearance of product is compared to the appearance of a product that
will be produced equally from mutant and wildtype KRAS. 
From 55 patients with PDAC-15/22 (68%) had mutations in juice and 12/33 (52%)
in bile. From 36 patients with chronic pancreatitis (CP), 7/27 (35%) had mutations in
juice and 4/9 (44%) in bile. In patients with ampullary carcinoma, 6/6 (100%) had
juice mutations and 6/9 (67%) bile mutations. Of patients with no pancreatic diseases,
4/9 (44%) had juice mutations and 14/42 (33%) had mutations in bile. The types of
mutation were correlated with mutations in biopsy/surgical samples. There was no
statistical correlation with age, smoking or alcohol history. 
Although the technique used has detected KRAS mutations in PDAC patients
successfully, it has also detected mutations in patients with CP and even in patients
with no pancreatic diseases. KRAS mutation detection therefore lacks the specificity
required to identify malignancy. Therefore KRAS mutation detection if it is to be used
as a diagnostic tool needs to be used in combination with other molecular analysis
approaches. 
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PRELIMINARY RESULTS OF PHASE I/II STUDY TO 
INVESTIGATE THE USE OF GEMCITABINE IN COMBINATION
WITH RALITREXED IN LOCALLY ADVANCED OR METASTATIC
ADENOCARCINOMA OF THE PANCREAS A Michael1, A Maravcyas2, 
M Hill3, H Wasan4, F Lofts1, 1St. George’s Hosp. London SW17 0QT,
2Princess Royal Hospital Hull HU8 9HE, 3GI Unit RMH Sutton Surrey,
4Hammersmith Hospital London W12 0HS
Gemcitabine has been shown to improve the clinical status of patients with carcinoma
of the pancreas relative to 5FU. Ralitrexed is a quinazololine folate analogue, specific
thymidylate synthase inhibitor with a similar mode of action to 5FU. At a dose of 
3 mg/m2 ralitrexed has been shown to be equally effective to 5FU/LV in metastatic
colon cancer. A phase II trial of ralitrexed in patients with advanced pancreatic cancer
revealed a response rate of 5%. Combining gemcitabine with ralitrexed may result in
increased response rate without marked increase in adverse events. We conducted a
phase I/II study of gemcitabine in combination with ralitrexed in locally advanced and
metastatic adenocarcinoma of the pancreas. Gemcitabine was given on day 1 and 8
with ralitrexed on day 1 of a 21 day cycle. Starting dose of ralitrexed was 3.0 mg/m2
with gemcitabine 1000 mg/m2. Gemcitabine was escalated by 200 mg/m2 for each
cohort up to a maximum dose of 1400 mg/m2. Dose limiting toxicities (DLT) were
defined as grade 3/4 haematologic toxicities according to NCIC-CTC and all grade
3/4 non-haematologic toxicities with the exception of nausea, vomiting, alopecia,
transaminitis. 
Six patient were recruited in cohort 1 (3M/3F), median age 66 (range 53–76) and
median Karnofsky PS 85%. There were 2 cases of grade 3 leucopenia and 2 cases of
neutropenic fever. One patient experienced grade 3 skin toxicity, with a pemphigoid-
like picture. 2 patients had positive clinical benefit response (CBR), 2 were not evalu-
able and 2 had negative CBR. On CT criteria there were 2 PD, 2 SD and two
non-evaluable patients. 
Twelve patients were recruited to cohort 2 (10M/2F) with data available on 9,
median age 57 (range 39–67) and median PS of 86%. 1 patient had neutropaenic fever
and 1 experienced diarrhoea. 2 patients had negative CBR, 3 stable and 0 had a posi-
tive CBR. On CT criteria there were 4 cases of PD, 3 cases of SD and 2 patients were
not evaluable. Due to poor tolerance of the dose level the study continues at a lower
dose level of ralitrexed at 2.5 mg/m2. 56 Poster presentations
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CHARACTERISATION OF OESTROGEN RECEPTOR 
TRANSCRIPTION COMPLEXES IN OVARIAN CANCER CELLS
AND IDENTIFICATION OF OESTROGEN-REGULATED RESPONSES 
AJM O’Donnell, D Burns, K Macleod, JF Smyth, SP Langdon, 
ICRF Medical Oncology Unit, Western General Hospital, Edinburgh 
The majority of ovarian cancers display expression of oestrogen receptors (ERs). Using a
range of ovarian cancer cell lines, we have demonstrated that ovarian cancer cells that express
moderate-high levels of ER, are growth-stimulated by 17b-oestradiol (E2) in vitro (Br. J.
Cancer: 62, 213, 1990). The anti-oestrogen tamoxifen is able to inhibit this growth stimula-
tion in vitro and in vivo and clinical studies have shown that it possesses some therapeutic
activity in ovarian cancer. Recent data have indicated that an oestrogen response in a target
tissue is not only determined by the amount of receptor present but also by the composition of
ER dimer and the presence of cofactors which integrate the receptor with components of the
basal transcriptional machinery. 
With an aim to characterising the composition of oestrogen transcriptional complexes
present within ovarian cancer cells we have investigated the expression of ER isoforms (ER-
a and ER-b) and transcription co-activators/co-repressors in a range of ovarian cell lines and
primary cancers. RT-PCR showed that ER-a mRNA was expressed in PE01 and PE04 cell
lines but not in the PE014 cell line. These results correlate with growth responsiveness to E2.
Interestingly however, ER-a mRNA was also found to be expressed in the SKOV3 cell line
which failed to be growth stimulated by E2. ER-b mRNA was found to be expressed in all 4
cell lines, with highest levels present in the ER-a negative PE014 cell line. The co-activators
SRC-1, TIF-2, AIB-1, p300 and ZAC-1, co-repressors NCoR-1 and SMRT, and other modu-
latory cofactors, SUG-1, BRG-1, FAP-1 and prothymosin alpha were all expressed to varying
degrees in ovarian cancer cell lines and primary tumours when measured by real-time PCR
and associations with transcriptional responses are currently being explored. Oestrogen-
regulated mRNA expression was investigated by differential display RT-PCR. Products that
appeared differentially expressed in PE01 ovarian cancer cells after treatment with 10-10M E2
for 24 h were excised from acrylamide, re-amplified by PCR and subcloned into pGEM-T
Easy vector. These were then sequenced and identified. These included NF-1 related locus,
ZXDA, Histone Deacetylase and S19 and expression levels of these are being quantified by
real-time PCR. mRNA from 10-10M E2-treated cells was also analysed on the Clontech Atlas
Human Cancer 1.2 cDNAexpression array. Of 1185 genes analysed, 19 increased in expres-
sion by at least 2-fold in PE01 cells treated with E2 relative to untreated PEO1 cells, while 
78 genes decreased. Among the expressed genes increasing after E2 treatment were FRA-1
and Cathepsin D while expression levels of erbB2, IGFBP-3, UPA and fibronectin were
decreased. 
This study highlights the complexity of the ER transcription complex and shows that
oestrogen-regulated expression of critical genes involved in the aetiology and progression of
ovarian cancer likely involves multiple transcriptional cofactors. 
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ERBB RECEPTOR ACTIVATION IS ASSOCIATED WITH
GROWTH, MIGRATION AND MORPHOGENESIS IN OVARIAN
CANCER JM Sewell, LMR Gilmour, JF Smyth and SP Langdon, ICRF
Medical Oncology Unit, Western General Hospital, Edinburgh, EH4 2XU 
Members of the erbB or HER family of (type I) tyrosine kinase receptors are
frequently over-expressed in human cancers, and increased expression of both the
epidermal growth factor receptor (EGFr, erbB1, HER-1) and erbB2 (HER-2) have
been associated with poor survival in ovarian cancer. Such data suggests an involve-
ment of these receptors in the growth and progression of this disease. Transforming
growth factor alpha (TGFa) activates the EGFr while the heregulins or neuregulins
(eg HRGb1) activate erbB3 and/or erbB4. Upon activation these receptors homo-or
heterodimerise with other family members, preferentially erbB2, initiating intra-
cellular signalling cascades such as the Ras/ERK kinase pathway. 
To assess the relative contributions of these receptors to growth, migration and
morphogenesis, a panel of ovarian cancer cell lines (PEO1, SKOV-3, OVCAR-5,
41M, PEO1cddp and A2780) were treated with either TGFa or HRGb1 (10-9M). TGFa
stimulated growth of SKOV-3, PEO1 and 41M cells while HRGb1 stimulated growth
of PEO1, 41M and OVCAR-5 cells. Use of blocking antibodies indicated that HRGb1
was acting via erbB3 and not erbB4. In all cell lines (except PEO1cddp cells which were
growth inhibited), HRGb1 was the more potent activator of growth. In migration
assays this trend was reversed; while HRGb1 stimulated migration of PEO1 and
OVCAR-5 cells on collagen and fibronectin, and OVCAR-5 on laminin, TGFa gave a
greater stimulation to each of these situations and also drove SKOV-3 cell migration
on all three matrices. Furthermore, TGFa but not HRGb1 stimulated morphogenic
changes in several of these cell lines. Statistically significant associations were 
identified between the extent of migration promoted by TGFa and erbB2 expression
levels (on collagen P=0.01, on laminin P=0.04: Pearson correlation), while using a
wider cell panel of 13 cell lines, a significant association between magnitude of
HRGb1 growth response and erbB2 expression was also observed (P=0.005: Pearson
correlation). 
TGFa exposure activated both the ERK pathway and PI3 kinase pathway in these
cell lines as indicated by Western blot detection of increased levels of phospho-ERK
and phospho-Akt respectively. The relative contribution of these two pathways to the
differing functions is being assessed by the use of specific inhibitors targeted to
components of these pathways. 
These data indicate that the erbB receptors are involved not only in growth regula-
tion but also in migration and morphogenesis. Our findings suggest that while erbB3
activation primarily drives growth, EGFr signalling is more related to migration,
although neither function is exclusive. 
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USE OF CA 125 TO DEFINE PROGRESSION OF OVARIAN 
CANCER IN PATIENTS WITH PERSISTENTLY ELEVATED
LEVELS Gordon JS Rustin, Maria Marples, Ann E Nelstrop, Mohamed
Mahmoudi, Tim Meyer, Department of Medical Oncology, Mount Vernon
Hospital, Northwood, Middlesex HA6 2RN, UK
Purpose To determine an accurate definition for progression of ovarian cancer in
patients with a persistently elevated serum CA 125. 
Patients and Methods A retrospective analysis was performed on 300 patients
with epithelial ovarian carcinoma with at least one measurement of CA 125. Eighty-
eight patients had persistently elevated CA 125 levels (>23 U/ml) on completion of
first-line chemotherapy. The date of progression according to clinical or radiological
criteria was ascertained in these patients, and compared with the date of progression
according to CA 125. This was defined as the date the CA 125 level first rose to at
least twice its nadir level confirmed by a second sample also at least twice the nadir. 
Results Eighty of the 88 patients had evidence of progression by both standard
and CA 125 criteria. In 6 of these patients no sample was obtained to confirm the
doubling of the CA 125, and in 13 patients CA 125 doubling was documented after the
date of clinical progression. Seven patients never developed doubling of CA 125; two
died from causes other than ovarian cancer, and five are counted as false negative.
Only one patient had a false positive prediction of progression according to CA 125,
dying from myocardial infarction before evidence of clinical progression. This gave
the CA 125 definition of progression a sensitivity of 94% and a positive predictive
value of 98.8%. 
Conclusion In patients with persistently elevated levels of CA 125, doubling of
CA 125 from its nadir level accurately defines progression. If confirmed, these CA
125 criteria should be used as additional endpoints in clinical trials, as proposed by
Vergote et al (JNCI 2000; 92:1534–5). 
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ANDROGENS HAVE DIRECT EFFECTS ON HUMAN OVARIAN 
SURFACE EPITHELIUM RJ Edmondson1,2, JM Monaghan2, 
BR Davies1, 1Dept of Surgery, University of Newcastle upon Tyne, 2Northern
Gynaecological Oncology Centre, Gateshead, Tyne and Wear
Introduction The pathogenesis of epithelial ovarian cancer remains unclear. From
epidemiological studies raised levels of androgens have been implicated to increase
the risk of developing the disease. In addition, epithelial ovarian cancer cells have
been shown to express the androgen receptor. The purpose of this study was to deter-
mine the responses of normal human ovarian surface epithelium (OSE) to androgens. 
Methods We have established primary cultures of human ovarian surface epithe-
lium from patients undergoing oophorectomy for benign disease. Epithelial phenotype
was confirmed by staining with a panel of cytokeration antisera. Total RNA was
isolated from these cultures and the presence or absence of mRNA encoding for the
androgen receptor (AR) was demonstrated using RT-PCR. The presence of androgen
receptor in sections of normal ovary was also investigated using an antibody against
androgen receptor. The effects of androgens on DNA synthesis and apoptosis was
determined using 3H thymidine incorporation and JAM assays respectively. 
Results Eight of eight (100%) cultures tested expressed mRNA encoding
androgen receptor. The presence of AR in OSE of sections of normal ovaries was
demonstrated in all sections. 
Mibolerone, a synthetic androgen, caused a marked stimulation of DNA synthesis
in 8 of 10(80%) cultures when used at a concentration of 1 nM. Two cultures showed
no significant induction of DNA synthesis. Mibolerone also caused a significant
decrease in apoptosis in 2 of 4 (50%) cultures tested. 
Conclusions We have demonstrated that the ovarian surface epithelium is an
androgen responsive tissue and that androgens, at physiological doses, can cause an
increase in proliferation and a decrease in apoptosis. These findings allow for the
possibility that androgens may be involved in ovarian carcinogenesis. Poster presentations 57
P92
A PHASE I INTRA- & INTER-PATIENT DOSE RANGING STUDY 
OF GEMCITABINE, CARBOPLATIN AND PACLITAXEL (GCP) IN
PREVIOUSLY UNTREATED PATIENTS WITH EPITHELIAL OVARIAN
CANCER, PRIMARY PERITONEAL MALIGNANCY, OVARIAN
CARCINOSARCOMA AND FALLOPIAN TUBE CARCINOMA CJ Poole, 
SD Jordan, HB Higgins, VR Archer, GE Pemberton, CRC Clinical Trials Unit,
University of Birmingham B15 2TT and City Hospital Birmingham, B18 7QH 
Introduction A Phase II trial of the GCP (C-AUC5, d1/G-800,d1&8/P-175,d1) triplet
has shown encouragingly high response rates in EOC, but troublesome thrombocy-
topenia(1). As the median MTD of carboplatin and paclitaxel determined by intra-patient
dose-escalation is comparable with that determined conventionally (2), we decided to
undertake an intra-patient dose escalation study to determine the range of inter-patient
variation in MTD and examine the feasibility of developing an individual dose optimisa-
tion nomogram. By using a novel hybrid inter-and intra-patient dose-escalation design we
hoped to discriminate acute from cumulative toxic effects. We also wished to test whether
co-scheduling paclitaxel with gemcitabine d1&8; might attenuate thrombocytopenia. 
Methods Entry level doses: G-800 mg/m2 d1&8; C-AUC5, d1 only; P-75 mg/m2
d1&8. Patients (pts) were treated with 6–8 cycles in 3–6 pt cohorts. One component
was dose-escalated by 10% each cycle (intra-patient), and successive cohorts started
one dose-level above that of the previous entry level dose (inter-patient) towards a
target ANC1.0–1.5´109/L, platelets 75–100´109/L, or grade<3 non-hematologic toxi-
city, all d22, thus defining MTD. Creatinine clearance was recalculated each cycle. 
Results All 21 pts registered have completed ³4 cycles (range 4–8) and 18, ³6
cycles. Cohort 1, (entry level, n=6), cohort 2 (P-82.5 mg/m2, n=3), cohort 3 (C-AUC5.5,
n=3) & 4 (P-90 mg/m2, n=3) are complete; entry level doses for cohort 5 = cohort 1,
cycle 5, ie G-900 mg/m2, C-AUC5.5, P90 mg/m2 and cohort 1, cycle 6 increases C to
AUC6. MTD’s occurred at all 9 dose levels, with a median of G-800 mg/m2 d1&8, C-
AUC5.5 d1, & P-90 mg/m2 d1&8, dose level 4. Myelosuppression was dose-limiting in
16 pts and grade 3 fatigue in 1 pt. 5/18 completed pts required platelet and 16/18, RBC
transfusions. One suffered neutropenic sepsis (ANC nadir = 0.3). All pts with baseline
raised CA125 (12/21) have Rustin-defined responses. Day 22 blood counts show
evidence of a dose-response curve for a paclitaxel neutrophil and platelet-sparing effect
in the range 75–90 mg/m2 (but not with gemcitabine doses >800 mg/m2). 
Conclusion the intra-patient/inter-patient dose-escalation approach is feasible;
GCP MTD’s are widely variable, which prompt consideration of dose individualisa-
tion; paclitaxel has modest dose-related neutrophil and platelet protection effects;
there is no evidence of cumulative myelosupression. 
1. SW Hansen, et al Proc ASCO 1999: Abstract 1379 
2. CJ Poole, et al, Annals of Oncology 2000: Vol 11; P141 
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ZD0473 PHASE II MONOTHERAPY TRIAL IN SECOND-LINE 
OVARIAN CANCER M Gore1, RJ Atkinson2, L Dirix3, D Rischin4, 
P Beale5, P Harnet6, D Hacking7, H Cure8, J Cosaert9, 1Royal Marsden
Hospital NHS Trust, London, UK, 2Belfast City Hospital, N Ireland;
3Oosterveldann, Wilrijk, Belgium, 4Peter McCallum Cancer Institute, 
St Andrews Place, East Melbourne, Australia; 5Royal Prince Alfred Hospital,
Camperdown, Australia, 6Nepean Hospital Penrith, Kingswood, Australia;
7Durban Oncology Centre, Mayville, South Africa, 8CAC Jean Perrin,
Clermont Ferrand, France, 9AstraZeneca, Alderley Park, UK 
New drugs demonstrating activity in platinum-resistant ovarian tumours are required.
ZD0473 is a new generation platinum drug that shows evidence of an extended spec-
trum of antitumour activity and overcomes platinum resistance mechanisms, and is a
good candidate for evaluation in refractory ovarian cancer. This Phase II open-label,
two-stage, multicentre trial aims to assess the efficacy and tolerability of ZD0473 as
second-line therapy in patients with ovarian cancer who have failed one prior plat-
inum-based chemotherapy regimen. Patients received ZD0473 (1-h iv infusion) on
day 1, every 3 weeks and were initially recruited at a dose level of 120 mg/m2. This
dosage was subsequently increased to 150 mg/m2 during the course of the trial, as the
original starting dose was well tolerated. Patients were evaluated in 4 cohorts related
to the time of relapse/progression following completion of first-line platinum-based
chemotherapy: those who relapsed/progressed after (1) ≤12 weeks having shown no
response; (2) ≤12 weeks having responded; (3) >12 weeks and ≤26 weeks; (4) >26
weeks. Cohorts 1–3 were considered to be resistant and cohort 4 sensitive. To date, 29
patients (15 resistant, 14 sensitive; median age 58 years; performance status 0/1) have
been recruited and have received 84 cycles in total. Cycle delay due to toxicity was
experienced by 7/29 patients. An objective response was observed in 2/14 evaluable
resistant patients (1CR, 1PR) and 5/12 evaluable sensitive patients (2CR, 3PR). Stable
disease was observed in 2 resistant and 3 sensitive patients, including evidence of
tumour shrinkage in 3 patients. ZD0473 had a manageable safety profile; there were
no drug-related withdrawals or deaths, and grade 3/4 haematological effects included
thrombocytopenia (14/29 patients), neutropenia (13) and anaemia (12). No evidence
of clinically significant nephrotoxicity or neurotoxicity was observed. Preliminary
results indicate that ZD0473 is active in second-line ovarian cancer, including resis-
tant disease. The trial is ongoing. 
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PHASE II STUDY OF OXALIPLATIN, 5-FU AND LEUCOVORIN 
IN PATIENTS WITH RELAPSED OVARIAN CANCER AL Thomas1,
A Osman1, B Morgan2, S Khanna1, RP Symonds1, K O’Byrne1, Depts of
Oncology1 & Radiology2, Leicester Royal Infirmary, Leicester LEI 5WW 
In relapsed ovarian cancer response rates to second-line therapies remain frustratingly
low. There is a need to develop more effective regimens which are well-tolerated as
these patients often have marked symptoms. Both oxaliplatin (OXA) and 5FU have
shown single agent activity in pts with recurrent ovarian carcinoma. In view of the
in vitro synergistic effect of OXA and 5FU and the tolerability of this combination in
pts with colorectal cancer, we studied these agents in pts with relapsed ovarian carci-
noma following failure of first-line platinum based chemotherapy. Oxaliplatin 85
mg/m2 IV two weekly and weekly 5FU 370 mg/m2 with leucovorin 30 mg IV were
administered and efficacy and safety data collected. To date 14 patients, with median
age 58 years (range 46–66) have been treated. Performance status was 0 in 2 pts, 1 in
7 pts and 2 in 5 pts. Pts had stage 3 (12 pts) or 4 (2 pts) disease. Twelve pts had at least
1 debulking operation 1 pt had 2 debulking procedures and 1 did not have any surgery.
All pts had 1 prior platinum based chemotherapy and 3 had been rechallenged with
carboplatin. Eight pts had also received a taxane. Pts received a median of 6 cycles of
treatment (range 2–11). Most common toxicities were nausea and vomiting (1 pt at
grade 3) and peripheral neuropathy (2 pts at grade 3). One grade 3 neutropenia and 1
grade 3 thrombocytopenia have been seen, however there has been no febrile
neutropenia. Only 3 pts needed dose reductions due to toxicity and of these 1 discon-
tinued treatment. Of 10 evaluable pts, 1 complete and 2 partial responses have been
documented, based on WHO criteria. Using the technique of Rustin et al. (JCO 1996,
14:5: 1545–1551) Ca125 responses occurred in 3 patients. Median survival has yet to
be reached. This combination of OXA and 5FU is extremely well tolerated and even
in this small pt group encouraging responses have been documented. Recruitment
continues and further data will be presented. 
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ASSESSMENT OF TUMOUR MARKERS AND APOPTOSIS 
IN LUNG CANCER CD Macdonald, A Michael, KW Colston, 
JL Mansi, Department of OGEM St. George’s Hospital Medical School,
London SW17 ORE
Lung cancer is the commonest form of cancer in both sexes in the UK and has a poor
prognosis. Numerous genes are associated with the growth and propagation of cancer
including tumour suppresser gene p53, anti-apoptotic bcl-2, proliferation marker ki67
and growth factor receptor IGF-1R. These oncogenes have been widely studied in
relation to prognosis and survival but findings have been inconsistent to date. There is
no information available with respect to changes in gene expression with time or
response to treatment. 
The aim of this study was to determine intra and inter tumour variability of the
markers ki67, bcl-2, p53 and IGF-1R and the level of apoptosis to determine if these
are constantly expressed throughout the tumour. 
Ten patients were selected at random from archived surgical material representing
all types of lung cancer. Ten serial sections, 4–6 microns thick, were sectioned from
each sample for each of the markers studied, a total of 50 slides per tumour. Onco-
gene expression was determined using an immunohistochemical kit from DAKO:
EnVision™. The apoptotic index was determined using a kit from Intergen:
ApopTag™. The slides were graded using two accepted methods by two independent
markers. The coefficient of variation was calculated to give a percentage variation. 
The results indicate that there is an inherent variation in expression of all the onco-
genes studied. Ki67 expression, for example, varied from 10 to 200%. This raises
questions about the reliability of these markers as a prognostic indicator when
assessed by immunohistochemistry. Further research is required in order to evaluate
the relevance of these tumour markers in a clinical setting. 58 Poster presentations
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BIOCHEMICAL EXPLORATION IN LUNG CANCER Maria 
Dogaru, Natalia Rosoiu, Faculty of Medicine, “Ovidius” University,
Constanta, Romania, Ro-8700 
The glucose concentration and lactate dehydrogenase (LDH) in pleural effusion and
blood samples guide the clinician for differential diagnosis between cancer and infec-
tious diseases. 
In this study we examined samples of pleural effusion and blood, collected from 
50 patients, hospitalized in Constanta Lung Pathology Hospital. In 10 cases the cancer
diagnosis have been confirmed; the other 40 have been diagnosed with infectious
diseases, including tuberculosis. 
We assayed the serum for glucose concentration (Glucose-oxydase method),
protein concentration (Biuret method), LDH, ALT, AST (Kinetic method), urea
(Urease method) and the pleural fluid for glucose, proteins, LDH (using the same
methods). 
In patients diagnosed with cancer, preliminary data were in accordance with the
references, showing a significant decrease of pleural glucose concentration (15–60
mg/dl), compared with normal values of glycemia (70–110 mg/dl). Moderate increase
of LDH (300–600 U/l) and moderate decrease (2,5–4,5 g/dl) of pleural proteins were
noticed. 
In infectious diseases, pleural glucose was slightly decreased or normal (50–100
mg/dl). Pleural LDH had high values (500–1000 U/l) compared to serum LDH
decreased values. Proteins were higher than in cancer (4.0–6.5 g/dl). 
In all patients, urea, ALT and AST had values in the reference range. 
Our research shows the importance of pleural glucose and LDH assay in
supporting diagnosis between cancer and infectious diseases. We consider that the
decrease of pleural glucose concentration is determined by the increased catabolism
of glucose in tumoral cells. 
In the specialty references we did not find data referring to glucose metabolites
(pyruvate, lactate, succinate), NAD+ and FAD in lung pathology. We continue our
research with the assay of these biochemical parameters and LDH isoenzyms in
pleural fluid and blood samples. 
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CANCER SPECIFIC GENOMIC INSTABILITY IN BRONCHIAL 
LAVAGE AS A METHOD OF LUNG CANCER DETECTION 
T Liloglou, P Maloney, G Xinarianos, M Hulbert & JK Field, Roy Castle
International Centre for Lung Cancer Research, The University of Liverpool,
200 London Road, Liverpool L3 9TA
Genomic instability is the most common molecular alteration detected in human
cancer1,2. Molecular alterations identified in lung cancer have also been detected in the
bronchial lavage and sputum of lung cancer patients indicating a potential diagnostic
use of such methods3–6. We have previously detected allelic imbalance and microsatel-
lite alterations in DNA from bronchial lavage (BL) from patients with lung cancer but
also individuals with no evidence of lung neoplasia posing the question whether
genomic instability is an exclusive phenomenon of malignant diseases3. We have
consequently established a robust multiplex fluorescent microsatellite assay and
assessed the interassay variation leading to a calculated threshold of 0.23. By using this
assay, we detected genomic instability in 95% of DNA specimens from lung tumours6.
In this study, we assessed the specificity of above assay by examining DNAs from 80
BL samples from patients with lung cancer and patients with no malignant lung
disease. When genomic instability at individual loci was analysed statistically in rela-
tion to clinical diagnosis, markers D3S1289 (P=0.033), D3S1300 (P=0.001), D13S171
(P=0.009) and D17S2179E (P=0.017) demonstrated significantly higher frequency of
instability in BL specimens from lung cancer cases compared to those with non-malig-
nant conditions. In contrast, markers D9S157, D9S161, D13S153 and D5S644 demon-
strated lower specificity (P>0.05) for lung tumours. These results suggest that genomic
instability in some regions may be related to high proliferation rates but not necessarily
to cell commitment to malignancy. When genomic instability was scored using only the
4 cancer-specific markers the assay produced a sensitivity of 73.9% and a specificity of
76.5%. On combining the results from the cytological examination and the molecular
assay, the detection sensitivity reached 82.6%. Our results indicate that genomic insta-
bility may be a potential marker for the early detection of lung cancer; however, we
need to extend our observations and establish set(s) of cancer-specific genomic insta-
bility (CSGI) markers. 
1. Perucho M (1996) Nature Med. 2: 630–631 
2. Lengauer C, et al. (1998) Nature 396: 643–649 
3. Field JK, et al. (1999) Cancer Res 59: 2690–2695 
4. Miozzo M, et al. (1996) Cancer Res 56: 2285–2288 
5. Ahrendt SA, et al (1999) JNCI 91: 332–339 
6. Powell, et al (1999) Clin Cancer Res 5: 2025–2034 
7. Liloglou T, et al. (2000), Int J Oncol 16: 5–14 
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SURVIVAL ANALYSIS AND PROGNOSTIC FACTORS IN NON-
SMALL CELL LUNG CANCER C Martin1, H Bozcuk2, 1Dept. of
Oncology, Norfolk and Norwich Hospital, Norwich, NR1 3SR, 2Oncology
division, Akdeniz University Medical Faculty, Antalya, 07070, Turkey
We analysed survival in relation both to time to starting treatment (hospital delay) and
other clinical parameters in non-small cell lung cancer (NSCLC) patients. All patients
diagnosed with NSCLC presenting in 1998 to Norfolk and Norwich Hospital were
reviewed (189 patients). Median time to starting treatment in all patients was 48 days.
In multivariate analysis, hospital delay did not affect survival in patients in any stage
of the disease. Median survival for the whole group was 147 days and by stage 81
days in stage 4, 158 days in stage 3 and not yet reached in stages 1 and 2 combined
(P<0.001). In stages 1 and 2, referral from GP to chest department as compared with
other referral routes was an independent good prognostic indicator (P=0.032, HR =
0.08) as was having a surgical resection (P=0.006, HR=30.33). In stage 3 patients,
laboratory normality (serum calcium <2.6 mmol/L, albumin < or = to 35 g/l, and Hb >
or = to 12 g/dl) was a good prognostic indicator (P=0.002, HR=0.39). In stage 
4 patients the presence of bone or liver metastases as opposed to other metastatic sites
was associated with shorter survival (P=0.005, HR=2.65). The use of chemotherapy
in stage 4 (P<0.001, HR=0.16) and in stage 3 the use of both radiation and
chemotherapy (P=0.015, HR=0.17) were also associated with improved survival
(non-randomised). The results suggest that expanding resources in oncology and
improving referral pathways are better strategies to improve NSCLC survival than
efforts in reducing hospital delay, although both are important. 
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REGULATION OF APOPTOSIS BY CD40-LIGAND IN 
MALIGNANT B-CELLS Claire Dallman, Peter Johnson and
Graham Packham, CRC Wessex Medical Oncology Unit, Cancer Sciences
Division, University of Southampton, Southampton General Hospital,
Southampton, SO16 6YD, UK
CD40 ligation promotes proliferation, immunoglobulin (Ig) production, Ig isotype
switching, induction of memory and rescue from apoptosis in normal B-cells. CD40
ligation also induces proliferation and apoptotic rescue in some malignant B-cell
lines, and in primary follicular lymphoma, mantle cell lymphoma and chronic
lymphocytic leukaemia cultures. It is also apparent that in some cellular settings,
CD40 activation paradoxically induces growth arrest and apoptosis. 
The ability of CD40 signalling to rescue B-cells from apoptosis has been shown to
correlate with expression of anti-apoptotic proteins. Various target proteins have been
described, including the Bcl-2 family proteins, Bcl-XL, Mcl-1 and Bfl-1, and A20.
However, analysis of these molecules is often restricted to cell lines, and a side-by-
side comparison of the extent and kinetics of their induction in various primary
lymphoid malignancies has not been performed. The role of pro-apoptotic molecules
in CD40 signalling is not known. The aim of this study is to perform a detailed
comparison of the expression of CD40 target proteins in low and intermediate grade
lymphomas. 
We have isolated malignant B-cells from lymph node biopsies of patients with
follicular lymphoma and diffuse large B-cell lymphoma. In all samples tested so far,
treatment of the cells with soluble CD40 ligand (CD40L) for 48 hours, lead to rescue
from etoposide-induced apoptosis and, in some cases, rescue from spontaneous apop-
tosis. We have prepared protein/RNA from the malignant B-cells with and without
CD40L and these materials will be used for analysis of CD40 target molecules. 
P101
PRESENTATION SERUM SELENIUM PREDICTS FOR 
OVERALL SURVIVAL IN PATIENTS WITH DIFFUSE LARGE
B-CELL (DLBC) LYMPHOMA Kim W Last1, Victoria Cornelius2, Trevor
Delves3, Jude Fitzgibbon1, Andy Wilson1, Ama ZS Rohatiner1 and T Andrew
Lister1, 1ICRF Dept. of Medical Oncology, St. Bartholomew’s Hospital,
London, UK, 2ICRF Dept of Statistics, Oxford, UK, 3Southampton General
Hospital, Southampton, UK
Epidemiological, laboratory and chemoprevention trial evidence suggests that the
essential micronutrient selenium can protect against the development of common
malignancies. Selenium can induce apoptosis in cell lines; augment paclitaxel and
doxorubicin induced cell death and prevent the development of cisplatin resistance in
a mouse model of ovarian cancer. This study was undertaken to test the hypothesis
that serum selenium concentration at presentation correlates with outcome in patients
undergoing treatment for DLBC lymphoma. The total selenium content was analysed
in frozen sera from a hundred patients using inductively coupled plasma mass spec-
trometry at a dedicated trace elements laboratory. The patients (median age 57 years,
range 19–85) presented between July 1986 and March 1999 and received anthracy-
cline-based chemotherapy and/or radiotherapy. Fifty-six patients were male. Twenty-
one patients had stage I, 25 stage II, 15 stage III and 39 stage IV disease. B symptoms
were present in 15 patients. The serum selenium concentration ranged from 0.33 to
1.51 mmol/l with a median of 0.91 mmol/l (UK adult reference range = 0.8–2.0
mmol/l). Twenty-seven patients had a level below the UK reference range and only 3
patients had a level above the UK median of 1.4 mmol/l. Selenium concentration was
not significantly correlated with age, gender, stage or presence of B symptoms. On
univariate analysis, age and selenium concentration correlated with overall survival.
On multivariate analysis, using a Cox proportional hazard model, selenium concentra-
tion, as a continuous variable, was predictive of overall survival (hazard ratio 0.76,
95% CI 0.60, 0.95, P=0.018), but not of response to first therapy. However, the
patients in the highest quartile (³1.11 mmol/l) had a significantly higher CR rate (57%
vs. 29%, c2=6.75, P=0.009). In conclusion, serum selenium concentration at presen-
tation predicts for long-term survival in patients treated for DLBC lymphoma.
Prospective validation of these findings will be undertaken. 
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THE ASSESSMENT OF IMMUNE CAPACITY IN PATIENTS  
WITH B CELL MALIGNANCIES H McCarthy, C Ottensmeier, 
S Chilton, A Duncombe, P Johnson, T Hamblin, F Stevenson, 
Cancer Sciences Division, Southampton University School of Medicine,
Southampton, SO16 6YD 
Background It is known that patients with B cell malignancies may have impaired
immune responses and that chemotherapy may add to this defect. 
Aim The aim of this study was to assess the integrity of the immune system in
patients with B cell malignancies at different stages of their disease and after first,
second or third line treatment by measuring the ability to respond to a known recall
immunogen (Tetanus Toxoid, TT). 
Method Three disease categories were investigated as follows: 1) chronic
lymphocytic leukaemia (CLL) Binet stage A, untreated, 2) diffuse large cell
lymphoma (DLCL) following treatment and 3) follicular lymphoma (FL) following
treatment. Cohorts of 14 CLL, 14 DLCL and 11 FL patients were studied. The
majority of subjects had previously been vaccinated with TT. 
Patients were vaccinated intramuscularly with 0.5 ml TT (Pasteur Merieux). Anti-
TT antibody levels were measured by ELISA on serum samples obtained pre-and one
month post-vaccination. The TT and WHO human antitoxin standard used in the
ELISA were obtained from the National Institute of Biological Standards. The results
were compared to those obtained from a cohort of 16 normal healthy volunteers. 
Results All of the normal volunteers had antibody levels that boosted by at least 2
fold from their baseline values. We therefore assigned those patients who also boosted
their baseline levels by 2 fold as responders and those that did not as non-responders.
In addition, those patients who failed to boost post-vaccination antibody levels above
the recognised protective value of ³0.1 IU/ml were also counted as non- responders.
Response rates were 57% (8/14) in CLL group, 71% (10/14) in DLCL group and 72%
(8/11) in the FL group. All three categories responded less well than the control group
(P=>0.05). The FL and DLCL cohorts were a heterogeneous group who had received
diverse treatments. In the DLCL and FL groups, 60% and 50% of responders were in
Ist clinical remission respectively. Numbers are currently insufficient for further
subgroup analysis. 
Conclusions The ability to elicit an antibody response to a recall antigen such as
TT is dependent on both cellular and humoral arms of the immune system.
Remarkably in our patient groups, a high proportion do respond positively to TT. This
suggests that the responding groups may be suitable candidates for new treatment
strategies or immunotherapy aimed at stimulating the patient’s own immune system to
combat their B cell malignancies. DNA vaccination using tumour derived idiotypic
determinants would be an example of this. 
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SUCCESSFUL RADIOIMMUNOTHERAPY (RIT) OF B-CELL 
LYMPHOMAS DEPENDS ON SYNERGY BETWEEN LOW
DOSE RATE IRRADIATION AND ANTIBODY (MAB) Y Du, J Honeychurch,
PWM Johnson, TM Illidge, CRC Oncology Department, Cancer Sciences
Division, Southampton General Hospital, Southampton, SO16, 6YD, UK
The aims of this study were to investigate the critical mechanisms involved in
successful RIT of B cell lymphomas. High dose-rate (HDR-1 Gy/min) and low dose-
rate (LDR-0.01 Gy/min) irradiation were compared with and without mAb in vitro
and in vivo using murine B lymphoma cell lines that also establish as syngeneic
animal models. Cell survival was assessed in vitro by analysing DNA content with
Propidium Iodide using flow cytometry, clonogenic assays in vitro and animal
survival. HDR and LDR irradiation was delivered using a modified 225 Kv X-ray
machine. All of the four cell lines (p-BCL1, BCL1-3B3, EL4 and 38C13) studied
demonstrated significantly more apoptosis (1.5–3 fold increase) and decreased clono-
genic survival with LDR compared to HDR (P<0.01). These observations were then
confirmed in vivo and a dose dependent increase in animal survival was seen with
LDR over HDR. We next investigated the role of increasing doses of low dose rate
irradiation by using therapeutically inactive mAbs to deliver “systemic radiotherapy”
as part of RIT. The BCL1 model was used to investigate a dose response for RIT.
Animals were inoculated with 105 tumour cells and RIT was given by intravenous
injection between 7–10 days later. A dose dependent increase in tumour protection of
around 10 days was seen as the RIT dose of 131I-labelled anti-Class II mAb was
increased from 3.7 to 18.5 MBq per animal. However, when unlabelled anti-Idiotype
(surface Ig) or anti-CD40 were added in addition to the 18.5 MBq of 131I anti-Class II
mAb highly significant increases in tumour protection of at least 30 days over that
seen in groups treated with 18.5 MBq of 131I anti-Class II mAb or unlabelled anti-Id
alone (P<0.001). For those treated with anti-CD40 and 18.5 MBq of 131I anti-Class II
mAb long-term tumour protection was seen (>150 days). We have demonstrated for
the first time in syngeneic animal models that there is a radiation dose response for
RIT. Our findings strongly suggest that LDR is more effective than HDR in inducing
apoptosis and that antibody and irradiation can be synergistic in vivo. We believe this
data provide new insights into our understanding of effective RIT in lymphomas. 60 Poster presentations
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IN VITRO EVIDENCE FOR DIFFERENCES IN 
6-MERCAPTOPURINE VERSUS 6-THIOGUANINE
METABOLISM DEPENDING ON TPMT STATUS L Hogarth, M Little*, 
L Minto, C Redfern, A Hall and S Coulthard, LRF Molecular Pharmacology
Group, Medical School, Newcastle University, UK. NE2 4HH 
The thiopurine drugs are given as part of continuing therapy in childhood acute
lymphoblastic leukaemia (ALL) and are key agents in preventing relapse. Variations
in the level of thiopurine methyltransferase (TPMT) activity appear to be a major
molecular determinant of the extent of thiopurine metabolism. TPMT cDNA was
cloned into an inducible expression vector and transfected into an embryonic kidney
cell line, EcR293. TPMT expression was induced in these cells to elucidate sensitivity
of these cells to 6-thioguanine (TG) and 6-mercaptopurine (6-MP). 
Using SRB assays, for cells treated with 6-TG, the IC50 was higher in the induced
cells (2.8 mM) compared to the un-induced cells (1.7 mM). Conversely, with the 6-MP
treated cells, the IC50 was four-fold higher in those with low TPMT activity (8 mM vs.
1.8 mM). Preliminary apoptosis measurements have supported these findings. In
TPMT over expressing cells treated with 6TG, less apoptosis was observed than in
cells with low TPMT expression. This was in contrast to 6MP treated cells, in which
less apoptosis was observed in cells with high TPMT expression compared to low
TPMT expression. Measurement of thioguanine nucleotide (TGN) incorporation into
DNA showed increased levels of TGNs in TPMT induced cells for both 6TG and
6MP. TGN levels were identical in high and low TPMT expressing cells treated at IC50
values for 6TG. However, treatment with IC50 values for 6MP showed dramatically
reduced incorporation in high TPMT expressing cells. These data suggest that the
cytotoxic effect of 6MP is not solely due to the incorporation of fraudulent bases 
into DNA. 
Studies are underway to measure levels of active methylated metabolites produced
from 6MP and 6TG in the TPMT transfected cells. These will be correlated along with
TGN incorporation into the DNA with cytotoxicity. 
This work is supported by The Leukaemia Research Fund. 
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MEASUREMENT OF ASPARGINE SYNTHETASE mRNA 
LEVELS BY REAL-TIME PCR M Leslie, MC Case, AG Hall, 
SA Coulthard, POU laboratory, CRU 2nd Floor, Cookson Bldg, Newcastle
University, Newcastle, NE2 4HH
L-Asparaginase (L-asp) is a potent chemotherapeutic enzyme and a standard compo-
nent in the treatment of patients suffering from acute lymphoblastic leukaemia (ALL).
However, it has potentially severe side effects, including anaphylactic shock, pancre-
atitis, liver dysfunction and coagulopathy. Intramuscular injection can be very painful
and cause local inflammation. Thus it would be beneficial if treatment could be
targeted to patients most likely to respond. A detailed understanding of the molecular
pharmacology of this drug in vivo will be advantageous in the individualisation of 
L-asp therapy. 
The cytotoxic effect of L-asp results from the complete depletion of asparagine
from blood and bone marrow. Leukaemic blasts lack asparagine synthetase (AS)
activity unlike normal cells and thus rely on circulating asparagine for cell survival.
Resistance to L-asp in vitro is due to increased cellular AS activity, though in vivo this
has yet to be confirmed. AS levels may not be consistent between patients, and so
there may be a subset of ALL patients expressing higher levels of AS at presentation
for which L-asp therapy may be of little or no benefit. Some patients with AML have
also shown favourable response to L-asp, however limited results have been published
regarding AS expression in these patients. 
There is a need for techniques sufficiently sensitive to provide direct evidence to
support the hypothesis that L-asp provides a selective cytotoxic effect because of the
reduced expression of AS in leukaemic blasts. We have developed a real- time PCR
assay to detect AS mRNA levels in the lymphoblasts of patients with acute leukaemia.
This newly described technique allows simple and accurate quantitation of mRNA
levels over several orders of magnitude using dual labelled fluorogenic hybridisation
probes. Real-time quantitative PCR requires the use of standard curves for both an
endogenously expressed transcript as a control and a standard curve for unknown tran-
scripts with known dilutions of cDNA template. The control in this case was human
transcription binding protein, which is expressed at similar levels in all cells. The
normalised AS mRNA levels in ALL patients varied from 0.09 ´ 10–2 to 3.9 ´ 10–2
(median = 0.19 ´ 10–2, n=7). Interestingly, preliminary data extracted from AML
patient samples assayed suggests a similar spread. We will present data showing
considerable variability in the expression of AS between patients of ALL and AML. 
This work is supported a Gordon Pillar Studentship (Leukaemia Research Fund). 
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SURVIVAL FROM RECURRENCE OF HODGKIN’S DISEASE: 
ST BARTHOLOMEW’S HOSPITAL, LONDON CS Barlow, 
J Shamash, R Gupta, M Powell, A Wilson, A Norton, AZS Rohatiner, 
TA Lister Division of Haemato-Oncology and ICRF Medical Oncology Unit,
St. Bartholomew’s Hospital, London ECIA 7BE
211 patients (m:f 134:77) responding to treatment for Hodgkin’s Disease at St.
Bartholomew’s Hospital between 1968 and 1999 developed recurrent disease and
form the basis of this analysis. 48% (102/211) originally had early stage disease, 52%
(109/211) being advanced stage. Patients had been treated according to the protocols
in place at the time. Outcome according to original treatment had been documented as
CR n=144, GPR n=52 and PPR n=15. Six patients died following 1st recurrence
without further therapy. 205 were retreated (CT=163, RT=32, CT&RT=10). 82%
(168/205) responded to treatment for 1st recurrence, 152 achieving CR or GPR. 19 of
these received consolidation with high dose therapy in second remission. 55% of
patients remain in continuous second remission. Second recurrence was documented
in 62 patients. 57 received a third treatment with 33 responses (CR or PR). The
median duration of 3rd remission was 3 years. Overall survival following first recur-
rence of Hodgkin’s Disease is 60% at 5 years and 25% at 30 years. No significant
difference was observed between those whose 1st remission was <12 months (58/211)
and those for whom it was more than 1 year (153/211). This analysis shows that recur-
rent Hodgkin’s disease is responsive to chemotherapy and that for a few, the long-term
outlook is still good. Factors identifying those at risk of recurrence and better treat-
ment for these patients is required. 
P107
p53, mdm2, p21/waf1, bc12 AND bcl-6 PROTEINS 
EXPRESSION IN NON-HODGKIN’S LYMPHOMAS 
SF Al-Othman1, JR Goepel2 H Al-Husaini3, J Martin4, JA Saad Aldeen5,
Lawry1, 2Division of Oncology and Cellular Pathology, 2Department of
Pathology, University of Sheffield, Sheffield, 3Department of Histopathology &
5Oncology Department, Riyadh Armed Forces Hospital, Riyadh, K.S.A.
4Department of Histopathology, King Faisal Specialist Hospital & Research
Centre, Riyadh, KSA
Methods We have investigated the immunohistochemical expression of p53,
p21/waf1, MDM2, bcl-6, and bcl-2 proteins in 3 reactive lymph nodes and 35 cases of
non-Hodgkin’s Lymphomas (14 follicular, 11 diffuse large B-cell (DLBC) nodular
lymphomas and 10 DLBC lymphomas of gastric origin). Samples were scored for
staining distribution and intensity using reactive lymph nodes as baseline controls. 
Results All the reactive lymph nodes studied showed relatively constant labelling
for three proteins, p53, MDM2, and p21, namely staining of isolated large germinal
centre cells, together with occasional activated lymphocytes in the inter-follicular
area. Conversely, bcl-6 expression was restricted to B cells within the germinal centre
and rarely in the inter-follicular zone. Bcl-2 proteins, in contrast, showed opposite
staining patterns to bcl-6 with expression in the inter- follicular zone, and other follic-
ular components, but rarely within the germinal centres. 
In malignant disease bcl-2 expression was identified in 87% (13 of 15) follicular
lymphoma yet only half of the DLBC lymphomas studied (41% -nodal cases, 50% -
extranodal cases). In contrast, bcl-6 protein expression was only detected in 33% (5 of
15) cases of follicular lymphoma, compared to 63% (12 of 22) cases of DLBC, with
increased expression in extranodal cases (70%) compared to nodal cases (42%). 
p53 protein expression was presented in 18 of 37 (48.6%) of non-Hodgkin’s
lymphoma, being more common in high grade (15 of 22, 68%) versus follicular
lymphoma (3 of 15, 20%). While p21 and MDM2 were positive in about half of the
nodal and gastric non-Hodgkin’s Lymphomas, their was greater expression in low
grade disease. 
Conclusions Follicular lymphoma was characterised by the reciprocal expression
of bcl-2 and bcl-6. 
Comparable staining was seen for p53, MDM2 and p21 between reactive and
malignant lymph nodes. However, there was an inverse correlation between p53 and
bcl-2 protein expression. As p21 and MDM2 proteins are inducible by wild type (wt)
p53, the expression of the three proteins (p53 / p21 / MDM2) may indicate functional
p53 pathways in lymphoma and therefore a more favourable clinical response to treat-
ment. 
Research was supported by the Kingdom of Saudi Arabia and Yorkshire Cancer
Research Poster presentations 61
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ChIVPP/EVA HYBRID CHEMOTHERAPY FOR PREVIOUSLY 
UNTREATED HODGKIN’S DISEASE (HD) – A HIGHLY
EFFECTIVE ETOPOSIDE CONTAINING REGIMEN WITH A LOW
INCIDENCE OF SECONDARY AML/MDS. UPDATED RESULTS FROM
CONSECUTIVE RANDOMISED CLINICAL TRIALS INVOLVING 701
PATIENTS JA Radford1, AZS Rohatiner2, WDJ Ryder1, DPD Deakin1, 
T Barbui4, NP Lucie3, A Rossi4, DJ Dunlop3, RA Cowan1, PM Wilkinson1, 
RK Gupta2, RD James1, J Shamash2, J Chang1, D Crowther1, TA Lister2,
1Christie Hospital, Manchester, UK, 2St. Bartholomew’s Hospital, London,
UK, 3West of Scotland Lymphoma Group, Glasgow, UK, 4Ospedali Riuniti,
Bergamo, Italy
Since 1984, a total of 701 patients (pts) with previously untreated HD, clinical stages
I/II (plus mediastinal bulk and/or B symptom) and clinical stages III/IV have been
randomised into two consecutive randomised phase III trials featuring ChlVPP/EVA
hybrid chemotherapy (chlorambucil 6mgs/m2 po, procarbazine 90 mg/m2 po, pred-
nisolone 50 mg/m2 po all on days 1–7, etoposide 75–100 mg/m2 po days 1–5,
vincristine 1.4 mg/m2 iv day 1, vinblastine 6mgs/m2 iv and Adriamycin 50 mg/m2 iv
both on day 8 of a 28 day cycle). Following chemotherapy and a restaging evaluation
radiotherapy was given to sites of previous bulk or residual radiographic abnormali-
ties. Median follow-up is now 11 years for trial 1 (versus MVPP, n = 419 pts) and 
4.9 years for trial 2 (versus VAPEC-B, n=282 pts) which was closed prematurely at
the planned third interim analysis in September 1996. 
In trial 1 the previously reported superiority of ChlVPP/EVA over MVPP has been
maintained and in trial 2 freedom-from- progression (FFP) event-free-survival (EFS)
and overall survival (OS) are all substantially better in the population treated with
ChlVPP/EVA for whom the 2 and 5 year results are 87% and 82% (FFP), 85% and
78% (EFS) and 92% and 89% (OS). In both trials, 18 of 355 pts treated with
ChlVPP/EVA have developed a second tumour and 11 have died of this complication.
In 3 cases the diagnosis was AML/MDS representing an actuarial incidence of 0.7%
and 1.4% at 5 and 10 years respectively. 
ChlVPP/EVA hybrid is a highly effective chemotherapy for previously untreated
Hodgkin’s disease and is associated with a low incidence of secondary AML/MDS
even after prolonged follow-up. Results will be further updated in April 2001. 
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WHAT EFFECT DOES CHEMOTHERAPY HAVE ON 
LYMPHOCYTE SUBSETS IN HIV RELATED LYMPHOMA? 
T Powles, M Nelson, A Mohith BG Gazzard and M Bower, Dept Medical
Oncology, Chelsea and Westminster Hospital. SW10 9NH
Chemotherapy causes prolonged suppression of lymphocyte subsets in the HIV nega-
tive population; the CD4 count can take up to 1 year to recover in adults. The recover
in children is faster due to thymic activity which tails of with age. Other lymphocyte
subsets return to normal levels over a shorter period of time. This study was designed
to estimate the effect of chemotherapy on immune markers in 20 patients treated with
both highly active antiretroviral therapy (HAART) and combination chemotherapy for
AIDS related lymphoma (ARL). The T helper (CD4), T-suppressor (CD8), B (CD19)
and natural killer cells (CD16 & 54) and HIV m RNA viral load were recorded before,
during and up to 6 months after chemotherapy. 
The CD4 and natural killer cells fell by 52% and 57% respectively but recovered 
to pre-treatment levels within 1 month of completing chemotherapy. There was no
significant change in the viral load or CD8 count during the study period. B cells fell
by >50% and the recovery was slower, taking 3 months. 
The recovery of CD4 count was faster than documented in the HIV negative popu-
lation and in HIV positive individuals not on HAART. We speculate that this recovery
is due to up regulation of thymic activity caused by the HAART, which is well docu-
mented in the HIV literature. This data also enables us to estimate the degree to which
the CD4 count will fall during chemotherapy, and therefore which individuals will
require prophylaxis against opportunistic infections. 
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A PILOT STUDY TO ASSESS THE FEASIBILITY OF USING 
3D DATASETS TO COMPARE RADIATION DOSE TO TARGET
TISSUES AND CRITICAL STRUCTURES FROM TWO RADIATION
TECHNIQUES Nicola Thorp, Isabel Syndikus, Elizabeth Richards, Kirstie
Brown, Joyce Warren, Helen Mayles, Department of Radiotherapy,
Clatterbridge Centre for Oncology, Wirral, Merseyside. CH63 4JY 
A technique comprising two modified tangential fields covering the breast (or chest
wall) and the axilla has been used at our centre for many years to give adjuvant radio-
therapy for early breast cancer. We aim to develop a method of comparing this
“monobloc” technique with conventional tangential fields using 3 dimensional (3D)
planning datasets. For this initial phase of the study, CT scans were performed on a
conventional scanner and the scans were transferred to Nucletron Plato Planning
Software. After outlining the relevant anatomical structures, isodose plans were
constructed for the two techniques. Integral dose volume histograms (DVH’S) were
calculated for target volumes and critical structures and the two sets of mean
percentage doses were compared. 
Nine patients were scanned for both techniques and one patient each was scanned
for the monobloc and conventional tangential technique only. The resulting DVH’s
were as expected. Both techniques treated the breast (or chest wall) adequately. The
monobloc also covered the axillary region but the mean percentage dose to the heart
and ipsilateral lung was significantly greater than with conventional tangential portals. 
It was necessary to modify the patients’ arm positions for computed tomography
(CT) scanning due to the limited aperture size. The conventional CT scanner therefore
has a limited role in 3D breast planning in view of the constraints on patient position.
We have now commenced the next phase of the study comparing the monobloc tech-
nique with 3 field techniques using a simulator with CT option which enables the
acquisition of CT slices in the actual treatment positions. 
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THE USE OF A PRE-TRIAL QUESTIONNAIRE IN 
DETERMINING RECRUITMENT INTENT IN A STUDY OF
SEQUENCING OF CHEMOTHERAPY AND RADIOTHERAPY IN BREAST
CANCER S Bowden1, I Fernando2, J Dunn1 for the SECRAB Steering
Committee
1CRC Trials Unit, Institute for Cancer Studies, The University of Birmingham, B15 2TT,
2Cancer Centre, Queen Elizabeth Hospital, Birmingham. B15 2THA survey by the Royal
College of Radiologists (RCR) in 1993 demonstrated that UK Oncologists were divided
on how to sequence adjuvant chemotherapy (CT) and radiotherapy (RT) for the treatment
of early breast cancer. 60% of Oncologists were giving CT and RT sequentially (CT®RT
or RT®CT) and 40% were using a synchronous schedule (CT®RT®CT). 
In 1997 a questionnaire was designed to determine 1) if Oncologists would partic-
ipate in a trial to determine the optimal sequence of CT and RT; and 2) the standard
CT and RT protocols used in the UK. This was sent to 200 Oncologists registered on
the CRC Trials Unit database as treating breast cancer. 113 Oncologists replied of
which 100 expressed an interest in participating in a trial. 10 different CT regimens
were recorded, including CMF, CMF + anthracycline, FEC, AC, CEF, and Sutton
MM. CMF was the most popular with 106 (96%) consultants using this alone or with
another regimen, most frequently CMF + Anthracycline (31%). 15 different RT
schedules were recorded, the most popular being 50 Gy in 25 F (33%), 40 Gy in 15 F
(26%), 45 Gy in 20 F (13%), 39 Gy in 13 F (6%) and 46 Gy in 23 F (4%). 
These data were used to design a national, phase III clinical trial to address the
sequencing question (SECRAB). The intention being to randomised 2000 women to a
sequential (CT®RT) or a synchronous (CT®RT®CT) schedule. The most
frequently used CT and RT regimens were chosen for use in the trial and all consul-
tants who expressed an interest were invited to participate. Recruitment commenced
in July 1998. Of the 100 Oncologists who expressed an interest only 29 had taken up
the invitation to participate in the trial at the end of January 2001 (a further 19 who did
not receive the initial questionnaire were also participating in the study). 
The data collected on the questionnaire has been compared to that provided at
randomisation. The CT regimen chosen at randomisation (70% CMF; 30% CMF +
anthracycline) mirrored the intent indicated on the questionnaire. In contrast the most
popular RT schedule chosen at randomisation was 40 Gy in 15 F as opposed to 50 Gy
in 25 F indicated on the questionnaire. The proportion of the other RT schedules did
however reflect current UK clinical practice as determined by the questionnaire. 
The results of this simple questionnaire and the survey performed by the RCR
clearly demonstrate the huge variation in the adjuvant treatment of patients with breast
cancer in the UK. SECRAB will determine whether the scheduling of CT and RT has
an effect on local recurrence, survival and morbidity of treatment. It is already the
largest trial in the world addressing this question. 62 Poster presentations
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AUDIT OF NON-COMPLETION OF RADIOTHERAPY 
TREATMENT NG Mikhaeel, S D’Arcy, Mount Vernon Centre for
Cancer Treatment, Northwood, Middlesex, UK
Background & Aim Demand on radiotherapy treatment is rising while current radio-
therapy resources are limited. Most oncology departments across the UK have a
waiting list for radiotherapy treatment. It is important to ensure that the current limited
resources are optimally used. We conducted a prospective audit in Mount Vernon
Centre for Cancer Treatment to assess the incidence of booked treatment courses
which were not delivered (not started or started but not completed) and the reasons
why. 
Methods The audit covered a six months period from January to June 2000 inclu-
sive. We kept a record of all patients who did not receive their radiotherapy treatment
and who started but did not finish the prescribed course. At the end of the six-month
period we reviewed the patients’ notes for data collection. 
Results There were 2169 radiotherapy courses booked in the audit period. 2054
courses (94.7%) were completed. Eighty (3.7%) courses were not started (i.e.
cancelled) and 35 (1.6%) were started but not completed. 71% and 69%, in the non-
start and non-completion groups respectively, were palliative treatments. 72% & 74%
respectively aged more than 60 years. In the non-start group, the most common cause
was death (68%). Eighteen percent were “too ill to attend” (TITA) at the time of treat-
ment. In the non-completion group, the most common cause was death (51%)
followed by TITA (20%). Disease progression during treatment accounted for 17% (6
patients). Seven patients received 1 out of planned 2 treatments of palliative radio-
therapy for lung cancer. Lung cancer was the most common diagnosis in both groups.
Comparison with a previous audit in 1997 showed a reduction in the non-completion
rate from 2.2% to 1.6% (27% reduction). 
Conclusion There was a high rate (94.7%) of completion of booked radiotherapy
treatment in our centre during the audit period. Most of the undelivered treatments
were palliative. There are some inevitable causes e.g. progression of disease during
treatment or sudden death from cancer-unrelated causes. Further prospective audit
with correlation to treatment waiting time is planned. Current data collection does not
allow audit of death within one month of radiotherapy. Low rates of non-completion
of treatment are possible and should be aimed for to optimise the use of limited
resources. 
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NATIONAL AUDIT OF CHEMO-RADIATION PRACTICE IN 
HEAD AND NECK TUMOURS IN THE UNITED KINGDOM 
RSD Brown, M McCormack, M Vilarino-Varela, L Melcher, HA Payne,
Meyerstein Institute of Oncology, Middlesex Hospital, Mortimer Street,
London WIN 8AA
Purpose To conduct a national audit of current chemo-radiation practice in the treat-
ment of head and neck malignancies (as part of a wider survey of chemo-radiation
practice for a range of different sites). 
Method A postal questionnaire sent to all consultant clinical oncologists in the UK
(April-July 2000), requesting details of current chemo-radiation practice. Consultants
treating head and neck cancers were asked to provide details of subsites, dose-frac-
tionation and chemotherapy schedules used. 
Results Overall response rate to the questionnaire was 311/385 (81%). Sixty-one
out of 82 (74%) of those treating head and neck cancer used chemotherapy and radio-
therapy, with 52/61 (85%) using concurrent chemoradiotherapy. The commonest sub-
sites treated with chemo-radiation were nasopharynx 30/61 (49%) and larynx 11/61
(18%). There was wide variation in total radiation dose and fractionation and in the
choice of chemotherapy drugs, dose and scheduling for all sites treated. Twenty-six
different radiotherapy regimes and 40 different chemotherapy regimes were used for
treating head and neck cancer. The most frequently used radiotherapy schedule was 66
Gray in 33 fractions (18/60, 30%). The most commonly used chemotherapy was
cisplatin, either alone (18/52, 35%) or in combination with 5-fluorouracil (22/52,
42%). However within each of these categories there were many different schedules.
Detailed analysis of these results is presented. 
Conclusions There is a wide variation in chemo-radiation schedules in current use
for the treatment of head and neck cancer in the UK. This may reflect the lack of
national guidelines, conflicting evidence from randomised controlled trials and a
desire by oncologists to minimize toxicity. 
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IMPACT OF LUNG CANCER MULTIDISCIPLINARY TEAM 
MEETING (MDT) ON RATES OF HISTOLOGICAL DIAGNOSIS
AND RADICAL THERAPY CJ Ferguson1, TK Rogers2, S Rogers2 and 
MQ Hatton1, 1Weston Park Hospital, Whitham Road, Sheffield, S10 2SJ,
2Doncaster Royal Infirmary, Armthorpe Road, Doncaster, DN2 5LT
Aim To see if our lung cancer MDT had improved the rate of histological diagnosis
and/or the proportion of patients referred for radical therapy. 
Introduction In Doncaster prior to 1997 no MDT lung cancer meetings occurred,
referral to an oncologist or cardiothoracic surgeon was at the discretion of the respira-
tory physicians. An audit of lung cancer patients was carried out in summer 1997.
Since October 1997 weekly meetings have occurred supported by a site-specialised
oncologist and thoracic surgeon. 
Methods The 1997 audit comprised a prospective evaluation of 63 consecutive
lung cancer patients, the “pre-MDT patients”. 
Between 1st October 1997 and 1st July 2000 599 incident cases of lung cancer have
been discussed at the MDT meeting, the “MDT patients”. Details of all patients
discussed have been recorded prospectively. 
Proportions were compared for significance usingx2 or Fischer’s exact test. 
Results There has been a trend towards MDT patients being older (59% of MDT
patients vs 51% of pre-MDT over 70) and less fit (13% vs 1.5% (P<0.005) inoperable
due to poor performance status). 
There has been an increase in the histological diagnosis rate (77% MDT patients vs
65% pre-MDT). 
There has been a reduction both in referral for thoracotomy (10.3% MDT patients
vs 17.4% pre-MDT) and in successful thoracotomy rates (8.2% vs 12.7%). 
Rates of referral for radical radiotherapy are unchanged (3%). 
Conclusion Despite an increased rate of histological diagnosis this study shows no
improvement in the rate of radical therapy as a result of the MDT. 
Analysis of the effectiveness of the MDT may be complicated by changing referral
patterns. 
It will therefore be important to compare survival rates to avoid this potential bias. 
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TWO YEAR RESULTS OF A MULTI-DISCIPLINARY LUNG 
CANCER SERVICE SG Russell, K Waite, L Magee, 
D Gilligan, Thoracic Oncology Unit, Addenbrooke’s and Papworth NHS
Trusts, Cambridge. CB2 2QQ
Introduction The improvement of cancer care in the UK currently has a high profile.
The Calman-Hine recommendations and the NHS Cancer Plan aim to improve and
provide equitable high quality care to those diagnosed with cancer. This abstract
reports the 2 year results of a well established multidisciplinary team (MDT) for lung
cancer. Patients suspected of having lung cancer attend the service on one day for a
series of programmed diagnostic investigations. They also undergo an initial specialist
nurse assessment to identify psychological or social problems likely to require early
intervention. The results are discussed within the same week at a multidisciplinary
meeting and a management plan made along agreed guidelines. 
Patients/Methods During 1998 306 new patients were seen in the clinic of which
211 (69%) had lung cancer, of which 201 were histologically proven (95%). 131 were
male (65%) and 70 female (35%). The mean age was 72 (range 40–91). 29 small cell
(14%), 172 Non-small cell (NSCLC) (86%). Of the NSCLC 34 had a surgical resec-
tion (20%). The other modalities of treatment were radiotherapy 105 patients (61%)
and chemotherapy 23 (13%). The staging was as follows 1–27 patients (16%), 11–24
(14%), IIIa-37 (22%), IIIb-28 (17%) and IV-49 (30%), 7 patients were not formally
staged. There were 29 Small cell cancers, 15 were limited and 14 extensive stage.
Treatment was with radiotherapy 7 patients, Chemotherapy 9 and both in 11.31% of
patients were entered into clinical trials of which 19% were randomised controlled
trials. The main outcome was survival and data was gathered for all patients, who
were followed until death or at least 2 years. 
Results The table below shows the overall NSCLC survival by stage. 
Stage 1 Year 2 Year 
I 70% 48% 
II 58% 50% 
IIIa 40% 27% 
IIIb 28% 21% 
IV 12% 0% 
Of the 35 patients who had a resection the median survival by stage in all stages
has not yet been reached with a median follow up of 30.7 months. In those with small
cell lung cancer the median survival in limited stage disease was 13.2 months and 2.8
months in extensive stage disease. 
Conclusions We believe these are the first published survival figures from a
comprehensive lung cancer service in the UK. These results will be compared to other
published series and discussed in context with Cancer Registry Data. Poster presentations 63
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INTERNATIONAL VARIATION IN PALLIATIVE 
RADIOTHERAPY REGIMENS FOR LUNG CANCER: DOES
EVIDENCE MATTER? A QUESTIONNAIRE SURVEY Elizabeth Toy, Fergus
Macbeth, Velindre Hospital, Cardiff, UK. CF14 2TL 
Background  Previous surveys have shown widespread variation in radiotherapy
practice in the palliative treatment of lung cancer. Nine randomised controlled trials
and a number of clinical guidelines have been published in the last 15 years. This
study was designed to assess the impact of this evidence on clinical practice. 
Method A systematic review of randomised trials of palliative radiotherapy in
NSCLC was presented at three international conferences (ECCO 1999, 2nd Consensus
Workshop in Palliative Radiotherapy and Symptom Control 2000 and The World
Lung Cancer Conference 2000). A questionnaire was distributed to members of the
audience who were invited to answer questions about their management of two hypo-
thetical patients (one with symptoms and poor performance status (PS) and one
asymptomatic with good PS) and about their response to the evidence presented. 
Results 110 questionnaires were returned, with respondents from 24 countries in
Europe, North America, Africa, Australia and the Far East. For the two cases a total of
49 different regimens were recommended (24 for case 1, 34 for case 2) with doses
ranging from 8Gy/IF to 70 Gy/35 F. The most frequent reason for the choice of
regimen (51%) was “departmental policy”. Research findings were mentioned by
39%. A minority of respondents (17%) would change practice in the light of the
evidence presented. 
Conclusions There is still widespread practice variation in palliative radiotherapy
and an apparent reluctance to change even in the light of good research evidence. 
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RADICAL RADIOTHERAPY FOR NON-SMALL CELL LUNG 
CANCER, OUTCOMES AND DELAYS IN TREATMENT – THE
CAMBRIDGE EXPERIENCE 1996–99 KJ Waite, SG Russell, L Magee and D
Gilligan. Thoracic Oncology Unit, Addenbrooke’s Hospital, Cambridge. CB2
2QQ and Papworth Hospital NHS Trust
Introduction Radical radiotherapy has been shown to cure a proportion of patients
with non-small cell lung cancer (NSCLC) who are considered to be medically unfit
for surgery or who refuse surgery. Delays in commencing treatment have also recently
been shown to be important. We present the results of our patients with NSCLC who
have been treated radically with radiotherapy between 1996 and 1999. 
Patients/Methods 53 patients with NSCLC, who were considered unfit or who
refused surgery, were treated between 1996–99 with radical radiotherapy. Patients
who were treated with chemo/radiotherapy have been excluded from this review. 38
were male and 15 were female. The mean age at diagnosis of this group was 71 years,
(range 54–82 years). The performance status of these patients was as follows: 7 were
P.S. 0, 30 P.S. 1, 10 P.S. 2, 1 P.S. 3 and the performance status was not recorded in the
remaining 5 patient notes. 96% of patients had histologically proven disease. 37 had
squamous cell carcinoma, 7 had adenocarcinoma, and 7 had undifferentiated lesions.
All had CT planning of their radiotherapy and most patients received a dose to the
tumour of 55Gy in 20 fractions daily, using 5–16 mV photons, (2 had 60Gy in 30 frac-
tions, 1 had 64Gy in 32 fractions and 1 40Gy in 15 fractions). The mediastinum was
not irradiated prophylactically. The median time between requesting radiotherapy and
commencing treatment was 46 days (range 11 to 84 days). Two patients were treated
with chemotherapy either immediately after radiotherapy or at the time of disease
recurrence. There was a mean interruption during the course of radiotherapy of 1.5
days (range 0–6 days). All patients have had a minimum of 1-year follow up. 
The overall one-year survival for this group of patients was 66.0% (35/53) and the
median survival was 630 days (20.8 months, 95% CI 454–916 days). Amongst T1/2
patients the one-year survival was 62.5% (25/40) and the median survival was 630
days (20.8 months, 95% CI 353–903 days). This compares with a one-year survival of
76.9% (10/13) and median survival of 580 days (19.2 months, 95% CI 454–1124
days) for those patients with T3/T4 lesions. There was no statistical difference in
survival between the T1/2 lesions and T3/4 lesions on the Log Rank Test (P = 0.63). 
Conclusion  Our results for patients with NSCLC who were considered to be
medically inoperable are very similar to other published series. There was no statis-
tical difference in survival between patients with T1/2 lesions compared with T3/4
lesions. 
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POOREST PROGNOSIS SMALL CELL LUNG CANCER 
(SCLC): TO TREAT OR NOT TO TREAT? HE Innes1, 
P Stockton2, J Hendry3, MJ Walshaw2 and E Marshall1, 1Clatterbridge Centre
for Oncology, Merseyside CH63 4JY, 2The Cardiothoracic Centre,
Merseyside L14 3PE and 3Whiston Hospital, Prescot L35 3QY
Overall survival in SCLC remains disappointing. Even in those with the most
favourable prognostic factors treated with dose-intense combination chemotherapy
there are few survivors beyond 2 years. Many patients present with at least one
adverse prognostic factor and for these patients the outlook is considerably worse. In
a large MRC study (1) of patients with performance status (PS) ³2 those treated with
combination CAV chemotherapy had median overall survival of approximately 
6 months. For those in the worst prognosis group the role of chemotherapy is less well
defined: in the MRC study only 38% were PS 3 or 4 and just over half had extensive
stage disease (57%). 
We have retrospectively reviewed the characteristics and outcome of all patients
with SCLC who were referred to a Medical Oncologist in central Liverpool between
October 1997 and June 2000. A total of 142 patients were referred: almost a third
(31%, 42) were PS 3 or 4, (37 PS3, 7 PS4) with a median age of 70y, (51 to 83y). Of
these, 37 (84.1%) had extensive disease and only 7 (15.9%) had limited disease and
the great majority (>90%) had significant co-morbidity. 20 patients either refused or
were considered ineligible for chemotherapy and received supportive care. Only 1
patient fulfilled entry criteria for a clinical trial. Of the 24 who received chemotherapy
this consisted of CAV (13), ACE (2), oral etoposide (8) or weekly chemotherapy (1).
58% had partial or complete responses, 17% had progressive disease and 25% were
not assessable for response. Median survival in the supportive care group was 3 weeks
and 12 weeks in the chemotherapy group. 71%, 48% and 26% of patients were alive at
1, 3 and 6 months respectively. Only 5 patients (21%) survived >40 weeks, of these 3
had presented with acute deterioration in PS due to SVCO, hyponatracmia and post
surgery. In conclusion, a significant proportion of SCLC patients present with very
poor performance status, extensive disease and significant co-morbidity. Few of these
are currently eligible for clinical trials. For these patients prognosis is dismal despite
chemotherapy. Future clinical trials should focus on quality of life issues, for example
shorter, less toxic chemotherapy regimens. 
1. MRC Lung Cancer Working Party, Lancet (1996) 348 563 
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OPEN ACCESS FOLLOW-UP FOR LUNG CANCER –
PATIENT AND STAFF SATISFACTION AM Henry1, J Joseph1,
JW Adlard1, CV Brammer2, GE Gerrard1, 1Yorkshire Regional Centre for
Cancer Treatment, Cookridge Hospital, Leeds and 2New Cross Hospital,
Wolverhampton 
Background Most lung cancer patients have incurable disease and treatments offered
are aimed at palliation. Rather than have regular follow-up at the hospital, a pilot
‘open access’ lung cancer clinic has been set up. Patients are discharged to the
community once initial palliative treatment has been completed and review at the
‘open access’ clinic can be arranged at short notice if needed. The outcomes and level
of satisfaction of patients, their relatives and staff to this method of follow-up have
been assessed. 
Methods Between June 1997 and June 1999, all new patients who attended the
oncology clinic at Halifax Royal Infirmary with primary thoracic malignancy were
identified. Patients who received palliative radiotherapy and/or chemotherapy were
given a routine out-patient follow-up appointment six weeks later. Those who
attended this appointment were identified prospectively and offered further follow-up
in the open access clinic. The care of patients who consented to ‘open access’ was
transferred back to primary care. In January 2000, questionnaires were sent to those
patients who were still alive and the next of kin of those who had died. Separate ques-
tionnaires were also sent to the local Macmillan nurses and the clinic nurses. For
patients with problems, the patient’s GP was contacted. Questionnaires were
completed and analysed anonymously. 
Findings 160 new patients attended in the period. Of these, 122 patients had pallia-
tive treatment or had no symptoms requiring intervention. 75 out of 122 attended at
six-week follow-up. 65 patients agreed to open access follow-up. During the study
period, 28 of the 65 patients had one open access visit, 10 patients had two visits and
6 patients had three visits. Therefore, there were a total of 66 visits made by 44 open
access patients. 50% of patients were seen within 4 days of requesting an appointment
(range 0.5 to 13 days). In January 2000 questionnaires were distributed to 59 of the
possible 65 patients or their next of kin. 40 were returned (68% response rate). 98% of
respondents felt care given was either good or excellent. 78% preferred open access to
routine follow-up. All Macmillan nurses, clinic nurses and GPs responded. Nurses felt
that 90% of patients knew how to make an appointment and had good support. GPs
also favoured the open access follow-up system for patients who could cope with it. 
Interpretation The outcomes and level of satisfaction of patients, their relatives
and staff to this method of follow-up were found to be positive. Open access 
follow-up may be useful for many patients following completion of initial palliative
treatment. 64 Poster presentations
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THE POTENTIAL DEMAND FOR CHEMOTHERAPY IN 
ENGLAND AND WALES: POPULATION-BASED
CALCULATIONS AND ESTIMATES MH Cullen1, and M Muers2, 1Cancer
Centre at the Queen Elizabeth Hospital, Birmingham, B15 2TH, 2Killingbeck
Hospital, Leeds, LS14 7UQ 
Introduction It is well known that, relative to most other developed countries, the UK
is extremely short of oncologists, particularly medical oncologists. A shortage of
specialists was cited as a factor contributing to poor cancer survival in the UK, in the
Eurocare study. The last decade has seen a huge increase in indications for
chemotherapy (CT), with wide regional variations in usage. This work sets out to esti-
mate the number of adult cancer patients in England and Wales (E&W) presenting
annually for whom CT may be considered at least once during their disease, to help
inform the National Cancer Plan implementation. 
Methods Data on efficacy were obtained from randomised trials and meta-
analyses; tumour incidence and age distribution figures from cancer registry statistics;
other key determinants for chemotherapy like stage, performance status (PS), grade
etc from unselected, prospective population-based data where available, and on esti-
mates where population-based data are not available (eg for PS in most tumours).
Rare cancers, those likely to amount to fewer than 600 cases annually for CT, paedi-
atric cancers, leukaemias and myeloma are omitted and, no account is taken of need
for CT at more than one stage (eg adjuvant, first line advanced, second line advanced
etc). 
Results There are over 37000 cases of lung cancer annually in E&W. Using popu-
lation-based data from the Yorkshire Lung Cancer Referral Patterns audit of 1999,
plus PS data from the RCP lung cancer bronchoscopy audit of 1680 patients (1999),
we calculate that 61% of patients with SCLC (2733) are eligible for consideration for
CT. This is the same as the figure reported for CT usage in Scotland and Yorkshire for
SCLC, supporting the validity of the model. For NSCLC the model suggests 50% of
cases (16336) eligible for chemotherapy. This compares with an actual usage varying
from <5–22.5% in different areas. For colorectal cancer 11804 cases (41% of the total)
are eligible for CT, and for breast cancer 15470 (48% of the total) should receive CT
at one or more stages in their disease. For stomach, pancreas, oesophagus, ovarian,
and testicular cancers, lymphomas, and melanoma a total of 17482 cases should be
offered chemotherapy (44% of the total) 
Conclusions For the commoner tumours where CT has an established place, 46%
of patients (63825 per annum in E&W) are eligible for CT at least once during the
illness. Resources for the delivery of chemotherapy need to expand urgently to
accommodate this growing demand safely and effectively. 
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ATTITUDES TO CHEMOTHERAPY FOR THE OLDER 
PATIENT WITH CANCER AE Brewster, P Hackett, 
TS Maughan, S O’Mahoney, L Branston, P Price, I Robbe, D Adams-Jones,
R Cannings, V Morrison, D Cohen, On behalf of the Welsh Cancer Care for
the Elderly Research Group. Velindre Hospital. Cardiff. CF14 2TL 
Background Evidence suggests that older patients are under investigated and under-
treated and experience worse outcomes than younger patients (1). Clinicians are
unsure about offering chemotherapy to older patients because of uncertainty about
whether the likely benefits in terms of survival and QOL are sufficiently worthwhile
to an older person when balanced against likely toxicity and costs of treatment. 
Methods A questionnaire has been developed, piloted and psychometrically vali-
dated to try and identify social attitudes towards cancer treatment for the older patient.
1000 questionnaires containing 24 individual and multidimensional questions were
sent to a random sample of the general public. 
Results The response rate, 17%, was low but analyses demonstrated 1). the relia-
bility of the questionnaire 2). clear attitudes to the use of chemotherapy with respect to
potential benefit and 3). that respondents understood the complex multivariable 
treatment scenarios. Although age modified response, QOL and survival benefits
remained the overriding consideration. Over 95% of respondents felt that chemo-
therapy should be considered for patients aged 56 or less but 71.6% felt that it should
still be considered even at age 79. 74.6% considered that a survival benefit of 
6 months or more, as seen with palliative colorectal or breast cancer, was worthwhile.
Survival benefits of between 1 and 10% (as seen with many adjuvant therapies)
produced a wide range of responses suggesting that clinicians cannot assume how
useful an individual may perceive a treatment. It is now our intention to send the 
questionnaire to a random sample of health professionals to compare and contrast 
attitudes. 
1. Vercelli M, Quaglia A, Casella C, et al. Relative survival in elderly cancer
patients in Europe. EJC 1998. 34 2264–2270 
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RECRUITMENT OF PATIENTS TO CLINICAL TRIALS: SIZE 
OF POPULATION REPRESENTED S Michael Crawford, 
Janet Peace, Dept of Medical Oncology, Airedale General Hospital, Skipton
Road Steeton, Keighley, West Yorkshire BD20 6TD
Large randomised clinical trials are accepted as the best way of answering questions
about the relative value of different approaches management and treatment. Recruitment
of sufficient patients to a large trial can take several years, which may mean that the
question is considered less relevant by the time the last patients are entered. 
Airedale General Hospital is the venue of care for the overwhelming majority of
residents of its catchment area. Since 1996, the medical oncology service has adopted
entry into the NEAT trial as standard policy for adjuvant chemotherapy for eligible
patients with breast cancer. Between 1995 and 1998 the QUASAR study was the policy
for colorectal cancer. We have used this population base to estimate the size of popula-
tion needed to recruit 1000 trial subjects per year when the policy for that population is
that eligible patients are entered. Patients with non-small cell lung cancer (NSCLC)
were entered into the Big Lung Trial (BLT) and those with small cell (SCLC) into
various regional studies. These were mainly patients with advanced disease and at the
time proportionally fewer incident cases were diagnosed in the hospital. 
The average recruitment was NEAT was 15 patients per annum, QUASAR 11 pa.
BLT 11 pa, SCLC 10 pa. The catchment population was derived using Northern and
Yorkshire Cancer Registry population statistics as follows: 
Number of  Histology  Grossed-up Crude Population
histological rate cases annual represented 
diagnoses (1998) incidence
Breast 147 0.88 167.0 55.9 298 829 
Colorectal 124 0.86 143.7 55.1 260 771 
NSCLC 54 0.64 84.4 60 140 625 
SCLC 14 0.64 21.9 15 145 833 
From this the required population to recruit 1000 cases per annum for adjuvant
chemotherapy is 19.92 million for breast cancer and 23.71 million for colorectal
cancer. For chemotherapy of advanced lung cancer the required population to recruit
1000 cases per annum is 14.59 million (SCLC) and 12.78 million (NSCLC). 
These observations indicate the magnitude of the task to make the culture of clin-
ical trials penetrate cancer services in the United Kingdom. 
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MALIGNANT CEREBRAL GLIOMA: IMPROVING THE CARE 
OF PATIENTS AND THEIR FAMILIES AM Parr1 and 
HR Gattamaneni2, 1SpR in Palliative Medicine, 2Consultant in Clinical
Oncology, Christie Hospital, Manchester M20 4BX 
We interviewed 35 patients with malignant cerebral glioma attending the Christie
Hospital regarding their difficulties, satisfaction with care and ideas for improving 
the service. Carers, who accompanied 29 patients, were also invited to comment. The
median time from diagnosis was 20 months. 43% of patients had relapsed disease. The
majority of patients were satisfied overall with their care and the level of support
offered by the hospital. Crises had generally been handled well. 
Sources of distress identified
1. Complex physical, social and psychological problems. 
2. Relatively infrequent and late input from occupational therapy, physiotherapy,
psychological support services and social workers. 
3. Inability to see the same doctor at each clinic visit. 
4. Insufficient communication between the various healthcare professionals involved
resulting in the need for patients to repeat information. 
5. Desire for more information and more time to discuss anxieties and difficulties. 
6. Insensitive delivery of information by some doctors. 
7. Concern about disturbing doctors for advice between clinic visits despite having
been encouraged to do so if necessary. 
8. Uncertainty about the availability of support from other services and organisations. 
9. Delays preceding investigation or treatment. 
Implications for practice
1. Staff should appreciate the wide-ranging impact of brain tumours on patients and
their families/carers and be proactive in enquiring about difficulties in order to
facilitate early referral to rehabilitation and support services and organisations.
Expert psychological support should be readily accessible. 
2. Communication skills training is essential for professionals involved in the care
of cancer patients. Time needs to be dedicated to listening and to giving informa-
tion. A manned information centre with internet access has recently been set up
within the hospital to improve the availability of information to patients about all
aspects of their disease, its management and sources of help and support. 
3. Care must be well co-ordinated and continuous, with adequate communication
between professionals. We devised a sheet to be placed prominently in each
patient’s notes to record dates of disclosure of key information and referral to
other services/ professionals in the hope that it would assist this process. 
4. A nurse specialist could potentially help to bridge gaps in the service, promote
better pre-planning and continuity of care, minimise delays and improve liaison. Poster presentations 65
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AUDIT OF THE USE OF IV PALLIATIVE CHEMOTHERAPY IN 
CANCER CENTRE AND LINKED CANCER UNITS A Mayer, M
Ward, R Benson, M Moody, Cancer Centre, Addenbrooke’s NHS Trust,
Cambridge CB2 2QQ 
An audit was performed to ascertain that palliative IV chemotherapy was given appro-
priately and according to departmental guidelines laid down in a consensus meeting in
January 1999. These require a potential survival or quality of life gain. Documentation
of measurable disease (clinical, radiological or biochemical), performance status (PS),
symptoms and the maximum number of cycles to be given was required at outset,
documentation of PS, symptoms and toxicity at each cycle and an interim assessment
after 3 cycles. A previous audit documented that second line palliative chemotherapy
prescription was evidence-based, but that documentation of performance status and
toxicity was insufficient. 
127 randomly selected notes of non-trial patients (10 per consultant) who
presented for their first cycle of chemotherapy on or after 1.4.99 were audited. 4
consultants practise at Addenbrooke’s Hospital and 9 consultants at cancer units
(Bedford, Bury St Edmunds, Huntingdon, King’s Lynn, Peterborough). 21% of the
patients had received prior chemotherapy. The maximum number of cycles to be
given was stated in 38% prior to starting treatment. In 95% the evaluable disease was
documented, clinically in 65%, radiologically in 88%, biochemically in 38%.
Symptoms and performance status before chemotherapy were documented in 83%
and 23%, respectively. At each of 559 cycles symptoms were documented in 45%, PS
in 14% and chemotherapy related toxicity in 62%. Interim assessment after 2–3 cycles
as required by departmental guidelines was carried out in 76%, however 17% were
not evaluable in this respect because they had received less than 3 cycles at the time of
evaluation. Appropriate ‘stopping rules’ were applied, i.e. treatment was never
continued in spite of disease progression and lack of symptomatic benefit. 66% of the
evaluable patients continued treatment, 63% had had no evidence of disease progres-
sion, 49% reported symptomatic benefit, 3% of those patients had signs of disease
progression. 
In summary patients received chemotherapy appropriately, documentation of
measureable disease was satisfactory and an interim assessment was performed as
required. However documentation of PS, symptoms and toxicity should be improved.
The extended use of flowcharts is currently being implemented, a reaudit will be
performed after appropriate changes have been made. 
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WHAT CONCERNS DO ONCOLOGISTS EXPRESS ABOUT 
SPECIALIST PALLIATIVE CARE? AM Parr1, WP Makin2, 
1SpR in Palliative Medicine, 2Macmillan Consultant in Clinical Oncology and
Palliative Medicine, Christie Hospital, Manchester M20 4BX 
Although most oncologists appear to appreciate the value of palliative care for their
patients, many do not yet seem able to place their full trust in palliative care services
and therefore reserve referral for those with far advanced disease. In order to explore
why this might be, all doctors working at the Christie Hospital were invited to anony-
mously complete a questionnaire regarding their perceptions of specialist palliative
care. 49 doctors (54%) replied, with no significant difference in response rates
between grades, sub-specialties or sex. Several factors that might contribute to reluc-
tance to use palliative care services at an earlier stage were highlighted: 
1. The failure of some oncologists to fully understand the goals of palliative care. 
2. A lack of appreciation of the range of investigations, procedures and interventions
that might be offered in some hospices. 
3. Fears of inadequate liaison with oncology services by palliative care specialists
and consequent loss of control over patient care. 
4. Anxiety about hospice staff managing their patients inappropriately through insuf-
ficient expertise, reluctance for active investigation and intervention, inadequate
provision of nutritional support and excessive use of sedation. 
5. A suspicion that palliative care professionals are generally less proficient than
oncologists in discussing the pros and cons of further anti-cancer therapy and may
tend more towards negotiating the discontinuation of treatment. 
6. Recognition of patient apprehension and a concern that patients would perceive
referral to palliative care services as an indication of the end of active treatment,
loss of all hope and impending death. 
7. The paucity of evidence for many of the management approaches used in pallia-
tive care. 
8. Problems with the accessibility and availability of hospice care. 
9. A belief that development of palliative care services would divert resources away
from oncological research and practice. 
Early referral to palliative care should be viewed as a positive step contributing to
optimal symptom control and quality of life throughout a patient’s illness. Improving
liaison between oncology and palliative care would help to ensure safe, continuous
care for patients with palliative care needs no matter what the stage of their disease.
Better communication would also guide appropriate decision-making, facilitate
learning, promote a mutual understanding, foster ideas for joint research and should
alleviate some of the oncologists’ anxieties. Work to address the evidence base in
palliative care and inequalities in access to services is underway. 
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CAN THE NHS CANCER PLAN TARGET FOR WAITING 
TIMES BE ACHIEVED IN RECTAL CANCER? P Chung, 
S Khanduri, S Sothi and RJ Grieve, Walsgrave Cancer Centre, Coventry CV2
2DX, UK 
The NHS Cancer Plan states that all patients with cancer should start treatment within
28 days of diagnosis by the year 2005. We performed a retrospective audit at our
centre to determine the time from diagnosis to treatment for all patients with rectal
cancers who underwent curative surgery. From January 1997 to March 2000, 154 such
patients were identified from databases in the oncology, pathology and radiology
departments. The dates of diagnosis (date rectal biopsy taken), staging investigations,
oncology appointment, start of radiotherapy and surgery were obtained. 
Median time from diagnosis to surgery for all patients was 33 days (IQR 21 to 52
days). 37% of patients had surgery within 28 days of diagnosis. Median time from
diagnosis to imaging request for ultrasound, CT scan, MRI scan and barium enema
were 5, 11, 14 and 7 days respectively. Median time from imaging request to scan for
ultrasound, CT scan, MRI scan and barium enema were 6, 10, 12 and 7 days respec-
tively. Median time from diagnosis to last investigation was 17 days and from last
investigation to surgery was 18 days. Short course pre-operative radiotherapy did not
significantly prolong time to surgery (median 36 days, IQR 27 to 51 days). Median
time from diagnosis to first oncology appointment was 14 days (IQR 8 to 20 days),
from first oncology appointment to start of radiotherapy was 13 days (IQR 10 to 20)
and from start of radiotherapy to surgery was 8 days (IQR 7 to 10 days). 
The recommended time from diagnosis to surgery of 28 days was achieved in only
a third of patients. This can be improved by organisational change using fast tracking
within the multidisciplinary team with pre-scheduling of diagnostic investigations,
which will reduce time from diagnosis to completion of staging investigations. Whilst
this will improve time to treatment it will be at the expense of longer waiting times for
routine requests. The most serious delay would still remain the time from the conclu-
sion of investigations to surgery. This can only be alleviated by an increase in
resources to reduce waiting lists for operation. With existing resources the NHS
Cancer Plan waiting time targets for rectal cancer cannot be achieved in our centre.
Any plan for reform can only succeed with substantial investment. 
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ANXIETY IN CANCER PATIENTS. D Stark1, M Kiely1, 
A Smith1, P Selby1 and A House2, 1ICRF Cancer Medicine
Research Unit, St James’s Hospital, Leeds, 2Dept. of Psychiatry and
Behavioural Sciences, University of Leeds, UK
Cancer patients often report anxiety (A), but morbid anxiety is poorly defined in this
setting. Recognition (and hence treatment) can be inadequate, and might be improved
by examination of the problems inherent in questionnaires and clinical diagnosis. 
Aims Describe the extent and nature of A. Compare self-reported (SRA) and
psychiatric A. Examine the relation of A to cancer specific Quality of Life. 
Method Subjects 178 out-patients with renal cell carcinoma, malignant
melanoma, or a lymphoma. Measures: 1. Questionnaires, using touch-screen moni-
tors; QLQ-C-30, HADS, and Close Persons Questionnaire (validated measure of
social support). 2. Psychiatric interview. 3. Cancer histories from case note review. 
Results Extent At cut-off of > 7/21 on the HADS A scale 85/178 had SRA. 26/85
fulfilled ICD-10 criteria for anxiety disorder (AD). 6/93 without SRA fulfilled criteria
for AD. 27/85 with SRA experienced somatic symptoms of A but insufficient for
psychiatric diagnosis. 32/85 with SRA reported no somatic A at interview. These
observations are examined using the tripartite model of mood disorders, separating
somatic anxiety from negative affect. 
Nature AD Paroxysmal/Panic:7 subjects, situational/phobic:12, free-floating/
generalised:3, mixed:7, organic:2, adjustment:1. SRA not AD: Panic type 2, free
floating type 10, phobia type 8, mixture 7. 
Onset AD 31% at ³ 6 months before cancer diagnosis, 38% within 6 months
before or after, and 31% at > 6 months after diagnosis. 
Associations In regression analyses, both SRA and AD are independently associ-
ated with gender, performance status, negative aspects of social support, depression
and past psychiatric history. Quality of Life. AD is associated with impaired emotional
functioning, and insomnia when controlled for gender, extent of disease and depres-
sion. Explanations for this are examined from a cognitive model. 
Conclusions A is frequently reported. Using the HAD-A scale, only 31% of SRA
is sufficient to fulfil psychiatric criteria. This scale may not to discriminate somatic A
from distress. AD by psychiatric criteria is often situational, but lesser degrees of free
floating anxiety are prevalent. 1/3 of anxiety disorders predate cancer diagnosis by 
> 6 months. Both SRA and AD are much less associated with events such as cancer
progression or treatment than with psychosocial variables and performance status. AD
is associated with a quality of life deficit, which could contribute to its recognition.
Cohort studies are ongoing to examine causation, prediction, and consequences of
SRA and AD, and their impact on doctor-patient communication. 66 Poster presentations
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DEVELOPMENT OF A SOCIAL PROBLEMS SCREENING 
INSTRUMENT (SPSI) FOR USE IN ONCOLOGY CLINICS 
EP Wright1, M Kiely1, A Cull2, PJ Selby1, 1ICRF Cancer Medicine Research
Unit, St James’s University Hospital, Leeds LS9 7TF, 2Imperial Cancer
Research Fund, Medical Oncology Unit, Western General Hospital,
Edinburgh, UK
Aim This research project seeks to explore the social problems and concerns of cancer
patients with particular reference to the clinically useful ways of measuring and eval-
uating them. While the existence of social problems has been recognized, there is little
information available concerning their prevalence and intensity or about how they
should be managed in routine practice. These studies aim to demonstrate that
screening for social problems in oncology practice is possible by presenting a specifi-
cally developed social problems screening instrument via a computer touchscreen to
patients in cancer clinics. 
Item generation method Items were generated independently for possible inclu-
sion on to the questionnaire from 3 sources, 1.) a review of the literature and existing
questionnaires 2.) oncology patients 3.) health and welfare staff in oncology. Items
from all sources were coded and the lists pooled. The pooled list was reviewed and
reduced in length by consensus of 6 oncology health and welfare experts to eliminate
overlapping items and item redundancy.
Results One hundred and eleven articles and 10 questionnaires were reviewed
with 51 items generated. Forty-nine staff participated in 7 face-to-face focus groups
generating 39 items. Ninety six patients participated in 16 telephone focus groups, 2
face-to-face focus groups, 12 in-depth interviews resulting in 49 generated items.
Items generated were grouped under broad social problem themes: in the home, health
and welfare services, employment, legal issues, relationships, self image and recre-
ation. Single items included housing, mobility, discrimination and isolation. The
pooled item total was 61 which was reduced to 28 items. 
Questionnaire design method The reduced item list was used as the framework
for a 28 item questionnaire. The time frame was over the last month and response
format a 4 point Likert scale. The first draft was reviewed by 7 oncology experts
before being pre-tested on 28 patients. The instrument was modified and piloted again
on a further 14 patients. 
Conclusions A 28 item social problems questionnaire has been developed which
patients found understandable, relevant and easy to complete. This now needs to be
tested on a larger sample to evaluate its reliability and validity. 
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A STUDY OF COMPLICATION RATES IN GROSHONG AND 
PICC VENOUS CATHETERS IN ONCOLOGY PATIENTS 
R Simcock, S Price, E Noon, M Renshaw, Sussex Oncology Centre, Royal
Sussex County Hospital, Brighton, East Sussex, BN2 5BE 
Introduction An increasing number of oncology patients require venous catheters
either for persistent venous infusion or poor venous access following previous treat-
ment. In our department we have both a nurse led PICC service and an anaesthetist led
Groshong® service. We aimed to evaluate these services to establish a departmental
protocol. 
Methods All lines placed in oncology patients between 1/11/99 and 30/10/2000
were retrospectively evaluated for complications, life-span of line and delays in inser-
tion. 60 patients were identified of whom 59 were available for study. 77 lines in total
were placed in these patients (43 Groshong and 34 PICC). 
Results There were longer delays in getting a Groshong placed (average 12.61
days) compared to PICC (8.4 days). In-patient admission was necessary for all
Groshong patients but avoided in all PICC patients. PICC lines showed greater
longevity than Groshong lines. 
The overall complication rate for both lines was high (62.8% Groshong vs. 58.8%
PICC) but in PICC lines these largely constituted clinically trivial exit site infections
requiring no treatment (26.5%). Complications considered of high clinical signifi-
cance (including pneumothorax, extravasation, SVC thrombus and line sepsis) were
more common in Groshong lines (23.3% vs. 8.9% in PICC). Line failures (fracture or
displacement) were similar in both groups (7% Groshong vs. 11.8% PICC). Procedure
related complications in the Groshong group (16.3% vs. 2.9%) may have been
reduced by the introduction of a fluoroscopic or USS guided line placement. Three
lines placed without fluoroscopy and subsequently re-manipulated because of poor
position leaked leading to an extravasation. Complications in the Groshong group led
to higher patient costs with more investigation and in-patient treatment. 
Conclusion The introduction of a nurse-led PICC service is more convenient, has
reduced treatment delays and resulted in a lower complication rate compared with
central venous Groshong lines over the same period. 
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AN AUDIT OF PERIPHERALLY INSERTED CENTRAL 
VENOUS CATHETERS (PICC LINES) IN PATIENTS WITH
SOLID TUMOURS K Jeffery, H McClelland & AL Thomas, Dept of Oncology,
Leicester Royal Infirmary, UK
In our centre the number of patients (pts) receiving infusional chemotherapy has
increased dramatically over the past 3 years with resultant major resource implica-
tions. To cope with the demand a ward-based PICC line service was established and
run by a clinician with 2 nurses. In total 68 lines have been placed over a 25 month
period. In 71% of cases the PICC line was requested for infusional chemotherapy, the
rest of placements being for poor venous access (12%), vesicant chemotherapy
(8.5%), inotropes or TPN (8.5%). Nine attempts were unsuccessful (in 4 pts unable to
cannulate, in 5 pts line would not advance to correct position). Five pts needed a
second line (3 pts initially had malpositioned lines, in 1 the line migrated, 1 line was
replaced after resolved infection). Duration of survival of the line was from 1–237
days (median 43 days). Reason for removal was completion of treatment in 73% and
line associated complications in the remainder. The complication rate for sepsis was
15%, line migration/blockage 7%, thrombosis 7% and irreparable fracture 1%. Of the
9 lines complicated with infection, 3 were treated with antibiotics by the GP and there
was no record of a swab taken of the exit site. In 3 pts the catheter tip was positive and
in 1 case the tip was negative when the exit site swab was positive. In 2 pts the line
was removed probably for mechanical phlebitis since both the exit site swab and tip
cultures were negative and the lines had been placed for less than 7 days. We found it
very difficult to elucidate from the literature the desired standards for this practice
since most of the literature deals with lines placed for parenteral nutrition or intra-
venous antibiotics. It is well-known that patients with solid malignancies pose
different problems due to their associated pro-thrombotic tendency. In a literature
search we found only 2 audits in a similar patient population against which to compare
our figures. The complication rates in these series were very similar to those described
here. We feel it is important for groups to report their PICC line figures so that
national standards can be devised, particularly since more infusional chemotherapy is
being prescribed. We have now developed a nurse-led clinic and organise a teaching
programme for district nurses to ensure the lines are adequately dressed to reduce our
infection rate. 
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CATHETER RELATED UPPER EXTREMITY THROMBOSIS 
IN ONCOLOGICAL PRACTICE – A STUDY OF INCIDENCE
AND RISK FACTORS Somnath Mukherjee, Velindre Hospital, Cardiff 
Background Central lines are becoming increasingly important in oncology, espe-
cially in gastrointestinal cancers, where they are retained for months to deliver infu-
sional chemotherapy. Yet data looking at line complications, like thrombosis, is scanty
in UK. The incidence of pulmonary embolism has been reported to be higher with
upper extremity deep venous thrombosis (UEDVT) and death due to UEDVT related
pulmonary embolism is nearly four times when compared to lower limb DVT. Factors
implicated for the higher incidence of thrombosis are displacement of lines into
peripheral veins and left sided insertions. No national guideline exists for prophylactic
anticoagulation of central lines; the multi-centre WARP trial is underway to evaluate
the benefits of warfarinisation in patients with central catheters in oncological prac-
tice. At our centre Peripherally Inserted Central Catheters (PICCs) are not routinely
anticoagulated. 
Aims To determine the incidence of catheter – related thrombosis in hospital prac-
tice, and to identify any risk factors. 
Material and methods This was a retrospective study looking at all PICC inser-
tions between 31.6.99 and 31.5.00. Data was obtained from the PICC register. A list of
patients referred for doppler of upper limb, doppler of neck veins and upper limb
venograms between the period 1.7.99–31.3.01 was used to evaluate the number of
catheter related thrombosis in the above cohort of patients. The following risk factors
were evaluated – side of insertion, single or dual lumen catheters, site of primary
tumour and the chemotherapy regimen 
Results 20 of the 385 central catheters were complicated by thrombosis. The
overall incidence of thrombosis was 5.2%. The mean time to thrombosis was 42.6
days (range 6–154 days). Males were at higher risk (5.5% vs 4.5%). Left sided inser-
tions were at no more risk than the right. Dual lumen catheters were significantly
more thrombogenic (11.8% vs 4.5%, 362 evaluable catheters). Overall risk for upper
gastrointestinal malignancies was higher (8.7%, stomach – 11.1%, esophagus – 8.6%)
The risk of PICC associated thrombosis was 2.8% for lower gastrointesinal malignan-
cies. Risk of thrombosis for patients receiving ECF chemotherapy was 11%, for
cisplatin and 5 Fluorouracil was 8.1%, and for continuous infusion 5 fluorouracil with
without mitomycin was 3.7%. 
Conclusions Overall incidence of catheter – related thrombosis was about 5%.
Routine prophylactic anticoagulation of all peripherally inserted central catheters is
probably not justified given the attendant risks of warfarinisation, especially in
patients with lower gastrointestinal malignancies and those receiving continuous infu-
sion 5 Fluorouracil with/without mitomycin. Patients with upper gastrointestinal
malignancies may, however, benefit from warfarinisation. Poster presentations 67
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COMPUTER-ASSISTED QUALITY OF LIFE 
QUESTIONNAIRES, AB Smith, G Velikova, and PJ Selby,
ICRF Cancer Medicine Research Unit, St. James’s Hospital, Leeds LS9 7TF
Aim We have used touchscreen technology successfully to present quality-of-life
questionnaires to cancer patients to enable us to assess psychological morbidity, and
social problems (Velikova et al., 1999). However, the standard questionnaires which
have been used were designed for use in clinical trials, and therefore can be too long
and time-consuming, thereby increasing the burden placed on patients, and may
ignore areas that are relevant to them. Similarly, these questionnaires may exclude
patients experiencing extremes of distress and/or social problems. Computer-assisted
questionnaires present areas of concern to patients on a touchscreen computer. This
enables patients to select aspects of their well-being which have been problematical
and answer further questions, from standard questionnaires, on these concerns alone.
In this way computer-assisted questionnaires can minimize or even eliminate some of
the problems encountered with standard questionnaires. 
Method A study was conducted to compare computer-assisted (CA) questionnaires
with standard questionnaires (EORTC-QLQ c30) completed by patients on the same
day. If patients respond to the questionnaires in the same way then agreement between
the different question formats should be high. Patients were recruited from oncology
wards and day clinics. Initially, to our surprise, the results demonstrated that absolute
agreement between the questionnaires was very poor (25%), although this improved to
75% when differences of one on the rating scales were included. It appeared that rather
than focusing on areas of concern, patients were reporting more problems on standard
questionnaires. A second study therefore investigated whether the wording of the CA-
questionnaires influenced patient responses. Two groups of 15 patients completed either
the existing CA-questionnaire or a more inclusively worded CA-questionnaire, and the
standard questionnaire. The results indicated only a slight improvement in agreement of
35% (absolute agreement). A third study investigated whether the amount of informa-
tion (known as “chunks”, Miller, 1956) presented to patients could explain differential
responses. Patients were presented with the CA-questionnaire with the number of items
reduced to 4 or 5 per screen. Greater agreement was observed between the two ques-
tionnaire format (75% absolute agreement). It is known that information capacity may
be reduced in patients due to stress which may effect selection and choice processes.
This is to be explored in future work.
Conclusion Computer-assisted questionnaires can reduce patient burden whilst
still reflecting an accurate picture of patients’ quality-of-life. However, this appears
only to work if the number of presented per screen is modest. Future work will explore
the interaction between psychological distress and selection processes on CA
questionnaires. 
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COMPUTER-ADMINISTERED INDIVIDUAL QUALITY OF 
LIFE ASSESSMENTS IN ONCOLOGY PRACTICE 
G Velikova1, J Brown2, A Smith1, D Stark1, T Perren1, P Wright1 and Peter
Selby1, 1ICRF Cancer Medicine Research Unit, St James’s Hospital, Leeds
LS9 7TF, 2Nothern and Yorkshire Clinical Trials and Research Unit, Leeds 
It is well recognised that oncologists should consider patients’ quality of life (QL) and
functioning when planning and delivering anticancer treatment, but a comprehensive
assessment how a patient feels requires a thorough inquiry. A standardised measurement
of patients’ QL may support clinicians in identifying important problems for discussion
during the limited time of the medical consultations. This project investigates the use of
individual QL data in practice and its impact on patients’ care and well-being. In the Ist
study we investigated the applicability of a standard QL questionnaire to individual
cancer patients. 114 consecutive patients completed the EORTC QLQ-C30 on a touch-
screen computer over a 6-month period. The QL results were compared with the corre-
sponding medical records at individual and group level. For individual patients the serial
measurement of QL allowed recognition of patterns over time corresponding to disease
course. At group level, a higher proportion of patients reported problems on EORTC
QLQ-C30, than were mentioned in the medical records (McNemar paired test, P < 0.01).
Most often clinicians mentioned pain (22%–39%), and at the initial visit role (66%) and
social issues (77%). For the rest of the symptoms and functions, the problems were
recorded in between 1% and 25% of the notes, but 20% to 76% of the patients reported
impairment. Problems which were not recorded in the medical notes tended to be of low
severity with a significant trend observed for pain, fatigue, nausea/vomiting, dyspnoea,
loss of appetite and physical function scale (c2 test 11.55–34.42, df = 1, P < 0.001). Thus
the QL data on individual patients was consistent with the clinical records but the QL
profiles had more information on symptoms and particularly on functional issues. 
In a 2nd study we assessed the feasibility of computer-administered individual QL
measurements in oncology clinics with immediate feedback of results to clinicians
and examined the impact of the information on consultations. The study employed a
prospective non-randomised design with pre-test post-test within subjects compar-
isons and involved 3 medical oncologists and 28 consecutive cancer patients. When
clinicians had the QL results they enquired more often about daily activities (Z =
–2.71, P = 0.007), emotional problems (Z = –2.11, P = 0.035) and work related issues
(Z = -1.89, P = 0.058). The computer measurement was well accepted by patients who
felt that the questionnaires were a useful tool to tell the doctors about their problems.
The clinicians perceived that the QL data broadened the range of the clinical inquiry
and helped them identify issues for discussion. 
The benefits for the patients from using individual QL data in practice is currently
investigated in a randomised study involving 260 patients and 25 oncologists. The
study will finish recruitment in May 2001. 
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BREAST CANCER PATIENTS USE OF A TOUCH SCREEN IN 
THE DAY TREATMENT AREA TO RECORD TOXICITY,
HEALTH STATE AND QUALITY OF LIFE – A 12 MONTH EXPERIENCE
RCF Leonard, B Vickery, S Povey Edinburgh Breast Unit 
Between the start and end of 2000, 256 patients with breast cancer had complete treat-
ment records against which to assess their recorded symptoms attributable to disease
and the effects of treatment on their lives whilst attending the day treatment area for
chemotherapy. They were asked to use a touch screen questionnaire at each atten-
dance for chemotherapy and individuals used the screen from once to 12 times. The
screen questionnaire was derived from standard recording systems to assess toxicity
severity and duration (31 questions) with 3 added questions on the patient’s assess-
ment of her health state, global quality of life and performance status. In this report
only the major features are shown from over 31000 data items thus obtained. The
records obtained were from 928 ‘form’ completions, 617 adjuvant or neoadjuvant and
311 metastatic. The data were stored in MS Access allowing ease use of data storage
and analysis. The patient data were then matched to the department treatment booking
database to link outcomes against disease stage and treatment given. The data are
presented as percentage scores for selected items in the 2 groups, metastatic and
secondly, adjuvant or neo adjuvant. 
fatig apptit diarr vom naus health QL PS 
11/8 89/64 80/71 91/86 54/38 4/23 5/28 44/23 A
30/28 4/22 13/20 6/11 32/39 12/32 38/29 35/32 B
41/43 4/9 5/7 2/2 7/17 56/44 28/38 17/35 C
18/21 3/15 2/2 1/1 7/6 28/1 29/5 4/10 D
Figures show % incidence metastatic / % incidence adjuvant; A = nil toxicity
or best health state; B = mild toxicity / impairmen of state; C = moderate
toxicity or impairment; D = severe toxicity or impairment; Bold figures
indicate clinically important differences between groups, either direction 
This is a rapid and accurate method to record toxicity, functional health state,
formal performance status and quality of life in a self-report, real-time format. It is
quick, patient-friendly and is an extremely powerful, inexpensive technique for
recording auditable data for non-trial as well as trial patients at all stages of disease for
patients on treatment. We have plans to extend its use to the OPD waiting area for
patients who may be on oral or hormonal therapy. 68 Poster presentations
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RETROSPECTIVE TREATMENT-RELATED MORBIDITY 
DATA DO NOT RELIABLY REFLECT CLINICAL
PERFORMANCE, AS Denton1, SJ Bond1, S Matthews2, SM Bentzen1 and 
EJ Maher1. 1Mount Vernon Centre for Cancer Treatment, Northwood,
Middlesex HA6 2RN, 2The Churchill Hospital, Oxford OX 3 7LJ
The drive for accountability has created interest in comparing individual institutions’
performance using league tables. We have used data from the UK audit of cervical
cancer treated with radiotherapy (RT) in 1993, to ask whether differences in morbidity
between centres could be used as an indicator of quality of care. 
A retrospective case-note audit of all patients receiving RT with curative intent for
cervical cancer in 1993 identified 1558 cases drawn from 96% of the UK treatment
centres. Severe toxicity (grade 3 and 4 according to the Franco-Italian glossary) was
recorded. In all the centres but one, morbidity was graded retrospectively at the time
of the audit. The 5-year prevalence of late severe morbidity was 6.1%, actuarial
rate 8%. 
Even if all the 53 centres had a common morbidity rate, testing each of them
against the national average would produce a 94% chance that at least one of them
was outside the acceptance region. We may reduce the overall risk of a false positive
result to 5% by enlarging the acceptance region, according to the Bonferroni correc-
tion. After correcting for multiple testing, 49/53 centres with apparently differing rates
of morbidity, were found not to be statistically different from the national average. Of
the remaining four institutions, the one which had the most complete, prospectively
collected data set, was the most statistically significant, p<0.001. The highest crude
morbidity rate occurred at another centre where two out three patients experienced
late morbidity. 
Therefore, these results would not be appropriate for use in league tables of insti-
tutional performance. Notably, the one centre that appeared to do worse than the
national average, was the only centre to have prospectively graded morbidity. League
tables may be completely misleading unless data of this nature are recorded prospec-
tively using standardised follow-up procedures. 
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A STUDY OF PSYCHOLOGICAL MORBIDITY IN ONCOLOGY 
INPATIENTS, S Amin1, D Fyfe2. 1Department of Psychological
Medicine, Queens Medical Centre, Nottingham; 2Department of Clinical
Oncology, Nottingham City Hospital, NG51FP
Psychological morbidity is common in Oncology patient samples (20–40%). The
Calman-Hine report (1995) stressed the importance of “providing psychosocial
support”. However, some patients with psychological morbidity may not be referred
for specialist psychological assessment and treatment. We performed a study to
compare different methods of identifying psychological morbidity, by nursing staff,
junior medical staff, and a self administered questionnaire, (the Hospital Anxiety and
Depression Scale (HADS), against a validating standard (a psychiatrist’s assessment). 
Methods 39 consecutive patients admitted to an oncology ward were assessed.
The psychiatrist interviewed the patients using a standardised interview (Clinical
Interview Scale-Revised (CIS-R)) and gave his diagnosis, the nursing staff rated the
patient on a 3 point scale (good/moderate/poor adjustment), and the Senior House
Officers were asked to give their psychiatric assessment. All assessments were given
independently, without knowledge of the others’. 
Results 2 patients were unable to comply with the interviews, due to their poor
performance status. 6 patients were diagnosed as suffering from a major psychiatric
disorder: severe needle phobia, mild depression, severe depression, generalised
anxiety disorder, panic disorder, and alcohol abuse (self harm). Only 1 of these was
correctly diagnosed by the SHOs, or felt to be coping poorly by the nurses. 11 patients
were suffering from an adjustment disorder; 2 of these with anticipatory anxiety might
have benefited from referral to a psychologist. There was good correlation between
the HADS and the CIS-R score (r = 0.81 (95% CI 0.66–0.90), P<0.001). There was
poor correlation between the nurses’ and SHOs’ assessments, and the psychiatrist’s
diagnosis. The SHOs tended to over-diagnose: they diagnosed depression in 4 and
adjustment reaction in 4 of 20 patients without a psychiatric diagnosis. However, this
may have been because they knew they were under scrutiny. 
Discussion Despite increased awareness of emotional problems in cancer
patients, many patients with psychological morbidity are still not correctly diagnosed
by junior medical staff. The HADS functioned well as a screening tool in this small
study, and could be considered as a means of identifying patients who might benefit
from referral. 
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THE EFFECT OF DEPRIVATION ON INCIDENCE, 
MORTALITY AND SURVIVAL FOR THE MOST COMMON
CANCERS IN ENGLAND & WALES. L Melcher1, DA Power1, RSD Brown1, 
M McCormack1, HA Payne1, A Brock2, P Babb2 and MJ Quinn2. 1Middlesex
Hospital WIN 8AA, 2National Cancer Intelligence Service, Office of National
Statistics SW1V 2QQ
Aims To examine the effect of socio-economic deprivation on the incidence,
mortality and survival of the ten most common malignancies in England and Wales. 
Method The latest national statistics were obtained from the Office of National
Statistics. The effect of deprivation was assessed using the ‘Carstairs Index’ of mate-
rial deprivation, which uses census-derived socio-economic measures. 
Results Incidence and Mortality – The incidence of six of the ten most common
malignancies was higher in the most deprived groups – lung, rectum in males only,
bladder, stomach, oesophagus & pancreas. There were no socio-economic differences
in incidence for cancer of the ovary, colon (in both sexes) or rectum (in females).
Three cancers had higher incidence in the more affluent groups – breast, prostate &
non-hodgkin’s lymphomas; breast cancer incidence is about 25% higher in the most
affluent groups. There were no differences in mortality for breast cancer or NHL
between deprivation groups. 
Survival – There were significant survival disadvantages for all the ten most
common malignancies in the more deprived groups. 
Conclusion The consistent differences in survival for adults in different socio-
economic groups represents an important public health issue. Differences in survival
could in theory be improved by addressing the deprivation gap. An even larger effect
on mortality could be obtained by eliminating differences in incidence between socio-
economic groups – principally by preventative measures including a reduction in
smoking. 
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A RANDOMISED TRIAL OF THE IMPLEMENTATION OF 
COMPUTERISED GUIDELINES IN CANCER PATHOLOGY
REPORTING: THE CROPS PROJECT LK Branston1, JM Abraham1, 
S Greening2, RG Newcombe3, R Daoud3, J Steward4, C Rogers2, 
NS Dallimore5, GT Williams31 Velindre Hospital, Whitchurch, Cardiff. CF14
2TL. 2Breast Test Wales, 18 Cathedral Road, Cardiff. CF11 9LH. 3University
of Wales College of Medicine, Health Park, Cardiff, CF14 4XN. 4Wales
Cancer Intelligence and Surveillance Unit, 14 Cathedral Road, Cardiff CF11
9LJ. 5Llandough Hospital NHS Trust, Penarth, Cardiff
Objectives To determine whether reporting guidelines and computerised proformas
improve the completeness of histopathological cancer data available for patient
management and population cancer registration. To evaluate the acceptability of the
intervention. 
Design Randomised controlled trial with a split unit design and stratified cluster
randomisation. 
Setting Pathology laboratories in Wales. 
Subjects 16 district general hospital laboratories employing 45 histopathologists
were randomly allocated to report breast or colorectal specimens by proforma. 
Interventions Reporting guidelines were agreed by pathologists. Participants
attended a training day on the cancer site they were randomised to report.
Computerised proforma reports containing the items described in the guidelines were
introduced. Audit meetings were held to review individual performance. 
Main outcome measures
l Completeness and precision of histological data available to clinicians and
cancer registry. 
l Acceptability of the intervention 
Results 1020 reports of resection specimens were analysed in the study arm, 1008
in the control arm. Use of proformas led to a 28.4% (15.7%–41.2% 95% CI) increase
in complete reporting of a minimum dataset required for cancer registration and a
24.5% (11.0%–38.0% 95% CI) increase in complete reporting of minimum data
required for patient management. Interviews suggested pathologists had changed their
working practice and generally favoured proformas, but there were some problems
with implementing the computer screens. The intervention also proved acceptable to
surgeons, and cancer registry. 
Conclusions A package of training, guidelines and proforma reports significantly
increases completeness of pathology reporting. Poster presentations 69
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ESTABLISHING EFFECTIVE NETWORKS TO SUPPORT 
CLINICAL CANCER RESEARCH: THE WALES CANCER
TRIALS NETWORK L Branston1, T Maughan1, N Stuart2, MD Mason1. 1Wales
Cancer Trials Network, Velindre Hospital, Whitchurch, Cardiff, CF14 2TL.
2Clinical Trials Unit, Ysbyty Gwynedd, Bangor, LL57 2PW
Background The Wales Cancer Trials Network (WCTN) was set up in 1998 with the
objective of increasing clinical cancer trials activity across Wales. 16,000 new cancer
cases are diagnosed annually in Wales and historically an average of 400 patients
(2.5%) entered multi-centre cancer trials each year. 
Methods The first phase of WCTN funding has provided 4 oncology research
nurses to 3 cancer centres (Cardiff, Swansea, North Wales) and 1 cancer unit (Bangor)
in Wales. WCTN staff have opened a portfolio of priority trials, supported new inves-
tigators and recruited patients to studies. The WCTN has provided training and educa-
tion for NHS staff in good clinical practice, informed consent and cancer therapies.
The WCTN central office provides managerial, networking and statistical support to
outlying trials offices and runs randomisation and data management for 4 trials
regionally. WCTN has taken a regional approach to problem solving with regard to
meeting the excess costs of clinical trials and making the ethics committee system
work more smoothly. 
Results Cancer trial recruitment has increased by over 50% since the introduction
of the Network. This represents an increase from 490 in 1997 to 741 in 2000 (4.6% of
new cancer cases). The WCTN aims to increase this to 10% of new cancer patients by
2006. 
Network staff have opened 48 trials in 103 separate ethical submissions. In order to
meet a 10% target we aim to broaden our portfolio of trials to include palliative and
primary care and cancer genetics. 
The Network has supported 21 investigators who were not previously research
active. 
We estimate that 1 WTE Research Nurse working in oncology trials can recruit
50–60 patients per year. 
Conclusions A 10% recruitment target will prove exacting for the UK cancer
service. Increased recruitment requires highly committed investigators particularly in
cancer sites with a broad and varied portfolio of high quality studies available. 
The Wales Cancer Trials Network is funded by The Cancer Research Campaign
and National Assembly for Wales. 
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DIFFERENTIATED THYROID CARCINOMA IN THE 
ELDERLY. L Vini, J Marshall, R A’Hern, C Harmer. Thyroid
Unit, Royal Marsden NHS Trust, London, SW3 6JJ, UK 
Aim This is a retrospective review aiming to assess the behaviour of thyroid cancer in
elderly patients and also evaluate the results of treatment. 
Patients – Methods Among 1448 patients with differentiated thyroid cancer
treated in our Unit over the past 60 years, we identified 111 patients who were over the
age of 70 at diagnosis (range 70–93 years). Follow-up ranged from 1–19 (median
follow-up 9 years). 
Results There were 28 men and 83 women (male/female ratio 1:3). The majority
of patients (80%) presented with a thyroid mass. Fifty-eight tumours were papillary,
46 follicular and 7 Hurthle cell carcinomas; 55 carcinomas were well-differentiated
tumours while the remaining were either grade II (22) or grade III (34). The majority
of patients had locally advanced disease (70% of tumours were T3 or T4 and 45%
were associated with involved lymph nodes); distant metastases at diagnosis were
documented in 26 cases (25%). Surgical management included: total thyroidectomy in
52 cases, lobectomy or hemithyroidectomy in 32 and enucleation or biopsy in 25; a
modified neck dissection was performed in 6 and a simple node excision in 12 cases.
Radioactive iodine was administered to 80 patients, 22 received an ablation dose of 3
GBq while 58 required multiple doses (cumulative activity 6.6–29 GBq). Adjuvant
external beam radiotherapy was given to 19 patients. Cause-specific survival was
75%, 50% and 50% at 5, 10 and 15 years respectively. Multivariate analysis identified
age over 75 years as the single most important independent prognostic factor for
survival while stage of the primary tumour had a significant effect on the risk of local
recurrence. 
Conclusions Differentiated thyroid cancer in elderly patients appears to behave
more aggressively and has a less favourable prognosis than in younger adults; a signif-
icant proportion of tumours show extrathyroid spread, there is a prevalence of follic-
ular histotype with features of poor differentiation, a higher incidence of distant
metastases mainly in bones and lungs with a relatively high proportion of those being
non-functioning. Early diagnosis and radical treatment i.e. total thyroidectomy plus
lymphadenectomy followed by radioiodine therapy are therefore required. 
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SUBSEQUENT MALIGNANCIES IN PATIENTS TREATED 
FOR DIFFERENTIATED THYROID CANCER. DA Wheatley, 
L Vini, A’Hern, C Harmer, Royal Marsden Hospital, Sutton
Aim This is a retrospective review to assess the risk of developing a second malig-
nancy amongst patients who had treatment for well-differentiated thyroid cancer. 
Method Between 1929–1999, 1448 patients with well differentiated thyroid
cancer were treated in our unit. Analysis so far has been performed on 1340 patients
who had a minimum follow up of one year after completion of treatment. Of these 938
patients have received radioiodine therapy, whilst 402 patients have not received
radioiodine. 
Results Overall 109 patients (8%) developed a second malignancy. The
commonest second primary sites were; breast in 23 patients, gastrointestinal in 18
patients, lung in 13 patients, leukemia or myelodysplasia in 13 patients, others in 40
patients. Seventy-nine patients had been previously treated with radioiodine (25 of
whom also received external beam radiotherapy). While 30 had not received radioio-
dine therapy (18 of those had been treated with radiotherapy). No significant differ-
ence was seen among these groups regarding the site of second primaries. 
Conclusions In our series only 8% of patients with differentiated thyroid cancer
developed a second malignancy; The incidence of second malignancies was not
significantly different among the patients who had been treated with radioiodine
(8.5%) compared to those not treated with iodine (7.5%). 
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TREATMENT OF UNRESECTABLE 
CHOLANGIOCARCINOMA: 8-YEARS EXPERIENCE FROM
ONE CENTRE. DA Power, M Beresford, NG Mikhaeel and MF Spittle. The
Meyerstein Institute of Oncology, The Middlesex Hospital, London W1N 8AA 
Aims To review the role of radiotherapy and chemotherapy in the management of
unresectable cholangiocarcinoma. 
Methods The management of forty consecutive inoperable cholangiocarcinoma
patients between 1993 and 2000 in The Middlesex Hospital was reviewed. All
patients received radiotherapy, either external beam alone or combined with high-
dose-rate brachytherapy. Fourteen patients received concomitant chemotherapy.
Primary end point was overall survival. The length of inpatient stay and use of
stenting procedures were also reviewed. 
Results 67 % were male and 33% female. Average age at diagnosis was 61.4 yrs
(range 43–77). One patient had undergone biliary resection prior to treatment for
relapse. Other patients were diagnosed radiologically (34/40) or at laparotomy (5/40).
73% (29/40) were histologically confirmed adenocarcinoma. Median survival from
time of diagnosis was 9 months (range 1–31). Average inpatient stay was 39 days.
69% required external and 92% internal stenting. Average number of internal stents
was 2.4 (range 1 to 8). There was no statistically significant difference in survival by
the use of more intensive radiotherapy regimens (>40Gy in 2Gy or less fractions) or
the addition of brachytherapy. Median survival increased with the use of concomitant
chemotherapy (16 months vs 7 months) but numbers are small and the difference is
not statistically significant. 
Conclusions Cholangoiocarcinoma has a poor prognosis with a median survival of
9 months. There is no evidence, from this retrospective study, that additional treat-
ments add to overall survival and palliation above the use of stenting procedures and
randomised controlled trials with quality of life assessment are required. 70 Poster presentations
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TOTAL SKIN ELECTRON TREATMENT FOR MYCOSIS 
FUNGOIDES – THE COVENTRY EXPERIENCE, P Chung, 
NC Thorp, DC Wilson, AM Stevens, JA Mills, and RJ Grieve, Walsgrave
Cancer Centre, Coventry CV2 2DX, UK 
Introduction Total skin electron radiation is effective in the management of mycosis
fungoides. Many methods have been described; the majority requires large treatment
rooms with machine modification. We modified the Christie Technique; this required
minimal machine and room modification. In order to achieve a more even distribution
of radiation, avoiding lateral fall off, the patient lies at an angle of 30˚ to the treatment
beam. Radiation is delivered using arcing beams of 6MeV electrons, arranged to have
their centres of rotation above the head and above the feet. Beam overlap is optimised
by immobilising the patient in VAC bags. Patients are treated in 8 sections – 4 anterior
and 4 posterior quadrants – with 2 quadrants treated each day, each quadrant receives
3 fractions, to a total dose of 24 Gy over 3 weeks. A prospective audit of dosimetry for
the first 20 patients treated was performed and is presented. 
Method Data was collected prospectively. Doses were measured with TLDs
placed on the top of the head, both shoulders, chest, both legs and soles, and at the
match point of the arcing treatment beams. 
Results The mean dose given to the skin surface of all the patients was 21.5Gy
(SD ± 4.7%). For the first 6 patients there was relative overdose at the top of the head,
shoulders and soles of the feet. For the subsequent 14 patients lead shielding was
applied to these areas, producing a dose that was acceptable. Lateral doses across the
patient were symmetrical. Longitudinally the mean doses even after shielding showed
a statistically significant variation (p <0.05); top of head 21.5Gy; shoulders 23.5Gy;
anterior chest 19.0Gy; anterior matchpoint 16.0Gy; anterior legs 22.3Gy; soles
22.5Gy. Posterior doses were similar. 
Discussion This technique was easily implemented with a standard Philips SL25
machine requiring minimal modification and conformed to AAPM Report No. 23
requirements. Patients completed the treatment but the 30˚ angle required is uncom-
fortable for some patients, who maintain this position for approximately 20 minutes.
There can be a relative underdose at the matchpoint of the arcing beams due to self-
shielding. Despite the short fraction technique, the treatment time of up to 45 minutes
makes a significant impact on a busy clinical department, only allowing one patient to
be treated at any one time. As few centres offer this treatment, a national waiting list
has developed. We are commissioning a Betatron that will treat patients using a beam
that scans along the patients’ length at an angle of 30˚. This allows the patient to lie
flat and be more comfortable. This system will improve the longitudinal inhomo-
geneity experienced with the present technique. Importantly, it will free linear accel-
erator time for routine work and because it will be solely dedicated for TSE treatment
it will enable us to provide treatment without delay. 
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GESTATIONAL TROPHOBLASTIC DISEASE IN THE ASIAN 
POPULATION OF NORTHERN ENGLAND AND NORTH
WALES BWL Tham, JE Everard, BW Hancock, YCR Department of Clinical
Oncology and Trophoblastic Tumour Centre, Weston Park Hospital, Sheffield
S10 2SJ
The aim of this study was to determine the incidence and trend of Gestational
Trophoblastic Disease (GTD) in the immigrant Asian population of Northern England
and North Wales. 
A retrospective case note review was undertaken of 312 Asian patients who were
registered with Weston Park Hospital, one of 3 UK Trophoblastic Screening Centres,
from 1991 to 1999. 
During the 9-year study period, the incidence of GTD in the northern part of
England and North Wales averaged 1 per 714 live births. The incidence of GTD in the
Asian population was 1.92 times higher than in the non-Asian population (1 per 400
live births versus 1 per 746 live births). There was an excess of molar pregnancies in
the extreme maternal age groups. The incidence in these women was about 2 times
higher than for the whole reproductive cohort. The frequency proportion of partial
(PM) to complete (CM) hydatidiform mole also increased with the age. The ratio of
PM to CM increased from 0.9 in the lower age to 3.3 in the older age group. There was
a slow but rising trend in the incidence of GTD in the UK. The increase was signifi-
cantly higher in the Asian than non-Asian population. 
Setting up of regional or national registration centres helped to provide more accu-
rate estimate of the true incidence of a disease. The incidence of GTD in Asian women
is higher than in non-Asian and is increasing. However, there must be a move to iden-
tify ethnic groups by self-ascribed ethnicity, together with alignment and conformity
in ethnic definition between centres so that meaningful results can be derived. 
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Ewing’s Sarcoma; 5 years experience at a tertiary referral 
centre in Pakistan. AH Sadozye, K Saeed Shaukat Khanum
Memorial Cancer Hospital (SKMCH) Lahore, Pakistan
Background Ewing’s sarcoma is an uncommon malignancy in adults. The treatment
is multi-modality including chemotherapy, surgery and radiotherapy. 
Materials and Methods Case notes of all patients seen at SKMCH, between
January 1995 and December 1999, with a histological diagnosis of Ewing’s sarcoma
or PNET, were reviewed in a retrospective manner. Attention was paid to the
following; Gender, date of first diagnosis, stage, visceral mets at presentation, skeletal
mets at presentation, local recurrence at presentation, chemotherapy, number of cycles
of chemotherapy, definitive surgery, definitive radiotherapy (XRT), post-operative
pathology, end-of-treatment (EOT) result, relapse, relapse free period, status at last
follow-up. 
Results A total of 24 patients were seen during the above-mentioned period with a
diagnosis of Ewing’s sarcoma/PNET. Of these 80% were male, median age was 24.5
years (range 17–44 yrs). At presentation 66% had metastatic disease. A minority
(5/24; 20%) presented after definitive surgery, performed up front. Chemotherapy was
administered to 14/24 (58%) patients. Of these 36% each had EVAIA and VAIA regi-
mens whereas 14% had VACA and 14% had other regimens. A median of eight
chemotherapy cycles were administered. Definitive surgery after neo-adjuvant
chemotherapy was performed in 20% (5/24) patients. The pathologic complete
response rate was 40% (2/5). Radiotherapy was given to 11/24 patients (45%). Only
15 patients (62%) had evaluable disease and end-of-treatment analysis shows an
overall response rate of 46%. At the time of analysis, with a median follow-up of 31
weeks (average 45 wks), 3/7 responders have relapsed. Only 24% patients were
disease free at their last follow-up visit. 
Conclusions A majority of our patients presented with metastatic disease, some of
them after having had erratic and maybe inappropriate treatment by physicians with
little knowledge of the disease. This is reflected in our poor survival. Early diagnosis
and referral to centres, with medical oncologists/surgeons and radiation oncologists
all having interest and expertise in the disease, is essential and needs to be highlighted
amongst the medical community in Pakistan. 
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THE NATURAL HISTORY OF ASYMPTOMATIC MALIGNANT 
MESOTHELIOMA. PV Murray, MER O’Brien, IE Smith, 
A Norton & S Ashley. Lung Unit, Department of Medicine, The Royal
Marsden Hospital, Surrey, and MidKent Oncology Centre, Maidstone
Studies have shown an overall median survival in malignant mesothelioma of 4–12.5
months (1)(2). A recent trial had a 10 patient subgroup, picked up by incidental chest
radiography, with a longer median survival of 21 months (3). 
Aims To study the natural history of mesothelioma in patients with absent or mild
symptoms seen at the Royal Marsden and MidKent Oncology Centre. 
Methods 33 suitable patients with a median age of 62 years (29 male) were identi-
fied between 1994 and 2000. Of this group, 24 patients were randomised in a trial
comparing best supportive care alone (n = 13) to best supportive care with SRL 172 
(n = 11), a heat-treated Mycobacterium vaccae used as immunotherapy, with
chemotherapy later if necessary. Data analysis has found no advantage in any group
receiving SRL172 compared to standard. Therefore for statistical purposes all patients
initially received best supportive care. Key dates and times were recorded for all
patients. 
Results The median survival in the whole group was 20 months from diagnosis.
The median time to worsening symptoms was 5 months and to start of chemotherapy
9 months. Those patients with mild symptoms had a median time of 3 1/2 months of
symptoms before the diagnosis was made. 
Conclusions Our study gives further evidence that, in advanced stage mesothe-
lioma, if relatively asymptomatic at diagnosis, prolonged survival without treatment is
possible. 
Implications This study was a natural history baseline to a new trial at The Royal
Marsden looking at early vs delayed chemotherapy in mesothelioma (The MED trial)
as a new approach to treatment. 
1. Law MR, Hodson M.E and Turner-Warwick M (1984) Eur. J Respir Dis 65: 162. 
2. Ruffie P, Feld R and Minkin S et al. (1989) J Clin Oncol 7: 1157. 
3. Yates D.H., et al (1997) Thorax 52: 507. Poster presentations 71
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COMPARISON OF THE CLINICO-EPIDEMIOLOGICAL, 
PATHOLOGICAL AND MOLECULAR FEATURES OF
ADENOCARCINOMAS AROUND THE GOJ K Dolan1, JK Field2, 
SJ Walker3, R Sutton3. 1Department of Surgery, Leeds General Infirmary,
Leeds LS1 3EX, and Departments of 2Molecular Oncology and 3Surgery,
University of Liverpool 
Adenocarcinomas of the cardia resemble adenocarcinomas of the oesophagus
epidemiologically in population studies based on the ICD-0 subsite classification,
which classifies carcinomas of the GOJ as carcinomas of the cardia. This study was to
determine if adenocarcinomas of the oesophagus and GOJ were similar in other
respects with particular emphasis on molecular features. 
Forty-seven adenocarcinomas arising in the proximity of the GOJ were subdivided
into 20 carcinomas located exclusively within the lower third of the oesophagus (L), 9
mainly within the oesophagus but extending distally across the GOJ (L/GOJ) and 18
straddling the GOJ (GOJ). Comparison of the clinico-epidemiological (age, sex and
survival), pathological (presence of Barrett’s oesophagus, length, grade and stage of
carcinoma) and molecular (allelic loss, microsatellite instability and TP53 mutations)
features was performed. 
Adenocarcinomas at each of the three subsites were similar in all of the features
studied, including the presence of Barrett’s oesophagus. There were no significant
differences in the location or frequency of allelic loss, and direct DNA sequencing
revealed identical TP53 mutations in adenocarcinomas at each of the three subsites,
suggesting a common aetiology. 
Adenocarcinomas located exclusively within the oesophagus and adenocarci-
nomas involving the GOJ are similar in all studied parameters, suggesting that they
may represent the same disease. Carcinomas involving the GOJ should not be classi-
fied with carcinomas of the cardia as a gastric malignancy, but should be classified as
an oesophageal carcinoma with subsite GOJ. 
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STENTING IN OESOPHAGEAL CANCER RELIEVES 
DYSPHAGIA BUT DOES NOT AMELIORATE NUTRITIONAL
STATUS: RESULTS OF A RETROSPECTIVE SERIES SY Abdallah, 
HL McCabe, A Early and A Maraveyas, Academic Department of Oncology,
Princess Royal Hospital, Hull
Background Weight loss and malnutrition are common problems in oesophageal
cancer (OC) patients. Weight loss leads to increased morbidity from surgery, radio-
therapy and chemotherapy, and is one of the most persistent complaints in OC
patients. Oesophageal stenting is used to relieve dysphagia in inoperable OC, but is
not known whether it is effective in maintaining nutritional status. The aim of this
retrospective study was to compare nutritional indices of patients with OC before and
after uncomplicated oesophageal stent insertion, who were dysphagia-free for over 8
weeks. 
Methods The notes of 107 patients with OC, who had undergone stent insertion in
our radiology department from 1995–2000, were reviewed. Weight, serum albumin
and lymphocyte count (recorded as markers of nutrition) were compared before, and 8
weeks after, stent insertion. 50 patients were excluded due to operation, PEG tube
insertion, complicated stent insertion, persistent post-stent symptoms or lack of data. 
Results Of 57 patients, 47 (82.5%) reported an improvement in dysphagia following
stent insertion, 6 (10.5%) reported no improvement, and data was not available in 4 (7%).
41 patients (72%) remained symptom free for a minimum of 8 weeks. Of these 41, 29
(71%) progressively lost weight over time (>5% of body weight). Weight was stable (+/-
5%) in 8 (19%), and increased (>5%) in 4 (9.7%). Serum albumin decreased by >10% in
24 of 41 patients (58%), remained stable (+/-10%) in 11 (26%), and increased (>10%) in
1 (2.4%). Albumin was not known in 5 (12%). Lymphocyte count decreased by >10% of
baseline in 23 (56%), remained stable (+/-10%) in 2 (4.8%) and increased by >10% in 11
(26%). Lymphocyte count was not available in 5(12%). 
Conclusion Oesophageal stenting relieves dysphagia in OC patients, but does not
appear to ameliorate nutritional status, as evidenced by progressive weight loss and reduc-
tion in serum albumin and lymphocyte count seen in most patients. Weight loss in patients
with gastrointestinal cancers is associated with more complications from chemotherapy
and radiotherapy and leads to dose compromise. It is correlated with a shorter disease free
survival and overall survival, decreased quality of life and performance status, compared
to patients without weight loss.[1] The simple alleviation of mechanical obstruction in
these patients is not an adequate treatment for this cancer-related symptom. Further efforts
are required to reverse weight loss and improve nutritional status in OC patients. 
1. Andreyev HJ et al. Why do patients with weight loss have a worse outcome when
undergoing chemotherapy for gastrointestinal malignancies? EJC 98;34(4):
503–509. 
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A RETROSPECTIVE ANALYSIS OF PATIENTS WITH SMALL 
BOWEL MALIGNANCIES SEEN AT MOUNT VERNON
CANCER CENTER OVER TEN YEARS, AEF Roy, M Harrison, Mount
Vernon Cancer Center, Northwood, Middlesex HA6 2RN 
Primary malignancies of the small bowel are rare. Management of these cases is there-
fore based on limited experience and no published randomised trials. The aim of this
project was to review how these malignancies had been treated at the Mount Vernon
Cancer Center over the last ten years. 
The Mount Vernon Cancer Database was searched for patients with primary malig-
nancies of the small bowel. Case notes were reviewed with respect to the tumour type,
location, TNM stage, surgery, chemotherapy and survival. 48 pts with small bowel
primaries were seen over the last ten years, and the case notes were available on 31
patients. The average age at presentation was 66 yrs with an even sex distribution. 17
pts (55%) had adenocarcinoma; 6 pts (19%) had lymphoma, and 7 pts (23%) had
carcinoid tumours. I patient had a malignant haemangioendothelioma. The adenocar-
cinomas were distributed evenly between the duodenum, jejunum and ileum. The
lymphomas and carcinoids occurred most frequently in the ileum. 
Of the 17 patients with adenocarcinoma, 12 (71%) had radical surgery. The others
had palliative procedures or no surgical intervention. The mean survival in those
considered suitable for radical surgery was 1 yr 8 m and only 8 mths in the others. Of
those that had radical surgery, 50% had post-operative chemotherapy. The selection of
those to receive chemo did not appear to depend on the TNM stage or tumour grade. 5
different regimes were used but all were 5FU based. The average survival in those that
received chemotherapy was 1 yr 3 mths and 1 yr 9 mths in those who did not receive
chemotherapy. 
All 7 patients with carcinoid tumours had surgical resection, 2 had adjuvant radio-
therapy (one of these also received De Gramont). The median survival was 8 yrs. 
Of the 6 patients with lymphoma, 4 had high-grade disease and received CHOP (1
recurred and had PMitCBO). Of the 2 with low-grade 1 recurred post-surgery and
received chlorambucil and radiotherapy. 5 of these patients are still alive 6–10 yrs post
diagnosis, the sixth died at 6 yrs from lung cancer. 
These results are comparable with other published series with regard to tumour
types and distribution. The survival figures are good for lymphoma and carcinoid
tumours. The numbers are too small for any statistical analysis, but there does not
seem to be any survival advantage to adjuvant chemotherapy in adenocarcinoma of
the small bowel. 
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SURVIVAL IN PATIENTS WITH ADVANCED COLORECTAL 
CANCER IS SIGNIFICANTLY INFLUENCED BY QUALITY OF
LIFE, NR Maisey, A Norman, M Watson and D Cunningham, Department of
Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT 
Background Quality of life (QoL) evaluation is recognised as an important outcome
parameter in oncology. The aim of this study was to investigate the influence of base-
line QoL on survival in patients treated within clinical trials of chemotherapy for
advanced colorectal cancer (CRC). 
Methods From 1992 to 1998 4 randomised clinical trials in advanced CRC were
conducted at this institution. Informed consent was obtained from all patients, and
studies received local ethical approval. The EORTC-QLQ-C30 questionnaire was
completed prior to the commencement of chemotherapy. An overall QoL score was
calculated from all domains of the EORTC-QLQ-C30 questionnaire. Data were
prospectively recorded and analyses were performed on median-dichotomised base-
line QoL and clinical prognostic factors. 
Results: Baseline QoL questionnaires were completed in 501 patients. Median age
was 62 (33–82), 63% were male, 98% had PS 0–2 and 82% had metastatic disease.
Median follow up was 2.84 years. All QoL domains other than financial, were signif-
icant predictors of survival in the univariate analysis. One year survival was 39.9%
and 72.0% (P<0.0001) for patients with overall scores below and above the median
(80) respectively. In the baseline Cox model, the following were significant indepen-
dent predictors of survival: PS, metastatic disease, haemoglobin, weight loss, CEA
and albumen. Other than emotional/cognitive functioning, constipation, diarrhoea and
financial domains, all QoL scales were significant independent predictors of survival
(P<0.035). In the final model the overall QoL score remained highly significant as an
independent predictor of survival (P<0.0001) with a hazard ratio of 1.68 (95% CI 1.3
to 2.16). 
Conclusion Baseline QoL is a strong independent predictor of survival in patients
with advanced CRC. QoL measurements should be routinely recorded in clinical trials
to stratify cohorts and aid trial comparison, and may also have relevance in the choice
of initial therapy in routine clinical work. 72 Poster presentations
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CLINICAL IMPACT OF A NATIONAL LYMPHOMA REVIEW 
PANEL – A PILOT STUDY E Toy1, J Lester1, I Kerby1, 
T Maughan1, C Poynton2, S Dojcinov3, R Attenoos3, C O’Brien3, A Caslin3,
1Velindre NHS Trust, 2University of Wales College of Medicine, 3All Wales
Lymphoma Panel 
Background In 1998 an All Wales Lymphoma Pathology Review Service was estab-
lished. The aim was multi-fold; to assess the accuracy of lymphoma diagnosis in Wales,
to identify diagnostic problem areas and to provide a higher ascertainment of diagnosis to
facilitate optimal clinical management. Over 32 months, 745 cases were submitted and
the overall histological diagnosis was changed in 34% of cases submitted – 230 patients. 
Method Case notes were obtained on a random sample of 33 patients whose diag-
nosis had been changed. Data regarding medical history including comorbidity, exam-
ination and investigation findings was extracted and presented to an expert panel. Two
hypothetical management plans were generated based on initial and revised histology
reports and the individual patient data. These were then compared. Data was also
collected on whether the actual management had changed due to the revision in diag-
nosis and whether submission to the panel resulted in a treatment delay. Patients
whose specimens were initially reported as “Lymphoma NOS” were not counted as a
change in management as it was assumed further steps would be taken to further
categorise the disease. 
Results 17 patients had a change in their hypothetical management. 
Change Number of Patients 
Different Chemotherapy Regimen 8 
Radiotherapy to Chemotherapy 3 
No treatment to chemotherapy 3 
Chemotherapy to no treatment 1 
Repeat biopsy to chemotherapy 1 
Chemotherapy to investigation 1 
However, in practice, only 12 (36%) had their first line management altered. 2 died
before change could be instituted, 1 was unfit for treatment and 2 who had experi-
enced a good response to initial treatment did not have this altered. The panel diag-
nosis affected one 2nd line therapy. Panel review delayed treatment in a minority of
cases (2 patients). 
Conclusions These data suggest that a significant proportion of patients are not
receiving optimal management of their lymphoma because the true diagnosis is
unknown to the clinician and patient. Central review of lymphoma is essential. 
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RISK ADJUSTED PROGNOSTIC MODELS FOR HODGKIN’S 
DISEASE (HD) AND GRADE II NON HODGKIN’S LYMPHOMA
(NHL): VALIDATION ON 6,728 PATIENTS. SE Low1, J Horsman1, P Smith2,
D Linch2, H Hancock1 and BW Hancock1. 1YCR Department of Clinical
Oncology, Weston Park Hospital, Sheffield, S10 2SJ, 2British, National
Lymphoma Investigation, The Middlesex Hospital, Mortimer Street, London,
W1N 8AA
Background The prognostic significance of 20 putative markers has been assessed in
a consecutive series of 1,198 patients with malignant lymphoma seen by the Sheffield
Lymphoma Group over three decades (Low et al., 2000. British Journal of Cancer 83
(Suppl 1): 83). Using significant factors from multivariate analyses, risk adjusted
prognostic models were derived for Hodgkin’s disease and NHL Grade II. Data from
an additional 6,728 patients on the British National Lymphoma Investigation database
was used for validation. 
Results In 536 patients with NHL Grade II our model, based on albumin, age,
ESR, LDH and stage, identified three risk groups with predicted five-year survival
rates of 55.7%, 44.0%, 34.9%. Five year survival rates of 94.3%, 82.9%, 64.6%,
51.7% were identified from 315 patients in the HD model using age, albumin and
lymphocyte count. These models were then applied to 4,411 patients with HD and
2,317 patients with NHL Grade II. Survival curves derived from these validation
groups showed significant differences according to our risk models, with 5 year
survival rates of 89.8%, 80.3%, 67.2, 46.2% for HD and 56.3%, 41.3%, 30.3% for
NHL Grade II for the different risk groups (P<0.0001). 
Conclusions The risk models we developed may be useful in predicting outcome
and to facilitate decisions on treatment for individual patients. Whilst these models are
to be tested prospectively, it is important to obtain data on new markers that will
further refine the identification of appropriate prognostic groups. 
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NON-HODGKIN’S LYMPHOMA PRESENTING WITH SPINAL 
INVOLVEMENT: THE SHEFFIELD LYMPHOMA GROUP
EXPERIENCE (1970–2000) HY Ching, J Horsman, C Radstone, 
H Hancock and BW Hancock, YCR Department of Clinical Oncology, Weston
Park Hospital, Sheffield, S10 2SJ 
Spinal non-Hodgkin’s lymphoma is rare. We retrospectively reviewed the clinical and
histopathologic records of 39 consecutive patients referred to the Sheffield
Lymphoma Group from 1970–2000 and analysed the prognostic differences between
localised (Stage IE & IIE) and secondary (Stage III & IV) spinal non-Hodgkin’s
lymphomas (S-NHL) patients. 45% of all patients were over 60 years old. More
patients were male (58%); presented with Stage IE and IIE (63%), mostly of interme-
diate/high grade histology (74%); over a third had ‘B’ symptoms; nearly a third (11
patients) were paraplegic and 14 had sphincter dysfunction at diagnosis. The overall
survival of all patients was 39% at 5 years (median 24.7 months), whilst that of
localised S-NHL was 51% (median 89.7 months). Univariate analysis showed better
survival for patients with good mobility status at presentation (P<0.01) and complete
response to initial treatment (P<0.001). In primary S-NHL, histology (P<0.05)
significantly influenced overall survival. In conclusion disease is frequently locally
advanced at presentation with aggressive histologic grade: thorough staging should
always be performed to exclude widespread disease. Good mobility status predicts for
good survival outcome. Optimal treatment is still uncertain. 
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MANAGEMENT OF LYMPHOMA PATIENTS IN A CANCER 
UNIT: AN AUDIT OF 15 YEARS’ EXPERIENCE IN A
DISTRICT GENERAL HOSPITAL. JD Chester1, M Howarth2, CJ Percy Clark,
DR Goldesbrough, SE Bogle, CJ Bradley and D Parker, 1ICRF Clinical
Centre, St. James’ University Hospital, Leeds; 2Manorlands Hospice,
Oxenhope, Keighley; Bradford Royal Infirmary, Duckworth Lane, Bradford
Until recently, many cases of lymphoma in the United Kingdom have been treated in
specialist regional centres. The results of studies from specialist centres may not be
representative of lymphoma patients as a whole. Furthermore, as a consequence of 
the Calman-Hine Report, there is an increasing tendency for lymphoma patients to be
treated locally, in Cancer Units. Relevant data for patients treated outside specialist
centres are therefore required. 
We have collected data prospectively on 208 consecutive lymphoma patients
presenting, on an all-comers basis, to the Medical Oncology Unit at Bradford Royal
Infirmary, between 1981 and 1996. Male:female ratio was 54%:46%. Median age 
of patients at diagnosis was 56 years (range 17–89 years). Tumours were initially 
classified according to the Working Formulation, and have subsequently all been re-
classified according to the REAL classification. 22% of patients presented with
Hodgkin’s Disease, the remainder having Non-Hodgkin’s Lymphomas. Patients were
treated with radiotherapy and/or chemotherapy, according to local protocols. Thirteen
(6.2%) patients required further management in the Cancer Centre upon disease
progression/relapse. 
Five year actuarial survival was 72.7% for Hodgkin’s disease and 55.7% for Non-
Hodgkin’s lymphoma. Age and stage of disease were the only predictors of survival in
a multivariate analysis. Histological classification was not a useful predictor of
survival in this analysis. Comparison of our local survival figures with those from
national and international registry data suggest that survival figures comparable to
those obtained nationally and across Europe are attainable in a Cancer Unit. 
Multiple pathways of referral of lymphoma patients operate in our region. Our
Unit treated only 22% of the patients registered in Bradford between 1986 and 1995 
as having lymphoma. The vast majority of the remainder were managed by
Haemtologists and/or Clinical Oncologists. 
This unique data set of lymphoma survival in a District General Hospital may
provide a comparator for future assessments of the success of lymphoma treatment in
Cancer Units, within the new Calman-Hine structure for cancer management. Poster presentations 73
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LOSS OF HETEROZYGOSITY ON CHROMOSOME 11Q24 IN 
COLORECTAL AND EPITHELIAL OVARIAN CANCER. 
KP Watt1, Li Li, GC Sellar1, EP Miller1, D Scott1, M Stewart1, JF Smyth1, 
H Gabra11 ICRF Medical Oncology Unit, Western General Hospital,
Edinburgh, UK 
Ten polymorphic microsatellite markers on chromosome 11q24 were amplified by
PCR from normal/tumour DNA pairs from 39 patients with colorectal and 65 patients
with epithelial ovarian cancer. Samples were run on the 310 ABI prism and allelotype
assigned using the genescan software. LOH rates at each marker were determined.
Bioinformatics resources, predominantly NIX analysis have been used to determine
the order of markers within the 11q24 region. Concurrently, genes and ESTs in the
region have been identified using the same approach. 
In the ovarian tumours, 2 regions of LOH have been identified from within
the previously defined 8.5 Mb minimum region of deletion (Cancer Res. 1996: 56
950–954). A 2 Mb region centred on the marker GATA69G01 is associated with
advanced stage disease (P=0.026) and adverse survival (P=0.013). In multivariate
analysis, LOH of the second region centred on D11S4131 is an independent adverse
survival variable (P=0.0043). 
Two regions of LOH were also identified in the colorectal tumours. A similar
region of LOH at D11S4131 was defined but showed no association with adverse
survival. A separate more centromeric region of LOH between D11S912 and
D11S4150 was also identified. 
Candidate tumour suppressor genes from these regions are being sought and inves-
tigated. Several ESTs near the D11S4131 marker have been identified and shown to
be weakly expressed by rtPCR in normal human ovarian surface epithelial cells.
Expression analysis of these ESTs in cancer cell lines has yet to be performed. 
This study demonstrates similarities and differences in the genetic lesions
sustained by these tumour types. It narrows the region of previously documented LOH
thus focusing attention on the region of chromosome 11q24 that houses the important
tumour suppressor genes. 
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FUNCTIONAL IDENTIFICATION OF RALDH2 
DYSREGULATION BY CDNA REPRESENTATIONAL
DIFFERENCE ANALYSIS IN CHROMOSOME 11 MEDIATED GROWTH
SUPPRESSION OF OVARIAN CANCER. C Blenkiron1, GC Sellar1, 
E Stronach1, GJ Rabiasz1, EP Miller1, DJ Porteous2, JF Smyth1, H Gabra1
1ICRF Medical Oncology Unit, 2Medical Genetics section, Department of
Medical Sciences, University of Edinburgh, Molecular Medicine Centre,
Western General Hospital, Edinburgh, EH4 2XU
Frequent loss of heterozygosity (LOH) at regions on chromosome 11p in epithelial
ovarian cancer suggests the presence of tumour suppressors in these locations.
Microcell-mediated chromosome transfer (MMCT) has been used as a method to
search for such genes. OVCAR3, a human ovarian cell line, contains only one copy of
chromosome 11, which is fragmented and rearranged throughout. Transfer of normal
chromosome 11 into OVCAR3 by MMCT produced microcell hybrids which display
growth and cellular migration suppression. 
Subsequently, mRNA from the parent OVCAR3 clonal line and from 11OH2.1, a
growth suppressed microcell hybrid, was used in the subtractive method of cDNA-
RDA. 
cDNA-RDA was successfully used to enrich for transcripts that were significantly
down regulated in the suppressed cell lines. cDNA-RDA of OHN, a clonal derivative
of the OVCAR3 parent line, versus 11OH2.1, identified transcribed sequences that
were clearly differentially regulated by RT-PCR. These included KIAA1058,
HSPC307, cdc37 and 2 novel transcripts. Also among these was Retinaldehyde dehy-
drogenase 2 (RALDH2), a gene that has been implicated in the production of all-trans
retinoic acid. RALDH2 was strongly downregulated by quantitative RT-PCR and
Northern blotting in association with chromosome 11 mediated growth suppression.
We have developed and transfected antisense constructs into a parental derivative cell
line OH1. Clones have been derived and will be used to confirm the functional impor-
tance of RALDH2 in the context of ovarian cancer growth suppression. 
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IDENTIFICATION OF PUTATIVE OVARIAN CANCER 
TUMOUR SUPPRESSOR GENES FROM CHROMOSOME
(CHR) 11 BY EXPRESSION DIFFERENCE ANALYSIS, EA Stronach1, 
GC Sellar1, C Blenkiron1, GJ Rabiasz1, C Massey1, DJ Porteous2, 
JF Smyth1, H Gabra1, 1ICRF, Medical Oncology Unit, 2Medical Genetics
Section, Department of Medical Sciences, University of Edinburgh Molecular
Medicine Centre, Western General Hospital, Edinburgh, EH4 2XU 
We and others have previously reported LOH on human chr 11 in ovarian cancer and
an association has been observed between adverse clinicopathological variables and
LOH on 11p15 and 11q24. Microcell hybrid transfer of chr 11 into the ovarian cancer
cell line OVCAR3, which has rearrangements on both 11p and 11q, confers both
growth and invasiveness suppression. The invasiveness suppressor has been localised
to 11q24; the growth suppressor lies outwith this region. 
In order to elucidate the pathways involved in these phenotypes several expression
difference analysis methodologies have been combined. The subtractive hybridisation
technique cDNA representational difference analysis (cDNA-RDA) has been used to
compare the expression profiles of parental and chr 11 recipient cell lines. Sixty inde-
pendent products have been identified in association with the growth suppressed
phenotype. Four of these products have been shown to map to chr 11. Similarly, differ-
ential display RT-PCR (DDRT-PCR) has identified one product expressed from chr 11
in association with growth suppression. Hybridisation of three distinct Atlas 1.2 k
microarrays (Clontech) have identified 36 products (four of which map to chr 11)
showing 3-fold or greater upregulation of expression in chr 11 recipient cells when
compared with parental cell lines. These three difference analysis methodologies have
complemented each other providing a powerful strategy by which to identify potential
components of the chr 11 mediated growth suppression phenotype. 
Verification of differentially expressed products identified from all three tech-
niques is underway using LightCycler (Idaho Technology) real-time quantitative RT-
PCR. To date, expression differences have been validated for epidermal growth factor
receptor (>3 fold), cathepsin D (>2 fold) and tissue inhibitor of metalloproteinase 2
(>2 fold). The role of these and other products verified to be upregulated in the growth
suppressed phenotype will ultimately be assessed using both sense and antisense
expression constructs and/or small molecule inhibitors where appropriate. 
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CHROMOSOMAL ABNORMALITIES IN OVARIAN CLEAR 
CELL CARCINOMA Jo Dent1, T Perren1, N Wilkinson1, 
I Richmond2, A Markham1, S Bell3, 1St James’s Hospital, Leeds, UK, 2Hull
Royal Infirmary, Hull, UK; 3University of Leeds, Leeds 
Ovarian clear cell carcinoma (CCC) accounts for a small but significant proportion of
all ovarian cancers and is a distinct clinical and pathological entity. It tends to be asso-
ciated with poorer response rates to chemotherapy and a worse prognosis. There is
little knowledge of any possible underlying genetic changes. Comparative genomic
hybridisation (CGH) is a powerful analytical technique that permits identification of
regions of chromosomes that have either undergone an increase or decrease in DNA
causing genomic imbalance. DNA was extracted from paraffin embedded samples of
18 cases of pure ovarian CCC and analysis for genetic imbalances was carried out
using CGH. 17 of the 18 cases (94%) showed genomic alterations. The mean number
of changes was 15 (range 2–30) indicating a moderate level of genetic instability.
Chromosome deletions were more common than amplifications. The most prominent
change involved chromosome 9q deletions in 8 cases (44%) and correlates with other
epithelial ovarian cancers. This deletion is currently being confirmed using
microsatellite analysis and looking for loss of heterozygosity at 4 separate loci on
chromosome 9 and may serve as a useful prognostic indicator. Other frequent dele-
tions involved 10q (22%), 5p (22%), 16 (27%) and 22 (33%). Chromosome gains
were most common at 3p (22%), 4q (22%), 13q (22%), 17 (33%) and 18 (33%). CGH
and microsatellite marker results will be presented in detail and correlated with patient
survival and other clinical parameters including age, stage at presentation and
response. 74 Poster presentations
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LOSS OF HETEROZYGOSITY ON CHROMOSOME 11 IS A 
MARKER OF RECURRENCE IN TCC OF THE BLADDER
CANCER. J Edwards1, P Duncan1, JJ Going2, AD Watters1 and 
JMS Bartlett1, Dept of Surgery1./Dept of Pathology2, Glasgow Royal Infirmary,
Glasgow, G31 2ER 
Approximately two thirds of patients diagnosed with superficial transitional cell carci-
noma (TCC) of the urinary bladder will recur within 2 years. It was recently reported
that loss of chromosomes 9 and LOH at 9q34 in primary TCC identifies a subset of
patients at high risk of recurrence (Bartlett et al. 1998, BJC. 77, 2193–2198 and
Edwards et al. 2000, BJC. 83 pg 190). 
This study explores genetic alterations at chromosomes 4, 8, and 11 as possible
predictors of recurrence. A total of 109 tumours were investigate, tumours were
obtained from 18 patients who did not recur (NR) and from 29 patients who recurred
(REC). Patient DNA was microdissected and extracted from archival normal/tumour
sections and analysed for loss of heterozygosity (LOH) at 10 loci. Fluorescent PCR
was performed and genotyping carried out on a Perkin Elmer ABI377™ sequencer. 
When the level of LOH spanning all informative markers on each chromosome
was compared for NR tumours versus primary REC tumours no significant differ-
ences were found. When the level of LOH for chromosomal areas and single loci were
compared it was noted that 25% (3/12) of NR tumours had LOH at D11S490
compared 81% (13/16) of REC primary tumours (P=0.004). An increase of 25% was
also noted at FGF3, which resides on the same arm of chromosome 11 as D11S490
although this result was not significant. No other chromosomal region or loci investi-
gated gave significant results when LOH in primary tumours were investigated. 
In summary LOH at D11S490 was demonstrated to predict recurrence in a subset
of TCC of the urinary bladder patients. 
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LOSS OF HETEROZYGOSITY AT A COMMON REGION OF 
DELETION ON 15q14–q15.2 IN TRANSITIONAL CELL
CARCINOMAS. Rachael Natrajan, Jari Louhelainen, Margaret A Knowles,
ICRF Clinical Centre, St. James’s University Hospital, Leeds, LS9 7TF
Deletions on chromosome 15 are common in many types of human tumours,
including both parathyroid adenomas and colorectal carcinomas, which suggests the
presence of potential tumour suppressor genes on chromosome 15. Common regions
of deletion identified in these tumour types are 15q15 and 15q21. 
In this study we have analysed the incidence of loss of heterozygosity (LOH) on
chromosome 15 to ascertain its potential involvement in the development and
progression of transitional cell carcinoma (TCC). A panel of 20 polymorphic markers,
spanning 15q12-q22, were used to analyse the presence of LOH in 29 TCCs of
various stages and grades. LOH was found in 62% (18/29) of informative tumours for
at least one marker in the region 15q14-15q15.2. Deletion mapping has defined two
minimal regions of deletion; proximally between markers D15S118 and D15S129 at
15q14; and distally between markers D15S968 and D15S659 at 15q15.1-q15.2. 
These regions may contain tumour suppressor genes, whose loss, or inactivation,
may be associated with TCC tumorigenesis. 
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ANALYSIS OF CANDIDATE TUMOUR SUPPRESSOR 
GENES ON CHROMOSOME 9 IN BLADDER CANCER CELL
LINES SV Williams and MA Knowles, ICRF Clinical Centre, St. James’s
University Hospital, Beckett Street, Leeds, LS9 7TF, U.K. 
Loss of all or part of chromosome 9 in bladder cancer is a common finding, and at
least four separate regions of minimal loss have been identified. We have looked at the
presence and expression status of candidate tumour suppressor genes from three of
these regions in a panel of bladder cancer cell lines. The main aim was to identify suit-
able cell lines for further functional studies of these genes. The CDKN2 region at 9p21
was homozygously deleted in several cell lines as shown by fluorescence in situ
hybridisation (FISH) and genomic PCR. In all but one cell line (T24) CDKN2A (p16
protein) was expressed when the gene was not homozygously deleted. No homozy-
gous deletions of TSC1 (tuberous sclerosis 1) at 9q34 were detected, and expression
was found by RT-PCR in all cell lines. DBCCR1 (Deleted in Bladder Cancer
Candidate Region gene 1) at 9q32-33 was present by FISH and genomic PCR in all
but one cell line (SHIM). As in normal urothelium, expression was at the limit of
detection by RT-PCR in most cell lines, but high levels were seen in one cell line
(253J). This suggests that TSC1 and DBCCR1 are rarely inactivated by homozygous
deletion or by loss of RNA expression. SHIM, a newly described cell line, is homozy-
gously deleted for both the CDKN2 region and DBCCR1. It will therefore be useful
for functional studies of these genes to elucidate their role in bladder tumorigenesis. 
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UNDER-REPRESENTATION OF 8p WITH A COMMON 
BREAKPOINT IN BLADDER CANCER. J Adams, SV Williams
and MA Knowles, ICRF Clinical Centre, St. James’s University Hospital,
Beckett Street, Leeds, LS9 7TF, U.K. 
At least two regions of the short arm of chromosome 8 show deletions in bladder
cancer. Deletions are found in 23% of bladder tumours overall and there is a signifi-
cant association with muscle invasion; 56% of muscle invasive tumours have demon-
strable loss of heterozygosity (LOH) in this region. 8p LOH is found in several other
tumour types including prostate and colorectal carcinomas, where it is also associated
with a more aggressive clinical phenotype. These findings suggest that there may be
one or more tumour suppressor genes, associated with an aggressive phenotype, on
8p. To examine the genetic events that occur on proximal 8p and to refine the locali-
sation of the regions of deletion, a panel of bladder cancer cell lines was examined,
some of which are predicted to have 8p LOH. Fluorescence in situ hybridisation
(FISH) analysis was performed using a chromosome 8 paint and a chromosome 8-
specific centromeric probe combined with a series of cosmid probes which contain
microsatellite markers of interest in 8p12. This has shown overall under-representa-
tion of 8p and over-representation of 8q. A common breakpoint has been identified on
proximal 8p. It is not clear whether this is the location of a tumour suppressor gene, or
whether the target gene is more distal and this common breakpoint is at a position
prone to breakage. Poster presentations 75
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IDENTIFICATION OF TRANSLOCATIONS AND 
ASSOCIATED EVENTS AT 14q32 IN MULTIPLE MYELOMA,
JAL Fenton, K sibley, and GJ Morgan, Department of Molecular Oncology,
Algernon Firth Building, University of Leeds, Leeds LS2 9JT
Cytogenetic techniques have shown that rearrangements of the immunoglobulin
heavy chain (IgH) locus at 14q32 can occur in up to 74% of cases of the haematolog-
ical malignancy multiple myeloma (MM). Recurrent chromosome translocations have
been identified in MM cell lines including t(11;14)(q13;q32), t(4;14) (p16;q23),
t(14;16) (q32;q23) and t)6;14) (p25;q32). We have isolated and characterised one
t(11;14) and six t(4;14) translocations from malignant bone marrow cells of MM
patients, using a combination of long range and inverse PCR methods. The break-
points in these reciprocal translocations are located in the IgH Sm switch region at
14q32, and a further downstream switch region (either Sg or Sa) with deletion of
intervening DNA. The breakpoint on chromosome 11 for the t(11;14) is currently
being characterised. For the six t(4;14) cases, five of the breakpoints on (der) 4 appear
to ‘cluster’ in the promoter and 5´ region of a gene, namely MMSET, in agreement
with previously published data. The t(4;14) event, in MM, is associated with fusion of
the MMSET and IgH genes on der (4), producing hybrid transcripts initiating from
IgH promoters. Interestingly we have isolated one further patient with a breakpoint
outside this region and so apparently unable to produce such hybrid transcripts. On the
reciprocal der (14) chromosome, the FGFR3 gene is brought into the proximity of
strong IgH elements and as a result is over-expressed in the majority, if not all, t(4;14)
MM cases. We have detected the overexpression of FGFR3 in RNA obtained from the
bone marrow of 7/65 MM patients using an RT PCR approach. Such a level of over-
expression (11% of MM) correlated well with several FISH studies where the t(4;14)
event has been described in approximately 10% of MM cases. FGFR3 is a putative
oncogene which is known to be frequently mutated in bladder and cervical carcinomas
at specific hotspots, and there is also evidence of similar mutations in MM cell lines,
which overexpress FGFR3. We are currently investigating whether there are any
mutations in the FGFR3 positive, primary MM samples. Initial findings have identi-
fied one presentation (diagnosis) sample where FGFR3 was not mutated. Interestingly
a sample from the same patient taken after post-treatment relapse was found to be
mutated. This could conceivably implicate mutations of overexpressed FGFR3 in
progression of MM disease.
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COMPARATIVE GENOMIC HYBRIDISATION ANALYSIS OF 
40 BREAST CANCERS WITH LONG TERM PATIENT 
SURVIVAL DATA. RG Hislop1, SC Stocks1, CM Steel2, M Sales3, N Pratt3,
D Goudie3, A Robertson1, AM Thompson 4Departments of Molecular and
Cellular Pathology1, Human Genetics3 and Surgery and Molecular Oncology4,
University of Dundee, DD1 9SY and University of St Andrews School of
Biology2, St Andrews KY16 9TS
Little is known of the precise sequence of genetic events that define malignancy or
underlie the clinical course in breast cancer. We have carried out comparative genomic
hybridisation (CGH) analysis of 40 primary breast tumours for which 7 year disease
recurrence and survival data were available.
Using CGH, the mean number of aberrations per cancer was 9; this comprised an
average of 5.5 amplifications and 3.5 deletions per tumour. Three tumours showed no
copy number changes and these patients did not suffer disease recurrence. The most
common regions of amplification were 1q (67%), 8q (47.5%), 17q (32.5%) and 20q
(22.5%). Most frequently deleted areas included 17p (30%), 8p (27.5%) and 19p
(25%). These results are consistent with acquisition of a distinctive pattern of large
scale (karyotypic) genetic change in malignant brease disease. In a proportion of
cancers 8q amplification and 8p deletion co-segregated and this may represent forma-
tion of an isochromosome 8q with loss of 8p. Some of the CGH data are consistent
with an underlying molecular pathology such as activation of myc (8q24). erb B2
amplification (17q12), cyclin D1 over-expression (11q13) and inactivation of tumour
suppressors p53 (17p13) and E-cadherin (16q22). In other instances, such as amplifi-
cation of 1q and 17q23 and deletion of 8p and 19p, strong candidate genes hve yet to
be identified.
While no single change correlated with recurrence or survival, a higher mean
number of deletions were seen in the group of cancers from patients who died during
the follow-up period than in those from the survivors.
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GENETIC PROFILING OF PRIMARY BREAST 
CARCINOMAS, SV Barrett1, TRJ Evans1, D Hansell2, 
M Rahilly3 and R Brown11 CRC Department of Medical Oncology, University
of Glasgow, Glasgow, G61 1BD, 2Department of Surgery, Stobhill Hospital,
Glasgow, G21 3UW, 3Department of Pathology, Stobhill Hospital, Glasgow,
G21 3UW
Paired frozen tumour and normal adjacent tissue samples have been collected in an
ongoing study from a cohort of 75 patients with primary breast carcinoma. Matched
lymphocyte and plasma has been obtained from the same group of patients before and
after surgery and chemotherapy. The present aims of this study are to characterise the
methylation status of specific loci, together with the presence of allelic imbalance and
allelic shift of the DNA from tumours and plasma DNA. The long-term aims will be
to correlate genetic alterations with available clinical data. 
Using a technique known as methylation specific PCR (MSP), it is possible to
investigate the methylation status of specific genes. Using this technique, it has been
shown for colorectal and other cancers that a subset of tumours display a methylator
phenotype, termed CpG island methylator phenotype (CIMP) in which multiple genes
are methylated (1). It is known that certain genes may be methylated in breast cancer
but little is known about the CIMP phenotype in breast cancer, its correlation with
other genetic markers or its clinical significance. Using MSP, the methylation status of
the above cohort of breast tumours is being analysed at the loci ER, BRCA1, HIC1,
MINT25 and MINT31. Results so far show tumour methylation in 6/14 (43%) at ER,
1/14 (7%) at BRCA1, 7/14 (50%) at HIC1, 1/14 (7%) at MINT25 and 11/14 (79%) at
MINT31. 
It is known that tumour cells release DNA into the circulation and this may then be
recovered from plasma (2). The tumour DNA extracted from tumour and normal adja-
cent tissue, lymphocytes and plasma in the above cohort of patients with breast cancer
is being analysed for allelic imbalance and allelic shift using PCR with a panel of fluo-
rescent primers. The following loci have been examined: p53, myc, APC, mfd15CA,
D2S123, Bat26, Bat40, GGAA4D07, GGAA2E02 in a subset of 24 of the above
patients. Results confirm the presence of allelic imbalance in the tumours analysed in
up to 34% of cases at specific primers, compared with normal adjacent and lympho-
cyte DNA. Examples of identical changes detected in plasma DNA compared to
tumour DNA have been identified at the loci p53, D2S123, GGAA2E02 and
mfd15CA. 
1. Toyota M., et al. CpG island methylator phenotype in colorectal cancer. Proc.
Natl. Acad. Sci. USA., 96: 8681–8686, 1999. 
2. Shaw J.A., et al. Microsatellite alterations in plasma DNA of primary breast
cancer patients. Clin. Cancer. Res. 6: 1119–1124. 2000. 
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CDNA MICROARRAY ANALYSIS OF TRANSFECTED 
BLADDER CANCER CELL LINES J Louhelainen, J Gill, 
N Hornigold, E Pitt, and MA Knowles. ICRF Clinical Centre, St James’s
University Hospital, Beckett Street, Leeds LS9 7TF 
The cDNA microarrays provide a powerful tool for studying changes in gene expres-
sion associated with the development and progression of cancer. The cDNA
microarray chip technology enables parallel assessment of gene expression for thou-
sands of genes in a single experiment. We have used this technology to compare the
expression of 10,000 genes in bladder cell lines transfected with the putative tumour
supressor genes TSC1 and DBCCR1. Total mRNA from transfected and untransfected
cell lines was isolated. Fluorescently labelled (Cy-3 and Cy-5) single-stranded cDNA
targets were generated using SuperScript™ First-Strand Synthesis System and
comparative hybridisation was performed with reciprocal replicates. The custom
microarrays of 10000 genes were scanned using GSI Lumonics glass slide scanner.
Data analysis was performed using QuantArray and GeneSpring software packages.
The TSC1 transfected cell lines had 6 upregulated and 2 downregulated genes whereas
the DBCCR1 transfected cell lines had 18 upregulated and 6 downregulated genes.
Full characterisation of these is currently underway. Several of the upregulated genes
of the DBCCR1 transfected cell lines were known calcium-dependent genes. We are
currently developing this method to be used with bladder tumour samples. 76 Poster presentations
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ALTERED GENE EXPRESSION IN CISPLATIN-RESISTANT 
OVARIAN CANCER AS DETECTED BY DIFFERENTIAL
DISPLAY AND MICROARRAY KG Macleod, P Mullen, LMR Gilmour, 
JF Smyth and SP Langdon. I.C.R.F. Medical Oncology Unit, Western
General Hospital, Edinburgh, EH4 2XU
The majority of ovarian cancer patients are treated with cisplatin and development of
resistance to this treatment can modify cell signalling responses. The erbB receptors
are important regulators of ovarian cancer and signalling via these receptors can
produce either growth stimulation or inhibition. We have developed a model system
wherein cisplatin treatment has altered responsiveness to ligands of the erbB receptor
family. The cisplatin-resistant ovarian carcinoma cell line PE01CDDP was derived from
the PE01 cell line by exposure to increasing concentrations of cisplatin and demon-
strates a 3-fold level of resistance. While PE01 cells are growth stimulated by 10–9 M
TGFa, NRG1a and NRG1b, the PE01CDDP line is growth inhibited by TGFa and
NRG1b but unaffected by NRG1a. TGFa increased apoptosis in PE01CDDP cells but
decreased apoptosis in PE01 cells as measured by annexin V using flow cytometry.
Comparison of the two cell lines indicated that expression levels of the erbB recep-
tors, extent and time course of tyrosine phosphorylation at the erbB receptors and
MAP kinase activation are similar for both lines and could not explain these differing
functional responses. 
Differential display RT-PCR was used to identify differences in mRNA expression
between PE01 and PE01CDDP cells. Products that appeared differentially expressed
were excised from acrylamide, re-amplified by PCR and subcloned into pGEM-T
Easy vector. These were then sequenced and identified. Expression levels were then
quantified by real-time PCR using specific primer pairs targeted to individual cDNAs.
Expression of mRNAs for TCP-1, antileukoprotease and PCNA were increased at
least 2-fold in PE01CDDP cells relative to PE01 while expression of ZXDA was
decreased. 
Differential mRNA expression was also analysed using the Clontech Atlas human
Cancer 1.2 array. Of 1185 genes analysed, 38 increased by at least 2-fold in PE01CDDP
relative to PE01 while 52 decreased. Confirmation of at least a 2-fold change in
mRNA levels has been verified by real-time PCR for the following genes: FRA-1,
E1AF, MCM2, UFO, HGIF, TRAP-1 and XRCC9 were increased in PE01CDDP cells
relative to PE01 while IGFBP-3, PGS1, TRAM, and cytokeratins 4 and 19 were
decreased. 
These results indicate that growth responses to ligands of the erbB receptors can
change in ovarian cancer cells after cisplatin treatment. Multiple differences in mRNA
expression have been identified using differential display and a microarray and these
are candidate molecules in pathways determining cisplatin-resistance and response to
erbB signalling. 
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IS N-MYC AND CYCLIN DEPENDENT KINASE PROTEIN 
EXPRESSION ASSOCIATED WITH POOR PROGNOSIS IN
NEUROBLASTOMA? SL Hankin1, M Gerrard2, S Variend2 & J Lawry1,
1Institute for Cancer Studies, University of Sheffield, Sheffield, 2Sheffield
Children’s Hospital, Sheffield
Neuroblastoma is characteristically heterogeneous, displaying a great clinical vari-
ability ranging from spontaneous regression to highly malignant disease. This
immunohistochemical pilot study aims to establish potential protein markers which
correlate to disease stage and tumour aggressiveness, which may interpret this diverse
clinical behaviour associated with neuroblastoma. 
Paraffin wax embedded tissue was obtained from 17 cases of neuroblastoma (1 ´
stage IVs, 1 ´ stage I, 2 ´ stage II, 3 ´ stage III and 10 ´ stage IV) and were analysed
with a panel of antibodies using standard immunohistochemical techniques. The anti-
body panel consisted of the cell cycle components CDK4 and CDK6, and apoptotic
associated-proteins: Bax, Bcl-2 and CD95. All neuroblastoma cases demonstrated
positive staining for the neuroblastoma marker NB84. The prognostic indicators N-
Myc and CD44 were also assessed in each neuroblastoma case. This same antibody
panel was then used to quantify protein expression using flow cytometry on the two
human neuroblastoma cell lines Kelly and SK.N.SH. 
Immunohistochemistry revealed that 82% (14/17 cases) showed positive staining
for CDK4, compared to 24% (4/17 cases) for CDK6 (1 ´ stage III and 3 ´ stage IV).
CDK6 positivity could potentially identify a unique sub-set of poor prognosis neurob-
lastoma cases. 
N-Myc oncoprotein was highly expressed in both cell lines, even though SK.N.SH
showed no N-Myc gene amplification determined by Fluorescent In Situ
Hybridisation. N-Myc oncoprotein was evident in 94% (16/17 cases) of neuroblas-
toma tested by immunohistochemistry, including the patients with no recorded N-Myc
gene amplification. 
Immunohistochemical Staining for N-Myc Oncoprotein in Neuroblastoma 
Stage Negative Weak Moderate Strong 
IVs, I & II 0% (0/4) 75% (3/4) 25% (1/4) 0% (0/4) 
III & IV 8% (1/13) 8% (1/13) 15% (2/13) 69% (9/13) 
This data suggests that N-Myc protein expression, as opposed to gene amplifica-
tion, could be a more valuable prognostic factor. This dual approach of both cell cycle
control and apoptotic analysis could potentially explain the clinical diversity associ-
ated with this childhood neoplasm. Research is funded by Yorkshire Cancer Research. 
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ELUCIDATION OF THE RELATIONSHIP BETWEEN EMAP-II, 
A TUMOUR-DERIVED PROINFLAMMATORY PROTEIN, AND
P43, A COMPONENT OF THE MAMMALIAN MULTISYNTHASE COMPLEX,
YM Heng and JC Murray, Division of Clinical Oncology, School of Clinical
Laboratory Sciences, University of Nottingham
The 20kDa proinflammatory polypeptide EMAP-II, found in tumour cell super-
natants, is synthesised as a 34kDa precursor. A 1.1 kb cDNA consistent with this
precursor form has been cloned. However, recently a cDNA encoding p43, the 43kDa
component of the hamster multisynthase complex, was reported to have very high
homology with that encoding human EMAP-II. The 1.25 kb p43 cDNA potentially
encodes additional N-terminal peptide sequence. Thus, the structure of the gene(s)
encoding EMAP-II/p43 remains unclear. We are currently using various genomic and
RNA-based techniques to elucidate the origins of the EMAPII and p43 proteins. By
database mining, we have identified a human genomic contig of ~117 kb containing
the functional EMAP-II gene. The human gene appears to be ~30 kb in size and to
comprise 7 exons, with an additional ~20 kb of genomic sequence upstream of the
first exon contained within this contig. However, none of the genomic sequence
within this contig has any similarity to the first ~170 bp of the hamster p43 cDNA.
Thus, it is possible that the 5¢ end sequence of the gene may have diverged between
human and hamster. Alternatively, the additional N-terminal sequence of the putative
p43 protein may be encoded by an additional exon not contained within this contig,
but located further upstream. We have simultaneously explored the expression of
EMAP-II mRNA by Northern analysis to determine the size and tissue distribution of
transcripts. Of 12 normal human tissues examined, EMAP-II RNA was most abun-
dant in the testis. Furthermore, we identified 3 hybridising transcripts of ~1.2 kb, 2.0
kb and 2.6 kb. Similar size transcripts were expressed in a range of tumour cell lines.
The smallest transcript (~1.2 kb), which appears to be longer than the cloned EMAP-
II cDNA (~1.1 kb), could theoretically encode the 34 kDa EMAP-II protein and
potentially a novel human p43 homologue. The significance of the 2 larger hybri-
dising transcripts is therefore unclear. These could represent alternatively or incom-
pletely spliced transcripts. Experiments are currently under way to clone the 5¢ end of
the EMAP-II cDNA by the 5¢ RACE method. 
This work is supported by the Cancer Research Campaign Poster presentations 77
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AN ABSENCE OF GENE AMPLIFICATION AT THE IBD2
LOCUS IN  INFLAMMATORY BOWEL DISEASE AND 
GI CANCERS. KL BRANSFIELD, PJ Hamlin, P Komolmit, GR Taylor, AF
Markham and PA Robinson. Molecular Medicine Unit, University of Leeds,
Clinical Sciences Building, St. James’s University Hospital, Leeds LS9 7TF, UK
Background The inflammatory bowel diseases, Crohn’s disease and ulcerative
colitis, have both shown linkage to chromosome 12q13 (IBD2). Amplification of
genes such as MDM2 and CDK2 at or near to this locus has also been observed in
various malignancies, including GI cancers. The increased risk of neoplasia in IBD
patients prompted us to determine gene dosage at this region in both IBD and GI
cancers. 
Methods DNA extracted from IBD (n=64) and GI cancer (oral n=31; oesophageal
n=13; colon n=39) lesions was subjected to a quantitative multiplex fluorescent poly-
merase chain reaction to determine gene dosage of individual genes at the IBD2 locus.
Primer pairs from two reference genes (UBE2L2 on chromosome 12q12 and CFTR on
chromosome 7q31) were multiplexed with a primer pair from a test gene localised to
12q13. PCR products were analysed on an ABI 373 gene scanner and peak ratios were
compared between test and control DNA. Glioma, sarcoma and breast tumor derived
DNAs were used as controls. 
Results We confirmed that gene amplification of 12q13 is a frequent event in
gliomas and sarcomas. Two deletions and one amplification of the locus under inves-
tigation were detected in the IBD cohort but appeared to encompass large regions of
12q. No amplification of the 12q13 region was evident in any of the GI cancers. In
contrast, amplification of the SOX4 gene on 6p was demonstrated in 38% and 23% of
the same cohort of oral and oesophageal cancer samples, respectively. 
Conclusion Our data demonstrate that amplification of the defined IBD2 locus is
not observed in IBD or GI cancer lesions, in contrast to gliomas and sarcomas, and
cannot therefore play a significant role in the progression of disease. 
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EXPRESSION OF THE RETAINED INTRON 4 SEQUENCE 
OF THE CONSTITUTIVELY ACTIVE CCK-2 RECEPTOR IN
HUMAN COLORECTAL CANCER, PA Clarke, DF McWilliams, S Grimes and
SA Watson, Academic Unit of Cancer Studies, University Hospital,
Nottingham, NG7 2UH
Background Recent evidence suggests that a splice variant of the human CCK-2
receptor, with retained intron 4, CCK-BRi4sv, is specifically expressed by human
colon cancer when compared to normal resection mucosa (Hellmich et al, 2000, J.
Biol. Chem, 275: 32122–32128). 
Aim To evaluate the immunoreactivity detected with two polyclonal antibodies
(GRE9 and GRE10) raised against different portions of the predicted intracellular
intron 4 sequence of the CCK-BRi4sv receptor. 
Methods Antibodies were raised against two predicted peptide sequences of the
retained intron of the CCK-BRi4sv receptor. Western blotting was used to assess their
binding to human colorectal cancer cell lines, human colorectal specimens (carci-
noma, adenoma and resection margin normal mucosa) and 3T3 cells transfected with
the classical CCK-2 receptor. 
Cellular localisation of the two antibodies was assessed by immuno-histochem-
istry. The ability of the antisera to displace125 IG17 from 3T3 cells transfected with the
CCK-2 receptor was assessed. 
Results Western blotting with both antisera raised against intron 4 of the CCK-2
splice variant showed an immunoreactive band of approx. 82 kDa on the human colon
cell lines C170HM2 and HT29, the CCK-2 transfected 3T3’s expressed no specific
immunoreactivity. A panel of human colorectal tumour, adenoma and normal speci-
mens expressed a specific band of the same molecular weight with both antibodies.
There was little discrimination between resection margin normal and malignancy. 
Immuno-histochemical analysis revealed the over-expression of both antisera in
tumour and adenoma compared to resection margin normal. The GRE10 antibody was
strongly and exclusively expressed in the cytoplasm of the respective cell lines and the
epithelial component of human tumour and adenoma specimens, whereas the GRE9
antibody was expressed equally intensely in the cytoplasm and nucleus. 125IG17 was
not displaced by the intron 4 directed antisera. 
Conclusions These results show the two antibodies display sequence directed
specificity to the CCK-BRi4sv and provide evidence for the expression of the intron 4
sequence in the CCK-2 receptor expressed by colon cancer cells 
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FUNCTIONAL ANALYSIS OF TSCI IN BLADDER CANCER. 
Nick Hornigold, Wendy Kennedy, Margaret A Knowles ICRF
Clinical Centre, St James University Hospital, Leeds, LS9 7TF
TSC1 (Tuberous Sclerosis Complex gene 1) lies in a region (9q34) commonly deleted
in bladder transitional cell carcinoma (TCC) of all grades and stages. We have previ-
ously shown that TSC1 is mutated in some primary tumours and TCC cell lines. We
report that re-introduction of functional TSC1 to a TCC cell line lacking an intact
copy of the gene leads to a marked reduction in cellular proliferation. Anchorage inde-
pendent growth and apoptosis rates are unaffected, but immunofluorescence studies
show changes in the distribution of Tuberin, b-4 Integrin, Paxillin and Actin (mAb)
within cells expressing TSC1. Transfected cells are being assayed for their tumori-
genic potential in an in vivo mouse model. Further studies are being carried out to
assess whether the anti-proliferative effects of TSC1 are dosage-dependent and how
cell-cell and cell-matrix interactions are affected. Deletion constructs are being used
to examine the role of the various protein domains of TSC1. This work will clarify the
mechanisms by which TSC1 influences tumorigenesis and indicate whether TSC1
deletion is an initiating event in TCC. 
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ISOLATION OF FULL-LENGTH cDNAs OF DIFFERENTIALLY 
EXPRESSED ESTs SPECIFIC TO ADENOCARCINOMA OF
LUNG. A Yagui-Beltran1, 2, L You1, D Jablons11 School of Medicine,
Department of Surgery and Cancer Center, University of California, San
Francisco, California, USA and 2Department of Surgery and Molecular
Oncology, University of Dundee DD1 9SY
Lung cancer is the leading cause of cancer death in the United States. Lack of suitable
genetic markers for detecting lung cancer at an early stage undermines the overall
survival rate of lung cancer patients. We aim to develop novel markers that can be
used for detecting molecular changes during the early development of lung cancer. 
We have used differential mRNA display methods and high-throughput cDNA
gene expression arrays to identify overexpressed mRNAs in the form of expressed
sequence tags (ESTs) from stage IA adenocarcinomas in the lung. 
A total of 30 ESTs were isolated, of which 27 were novel sequences. The magni-
tude of overexpression of ESTs was 3 to 12-fold higher in stage IA adenocarcinoma
than adjacent normal lung. Five overexpressed ESTs were tested and confirmed using
RNA northern blot analysis on a panel of lung cancer samples. To isolate full-length
cDNA clones for the overexpressed candidate ESTs, we have used a library-free
system for direct cloning. Biotinylated primers designed from EST sequences were
hybridized with anchor ligated first strand cDNAs. EST-specific first strand cDNAs
were isolated using streptavidin coated magnetic bead capture and amplified using
high-fidelity DNA polymerase. The amplified cDNAs were cloned into plasmid
vector. We have isolated three full-length cDNA clones for the five overexpressed
ESTs to date. The cDNA inserts were 2.5–3.8 kb in size, respectively and the
complete cDNA inserts for the clones are now undergoing sequencing. These ESTs
and their full-length cDNA clones could be useful candidate gene markers for the
early diagnosis of lung cancer. 78 Poster presentations
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CYTOCHROME P450 1B1 (CYP1B1) EXPRESSION IN HUMAN 
CERVICAL INTRAEPITHELIAL NEOPLASIA TTV Hoang, 
MD Burke, PC Butler, A Seaton, LA Stanley, School of Pharmacy and
Pharmaceutical Sciences, De Montfort University, Leicester LE1 9BH 
Cervical cancer is the second most common cancer in women worldwide (Schoell et
al., 1999). Limitations of the present screening method, the Papanicolaou (Pap) test,
have lead to the requirement for a more objective method of screening. 
Several studies have indicated that the cytochrome P450 isozyme, CYP1B1, may be a
marker for tumourigenesis (McKay et al., 1995; Murray et al., 1997). Our studies aim to
determine the significance of CYP1B1 as a marker of neoplasia and as a possible indicator
of neoplastic risk in the cervix. Results from a pilot study on cervical biopsy samples indi-
cate that there is differential expression of CYP1B1 in the different stages of cervical
intraepithelial neoplasia (CIN). This communication reports on the results of this study. 
A mouse IgG1 monoclonal antibody (LDS101), raised against the predicted
sequence of the CYP1B1 C-terminus coupled to Keyhole Limpet Haemocyanin, was
used to study the expression of the CYP1B1 protein in normal and preneoplastic
cervical specimens by immunohistochemistry. 
In normal smears CYP1B1 expression was not detectable. In contrast, in biopsy
samples diagnosed with CIN 1 to CIN 3, expression was detectable in abnormal cells
within the squamous epithelium. The pattern of staining seen suggests that CYP1B1
expression corresponds with increasing stages of CIN (Table 1). 
Table 1 Summary of pilot study results showing number of samples stained
positive for CYP1B1 and the type of staining pattern observed for the
different stages of CIN. 
CIN Stage Number of  Number of  CYP1B1 Staining
Samples Positive Pattern 
Samples
CIN 1 9 8 Staining of lower 1/3 of epithelium 
CIN 2 10 10 Staining of lower 2/3 to whole of 
epithelium 
CIN 3 10 10 Staining of majority to whole of 
epithelium 
We suggest that CYP1B1 may be a potentially useful marker for detection of CIN
in routine cervical screening. A study of patients undergoing colposcopic examination
for cervical abnormalities is currently underway to investigate these results further. 
1. McKay, J.A. et al., (1995). FEBS Letters, 374, 270 
2. Murray G.I., et al., (1997). Cancer Research, 57, 3026 
3. Schoell W.M. et al., (1999). Seminars in Surgical Oncology, 16, 203 
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IS DDX1 AN ONCOGENE? HOW DOES ITS PATTERN OF 
EXPRESSION RELATE TO ITS AMPLIFICATION STATUS? 
JL Elsden1, RM Kenyon1, RE George2, R Godbout3, ADJ Pearson4 and 
J Lunec1, Cancer Research Unit1 and Department of Child Health4, University
of Newcastle, Childrens Hospital, Harvard2, University of Alberta, Canada3 
Neuroblastoma (NB) is the third most common childhood cancer, accounting for 15%
of all childhood cancer deaths. A major problem with the treatment of neuroblastoma
is that diagnosis often occurs after metastasis, leading to rapid tumour progression and
a fatal outcome. Once diagnosed the behaviour of neuroblastoma is unpredictable
with the likelihood of tumour progression varying widely according to tumour stage
and age at diagnosis. 
The MYCN gene is amplified in 20–30% of NB tumours and this amplification is
strongly correlated with poor prognosis. DDX1 maps to the same chromosomal posi-
tion as MYCN (2p24) and is co-amplified with MYCN, in approximately 50% of cases.
DDX1 is a member of the family of genes that code for proteins containing the D-E-A-
D box protein motif and is a putative RNA helicase. Patients with co-amplification of
both genes have a shorter post-treatment relapse period compared with patients with
MYCN amplification alone. 
Cloned DDX1 cDNA, was stably introduced into NIH3T3 cells using calcium-
phosphate mediated transfection methods. Initial selection for successfully transfected
clones was performed using G418 resistance. From ten G418 resistant clones, four
clones were isolated that showed increased levels of DDX1 protein expression by
Western blotting. All four clones reproducibly showed both increased growth rates
and greater ability to grow in soft agar compared with the parental cell lines or cells
transfected with PCR3.1 vector alone. DDX1 was also successfully transfected into
the neuroblastoma cell line SH-EP and these cells are being tested for altered behav-
iour, including differentiation status and oncogenicity. Initial experiments indicates
that DDX1 transfected SH-EP cells may have a faster growth rate than the negative
controls. Evidence so far suggests that DDX1 has an oncogenic role in its own right. 
An initial study of DDX1 and MYCN protein expression in 22 neuroblastoma
tumour samples has shown considerable variation in protein expression, including
increased protein levels in 5 samples, which have neither MYCN nor DDX1 amplifica-
tion. This indicates that DDX1 expression varies in NB and high expression can result
from mechanisms other than DDX1 amplification. 
Future work will include co-transfection of both DDX1 and MYCN into NIH3T3
and SH-EP cells. These cells will then be used as a model to determine the role of co-
amplification of MYCN and DDX1. 
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IDENTIFICATION OF NOVEL CODING EXONS WITHIN THE 
NEUROBLASTOMA AMPLIFIED GENE, NAG. DK Scott1, 
ADJ Pearson2, J Lunec1. 1Cancer Research Unit, University of Newcastle
upon Tyne, NE2 4HH, UK; 2Dept of Child Health, Royal Victoria Infirmary,
Newcastle upon Tyne, UK
Amplification of the MYCN oncogene in neuroblastoma tumours is predictive of a
poor outcome. However, within this subset of tumours there is heterogeneity of
phenotype, with instances of individuals remaining alive and disease free with
minimal or no treatment. The amplified unit of DNA varies in size, and can be up to 1
Mb long. Other genes situated at the MYCN locus may be coamplified with the onco-
gene, affecting tumour phenotype. Identification of these could ultimately lead to
increased accuracy of prognosis and give targets for new therapies. 
The NAG gene has been independently isolated in two laboratories using genome
scanning techniques. The gene was subsequently found to be coamplified with MYCN
in neuroblastoma1,2. Wimmer et al reported the presence of a 4.5 kb NAG gene tran-
script in neuroblastoma cell line RNA1; Fruhwald et al, in contrast, performed
Northern blots on normal tissue RNA and obtained a signal of about 7 kb2. In this
laboratory, Northern blots on neuroblastoma cell line RNA also indicated the presence
of a 7–8 kb transcript. The aim of this research was therefore to identify and charac-
terise the extra 3 kb of mRNA sequence. 
Alignment of the 4.5 kb NAG cDNA sequence with genomic DNA sequence from
the Human Genome Project (HGP) indicated an unusually large 150 kb gap between
exons 4 and 5 of the gene. RT-PCR on IMR-32 neuroblastoma cell line RNA
confirmed the presence of additional expressed sequence between exons 4 and 5. The
7.5 kb PCR product has now been cloned and is being characterised. In parallel, a
NAG gene probe was used to identify positive clones within cDNA libraries from
normal tissues. A 5 kb cDNA clone was isolated from a skeletal muscle library and
the sequence obtained by automated fluorescent sequencing. Comparison of this with
the HGP genomic clones indicated the presence of 9 novel exons within the gap
between the previously designated exons 4 and 5. Northern blots show the presence of
a 7 kb transcript in skeletal muscle2. Work continues to establish the biological role of
the full-length NAG gene. 
1. Wimmer K, Zhu XX, Lamb BJ, Kuick R et al (1999) Oncogene 18: 233 
2. Fruhwald MC, O’Dorisio MS et al Rush LJ (2000) J Med Genet 37: 501 
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ECTOPIC EXPRESSION OF REG AND ITS PUTATIVE 
RECEPTOR EXTR-1 IN COLORECTAL CANCER. 
IA Hunter, SM Farmery, K Bransfield˚, PA Robinson˚, DS O’Riordain, 
PJ Guillou, Academic Department of Surgery, St. James’s University
Hospital, and ˚Molecular Medicine Unit, Leeds University 
Aims EXTR-1 has recently been reported to act as a receptor for REG (regenerating
protein), a protein that is implicated in the control of cell proliferation and apoptosis.
REG expression in early stage colorectal carcinoma is associated with an increased
incidence of disease recurrence. The aims of this study were to investigate the expres-
sion of EXTR-1 and REG, and their relationship to tumour stage, in colorectal cancer. 
Methods RT-PCR was used to establish the presence of EXTR-1 and REG tran-
scripts in 28 colorectal cancer and matched normal mucosa specimens. Alterations of
EXTR-1 at the genomic level were analysed using quantitative fluorescent-labelled
multiplex PCR of DNA. Tumour stage was determined from hospital pathology
records. 
Results REG expression was in keeping with previously reported levels being
detected in 18 of 28 (64%) cancers versus 8 of 28 (28%) matched normal mucosa
specimens (c2 P<0.05).  EXTR-1 transcripts were also more frequently present in
tumour tissue, being detected in 23 of 28 (82%) cancers versus 9 of 28 (32%) matched
mucosa specimens (c2 P<0.05). Of the 18 REG positive tumours 16 also expressed
EXTR-1, although this relationship was not significant. There was no relationship
between expression of either gene and tumour stage. Genomic analysis of EXTR-1
detected no amplification or deletion of the gene suggesting that increased expression
is regulated at the transcriptional level. 
Conclusion Expression of both REG and its putative receptor EXTR-1 are
increased in colorectal cancers. EXTR-1-REG interactions may contribute to the
development of disease recurrence associated with REG expression in early stage
disease. 
Abbreviations EXTR-1, Exostoses related gene 1; REG, regenerating gene; RT-
PCR, reverse transcription and polymerase chain reaction amplification; c2, Yates’
corrected Chi-squared test. Poster presentations 79
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COEXPRESSION OF PAX6 AND GLI1 IN DESMOPLASTIC 
MEDULLOBLASTOMA R Przkora1, JC Tonn2, N Sörensen2,
OD Wiestler1, & T Pietsch1, 1Dept of Neuropathology, University of Bonn,
2Dept of Neurosurgery, University of Würzburg 
Medulloblastoma is the most frequent malignant brain tumor of childhood. The
classic and the desmoplastic variant display markers of different cerebellar cell
lineages and show a distinct pattern of localization in the cerebellum. Neuronal
precursor cell proliferation and differentiation in the cerebellum is controlled by Sonic
hedgehog and homeobox genes. 
Procedures In this study we analyzed the mRNA transcripts of PAX5, PAX6 and
GLI1 as target gene of SHH in 20 classic MBs (cMB), 13 desmoplastic MBs (dMB),
2 medullomyoblastomas (MMB), 2 adult and 2 fetal cerebelli. A competitive RT-PCR
with external PAX5, PAX6 and GLI1 gene standards was established for quantitative
mRNA analysis compared to b2-microglobulin. 
Major findings We detected PAX5, PAX6 and GLI1 transcripts in all variants,
including the adult and fetal cerebelli. The dMB exhibited significantly higher PAX6
(Kruskal-Wallis, P =0.0032) and GLI1 (P=0.0005, K-W) m-RNA levels. The expres-
sion signal of PAX6 was significantly lower in the 8 MB cell lines compared to the
tumor samples (P = 0.001, Kruskal-Wallis). There was a significant correlation
between the PAX6 and GLI1 signal in dMB (Spearman-Rank, P = 0.009). 
Conclusion Our results are supporting the hypothesis, that the dMB arises from
the external granule cell layer (EGL). The correlation of PAX6 and GLI1 as target of
the SHH signal transduction cascade in the desmoplastic variant suggests an inter-
action of these developmental control genes in the pathogenesis of dMB. 
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MUTATION OF FGFR3 IN TRANSITIONAL CELL 
CARCINOMA Kathryn Sibley1,2, Wendy Kennedy1 and
Margaret Knowles1. 1ICRF Clinical Centre, St James University Hospital,
Leeds, LS9 7TF, 2Department of Haematology and Oncology, University of
Leeds, Leeds, LS2 9JT 
4p16.3 has previously been identified as a region of non-random loss of heterozy-
gosity (LOH) in transitional cell carcinoma (TCC), suggesting the presence of a
tumour suppressor gene. One candidate within this region is fibroblast growth factor
receptor 3 (FGFR3). We investigated the frequency and nature of FGFR3 mutations in
a panel of TCCs and cell lines and studied the possible link between mutation and
LOH on 4p16.3. 
FGFR3 coding sequence from 63 TCCs of various stages and grades, and 18 cell
lines was analysed by fluorescent SSCP. 31/63 tumours had previously been assessed
to have LOH at 4p16.3. 26/63 tumours (41%) and 4/18 (22%) of the cell lines had
missense mutations in FGFR3. All mutations detected in our panel have been reported
in the germline where all apart from one cause lethal conditions. Tumours with and
without LOH at 4p16.3 had mutations in FGFR3 suggesting that these two events are
not causally linked. 
Subsequently, we investigated the frequency of FGFR3 mutation in a panel of 125
tumours and 13 cell lines from various other organs (stomach, rectum, colon, prostate,
ovarian, breast, brain, renal or cervical tumours). We found only one mutation in 1/28
cervical carcinomas analysed suggesting that these mutations are important only in
the development of certain types of tumour. 
In addition to mutations of FGFR3, we have also detected alterations in the expres-
sion of FGFR3 splice variants (IIIb and IIIc) at the mRNA level in TCC cell lines. It
is possible therefore that both mutation and alterations of FGFR3 expression
contribute to bladder tumour development. 
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A GERMLINE MUTATION IN EXON 5 OF p53; DISEASE-
CAUSING OR NOT? Jodie Rutherford1, Diana Barnes2, Diana
Eccles3, Paula Duddy1, Richard Camplejohn1: 1Richard Dimbleby Dept., 
St Thomas’ Hosp., SE1 7EH, 2ICRF Clin Oncol. Unit, Guy’s Hosp., SE1 9RT;
3Wessex Clin. Genetics Service. Princess Ann Hosp., Southampton, SO16
5YA
The p53 gene from a patient with Li-Fraumeni like syndrome was sequenced and a
germline mutation was found in exon 5. This was a point mutation resulting in an
amino acid change from arginine to histidine. Initially two functional assays were
carried out using peripheral blood lymphocytes from the patient, the apoptotic assay
(Camplejohn et al. Br J Cancer 72: 654, 1995) and the FASAY (Flaman et al. PNAS
92: 3963, 1995). The apoptotic assay measures the apoptotic response of PBL after
treatment with 4 Gy irradiation and the FASAY is a yeast-based assay investigating
transactivational ability of p53. Both of these assays yielded wildtype results, the
apoptotic assay giving a 41% increase in apoptosis after irradiation and the FASAY
giving only 2% red colonies (any value under 10% is considered wildtype). The muta-
tion was manufactured by site directed mutagenesis and used in four different
FASAYs, investigating the ability to transactivate bax, p21, PIG3 and RGC. The
results for all these experiments were wildtype i.e. between 2 to 4% red colonies. The
mutation was cloned into a mammalian expression vector, pC53-SN3 and transfected
into Saos-2 cells to investigate induction of apoptosis, suppression of colony growth
and transrepression. The mutant p53 had 90% of the ability of wildtype p53 to induce
apoptosis and the suppression of colony growth assay showed that the mutant and
wildtype p53s had similar abilities to prevent the growth of Saos-2 colonies. For tran-
srepression, the mutant protein had 70% of the ability of wildtype to repress the SV40
promoter, which may represent a deficiency in transrepression. Despite this finding,
the functional assays used so far have failed to detect a clear defect in the mutant
protein’s biological activities. The induction of apoptosis experiments were carried
out for a second time, using only small amounts of plasmid DNA for transfection, in
order to investigate the effect of lower level expression of the mutant protein. Even at
these lower levels, this mutant could still induce apoptosis at levels that were not
significantly different to wildtype p53. Immunoprecipitations and the yeast-2-hybrid
assay showed the mutant could bind to Mdm-2 protein. Therefore, no clear functional
defects have been found in this protein, although the mutation appears to segregate
with disease in the patient’s family (five breast tumours, a childhood ALL, a
lymphosarcoma and an adenocarcinoma in three generations) and has been reported in
another LFS family. An inducible expression system has been set up with this mutant
and wildtype p53 in Saos-2 cells. This system is being used along with microarray
technology to try to confirm the presence or absence of a transrepression defect. 
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THE YEAST FUNCTIONAL ASSAY FOR P53 MUTATION: 
COMPARISON WITH THE HOT TECHNIQUE AND
CLINICAL/PATHOLOGICAL PARAMETERS A Yagui-Beltran1, TR Hupp2, 
AM Thompson1, Departments of 1Surgery and Molecular Oncology and
2Molecular and Cellular Pathology, University of Dundee DD1 9SY
The assessment of p53 function in breast cancer is controversial. Mutational studies of
p53 (usually examining only part of the gene) have produced a wide range of p53
mutation frequencies; expression studies, particularly using immuno-histochemistry,
are open to varied interpretation. We therefore sought to compare a comparatively
new functional assay of p53 with an established technique for mutation detection. 
Total ribonucleic acid (RNA) was extracted from 16 primary breast cancers and
2 benign breast tissue samples from unrelated patients. Using reverse transcription
polymerase chain reaction (RT PCR) cDNA was amplified and transfected into 
S cerevisiae and grown on selectable media. The human p53 inserted into the yeast
activates a cotransfected ADE2 gene giving white colonies (wild type p53) or red
colonies (mutant p53) if the p53 is functionally inactive. A spontaneous mutation rate
due to PCR infidelity of 5% may occur, producing some red colonies even for wild
type tissue. A cut off of 10% was therefore used to differentiate between mutant
(>10%) and wild type (<10%) p53. The well established Hydroxylamine Osmium
Tetroxide (HOT) technique was used to examine exons 5–9 of the p53 gene in the
same 18 samples. 
Fifteen of the sixteen cancers showed mutation according to the Yeast Functional
Assay; both benign samples expressed wild type p53. Four of the cancers exhibited
mutation using the HOT technique, cancers which grew 24%, 36%, 50% and 84% red
colonies respectively. 
There was no association between the percentage of red colonies using the func-
tional yeast assay and clinical or pathological parameters. These data suggest that the
functional yeast assay may indeed be the key p53 assay for future breast cancer trials
such as EORTC-10994. 80 Poster presentations
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THE DEPENDENCE OF P53 INDUCTION AND ACTIVITY ON 
POLY (ADP-RIBOSE) POLYMERASE-1, PA Jowsey, 
G Farnie, BW Durkacz, and J Lunec, Cancer Research Unit, University of
Newcastle upon Tyne, UK 
PARP-1 is an enzyme involved in the immediate cellular response to DNA damage.
Studies have suggested a functional relationship between PARP-1 and another DNA
damage response protein, p53. This study investigated the possible function of PARP-
1 as an upstream regulator of p53 and mdm2. PARP-1 +/+ and PARP-1 –/– mouse
embryo fibroblasts (MEFs) were established from mouse colonies obtained from
Gilbert de Murcia (Ecole Superieure be Biotechnologie de Strasbourg). The genotype
and PARP-1 expression in these cells was confirmed using Southern blotting and
Western blotting, respectively. The PARP-1 +/+ MEFs were found to contain constitu-
tively high levels of p53, which was not induced in response to DNA damage. cDNA
sequencing revealed that the PARP-1 +/+ cells contained a mutant p53, with an Asp-
Glu substitution at codon 278. This mutation is in a conserved region of the DNA
binding domain of p53 and is consistent with the inability to induce mdm2 or p21waf-1.
However, the PARP-1 –/– cells did exhibit a p53 induction, which in turn induced
mdm2 and p21waf-1 3–6 hours after IR or UV treatment. Permeabilised cell assays
measuring PARP activity by the incorporation of radiolabel from [32P NAD] into
ADP-ribose polymers showed that PARP-1 –/– cell lines possessed 5% residual PARP
activity which cannot be attributed to PARP-1. This activity was independent of DNA
ends, present as synthetic oligonucleotides to simulate DNA breaks and could be
completely abolished by treatment of cells with a potent PARP inhibitor (PI) with a ki
<6nM. In contrast PARP-1 +/+ cells exhibited PARP activity that was dependent upon
DNA ends. The PI also drastically reduced luciferase production from a p53 depen-
dent promoter (MDM2 P2) in a luciferase gene reporter system in HCT 116 human
colorectal cells. This suggests a role for PARP in p53 transcriptional activity. Work is
in progress to identify the PARP protein responsible for the activity in the PARP-1 –/–
MEFs and, using both PARP inhibitors and the PARP-1 –/– cells, to investigate poten-
tial roles for alternative PARPs in the regulation of p53 and mdm2. 
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GENE DOSAGE OF THE CDKN2 REGION USING REAL 
TIME QUANTITATIVE PCR IN BLADDER CANCER 
Joanne S Aveyard, Emma J Chapman and Margaret A Knowles, ICRF
Clinical Centre, St James University Hospital, Leeds, LS9 7TF 
Homozygous deletions have been identified at 9p21 in bladder cancer cell lines and
tumours. Previously we have shown that CDKN2A (p16) or both p16 and CDKN2B
(p15) were deleted in many cases. Subsequently, p14ARF has been identified as an
additional transcript from this region with its first exon between p15 and p16. The
individual contribution of these three genes to bladder tumour development has not
yet been fully investigated. 
Recently, it has been discovered in a melanoma-astrocytoma syndrome family,
using real time quantitative PCR, that both copies of p16 are retained (gene dosage
ratio = 1) and one copy of p14ARF is deleted (gene dosage ratio = 0.5). This suggest
that deletion of p14 ARF may be critical in some cases and not p16. We have there-
fore, carried out high density homozygous deletion mapping of this region in a series
of bladder tumour cell lines including 10 newly established cell lines. 
Homozygous deletions are difficult to detect by conventional PCR in tumour
samples due to the presence of contaminating normal cells. We have used Real time
quantitative PCR to work out gene dosage ratios and improve the sensitivity of detec-
tion of homozygous deletions of p16, p15 and p14ARF in TCC cell lines and tumours.
For the first time this allows the precise mapping of homozygous deletion breakpoints
at 9p21 in DNA samples from primary tumours. 
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RELATIONSHIP BETWEEN ACTIVE MMP-2 AT THE 
PROTEIN LEVEL AND A DECREASE IN MMP-2
EXPRESSION AT THE GENE LEVEL IN VITRO AND IN VIVO 
R Asher-Dean*, HM Collins, WJ Speake and SA Watson, Academic Unit of
Cancer Studies, University Hospital, Nottingham, NG7 2UH
Background & Aims Over expression of various matrix metalloproteinases (MMPs)
have previously been speculated to correlate with tumour progression in a variety of
cancers. The aim of this study was to investigate the activation of proMMP-2 at the
protein level and correlate this with the expression of MMP-2 and MT1-MMP at the
gene level in a human fibrosarcoma cell line transfected with MT1-MMP and three
colorectal adenoma cell lines, in vitro and in vivo. 
Methods Gelatin zymography, western blotting and real-time PCR were used to
investigate the protein and gene expression of MMP-2 and MT1-MMP in vitro and in
vivo in two human fibrosarcoma cell lines: HT1080 wild type; HT1080 transfected
with MT1-MMP, and three adenoma cell lines: RGC2/42 (non tumourigenic, full
length APC); AA/C1 (non-tumourigenic, truncated APC, heterozygous for codon 12
mutation in K-ras); AA/C1/SB10C (tumourigenic, truncated APC, homozygous
codon 12 mutation in K-ras), obtained from Professor C. Paraskeva. 
Results The human fibrosarcoma cell line transfected with MT1-MMP produced a
significant 1.5 fold increase in active MMP-2 (62kDa) and a 6 fold decrease in
proMMP-2 (72kDa) compared with that of the HT1080 wild type cells at the protein
level in vitro. This increase in activation was also observed by western blotting, with an
8 fold increase in the proteolytic form of MT1-MMP (43kDa) which is associated with
MMP-2 activation in the transfected cell line. This cell line showed a significant
decrease in MMP-2 at the mRNA level (P<0.01) and an increase in MT1-MMP expres-
sion (P<0.01). In vivo, both cell lines produced active MMP-2 at the protein level and
this correlated with a decrease in mRNA expression of MMP-2 in the wild type cells
(P<0.01). The two APC truncated cell lines (AA/C1 and AA/C1/SB10C) had signifi-
cantly higher levels of MT1-MMP mRNA expression (P<0.01) in vitro compared with
that of the full length APC cell line (RGC2/42) but only AAC1 had high levels of MMP-
2 (P<0.01). Zymography showed slight activation of MMP-2 in all three cell lines but
western blotting only detected the proteolytic fragment of MT1-MMP in the tumouri-
genic AA/C1/SB10C. When grown in vivo, AA/C1/SB10C had low levels of MMP-2
gene expression and high levels of active MMP-2 at the protein level.
Conclusion We have shown that an increase in MT1-MMP mRNA correlates with
an increase in active MMP-2 at the protein level in human fibrosarcoma cells in vitro.
This increase in active MMP-2 produces a decrease in MMP-2 expression at the gene
level in vitro and in vivo, suggesting that there is some form of negative feedback
occurring. This decrease in MMP-2 mRNA was also observed in vivo with the
tumourigenic adenoma cell line AA/C1/SB10C. The lack of the 43kDa fragment of
MT1-MMP in the AA/C1 compared with that of the tumourigenic cell line suggests a
different intracellular processing of MT1-MMP. 
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INVESTIGATION OF THE REGULATION OF CYCLIN D1 
DEGRADATION BY A PHOSPHORYLATION DEPENDENT
MECHANISM Simon R Stockwell, Craig McAndrew, Michelle D Garrett,
Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG 
Over-expression of cyclin D1 has been observed in numerous examples of cancers,
particularly those of the head, neck and breast. In the light of the recent reports
connecting cyclin D1 over-expression with oncogenesis, the post-transcriptional
mechanisms regulating the destruction of this protein are the focus of this study. 
Phosphorylation of cyclin D1 at threonine 286 (T286) has recently been shown to
initiate its ubiquitin-dependent degradation. Although glycogen synthase kinase-3
beta (GSK3b) immunoprecipitated from mouse NIH3T3 cells has been found to be
capable of this modification in vitro, it has yet to be shown if it is the sole activity that
can perform this phosphorylation. 
To detect such an activity in human cells a novel rabbit polyclonal antibody has
been raised against T286 of human cyclin D1 in its phosphorylated state. Specificity
of the affinity-purified phospho-antibody has been demonstrated by ELISA and
phospho-peptide competition experiments. This novel reagent has been successfully
employed in conjunction with a non-radioactive kinase assay to detect T286-kinase
activity in crude cell extracts from several human cancer cell lines (HeLa, MCF7,
U20S). 
Although GSK3b has been detected in all these cell lines, the identity of the T286-
kinase(s) has yet to be shown. A comparison of the sensitivity of lysate-based T286-
kinase activity and recombinant GSK3b to lithium and hymenialdisine (GSK3b
inhibitors) has been performed in an attempt to rule out endogenous GSK3b. This has
hinted at a differential sensitivity in the lysates when compared to purified GSK3b.
We are now in the process of fractionating the putative T286 kinase activity(s) by
column chromatography with a view to identification. Poster presentations 81
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THE PROGNOSTIC INFLUENCE OF BCL-2 IN MALIGNANT 
GLIOMA; A MULTIVARIATE ANALYSIS FE McDonald1, 
JW Ironside2, A Gregor2, E Wyatt2, M Stewart3, R Rye3, J Hadley4, H Potts4,
1Northern Centre for Cancer Treatment, Newcastle General Hospital,
Westgate Road, Newcastle upon Tyne. NE4 6BE, 2Departments of Pathology
and Clinical Oncology, Western General Hospital, Crewe Road, Edinburgh.
EH4 2XU, 3ICRF Trials Office, Western General Hospital, Crewe Road,
Edinburgh EH4 2XU, 4ICRF Medical Statistics Group, Institute of Health
Sciences, PO Box 777, Headington, Oxford, OX3 7LF 
The bcl-2 gene is one of a complex group of genes which contrl programmed cell
death. Bcl-2 acts to extend cell survival by blocking apoptosis, and thereby may 
influence tumour prognosis. This study of 187 high grade gliomas reviews clinico-
pathological prognostic features and the relationship to bcl-2 expression. Bcl-2
immunostaining was assessed in 159 specimens from these patients, by scoring
systems of 0 to 3 for intensity of scoring and proportion of cells staining. Age,
histology, pre and post-operative performance status were found to be strongly predic-
tive of survival (logrank test P<0.0001). The type of surgery performed did not influ-
ence survival in this group of patients. The expression of bcl-2 had a significant
relationship with survival (univariate Cox model P=0.0302, hazard ratio 0.8, 95%
confidence interval 0.65–0.98), with increased staining associated with improved
survival. Multivariate analysis showed performance status, histology and proportion
of cells staining for bcl-2 to be independently predictive of survival. Bcl-2 staining
was not related to histological grade of tumours. 
Keywords: high grade glioma; bcl-2; multivariate analysis 
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INHIBITING THE MDM2-P53 INTERACTION USING LOW 
MOLECULAR WEIGHT COMPOUNDS G Farnie1, 
H Atkins1, AH Calvert1, NJ Curtin1, BT Golding2, RJ Griffin2, I Hardcastle2, 
M Kitching2, DR Newell1, J Northen2, R Reid2, J Lunec1, Cancer research
Unit1, Dept Chemistry2, University of Newcastle upon Tyne, UK
Levels of p53 within normal cells are regulated via an autoregulatory feed back loop
involving MDM2 and p53, in which p53 both activates the transcription of MDM2
and is also subject to inactivation and downregulation by binding of the MDM2
protein. Prevention of the interaction between wild type p53 and MDM2 has been
shown to release p53 activity, resulting in cell cycle arrest or apoptosis. Libraries of
low molecular weight compounds have been screened for antagonists of p53-MDM2
binding, using cell free binding assays and both functional and cytotoxicity studies
with intact cells. 
A gene reporter assay was developed using a luciferase reporter gene plasmid
construct (pGL3-P2) with the p53-dependent MDM2 P2 promoter inserted. Isogenic
paired cell lines, A2780 ovarian (wild type p53) and CP70 (cisplatin resistant p53
heterozygous mutant), colorectal HCT 116 (wild type p53) and HCT 116 N7 (E6
degraded), and the SaOs-2 (p53 null) osteosarcoma cell line, were transiently trans-
fected with pGL3-P2. Results with A2780 and HCT 116 wild type cell lines showed
that the P2 region had strong basal promoter activity, 500 and 780 fold increased from
pGL3 vector only controls, respectively. P2 promoter activities were 150 and 390 fold
lower in the mutant/degraded p53 cell lines CP70 and HCT116, compared to the wild-
type p53 cell lines, but not completely abolished. No significant difference in
promoter activity was observed compared with vector only negative controls in p53-
null SAOS cell line. In addition after exposure to g-irradiation (6.3 Gy) p53 was
induced in transfected wild-type p53 cell lines with a corresponding increase in
luciferase/P2 activity with time. These results showed that the P2 promoter activity
was being driven in a p53 dependent manner. The effects of potential inhibitors of the
MDM2-p53 interaction were studied using the gene reporter assay. 
From the initial series screened, three compounds (NU8001, NU8006 & NU8009)
showed the highest levels of activity in both binding and cytotoxicity assays and
NU8001 induced p53-dependent luciferase activity in the reporter assay. Growth inhi-
bition of the A2780 (wild type p53) cell line using NU8001, NU8006 and NU8009
was also greater than for the CP70 (heterozygous mutant) cell line (e.g. for NU8001,
Gl50 = 22mM and 34mM, respectively). Further compounds are being tested to deter-
mine structure activity relationships for antagonism of the MDM2-p53 interaction. 
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MDM2 BLOCKS MTBP INDUCED GROWTH ARREST BY  
RELOCALISING MTBP TO THE CYTOPLASM D Marcus
Gore1, Nikolina Vlatkovic1, David Spiller3, Michael White3, Andrew Dodson2,
Robert Sutton1 and Mark T Boyd1, 1Depts of Surgery, 2Pathology and 3School
of Biological Sciences, University of Liverpool, Liverpool L69 3GA
The MDM2 protein, through its interaction with p53, plays an important role in the
regulation of the G1 checkpoint of the cell cycle. In addition to binding to and
inhibiting the transcriptional activation function of the p53 protein, evidence is accu-
mulating for the existence of p53 independent or downstream activities of MDM2. In
an attempt to investigate these MDM2 pathway/s we have continued our studies of a
novel MDM2 binding protein Mdm Two Binding Protein (MTBP) that we have iden-
tified. MTBP induces a p53 independent G1 arrest and this is abrogated by ectopic
expression of MDM2. Our published work (Boyd et al. (2000) J. Biol. Chem. 275;
31883–31890) has suggested that this might be the result of direct binding of MDM2
to MTBP but further studies were needed to determine this. 
Using a polyclonal anti-MTBP peptide serum we have found that MTBP is a
predominantly nuclear protein that co-localises with MDM2. Moreover, under condi-
tions in which MDM2 blocks the cell cycle arrest induced by MTBP, we find that
MTBP is re-localised with MDM2 to the cytoplasm. This clearly supports a hypoth-
esis in which MDM2 regulates the activity of MTBP by modulating the localisation of
MTBP. Using an inhibitor of nuclear export, leptomycin B, we have found that a
complex containing MDM2 and MTBP can be retained in the nucleus and thus we
conclude that binding of MDM2 to MTBP in the nucleus (most likely) leads to re-
localisation of this complex to the cytoplasm. 
Interestingly, we have observed that MTBP may also re-localise MDM2 from the
nucleus to the cytoplasm and thus the actual physiological nature of this interaction
might be to regulate MDM2’s ability to control p53 activity. To investigate the physi-
ological context in which this interaction may normally act we have studied the
expression of MTBP by immuno-histochemistry. The results of these studies will also
be presented. 
Our results support our earlier investigation in suggesting that MTBP can be added
to the list of growth regulatory proteins that are genuine targets of MDM2 and more-
over, that are re-localised to the cytoplasm by MDM2. 
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EXPRESSION OF THE GASTRIN/CHOLECYSTOKININ-B 
RECEPTOR IN RELATION TO THE CELL CYCLE, 
SA Evans1, DF McWilliams1, RA Robins2 and SA Watson1, 1Cancer Studies
Unit, 2Dept of Immunology, Queen’s Medical Centre, Nottingham NG7 2UH 
Background & Aims Gastrin has growth promoting effects on both normal and
malignant tissues of the gastrointestinal (G1) tract. However, the extent of its role in
cancer development remains controversial. The expression of the gastrin/CCK-B
receptor (CCKBR) has been investigated in various G1 cell lines and in relation to the
cell cycle stage in synchronised cells. 
Methods Total RNA was extracted from human stomach, gastrointestinal (G1) cell
lines and NIH3T3 fibroblasts transfected with the gastrin receptor (NIH3T3-CCKBR,
obtained from Prof Matsui, Kobe, Japan) using RNAzol-B (Biogenesis, UK). Reverse
transcription was performed with using random primers. Fluorescent real time RT-PCR
was used to quantitatively determine relative gene expression levels of CCKBR in all of
the samples. The PCR products were detected using the minor groove-binding dye, Sybr
Green, and the fluorescence of the amplification reactions were monitored in real time
using the ABI 5700 Sequence Detection System (Applied Biosystems, UK). The cycle
number when the accumulated fluorescence crossed an arbitrary threshold was recorded
(termed the ct value) for CCKBR and GAPDH PCR’s. The relative gene expression
levels, the DDct values, of sample cDNA’s were calculated according to manufacturer’s
instructions. The G1 cell lines were assessed along with cell populations that had been
thymidine synchronised and then released. Parallel samples were fixed and stained with
propidium iodide for determination of the cell cycle stage by flow cytometry. 
Results Real time PCR showed CCKBR expression in each of the cDNA’s from
NIH3T3-CCKBR, GI cell lines and the human stomach. The human stomach showed
statistically higher gastrin receptor mRNA levels than the CCKBR transfectants
(P<0.05, Mann-Whitney). Both stomach and NIH3T3-CCKBR transfectants expressed
significantly higher levels of gastrin receptor mRNA than G1 carcinoma cell lines
(P<0.01, Mann-Whitney). The NIH3T3-CCKBR cell line was the focus of synchronisa-
tion studies. Flow cytometry results indicated that following release from synchronisa-
tion, the cells passed from G1, through S-phase and into G2 in approximately 10 hours.
Real-time PCR results indicated that the expression of CCKBR mRNA increased steadily
after release from synchronisation, peaking at 6 hours, at a level higher than unsynchro-
nised control cells. This time point corresponds to when most cells are in S-phase. 
Conclusion These results indicate that there is a correlation between the cell cycle
stage and the level of receptor expression. The influence of the gastrin ligand on this
relationship has been investigated. The stages of the cell cycle at which high and low
expression occur may have implications for coupling to receptor signalling pathways
and the stimulatory effects of gastrin. 82 Poster presentations
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DIFFERENTIATION OF HUMAN MELANOMA CELLS 
THROUGH p38 MAP KINASE IS ASSOCIATED WITH
DECREASED RETINOBLASTOMA PROTEIN PHOSPHORYLATION AND
CELL CYCLE ARREST KSM Smalley and T Eisen. Institute of Cancer
Research, Chester Beatty Labs, Fulham Road, London, UK
The 13-amino acid peptide a-melanocyte stimulating hormone (a-MSH) induces
differentiation of B16 murine melanoma cells through activation of p38 MAP kinase
(Smalley & Eisen, FEBS Lett 476, 198). Recent studies have also highlighted the
importance of the the retinoblastoma protein (pRB) in the process of terminal differ-
entiation (Dyson, Genes Dev. 12, 2245). The aim of the present study was to investi-
gate whether a-MSH-induced differentiation of human COLO 853 melanotic
melanoma cells proceeds via a p38 MAP kinase pathway and whether this was linked
to the downstream modulation of pRB. 
Treatment of COLO 853 cells with a-MSH induced time (0–8 hours) and concen-
tration (0.01–100 nM)-dependent increases in the phosphorylation of p38 MAP
kinase. This corresponded with the ability of a-MSH (10 nM, 72 hours) to induce
differentiation, as characterised by increased accumulation of extracellular melanin
(319 ± 20% basal melanin accumulation per cell) and reduced cell growth (51.0 ±
4.6% of control cell growth). Pre-treatment of cells with the p38 MAP kinase
inhibitor, SB 203580 (10 mM), reversed the effects of a-MSH on both melanin accu-
mulation and cell growth; implicating p38 MAP kinase in the a-MSH induced differ-
entiation of COLO 853 cells. 
Differentiation is often associated with cell cycle arrest. Flow cytometric analysis
revealed that treatment with a-MSH (72 hours, 10 nM) increased the proportion of
cells in the G1 phase of the cell cycle, from 52.9 ± 1.3% (in control cells) to 67.4 ±
2.1%, with a corresponding decrease in the proportion of cells in the G2/M phase.
Incubation of cells with SB 203580 (10 mM) prior to a-MSH treatment, reduced the
proportion of cells in the G1 phase to 59.9 ± 1.3%. Treatment of COLO 853 cells with
a-MSH (10 nM, 72 hours) led to a dramatic decrease in the levels of phosphorylated
pRB protein, with no change in levels of total pRB. The role of p38 MAP kinase in the
a-MSH-mediated decrease in pRB phosphorylation was demonstrated by the finding
that SB 203580 pre-treatment reversed this effect. 
The fact that pRB protein is able to directly interact with the melanocyte transcrip-
tion factor, micropthalmia gene product (Yavuzer et al. Oncogene 10, 123), suggests
that a-MSH may regulate melanocyte specific gene transcription via activation of p38
MAP kinase and modulation of pRB activity. 
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MODULATION OF THE CALPAIN CALPASTATIN 
PROTEOLYTIC SYSTEM CONTRIBUTES TO SRC-
REGULATED TRANSFORMATION NO Carragher, VJ Fincham and 
MC Frame, Beatson Institute for Cancer Research, Cancer Research
Campaign Beatson Laboratories, Glasgow, G61 1BD
Integrin associated focal adhesion complexes provide the main adhesive links
between the cellular actin cytoskeleton and the surrounding extracellular matrix
(ECM) environment. In vitro studies provide evidence that motile cells utilize a
complex spatial and temporally regulated mechanism of focal adhesion assembly at
the leading edge of the cell co-ordinated with focal adhesion disassembly at the
trailing edge to permit cell migration. Recent studies indicate that the calpain family
of proteolytic enzymes can promote limited proteolytic cleavage of several compo-
nents of the focal adhesion complex leading to disassembly of these complexes
followed by decreased substrate adhesion and increased cell migration. Such mecha-
nisms that regulate migration of normal cells may be deregulated under pathological
conditions characterized by increased cell motility such as tumour invasion. v-Src
induced oncogenic transformation is associated with loss of focal adhesion structures
and transition to a less adherent more motile phenotype. To further elucidate the
signalling pathways downstream of v-Src that promote the transformed cell pheno-
type, we have investigated the role the calpain-calpastatin proteolytic system plays
during oncogenic transformation induced by v-Src. Our studies have characterized a
positive feedback loop mechanism describing an increase in protein synthesis of
calpain following v-Src activation that leads to proteolytic degradation of the endoge-
nous calpain inhibitor, calpastatin, thereby enhancing calpain activity in transformed
cells. We further demonstrate that v-Src induced disassembly of focal adhesions and
cell transformation is accompanied by calpain mediated cleavage of the focal adhe-
sion kinase (FAK). Overexpression of calpastatin or treatment with calpain inhibitors
repress, FAK cleavage, focal adhesion disassembly, cell migration and also cell cycle
progression in v-Src transforming cells. This data suggests that v-Src induced modu-
lation of the calpain-calpastatin proteolytic system contributes significantly to the
process of oncogenic transformation. Thus, manipulation of the calpain-calpastatin
proteolytic system may represent a novel therapeutic approach for inhibition of
tumour growth and invasion. 
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CHANGES IN GENE EXPRESSION ASSOCIATED WITH 
BREAST CANCER INVASION G Zhu1, T Crnogorac-Jurcevic2
and IR Hart1, 1Richard Dimbleby Department of Cancer Research/ ICRF
Labs, St Thomas’ Hospital, London SE1 7EH, 2ICRF Molecular Oncology
Unit, Hammersmith Hospital, London W12 0HS 
Gene expression changes may play an important role in cancer invasion. To evaluate
this possibility, the PALM micro-laser dissection and capture system was employed to
isolate pure populations of tumour cells from ductal carcinoma in situ (DCIS) which
then were used for molecular genetic analysis. We dissected the central and peripheral
areas of DCIS lesions separately and pooled tissue from 10 sections which were
obtained from 5 different patients. By using the TRZoL kit, total RNA was extracted
from microdissected tissue. The Atlas SMART™ Probe Amplification Kit was used
to synthesise and amplify cDNA. Probes from the margin and from the centre were
hybridised to duplicates of Atlas Human Cancer 1.2 Arrays which contain 1,176
known genes. The absolute intensity of each individual cDNA spot was determined by
phosphorimager scanning. After comparing images by AtlasImage™ 2.0, we have
found that 32 genes changed their expression level in the periphery of tumour lesions
relative to the central regions of these tumours. 26 genes are up-regulated, and 6 genes
are down-regulated (arbitrary level of 2-fold or greater). Verification that this proce-
dure was identifying genes of importance in tumour invasion was provided by the
observed down-regulation of the metalloprotease inhibitor 1, TIMP 1, at the
periphery, upregulation of the mesenchymal marker vimentin at the periphery and up-
regulation of the hyaluronan receptor, RHAMM, a protein already shown by us to be
increased at the invading edge of breast cancers (Assmann et al, In Press). Such
changes in DCIS appear to indicate that the rim of these precursor regions contain
cells better able to become more invasive. 
This method enables us to compare gene expression in various regions of a pure
tumour cell population and to identify changes in gene expression associated with
varying anatomical locations within the developing tumour mass. 
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MECHANISMS OF ADHESION-DEPENDENCE IN MOUSE 
MELANOCYTE-DERIVED CELL LINES Ruth Gilchrist, Helen
Stafford, Paula M Duddy, John F Marshall, Richard S Camplejohn, Ian R
Hart, Richard Dimbleby Department of Cancer Research/ICRF Laboratory,
Rayne Institute, St Thomas’ Hospital, Lambeth Palace Road, London, SE1
7EH
We previously characterised a panel of C57/B1 mouse melanocyte-derived cell lines
with regard to cell cycle alterations involved in adhesion-dependent and adhesion-
independent growth (Br.J.Cancer, 80(2), 25, 1999). Using BrdUrd labelling tech-
niques we reported that, in suspension culture, Melan-a (immortal melanocyte) cells
arrest immediately in G1. Melan-a cells are non-tumourigenic and require supple-
ments of TPA and Cholera Toxin to proliferate. When maintained in culture for more
than thirty passages, Melan-a cells spontaneously acquire the ability to proliferate in
suspension culture; these cells were termed Mel* (at 24 hrs of anchorage-independent
growth, S-phase Melan-a <1%, S-phase Mel* >15%). When injected into C57/B1
mice, the Mel* cell line remained non-tumourigenic (n = 10 animals, 1 ´ 106 cells, no
tumour growth by six months). Growth curve data also show that Mel* retained
growth-factor dependency. Thus Mel* cells resembled Melan-a cells phenotypically
except in terms of adhesion dependence. Protein lysates were obtained from both cell
lines 24 hrs after plating on serum-coated or polyheme-coated plastic. Analysis of G1
cell cycle control proteins by Western blotting showed that Mel* cells maintain Cyclin
D1 expression when grown in suspension, unlike Melan-a cells which rapidly down
regulated Cyclin D1 levels. The ability to maintain Cyclin D1 levels in turn main-
tained levels of hyperphosphorylated Rb as determined by Western blotting. To deter-
mine whether overexpression of Cyclin D1 in Melan-a cells was sufficient to induce
an adhesion-independent phenotype, cells were infected with FLAG-tagged Cyclin
D1 (gifted from Gordon Peters, ICRF, London). To date, such infected cells remain
adhesion-dependent. Elucidation of the additional biochemical events involved in
conversion from monolayer to suspension growth will shed light on the step-wise
tumourigenic conversion of cells of the melanocyte lineage. Poster presentations 83
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MMP-7 EXPRESSION: RELATIONSHIP TO APC/b-CATENIN 
STATUS HM Collins2, JH Scholefield2, SA Watson1, 1Academic
Unit of Cancer Studies, 2Division of GI Surgery, University Hospital,
Nottingham, NG7 2UH
Introduction Matrix metalloproteinases are a family of proteolytic enzymes which
are capable of degrading the extracellular matrix. MMP-7 is predominantly expressed
by epithelial cells and is overexpressed at an early stage in colorectal cancer. The roles
of APC/b-catenin mutations have been investigated as possible mediators for tran-
scriptional induction of MMP-7. 
Methods We examined MMP-7 mRNA expression (i) following induction of wild
type APC in the colorectal cancer cell line HT29 which has a zinc inducible APC
gene, and (ii) in two adenoma cell lines grown in vitro (with different APC muta-
tions). The HT29 cell line was grown under standard tissue culture conditions with
various concentrations of zinc. Total RNA was extracted using RNAzol B and reverse
transcribed to cDNA. MMP-7 gene expression was quantified using real time PCR
and the levels normalised to both GAPDH and baseline MMP-7 expression. All
assays were controlled by the inclusion of wild type HT29 and a vector control cell
line.
b-catenin was examined in all cell lines using western blotting. 
Results MMP-7 mRNA is expressed in all cell lines examined, this was irrespec-
tive of the induction of wild type APC. In HT29 induced to express wild type APC
there was a decrease in MMP-7 mRNA expression compared to the control cell lines,
this corresponded to a decrease in b-catenin protein levels. MMP-7 is expressed by
the adenoma cell lines examined. RGC2/42 which has full length APC expresses
MMP-7, albeit at a lower level than AA/C1. RGC2/42 has a truncated b-catenin
protein as determined using western blotting. 
Conclusions b-catenin status is important in the regulation of MMP-7 expression.
Expression may be related to the breakdown of the interaction between APC and b-
catenin. MMP-7 mRNA expression is generally increased by the addition of zinc,
however this is reversed following restoration of wild type APC. Wild type APC
sequesters b-catenin in the cytoplasm for subsequent proteasomal degradation, there-
fore it is not available for transcription. Studies are ongoing to establish the role of
b-catenin in controlling MMP-7 transcription. 
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OVEREXPRESSION OF Rho-A IN COLORECTAL 
CARCINOMA CELL LINES AND ITS EFFECTS ON
ADHESION, INVASION AND MOTILITY O Dewhurst, D Jayne & PJ Guillou,
Academic Unit of Surgery, Clinical Sciences Building, St James’s University
Hospital, Leeds, LS9 7TF
Members of the small Rho-GTPase family of proteins are vital for a broad range of
cellular functions including adhesion, motility and invasion, which are necessary for
the metastatic cascade. Our group is particularly interested in the family member, Rho
A which is required for cytoskeletal dynamics. 
Several human colorectal cell lines were transfected with a pcDNA3 based, CMV
driven vector. The expression vectors contained wild-type RhoA and a constitutively
active mutant (kind gifts from Kazuyuki Itoh, Japan). DNA was prepared and trans-
fected into SW948 and SW480 (adherent cell lines) and COLO 320 (non-adherent cell
line). As a control, sham transfectants were made where cells were transfected with
vector alone. Successful transfection confers neomycin (G418) resistance to cells and
was therefore used for selection of transfected cells. The expression vectors contained
an N-terminus octapeptide epitope (DYKDDDDK) FLAG-tag. Transfected cells were
then identified by immunofluorescence and SDS-PAGE/Western Blotting using a
FLAG M5 antibody. 
Overexpression of both wild-type and constitutively active forms of RhoA have
resulted in increased levels of invasion through an in vitro Transwell based invasion
assay. Invasion in transfected and control cells was totally inhibited following pre-
incubation of cells for 48 hours with the RhoA specific inhibitor, botulinum toxin C3
exoenzyme. Little difference has so far been observed in levels of motility over 48
hours between transfected and control cells, using the colloidal gold migration assay.
Glass coverslips are coated with bovine serum albumin (BSA) and colloidal gold.
Cells are then added to the coated coverslips and as they ingest the BSA, particles of
the collodial gold are also ingested. As the cells paths are cleared on the coverslip
which are visible under dark-field illumination. We are currently in the process of
developing a method using the LUCIA image analysis software to quantitate the area
cleared by the cells. Using a 96well micro-titre plate adhesion assay, we have shown
that SW480 cells expressing constitutively active RhoA achieve maximum attach-
ment after 20minutes compared with 60minutes in the control cells. We have also
observed altered growth patterns in adherent cell lines, whilst the non-adherent cell
line, COLO320 have become adherent. We believe that through these studies and our
continuing work in this area that we may further our understanding of the role of
RhoA in the peritoneal metastasis of gastrointestinal carcinoma. 
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EXPRESSION OF HEPATOCYTE GROWTH 
FACTOR/SCATTER FACTOR, C-MET, HGF ACTIVATOR AND
INHIBITORS IN HUMAN CANCER CELLS C Parr, and WG Jiang, Dept. of
Surgery, University of Wales College of Medicine, Cardiff CF14 4XN, UK
Hepatocyte growth factor/scatter factor (HGF/SF) elicits a number of functions that
are tumourigenic and enhance the metastatic potential of cancer cells. Pro-HGF/SF
becomes bio-active upon activation by the HGF/SF activator (HGFA). This study
analysed the expression of HGF/SF, its receptor, cMET, HGFA and HGFA inhibitors
(HAI) in various human cancer cell lines including breast, prostate, colon, pancreas,
liver, and bladder, while also comparing against normal cells such as fibroblasts and
endothelial cells. 
Reverse-transcriptase/polymerase-chain reaction (RT-PCR) was employed to
determine the degree of expression of the HGF, c-met, HGFA, HAI-I and HAI-2 genes
in the cell lines examined. Results have shown that the only cell line producing a
significant amount of HGF/SF was the human fibroblasts (MRC5), and that these
fibroblasts also expressed c-met plus HGFA, thus allowing autocrine regulation of
HGF/SF activity, and importantly there was virtually no inhibitor presence to inhibit
the biological function of HGF/SF. Breast cancer cells (MDA231) expressed large
amounts of both c-met and HGFA to allow maximum influence of HGF/SF and also
did not express the HAI-1 gene, but in contrast did express HAI-2 to a large degree.
The pattern of the inhibitors generally shows that they are not present in similar
proportions in the same cell line and that although HAI-2 is present to some degree in
all cell lines tested, HAI-1 was either absent or expressed at a lower level than HAI-2.
Interestingly, the cell lines that displayed little or no HAI-1 expressed HGFA or
HGF/SF. Liver cancer cells (PLC) only expressed the HGFA gene. The metastatic
potential of a cell type (breast cancer or prostate cancer cells in study) correlates to the
degree of c-met and/or HGFA expression. 
In conclusion, HGF/SF, its activator and inhibitors are expressed in different
patterns in cancer cells and fibroblasts. High levels of HGFA expressed in cancer cells
and fibroblasts may contribute to the autocrine and paracrine activation of HGF/SF. 
P198
SUPPRESSION OF EXPRESSION OF HGF/SF IN 
FIBROBLASTS AND ITS RECEPTOR, c-MET, IN BREAST
CANCER CELLS USING HAMMERHEAD RIBOZYMES WG Jiang1, 
D Grimshaw1, J Lane1, TA Martin1, R Abounder2, J Laterra2, RE Mansel1,
1Dept of Surgery, Univ Wales College of Medicine, Cardiff, UK, 2Dept
Neurology, Kennedy Krieger Institute, Johns Hopkins Univ. School of
Medicine, Baltimore, USA 
HGF/SF, via its receptor cMET, has been implicated to play a pivotal role in breast
cancer development and progression. This study examined a transgene consisting of a
combination of U1snRNA, hammerhead ribozyme and antisense, designed to inhibit
expression of HGF/SF and its receptor, c-met, and its impact on the migration and in
vitro invasion of breast cancer cells. 
Human breast cancer cells, MDA MB 231 and MCF-7 were transfected with the c-
MET ribozyme-containing plasmids by electroporation. Human fibroblast cells,
MRC5, were infected with a retroviral ribozyme containing HGF/SF antisense. Stable
transfectants of breast cancer cells almost completely lost c-MET at both mRNA and
protein levels, as shown by RT-PCR, Northern blotting and Western blotting, respec-
tively. MRC5 infected with ribozyme exhibited a similar reduction of HGF/SF, as
determined by RT-PCR and an HGF/SF bioassay. Met-ribozyme transfected cells
exhibited a reduction of migration (determined by motion analysis) and in vitro inva-
siveness through extracellular matrix (Matrigel) in response to rhHGF/SF, compared
with the wild type cells and cells transfected with empty plasmid. MRC5 carrying
HGF/SF ribozyme also lost their ability to induce in vitro invasion of breast cancer
cells. 
It is concluded that targeting HGF/SF and its receptor, cMET, by way of hammer-
head ribozymes encoding antisense to the molecules is an effective approach in
reducing the invasiveness of breast cancer cells. 84 Poster presentations
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NK4, AN HGF/SF ANTAGONIST INHIBITS HGF/SF INDUCED 
CHANGES IN TIGHT JUNCTION PROTEINS TA Martin, 
WG Jiang and RE Mansel, University Department of Surgery, University of
Wales College of Medicine, Heath Park, Cardiff, CF14 4XN
Permeability of endothelial cells is governed by tight junctions, the most topical struc-
tures in the endothelium. Interaction and penetration of the endothelium by cancer
cells is an important step in the formation of metastases, indicating that changes in
tight junction formation will be an early and key aspect. NK4 is a variant of HGF/SF
(Hepatocyte Growth Factor/Scatter Factor). We have already shown that NK4 can
prevent HGF/SF induced changes in tight junction function1,2 and that NK4 is antago-
nistic to HGF/SF3. 
Purpose This study sought to determine the effect of HGF/SF and its antagonist,
NK4 on the expression of molecules involved in tight junction structure and function. 
Methods Human umbilical vein endothelial cells (HUVEC) were co-cultured with
HGF/SF (10 ng/ml) and/or NK4 (100 ng/ml) for up to 24 h in order to investigate any
changes in expression of the tight junction proteins ZO-1 and occludin. Western blot-
ting was used to ascertain changes in protein levels. mRNA was extracted from co-
cultured confluent cells followed by RT-PCR to observe any changes in the tight
junction proteins claudin-1, claudin-5, junctional adhesion molecule (JAM), in
parallel to investigating changes in tight junction function, assayed by measuring
transendothelial resistance (TER) and paracellular permeability. 
Results Western blotting revealed that HGF/SF decreased the protein level of 
ZO-1 (decreased over the 24 h of culture with HGF/SF from an initial relative density
of 230 to one of 175 at 24 h co-culture), but did not cause a change in level of
occludin. RT-PCR revealed that addition of HGF/SF caused no change in signal for
claudin-5 or JAM, but decreased the signal for claudin-1. NK4 was able to prevent the
decrease in levels of ZO-1 and claudin-1 by HGF/SF. In a parallel study NK4 was able
to prevent HGF/SF induced decrease and increase in TER and paracellular perme-
ability respectively1. 
Conclusions We conclude that HGF/SF induces changes in tight junction function
via modulation of proteins involved in tight junction function and structure. NK4
inhibits these effects of HGF/SF and may therefore have a role to play in the control of
invasion of endothelium by cancer cells. 
1. Martin et al (2000) Breast Cancer Res Treat 64(1): 108. 
2. Martin et al (2000) Breast Cancer Res Treat 64(1): 133. 
3. Jiang et al (1999) Clin Cancer Res 5: 3695. 
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MODULATION OF PTEN EXPRESSION BY TGF-b1
R Crosland1, M Wells2, ME Blair1, 1BMRC, Sheffield Hallam
University, Sheffield S11 WB, 2Dept. of Pathology, Sheffield University
Medical School, Sheffield S10 2JF
Genetic and biochemical studies have identified a tumour suppressor gene at 10q23.3
which has been termed PTEN for Phosphatase and Tensin Homologue Deleted on
Chromosome Ten. Somatic mutations in the PTEN gene have been found in many
types of cancer, but most frequently in cancer of the prostate, endometrium, glioblas-
tomas and melanomas. PTEN is currently considered to be the most frequently after
p53 tumour suppressor mutated in cancer. Germ-line PTEN mutations have been also
detected in three rare autosomal dominant disorders with overlapping clinical
features: Cowden disease, Bannayan–Zonana syndrome and Lhermitte–Duclos
disease. PTEN is a 403aa protein with homology to protein phosphatases and tensin
and auxilin. It has been established, however, that in spite of homology to dual speci-
ficity protein phosphatases, PTEN is an inefficient protein phosphatase in vitro and
that its main substrate is phosphatidylinositol (3,4,5) trisphosphate (PIP-3), which acts
in cells as a second messenger. In this study modulation of PTEN expression by TGF-
b in HEC 1B cells derived from endometrial carcinoma was investigated. For this
purpose cells were grown in McCoy’s modified 5A medium with reduced (1%) FCS
and treated with 2ng or 5 ng/ml TGF-b1. Untreated cells were used as a control.
Levels of PTEN mRNA and protein were determined by RT-PCR and Western blot-
ting, respectively. Up-regulation of PTEN by TGF-b1 was detected. The possible
significance of this for inhibition of cell proliferation in the endometrium will be
discussed. 
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MOLECULAR MODELLING OF DNA-BINDING INHIBITORS 
OF HUMAN TELOMERASE D Cairns, TC Jenkins1 and 
SP Mackay2 Institute of Pharmacy and Chemistry, University of Sunderland,
Sunderland, 1YCR Laboratory of Drug Design, University of Bradford,
Bradford, 2Dept. of Pharmaceutical Science, University of Strathclyde,
Glasgow
Telomerase is an RNA-dependent DNA polymerase enzyme responsible for the elon-
gation of repeating telomeric sequences found at the 3¢-end of eukaryotic chromo-
somes. Telomerase is not active in healthy somatic cells but is overexpressed in
almost 90% of human cancers, As a result telomerase has attracted considerable atten-
tion as a possible target for anti-cancer chemotherapy. Recently, a number of mono-
and bis-substituted anthraquinones were synthesized, fully characterized and tested
for their ability to inhibit telomerase and Taq polymerase using a modified TRAP
(Telomere Repeat Amplification Protocol) assay and their toxicity determined in a
panel of ovarian carcinoma cell lines (A2780, CH1 and SKOV-3) using a sulforho-
damine B assay1. All compounds tested displayed inhibition of telomerase of up to
43% at concentrations of 10 mM. Importantly, none of our compounds inhibited the
related enzyme, Taq polymerase, at concentrations of up to 50 mM, nor did any
display significant general cell toxicity. In an attempt to explore the structural require-
ments for telomerase inhibition, molecular modelling studies were undertaken.
Briefly, an intercalation site was introduced into the intramolecularly folded tetraplex
solution NMR structure of the human telomeric DNA sequence d[AG3(T2AG3)3]2 and
the structure minimized using a distance dependent dielectric of 4.0. Anthraquinones
were manually docked and the resulting complexes minimized to yield plausible
starting conformations. Molecular dynamics simulations were then undertaken to
allow the anthraquinones to explore the intercalation site. Finally, the average trajec-
tory from the dynamics was minimized and the net binding enthalpy calculated. All
simulations were carried out in an aqueous solvent environment in order to replicate
as much as possible the situation in vivo. The modelling results show a similar order of
potency to the experimental data thereby validating our model and suggesting that
intercalation into the G-tetraplex associated with human telomeric sequences is an
important feature of the molecular mode(s) of action of telomerase inhibitors of this
type. 
1. Gibson, V. Anderson, R.J., Jenkins, T.C. and Cairns, D. (1999) Pharm.
Pharmacol. Comm. 5, 669 
2. Wang, Y. and Patel, D.J. (1993) Structure, 1, 263 
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TOWARD NON-TOXIC THERAPIES: DESIGN, SYNTHESIS 
AND DNA SELECTIVITY OF SECOND-GENERATION
TELOMERASE INHIBITORS PJ Perry and TC Jenkins, YCR Laboratory of
Drug Design, University of Bradford, BRADFORD BD7 IDP, UK
Anthraquinone-based molecules are known to interact with a varied number of
nucleic acid targets. For example, the anticancer drug mitoxantrone exerts at least a
proportion of its biological effects through interaction with duplex DNA. More
recently, examples of this class of molecule (e.g. 1) have found application through
interaction with higher-order DNA structural forms. Stabilisation of DNA triplexes by
such molecules may facilitate highly-specific inhibition of gene expression1 whilst
interaction with guanine-tetraplex structures formed by the intramolecular folding of
G-rich DNA has been shown to inhibit telomerase,2 a tumour-specific enzyme essen-
tial for sustained cellular proliferation in tumour cells. 
However, for these therapies to be effective it is essential that acute toxicity is
minimised or preferably “designed-out” completely.3 To address these issues, we have
rationally designed two second-generation drug series (2 and 3) wherein duplex-
binding, and thus cytotoxicity, is minimised yet binding to higher-order DNA
triplexes and tetraplexes is retained with biological efficacy.4, 5 Structural selectivity
for nucleic acid binding is assessed using competitive dialysis and a correlation
between duplex binding and cytotoxicity is established for a panel of cell lines. 
1. MD Keppler et al 1999 Eur. J. Biochem 263: 817–825. 
2. PJ Perry et al., 1998 J. Med. Chem 41: 4873–4884. 
3. PJ Perry, TC Jenkins 1999 Expert Opin. Invest. Drugs, 8: 1981–2008. 
4. PJ Perry et al., 1999 J Med. Chem., 42: 2679–2684. 
5. PJ Perry et al., 1999 Anti-Cancer Drug Des., 14: 373–382. 
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HTERT EXPRESSION IS SIGNIFICANTLY HIGHER IN 
BREAST CANCER TISSUE THAN IN ADJACENT NON-
CANCEROUS TISSUE KL Kirkpatrick1, R Carpenter1, W Ongunkolade1, 
C Laban1, A Elkak1, M Ghilchick2, S Bustin1, PJenkins1, K Mokbel3, 1Barts
and The London NHS Trust, 2Central Middlesex Hospital, 3St George’s
Hospital
Introduction Telomerase is a ribonucleoprotein responsible for synthesising the
repetitive nucleotide sequence which makes up telomeres at the end of chromosomes.
Without telomerase activity each round of cellular division results in shortening of the
telomeres. This can lead to chromosomal instability and cell senescence, whereas
continued telomerase activity allows the possibility of cellular immortality.
Telomerase is active in 85–90% of human cancers but is undetectable in most normal
somatic cells. Three components have been identified, of which hTERT (human
telomerase reverse transcriptase) is the one which appears to confer enzyme activity. 
Aims Our aim in this study was to investigate the expression of hTERT in human
breast cancer and adjacent non-cancerous tissue (ANCT) using quantitative RT-PCR. 
Materials and Methods Samples of breast tumour and macroscopically normal
breast tissue 1 cm from the tumour were taken from 32 patients undergoing breast
cancer surgery. Total cellular RNA was extracted using the RNeasy (Qiagen) kit.
Following quantification of RNA (Ribogreen reagent – Molecular Probes Europe BV)
RT-PCR was performed in duplicate for each sample using the ABI PRISM 7700
Sequence Detector (Perkin-Elmer Applied Biosystems). 
Results For adjacent non-cancerous tissue the median copy number for hTERT
mRNA was 12.1 copies per hg of RNA (range 0–9850). Of 32 specimens 30 (94%)
had less than 1000 copies of hTERT RNA per hg of total RNA. 
For breast cancer tissue the median copy number for hTERT mRNA was 152,000
(range 6.55 to 7,910,000). Of 32 specimens 26 (81%) expressed more than 1000
copies of hTERT per hg of total RNA. Statistical analysis using the c2 test gave a
value of 51 (P<0.001). 
Conclusions These results show that there is a significant difference in the expres-
sion of hTERT mRNA between cancerous and non-cancerous breast tissue. There is
potentially a use for hTERT as a diagnostic marker for breast malignancy, particularly
using a cut-off point for significant levels of expression. 
P204
T ELOMERASE ACTIVITY IN IRANIAN PATIENTS WITH 
ESOPHAGEAL SQUAMOUS CELL CARCINOMA S Kazemi
Noureini*, AA Ziaee, M Yazdanbod+ *Institute of Biochemistry and
Biophysics, University of Tehran, Iran; +Dept. of Surgery, Shariati Hospital,
Medical Science University of Tehran 
Telomerase is one of the tools which immortalize stem or cancerous cells. This special
reverse transcriptase elongates telomeres and prevents telomere erosion naturally
ocurr in every cell cycle. In about 80–90% of the different types of cancer cells telom-
erase is activated, while in most somatic cells this enzyme is switched off. Therefore
telomerase can be a good tumor marker and also convenient for cancer therapy.
Esophageal cancer is the fifth most ferequent cause of cancer death worldwide and
esophageal sqoamous cell carcinoma (ESCC) is highly associated with cultural habits,
environmental chemicals and nutrients. In the persent work telomerase activity in
Iranian patients suffered from ESCC was observed applying Telomerase Repeat
Amplification Protocol (TRAP) according to Kim, N. et al 1994 with some modifica-
tions. In more than 90% of the 22 samples of different stages of ESCC telomerase
activity was detected, therefore this suggests that telomerase activation happens in an
initial step of carcinogenesis pathway of ESCC. However further studies should be
done for clarifying the exact time of this enzyme activation. Anyway activation of
telomerase precede mutation/loss of heterozigosity of p53. Although telomerase
activity could be considered as a good tumor marker in ESCC, there is no correlation
between the amount of telomerase activity and the progress of this kind of cancer. On
the other hand, a very slight activity was observed in normal epithelial tissues adjacent
tumor that can be due to the presence of epithelial stem cells or some small contami-
nation with cancerous cells. It is also possible that ESCC could be resulted from
incomplete differentiation or a failure in telomerase gene switching off which
normally ocurres in normal differentiation. 
P205
TRAP ASSAY ANALYSIS OF TELOMERASE ACTIVITY IN 
BARRETT’S OESOPHAGUS AJ Fletcher-Monaghan1, 
JJ Going2, R Stuart3 and WN Keith1, 1CRC Dept Medical Oncology, University
of Glasgow, CRC Beatson Labs., Glasgow G61 1BD, 2University Dept
Surgery & 3University Dept Pathology, Glasgow Royal Infirmary
Background Barrett’s oesophagus is a pre-neoplastic lesion of the oesophagus. The
squamous epithelium of the lower oesophagus is replaced by a metaplastic columnar
epithelium due to severe tissue injury caused by acid reflux. Most cases of
oesophageal adenocarcinoma arise in a pre-existing area of Barrett’s oesophagus and
the cancer risk is approximately 30 fold that of the general population. However, less
than 10% ever develop cancer. Telomerase is a ribonucleoprotein, which replicates the
terminal sequences of eukaryotic chromosomes and is active in germ line tissues. It is
absent from most normal somatic cells but is expressed in 85% of cancers. 
Aim To investigate the differential expression of telomerase in normal mucosa of
oesophagus and stomach compared to Barrett’s oesophagus with a view to identifying
a biomarker for disease progression. 
Methods Biopsies were taken (between 4 and 11) from each patient along the
length of the GI tract. We determined the telomerase activity of 344 biopsies from 49
patients (31 with Barrett’s oesophagus, 13 with gastric cancer, 3 with oesophageal
cancer and 2 with cancer of the oesophago-gastric junction) using the telomeric repeat
amplification protocol (TRAP) assay. 
Results 56% of patients were found to have at least one Barrett’s biopsy positive
for telomerase. Less than 1% of normal stomach (antrum and body) biopsies were
found to be positive. 87% of patients were found to have normal squamous oesoph-
agus biopsies positive for telomerase. 
Conclusions There is a significant difference in the percentage of patients with a
Barrett’s biopsy positive for telomerase compared with normal stomach. This may be
an indication of which patients will progress to invasive disease and will be monitored
in an ongoing study. It should be noted however, that multiple samples were taken
from each patient to enable us to identify those patients who had a Barrett’s biopsy
positive for telomerase. Telomerase is believed to be constitutively expressed in
permanently renewing epithelia. Consequently, normal squamous oesophagus should
not be used as a negative control. 
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IN VITRO MODELLING OF THE PROSTATE: 3D CULTURE 
OF PROSTATIC CELLS IN MATRIGEL SH Lang, M Stark1, 
J Hall, K Hyde, M Stower2 and NJ Maitland YCR Cancer Research Unit,
Dept. of Biology1, University of York and York District Hospital2, York,
YO10 5YW, UK
The aim of our work is to develop a three dimensional in vitro model of the prostate
which reflects both architectural and functional aspects of the prostate and incorpo-
rates both stromal and epithelial cells. 
Epithelial and stromal cultures were derived from prostatic tissue of patients
undergoing surgery for non-malignant disease. Epithelia were seeded into Matrigel (a
commercially available basement membrane) in the presence or absence of stroma
and prostatic hormones. Epithelial spheroids were grown for up to three weeks and
then analysed by electron microscopy and immunohistochemistry. 
Spheroids contained 1–2 epithelial cell layers which were positive by immuno-
histochemistry for epithelial (cytokeratin, E-cadherin) and prostatic markers (PSA,
PSMA). In the presence of stroma, serum and hormones the epithelial cells became
more columnar and polarised (demonstrated by confocal and transmission electron
microscopy). Microvilli, secretory vesicles, Golgi bodies and PSA expression were
consistently luminal whilst beta 1 integrin expression was basal. The presence of
stromal cells also increased spheroid forming efficiency. 
Primary epithelium was compared to epithelial cell lines. We cultured both PC-3
(metastatic) and PNT2-C2 (normal) prostatic cell lines in Matrigel. PC-3 cells formed
hollow spheroids, with predominantly one cell layer and evidence of polarisation,
whilst PNT2-C2 cells formed spheroids of solid cells. 
We have produced a three dimensional model capable of reflecting prostatic acini
architecture and function. Such a model will allow us to study (and manipulate)
cellular interactions and how they change with progression of prostate and provide a
relevant model to test new drugs and treatments prior to human clinical trials. 86 Poster presentations
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IN VITRO MODELLING OF THE PROSTATE: 3D CULTURE 
OF PRIMARY PROSTATE CELLS IN COLLAGEN GELS 
J Hall, M Stower2 and NJ Maitland. YCR Cancer Research Unit, Dept. of
Biology1, University of York and York District Hospital2, York, YO10 5YW, UK 
Introduction Despite the prevalence of prostate cancer (CaP) there are few good in
vitro models with which to predict why some cancers metastasise while others remain
organ confined. Alterations in stromal epithelial interactions play an important role in
advancement to a malignant phenotype. Our model aims to shed light on conflicting
evidence relating to the effects that stromal cells have on prostate epithelial cell
growth, motility and invasion: i.e. do they stimulate or inhibit and does this change
with disease progression? 
Methods Fibroblasts derived either from BPH tissue (BPHFb) or from CaP tissue
(TFb) were seeded into a collagen type 1 gel and allowed to form a matrix. PEC
derived from human BPH tissue or Cap tissue were cultured on the surface of the
fibroblast-populated collagen gels for 15 days. Cultures were examined morphologi-
cally, after frozen sectioning, using light microscopy and immunohistochemical
analysis with markers for prostate specificity, cellular differentiation and cell adhe-
sion. 
Results A difference was found in the invasion of PEC derived from CaP tissue
and BPH tissue when grown on BPHFb or TFb gels. On TFb gels PEC remained at the
surface of the gel whereas on BPHFb gels PEC invaded into the gel. In the case of
PEC derived from BPH tissue they formed acinus like structures which stained
strongly for basal CK and less strongly for luminal Ck. They also stained positively
for the prostate specific markers PSMA and PSA. Strong cell to cell E-cadherin
staining showed that the cells were adherant. 
Conclusion Our in vitro 3D culture model, based on a primary prostate fibroblast
populated type 1 collagen lattice, allows us to move closer to the in vivo situation to
study stromal epithelial interactions in the prostate and indicates distinct differences
between normal and malignant tissues. 
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MOTOGEN INDUCED DISSOCIATION OF THE E-
CADHERIN/CATENIN COMPLEX AND ASSOCIATION OF 
b-CATENIN WITH SIGNAL TRANSDUCTION PATHWAYS IN PROSTATE
CANCER CELLS, G Davies*1, W Jiang1 and M Mason2, 1Depts. of Surgery
and 2Clinical Oncology, University of Wales College of Medicine, Cardiff,
CF14 4XN
The effect of Hepatocyte Growth Factor/Scatter Factor (HGF/SF) was investigated on
its tyrosine kinase receptor c-Met, on E-cadherin/b-catenin function and on the 
b-catenin/APC/GSK3b complex (Axin complex) using an E-cadherin positive
(LNCapFGC), or E-cadherin negative (PC-3) prostate cancer cell line. Incubation
with the motogen HGF/SF, showed no change in the co-precipitation status of APC
with either GSK3b, or b-catenin in both prostate cell lines using immunoprecipitation.
In contrast, co-precipitation between GSK3b and b-catenin was found to be increased
upon continued exposure to HGF/SF in LNCapFGC cells. Furthermore, continued
exposure to HGF/SF increased the level of co-precipitations between the E-
cadherin/b-catenin complex with c-Met, and also increased tyrosine phosphorylation
of c-Met. Using immunofluorescence, continued exposure to HGF/SF decreased the
level of co-localised peripheral staining between the E-cadherin/b-catenin complex
with the c-Met receptor, and increased the level of co-localised cytoplasmic staining
between b-catenin and GSK3b. RT-PCR revealed that there were no mutations within
the binding regions between b-catenin and GSK3b. In conclusion, uncomplexed cyto-
plasmic pools of b-catenin associate more readily with the Axin complex in the
absence of E-cadherin. Whereas, in the presence of E-cadherin, b-catenin is stabilised
by forming tight cell-cell contacts. Furthermore, the association between the E-
cadherin/b-catenin complex with the HGF/SF receptor c-Met, may regulate intercel-
lular adhesion in prostate cancer following stimulation by HGF/SF. 
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INHIBITION OF HGF/SF-INDUCED CELL-MATRIX 
ADHESION, INVASION, MIGRATION & PAXILLIN
PHOSPHORYLATION, IN PROSTATE CANCER BY THE HGF/SF
ANTAGONIST, NK4 C Parr1, G Davies1, S Hiscox1, T Nakamura2, 
K Matsumoto2, and WG Jiang1, RE Mansel1, 1Dept. of Surgery, University of
Wales College of Medicine, Cardiff CF14 4XN, UK, and 2Dept. of
Biochemistry, University of Osaka, Osaka, Japan
Hepatocyte growth factor/scatter factor (HGF/SF) plays a key role in regulation of
migration, cell-matrix adhesion, invasion and angiogenesis in cancer, through the
phosphorylation of its specific receptor, the c-met tyrosine kinase. This study sought
to examine the effects of the recently discovered HGF/SF variant, NK4, on the influ-
ence of HGF/SF in prostate cancer cells. 
Human prostate cancer cells PC-3 and DU145 were tested. Tumour cell adhesion
to the extracellular matrix (Matrigel) was significantly increased by HGF/SF (number
of adherent cells 94.1±7.6 with HGF/SF vs 51.3±4.9 in control, P<0.01). However,
this increase was reduced in the presence of NK4 (50.2±4.49, P=0.01). In an in vitro
invasion assay, NK4 was also found to suppress the invasion induced by HGF/SF
(invasion index being 73.1±2.0 with HGF/SF and 52.8±4.2 with HGF/SF plus NK4,
P<0.01). In a real time cellular motion analysis, NK4 was also found to significantly
reduce the migration of these cells (migration distance over 100 mins being 18.7±6.5
in a control, 34.6±10.7 with HGF/SF and 25.5±6.5 in a combination of HGF/SF and
NK4). It was further shown that HGF/SF stimulation of the cells resulted in an
increase in the degree of phosphorylation of paxillin (immunoprecipitation and
Western blotting) and also an increase in the immunofluorescent staining of paxillin in
the focal adhesion complexes. Once again, the influence of HGF/SF on paxillin phos-
phorylation was antagonised in the presence of NK4. 
In conclusion, this study shows that HGF/SF stimulates cell-matrix interactions,
tumour cell motility and matrix invasion. These properties, required for metastatic
spread, can be inhibited by NK4. 
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SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR AS 
A STRATEGY TO INHIBIT PROSTATE TUMORIGENESIS, 
AF West, DE Neal and HY Leung. Prostate Research Group, Dept of
Surgery, University of Newcastle upon Tyne, Framlington Place, Newcastle
upon Tyne NE2 4HH
Introduction Carcinoma of the prostate remains a major clinical problem. The family
of fibroblast growth factors (FGFs), and their high affinity membrane tyrosine kinase
receptors (FGFRs), play key roles in development and progression of this cancer. A
variety of approaches have been employed to bring about inhibition or down-regula-
tion of growth factors and/or their receptors, with beneficial effects against human
malignancies. Using the strategy of dominant-negative inhibition, Celli and
colleagues expressed a soluble form of the FGFR (sFGFR) in a transgenic mouse
model and demonstrated potent inhibition of FGF-mediated organogenesis [1]. We
hypothesised that the expression of such sFGFR inhibits proliferation of prostate
cancer cells. 
Materials and Methods The full-length cDNA for FGFR1-IIIc was used as
template in a polymerase chain reaction, using primers for the extracellular domain of
the receptor. The construct obtained was subcloned into a selectable adenoviral
expression system with a green fluorescent protein (GFP) reporter [2]. Western blot
analysis was used to verify expression of the sFGFR1 in 293 cells and human prostate
cancer DU145 cells infected with the generated recombinant adenovirus (Ad-IIIcR1),
and to examine the effect of sFGFR1 on FGF-induced MAP kinase phosphorylation.
The effect of sFGFR1 on proliferation of DU145 cells was assessed by WST-1 assay. 
Results Expression of the activated MAP kinase, pERK1, induced by exogenous
FGF-1/heparin was almost completely abolished in Ad-IIIcR1-infected DU145 cells
in contrast. Control-infected cells showed no such effect. Proliferation of Ad-IIIcR1-
infected DU145 cells maintained in full culture media was reduced by almost 50% in
comparison with controls. 
Conclusions We have demonstrated for the first time that expression of soluble
FGFR in human prostate cancer cells may have a potential role in the development of
therapy. This model will be further developed for in vivo assessment. 
REFERENCES 
1. Celli et al., (1998) EMBO; 17: 1642 
2. He et al., (1998) PNAS; 95: 2509 Poster presentations 87
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MATRIX METALLOPROTEINASE 9 EXPRESSION IN 
PROSTATE TUMOUR AND STROMAL CELLS MJ Thompson,
J Crimmins, S Ganta and PM Loadman, Cancer Research Unit, University of
Bradford, Bradford, West Yorkshire BD7 1DP
Prostate cancer is the 2nd most common cancer in males in the UK with over 18,000
new cases registered per year (CRC figure for 1995). Tumour progression in prostate
cancer is a common occurrence that often accompanied by metastasis and leads to a
largely untreatable disease state. Tumours that lack metastasis present with a good 5
year survival rate. Past work has demonstrated that MMP9 mRNA is upregulated in
the more aggressive, metastatic prostate tumours. Similarly, western blotting has
shown an increase in MMP9 protein within tumour tissues. The work presented here
aims to examine the cellular localisation of the MMP9 protein within prostate tumour
tissue and to begin to determine the extent to which stromal cells contribute to the
observed MMP9 expression. 
Archival paraffin embedded tumour tissues were obtained from the Bradford
Royal Infirmary NHS Trust. The tissues were paired into pre and post androgen inde-
pendence for each patient and tumour areas were identified in consultation with rele-
vant urological and pathological clinicians. Serial sections were then immunostained
for MMP9 and CD68 (a macrophage specific marker) using standard methods.
Scoring was carried out blind by two researchers. 
MMP9 expression was examined in tumour cells and found to be positive (where
>90% of tumour cells were stained) in 56% of the cases (18/32). A lower level of
staining (where 80–90% of cells were positive) was observed in an additional 12.5%
of cases (4/32). In a majority (90%) of cases (29/32), strong MMP9 expression was
noted in CD68 positive macrophages present within the tumour tissues. This study
therefore demonstrates that in this sample, immunodetectable MMP9 expression does
not appear to significantly alter when prostate tumours progress from the hormone
dependent to hormone independent state. The expression of MMP9 within these
tumours is shown to arise from both the tumour cells and from normal, stromal
macrophages. The manipulation of MMP9 activity in prostate tumour or stromal cells
may therefore be a viable therapeutic strategy. 
This work was supported by the Cancer Research Campaign 
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DIFFERENTIAL EXPRESSION OF ECE AND NEP 
METALLOPROTEINASE IN PROSTATE CANCER, 
BA Usmani1, NJ Maitland2, DM Nanus3, AJ Turner1, 1School of Biochemistry
& Molecular Biology, University of Leeds, Leeds LS2 9JT, 2YCR Unit, Dept. of
Biology, University of York YO10 5YW, 3Depts. of Medicine & Urology; Weill
Medical College of Cornell University; NY, NY 10021
Prostate cancer is now the most common cancer and the second highest cause of
cancer death in men in Western society. Recently, clinical and pre-clinical data have
indicated a mitogenic role for neuropeptides in prostatic disease. Endothelin-1 (ET-1)
is produced by prostatic epithelium and prostate cancer cell lines, and plasma ET
concentrations are significantly elevated in men with metastatic prostate cancer.
Therefore, a prospective therapeutic approach might be to block ET-1 activity in
prostate cancer through the modulation of the Endothelin-Converting-Enzyme (ECE),
a metalloproteinase which converts the inactive precursor (big ET) to the active ET
peptide. Recently, the consequence of loss of a related cell surface peptidase, NEP, has
been shown to contribute to androgen-independent progression of human prostate
cancer (Papandreou, CN, Usmani, BA, et al. (1998) Nature Medicine 4:50–57). The
present study aims to examine ECE expression in prostate cancer, the cellular local-
ization of ECE, and whether changes in ECE expression may contribute to androgen-
independent disease. Established prostate epithelial cell lines from transformed
(PNT1a, PNT2-C2, P4E6) and tumour (LNCaP, PC-3, DU145, TsuPr1, PPC-1)
origins were utilized in this study, as well as available tumour biopsy and radical
prostatectomy material. Western analysis revealed that ECE-1 is abundantly
expressed in all metastatic cell lines, but weakly expressed in LNCaP cells. In
contrast, LNCaP cells were seen to express high levels of NEP, whilst PC-3, DU145
and other metastatic cell lines tested lacked detectable NEP activity. Primary epithe-
lial cells of BPH origin expressed much higher levels of NEP than their malignant
counterparts, but neither showed ECE expression. An absence of epithelial ECE
might indicate a role for stromal interaction and paracrine production of ECE within
the host. Immunohistochemical analysis does in fact reveal stromal ECE activity in
primary prostate tumour tissue. In contrast, the up-regulation of ECE in metastatic
epithelial cell lines in culture may further indicate a critical role for ECE in ascerting
a metastatic phenotype. 
In conclusion, a differential profile of NEP and ECE would allow for an abundance
of mitogenic peptides contributing to the progression of prostate cancer. ECE is up-
regulated in stromal cells surrounding tumour tissue. Paracrine up-regulation of ECE
leads to an increase in mitogenic endothelin peptide concentration, and this may be a
critical early step during the progression of androgen-independent prostate cancer. 
P213
ABNORMAL EXPRESSION OF MITOGEN-ACTIVATED
PROTEIN KINASE KINASE-5 (MEK5) IN HUMAN PROSTATE
CANCER, PB Mehta, R Brown, L Thilak, AB Pulimood, CN Robson, 
DE Neal and HY Leung, e-mail: H.Y. Leung@ncl.ac.uk. School of Surgical
and Reproductive Sciences, The Medical School, University of Newcastle
upon Tyne, NE2 4HH, UK 
We applied the technique of arbitrarily primed Polymerase Chain Reaction (PCR) to
genotype variants of the human LNCaP prostate cancer cell line that have different
metastatic phenotypes (LNCaP-Pro5 and LNCaP-LN3 (most invasive)). A DNA frag-
ment (Prosl), lost in the LNCaP-LN3 variant, had a perfect match to the human
mitogen-activated protein kinase kinase-5 (MEK5) gene. 
Immunoprecipitation and western blotting confirmed the loss of MEK5 protein
expression in LNCaP-LN3 cells, when compared to the parental variant LNCaP lines.
Tissue in situ hybridisation (TISH) and immunohistochemistry (IHC) demonstrated
abnormal expression of MEK5 in the malignant epithelium while adjacent areas of
BPH were negative. Occasional signal was observed in the basal cells of some BPH
cases. Data from both TISH and IHC studies suggest highest levels of MEK5 expres-
sion in about 50% of prostate cancer, with no significant difference observed among
tumours of different Gleason scores. Furthermore, stromal smooth muscle express
MEK5 at low levels, in keeping with a physiological role of MEK5 in the mainte-
nance of myocyte lineage. 
To further investigate its potential roles in invasion, a constitutively active form of
MEK5 (MEK5D) was co-transfected with matrix metalloproteinase (MMP) promoter
driven luciferase reporter constructs into COS-7 cells. The promoters for MMP-1, -2
and 9 were examined. MEK5D stimulated MMP-9 promoter the greatest, MMP-1
moderately, but had no effect on MMP-2 promoter activity. In summary, we identified
MEK5 as a gene potentially associated with increasing invasiveness in prostate cancer
cells and confirmed its abnormal expression in the resected primary tumour speci-
mens. Of interest, MEK5 may be an important signalling molecule required in the
induction of MMP-1 and MMP-9 genes. 
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A STUDY OF SURVIVIN AND p21CIP1/WAF1 EXPRESSION IN 
PROSTATE CANCER, MJ Thompson, S Ganta & J Seargent,
Cancer Research Unit, University of Bradford, Bradford, West Yorkshire BD7
1DP 
Prostate cancer is a common male cancer that is increasing in both incidence and
mortality. Treatment is initially successful via withdrawal of androgenic hormones,
but a relapse into an androgen independent state is commonly observed and difficult
to treat. The initial response of the prostatic tumours to hormonal withdrawal is via
apoptosis. The novel antiapoptosis protein survivin is a member of the inhibitor of
apoptosis protein (IAP) family that links apoptosis and cell cycle progression,
ensuring that cells maintain viability and proper cell cycle progression. It is expressed
normally in the G2/M phase of mitosis, associating with the mitotic spindle micro-
tubules and the CDK inhibitor p21cip1/waf within the centrosome. Over-expression of
survivin therefore appears to be a mechanism by which cells can produce an antiapop-
totic environment through their cell cycle. This work aims to study whether the
expression of survivin is related to prostate tumour progression from being hormone
dependent to a hormone independent state and to determine whether survivin expres-
sion was associated with p21cip1/waf expression. 
Archival paraffin embedded tumour tissues were obtained from the Bradford
Royal Infirmary NHS Trust. The tissues were paired into pre and post androgen inde-
pendence for each patient and tumour areas were identified in consultation with rele-
vant urologists and pathologists. These were then immunostained for survivin and
p21cip1/waf using standard methods. Scoring was carried out blind by two researchers.
Survivin expression was found in a majority of tumours (35/38). When the paired
tissues were examined, no significant difference was found between the scores for the
pre (1.61 ± 0.29) and post-relapse (1.33 ± 0.26) states. Similarly, p21cip1/waf expression
was observed in a majority of tumours (37/38) but no significant difference was
observed between pre (2.17 ± 0.24) and post-relapse (1.85 ± 0.29) groups. This work
demonstrates that survivin is expressed by a majority of prostate tumours but this is
not associated with androgen independence or p21cip1/waf. Manipulation of survivin
function may therefore represent a relevant approach in the treatment of prostate
cancers. 
This work was supported by the Cancer Research Campaign 88 Poster presentations
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THE MOLECULAR DETECTION OF PROSTATE CANCER 
K Patel1, P Harndon1, P Whelan1, PJ Selby1 and S Burchill1
1Imperial Cancer Research Fund Clinical Cancer Centre, St. James’s
University Hospital, Leeds, UK. e-mail: medkp@cancermed.leeds.ac.uk 
Sensitive methods for the detection of prostate cancer may be useful in defining prog-
nosis and in directing future therapeutic strategies. Reverse-transcriptase polymerase
chain reaction (RT-PCR) for PSA mRNA has been extensively studied in patients with
prostate cancer with variable results. This study evaluated the sensitivity and speci-
ficity of RT-PCR and compared it to microsatellite analysis for the detection of
prostate cancer in the peripheral blood (PB). 
RT-PCR for PSA was performed on PB from 21 patients with metastatic
prostate cancer and 24 healthy volunteers’ blood samples. Ten of the patients with
metastatic disease already evaluated by RT-PCR were examined for microsatellite
instability (MSI) and loss of heterozygosity (LOH) in their plasma using 14 poly-
morphic and 2 monomorphic fluorescently labelled markers. Microsatellite
analysis was also performed on plasma samples from 9 healthy volunteers. 
RT-PCR for PSA was very sensitive, detecting 10 prostate cancer cells spiked in 
1 ml of PB, although PSA mRNA was only detected in the PB samples from 6/21
patients. Furthermore, PSA mRNA was detected in normal PB (4/24 samples). MSI
and LOH were detected in 6/10 prostate tumours, but only LOH was detected in
matching plasma samples from 2/10 patients. These two patients were also RT-
PCR-positive for PSA mRNA in the PB. 
In summary, RT-PCR for PSA is a sensitive method for the detection of prostate
cancer cells, however the detection of PSA mRNA in normal PB may limit its clinical
utility. Microsatellite analysis is specific for the identification of disease but detection
of tumour derived DNA is low in patient plasma samples. The role of real-time quan-
titative RT-PCR for PSA mRNA in distinguishing between healthy and diseased
populations will be evaluated and the results will be presented. 
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EXPRESSION OF TIP60, AN ANDROGEN RECEPTOR 
CO-ACTIVATOR, IN PROSTATE CANCER, K Chalkidou, 
VJ Gnanapragasam, ME Brady , S Cook , DE Neal , CN Robson, Dept. of
Surgery, University of Newcastle Medical School, Newcastle-Upon-Tyne,
NE2 4HH 
Prostate cancer is currently the second leading cause of cancer deaths in males. While
early treatment is by androgen ablation, there are few treatments for recurrent disease.
Recent evidence has suggested that the androgen receptor (AR) continues to be active
in hormone refractory cancer and one of the mechanisms may be by overactivity of
steroid receptor coactivators. We have previously identified Tip60 as a coactivator of
the human AR showing that it enhances AR dependent transactivation and interacts
physically with the AR in vivo. The role and expression of Tip60, in clinical prostate
cancer however is still unknown. We were therefore interested in investigating Tip60
expression in both benign and malignant prostatic tissue. 
Materials and Methods In situ hybridisation In vitro transcription was per-
formed from Tip60 cDNA to generate anti-sense and sense probes using digoxigenin
labelling. Anti-Tip60 Ab: A rabbit polyclonal anti -Tip60 antibody was raised using a
C terminal Tip60 peptide. Tip60 antiserum was then isolated and affinity purified on a
peptide column. Western blot: Western blot was performed on COS 7 (monkey
kidney) cells transfected with HA-tagged Tip60 or plasmid vector control. Plasmid
expression was confirmed by probing for the HA tag. Immuno-histochemistry:
Purified antibody was used to study the expression of Tip60 in clinical cases of
paraffin embedded BPH and prostate cancer (sections obtained by TUR biopsies)
using an Avidin-Biotin staining system. 
Results In situ hybridisation showed that Tip60 was expressed at the transcript
level in prostatic tissue. Malignant tissue demonstrated weak but positive expres-
sion of Tip60 mRNA in some cells. In benign tissue there was more convincing
staining of glandular basal cells. In both cases stroma exhibited weak non-specific
staining. In the western blot, Tip60 antibody produced a single band of the predicted
size in HA-tagged Tip60 transfected COS 7 cells, but not in un-transfected cells.
Expression levels correlated with a probe for the HA tag. Immunohistochemistry
demonstrated that in sections of BPH, Tip60 localised weakly to epithelial cells with
predominantly nuclear staining. In malignant epithelium, there was more intense
staining of nuclei with scattered stains in the cytoplasm. Controls using no primary
antibody exhibited no staining. 
Conclusion We have identified Tip60 mRNA expression in prostatic tissue. We
have also produced and characterised a novel Tip60 antibody and confirmed protein
expression in both benign and malignant tissue. Further data will be presented of
Tip60 expression in prostate cancer and correlation with stage and grade of disease. 
P217
POTENTIAL OF INTERMITTENT HORMONE THERAPY FOR 
M+ AND M0 PROSTATE CANCER PATIENTS RTD Oliver1, 
A Lee2, D Farrugia1, W Ansell1, F Chinegwundoh2 Dept of Medical Oncology1,
and Urology2, St Barts & Royal London School of Medicine, London ECIA 7
UK 
Increasingly animal and clinical studies suggest that intermittent therapy may improve
duration of hormone dependence in patients with prostate cancer. However there
remains uncertainty as to optimal duration of treatment, level of PSA before treatment
is restarted and whether it is safe to use this strategy in patients with M0 disease. The
aim of this study is to compare outcome in prostate cancer patients with M+ and M0
disease receiving intermittent hormone therapy. 
Patients and methods Any patients who had achieved PSA complete remission
after hormone therapy for metastatic or locally advanced prostate cancer were
included in the study. Patients restarted treatment when symptoms developed or if
PSA rose above pretreatment levels. 
Results Fifty patients (M+ n = 17, M0 n = 33) entered on intermittent hormone
therapy (HT) after achieving a PSA complete remission. Overall 57% remain off
treatment at 12 months and the median time for restarting further hormone therapy
was 14 months. 95% of patients retreated are progression free at 1 year and overall
92% are alive at 3 years. 16 patients have completed a second cycle, 12 a third cycle
and 3 have begun a 4th cycle. 
There was a slower progression to require treatment in M0 v M+ patients (70% v
37% continue off hormones at 1 year) Furthermore in a subset of four M0 patients
with a short first cycle time off HT alone (2,7,7,13 mean 7.3 mths) radiation consoli-
dation prolonged their second cycle off HT (19, 14, 19, 28 mean 20 months). Despite
this small sub-group of early relapses, overall 53% of M0 patients treated without
radiation remained off hormones at 3 years. 
Prompted by these findings a randomised phase 2 study has been initiated to inves-
tigate immediate versus deferred radiation in M0 patients who received 9 months
intermittent hormone therapy. To date 52 have been randomised and currently at 6
months 1 of 12 hormone alone patients versus 1 of 11 hormones plus radiation patients
have achieved PSA complete response. 
Conclusion It is clearly safe to consider patients with M0 prostate cancer for
intermittent hormone therapy alone. Furthermore there is a suggestion that it may be
safe to restrict radiation to consolidate response of the minority having a short dura-
tion of time off therapy in first cycle, though a randomised phase 2 trial will be
required to confirm this. 
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ANDROGEN RECEPTOR AMPLIFICATION IN HORMONE 
REFRACTORY PROSTATE CANCER J Edwards1, 
MA Underwood2, NS. Krishna1, R. Mukherjee2, AD. Watters1 and 
JMS Bartlett1, Dept of Surgery1/Dept of Urology2, Glasgow Royal infirmary,
Glasgow, G31 2ER 
To aim of this study was to examine the role of AR gene amplification and aneusomy
of chromosome X in the development of anti-androgen resistant prostate cancer. 
Twenty patients with recurrent prostate cancer resistant to androgen deprivation
therapy were selected for study. Pre and post anti androgen therapy tumours and full
clinical follow-up were retrieved for each patient. AR gene amplification and X chro-
mosome copy number were assessed by fluorescent in situ hybridisation (FISH) using
a Spectrum Orange™ labelled probe at locus Xq11–13 for the AR gene (Vysis, UK,
Ltd) and a Spectrum Green™ labelled alpha satellite probe for the X chromosome
(Vysis, UK, Ltd). A minimum of 20 nuclei were scored over 3 tumour areas by 2 inde-
pendent observers. 
Aneusomy of chromosome X was reported in 35% (7/20) pre and 55% (11/20) post
relapsed tumours and AR gene copy number was 2 or more in 35% (7/20) of pre and
65% (13/20) of post relapse tumours. AR gene amplification was found in 5% (1/20)
of pre relapse tumours and 15% (3/20) of post relapsed tumours. 
The rate of AR gene amplification is too low to be solely responsible for the devel-
opment of anti-androgen resistant prostate cancer. Also the presence of amplified AR
and cells aneusomic for the X chromosome in primary tumours that respond to
androgen deprivation therapy suggests that an increase in AR gene copy number does
not prevent a tumour from responding to androgen deprivation therapy. Therefore
protein levels of AR and other mechanisms which could cause hormone refractory
prostate cancer must be investigated before we understand why so many patients with
this disease relapse with an anti-androgen resistant tumour. Poster presentations 89
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PHASE I TRIAL OF bcl-2 ANTISENSE (GENASENSE™) AND 
DOCETAXEL (D) IN HORMONE-REFRACTORY PROSTATE
CANCER JS de Bono, EK Rowinsky, J Kuhn, L Ochoa, G Schwartz, 
A Patnaik, H Fingert, S Weitman, I Thompson, AW Tolcher, Institute For Drug
Development, University of Texas at San Antonio, Genta Inc, Berkeley
Heights, NJ
Hormone refractory prostate cancer (HRPC) is relatively resistant to therapeutics that
induce apoptosis due, in part, to the proto-oncogene bcl-2, which is overexpressed in the
majority of HRPC and which appears to be a determinant of androgen-independence
and chemoresistance. D has, however, been shown to induce PSA responses in
patients with HRPC. Genasense™ (G), an antisense oligonucleotide directed to the
first 6 codons of bcl-2 mRNA, downregulates Bcl-2 protein expression and enhances
D chemosensitivity in prostate cancer xenografts. This rationale is the basis for this
phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of G3139 adminis-
tered prior to treatment with D in patients with HRPC. In this study, G is administered
as a continuous IV infusion for 5 days followed by D administered over 1 hr, with
cycles repeated every 21 days. Sixteen patients with HRPC (median age – 66, median
PS 1) have received 50 courses with escalating dose levels: G 5 to 7 mg/kg/day with
D 60 to 100 mg/m2. Four patients had received prior radiotherapy and 7 patients prior
chemotherapy including 3 patients with prior taxane therapy. Toxicity has not been
dose limiting with uncomplicated grade 4 neutropenia in 4 patients, grade 1 fever in 
5 patients and grade 1 mucositis in 2 patients. No drug-drug PK interactions have been
noted, as both D and G PK parameters have been similar to PKs in single-agent
studies. G plasma concentrations have consistently exceeded target levels in preclin-
ical studies (1 mg/ml) with Css values averaging 3.09 and 5.36 mg/mL at the 5 and 
7 mg/kg/day dose levels, respectively. Both flow-cytometric and western blot
analyses indicate marked downregulation of Bcl-2 protein by day 5 in peripheral
blood mononuclear cells. To date, durable PSA responses have been seen in 4 of 
8 taxane-naïve patients, including a 50-fold reduction in PSA and major objective
responses in liver and viscera. Genasense can be safely administered in combination
with docetaxel, effectively downregulating Bcl-2 protein in vivo. The preliminary
antitumor activity and safety data support expanded clinical development for patients
with HRPC. 
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COMBINED EXTERNAL BEAM AND BRACHYTHERAPY 
BOOST FOR LOCALISED PROSTATE CANCER: A REPORT
OF PROCEDURAL COMPLICATIONS AND ACUTE RADIATION TOXICITY
J Dickson1, P Bownes1, P Ostler1 and PJ Hoskin1, 1Mount Vernon Cancer
Centre, Rickmansworth Road, Northwood, Middlesex, HA6 2RN 
Introduction In patients with apparently localised prostate cancer, conformal radia-
tion therapy using combined external beam (EBT) and temporary implantation (BB)
has been developed at Mount Vernon, covering potential sites of microscopic disease
in the extracapsular region and seminal vesicles with 35.7Gy in 13 daily fractions
EBT, followed by a fractionated HDR implant delivering 17Gy in 2 fractions. This is
currently being compared with EBT alone in a randomised phase III trial. This series
reports our initial experience in seventeen patients refusing randomisation who were
treated off-study, but according to protocol. 
Materials and Methods Data were collected retrospectively from patient notes
using a standard pro-forma: this covered patient demographics, treatment details,
procedure-related complications and acute radiation toxicities. Data were recorded on
Info flex 4, with analysis using SPSS. 
Results Results are available from seventeen patients, with a median age at treat-
ment of 67 years (range 53–74). Eight patients (47%) were asymptomatic at diag-
nosis. Five patients had stage I and II stage II disease. Disease stage was unavailable
in 1 patient. Median PSA at presentation was 14.2 ng/ml (range 4.6–38.7). All
patients were treated radically, according to protocol. The median planning target
volume, as defined by CT, was 102 cc (range 49–137). The maximum urethral dose
ranged from 15–22.2Gy over two fractions (median 20.1). The median maximum
anterior rectal wall dose was 12.7Gy, over two fractions. Eight patients (47%)
required narcotic analgesia whilst the implant was in situ. No patient had any other
procedure-related complication. Initial follow-up was at a median of 4 weeks post-
treatment (range 2–6). Five patients had significant urinary symptoms at this time: 1
had dysuria and 4 had frequency during the day of every 2 hours or less. Three
patients had bowel symptoms: 1 had PR bleeding and 1 had mucous rectal discharge,
both intermittent. One patient required regular medication to control his bowel habit.
Data concerning late toxicity was available on ten patients with a median follow-up of
12 months (range 6–20). No patient had biochemical disease relapse. Three patients
had RTOG grade I/II urinary symptoms and bowel symptoms, respectively. 
Discussion This series represents an initial overview of the procedural complica-
tions and acute radiation morbidity in 17 patients treated off-study with combined
EBT and BB. The procedure is generally well tolerated. Acute radiation morbidity is
acceptable when compared with standard external beam protocols. Further follow-up
will define rates of tumour control and late radiation morbidity. 
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ANORECTAL IRRADIATION DURING RADIOTHERAPY FOR 
CARCINOMA OF THE PROSTATE: A COMPARISON OF
HELAX PREDICTED AND DIODE MEASURED DOSES D Hayne1, 
U Johnson2, R Brown3, D D’Souza2, C Hare4. PB Boulos1, H Payne3, 1Dept of
Surgery, 2Dept of Medical Physics, 3Meyerstein Institute of Oncology’ 4Dept.
of Radiology Royal Free and University College Medical School London 
Objectives To validate anorectal radiation doses predicted by a HELAX™ treatment
planing system by comparing them to doses measured using a Scanditronix rectal
probe containing 5 n-type photon-detecting diodes. 
Background Anorectal symptoms after radiotherapy for prostate cancer are
extremely common and cause significant morbidity. The degree of anal canal irradia-
tion and its effect on subsequent symptoms has not been investigated. For this purpose
an accurate assessment of anorectal dose was required. 
Methods Ten patients were CT planned with the probe in the anorectum and
HELAX™ was used to predict doses for each of the diodes and to determine the rela-
tion of each diode to the target volume (in the volume, at the edge of the volume,
outside of the volume). Doses were then measured with the probe on 5 consecutive
fractions and the average diode-measured doses compared with those predicted by
HELAX™. 
Results For diodes situated in the target volume, the average difference between
measured and HELAX™ predicted doses was 6%. Large differences were found
between measured and predicted doses in diodes at the edge and outside of the target
volume (average variation compared to HELAX™ predicted dose was 55% and 40%
respectively). Diodes outside the target volume were higher than the HELAX™
predicted doses, to a statistically significant degree (P < 0.022). 
Conclusions HELAX™ predicted doses appear accurate within the confines of
the target volume. Probe movement, set-up error and internal organ movement may
explain the large variation between measured and predicted doses for diodes not
within the target volume. Due to the averaging of doses on five consecutive fractions,
measured doses are likely to represent a more accurate reflection of anorectal irradia-
tion over an entire treatment period.
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USE OF 14C METHYL CHOLINE TO MONITOR INHIBITION
OF THE EXTRACELLULAR SIGNAL-REGULATED KINASE
CASCADE: A NOVEL APPROACH TOWARDS IMAGING OF SIGNAL-
TRANSDUCTION INHIBITION OC Hutchinson1, D Liu1, S Osman2, P Price1
P Workman3 and EO Aboagye1, 1PET Oncology Group, Imperial College
School of Medicine, London, 2MRC Cyclotron Unit, Hammersmith Hospital,
London; 3CRC Centre for Cancer Therapeutics, Institute of Cancer Research,
Sutton 
Background Phosphocholine levels are found to increase with malignant transfor-
mation of mammary epithelial cells in vitro. There is evidence to suggest that the
phosphocholine production is regulated by the receptor-Ras-Raf-MAPK-kinase
(MEK)-Mitogen Activated Protein Kinase (MAPK) cascade. In this study, the regula-
tion of choline phosphorylation by the MAPK pathway was investigated by using signal
transduction inhibitors. The ultimate aim is to develop and validate [methyl-11C]choline
as a positron emission tomography (PET) probe for quantifying the pharmacodynamics
of signal transduction inhibition. 
Methods We studied the effects of Geldanamycin and 17 AAG (Raf-1 inhibitors),
U0126 (specific MEK inhibitor), Roscovitine (cyclin-dependent kinase-2 inhibitor),
and LY294002 (PI3K Inhibitor) on choline uptake and phosphocholine production. In
parallel experiments, the effects of these drugs on the phosphorylation of extracellular
signal-regulated kinase (ERK-1/2), and cell proliferation were also assessed. 
Results In exponentially growing HT29 cells, inhibition of ERK-1/2 phosphory-
lation by Geldanamycin and U0126 was associated with a concentration-dependent
reduction in choline uptake, phosphorylation production and cell proliferation. Brief
exposure to high concentrations (100 mM) of U0126 inhibited phosphocholine
production to the same extent as Hemicholinium-3 (1 mM), an inhibitor of choline
transport and choline kinase activity. In contrast to these inhibitors which act upstream
of MAPK, Roscovitine (1,10 mM) failed to suppress phosphocholine production.
Furthermore, LY294002 (5,50 mM) also failed to suppress phosphocholine produc-
tion. 
Conclusion Choline phosphorylation is regulated by the MAPK cascade. This
suggests that using [methyl-11C]choline maybe useful as a PET probe for the in vivo
quantification of pharmacodynamics of signal transduction inhibitors that act on the
receptor-MAPK cascade. 90 Poster presentations
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DIAGNOSTIC ACCURACY OF DIFFUSION WEIGHTED
IMAGING IN THE PROSTATE P Gibbs, DJ Tozer, 
LW Turnbull MRI Centre, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ 
Introduction Over the past few years MR imaging of the human prostate has become
more prevalent. However, due to the similarity in signal intensity between prostatic
carcinoma (PCa) and benign prostatic hyperplasia (BPH) on T2 weighted imaging, the
usefulness of conventional MRI is reduced. An alternative approach may involve the
utilisation of diffusion weighted imaging, which has seen increasing clinical relevance
in the brain. Diffusion weighting involves sensitising the imaging sequence to the
random motion of extracellular water. Variations in apparent diffusion coefficient
(ADC) in malignant tissue are often attributed to changes in the extracellular volume
fraction and increased tortuosity of the extracellular space. 
Methods All imaging was performed using an IGE 1.5 T scanner and a commer-
ical pelvic phased array coil. Seventy-six patients with transrectal ultrasound guided
biopsy proven prostatic carcinoma aged between 51 and 83 years (mean 68 years)
were scanned. Diffusion weighted images of a single axial slice through the prostate
were acquired. Data was obtained with diffusion gradients applied along each of the
three main axes in turn. For each direction 8 images were obtained at different diffu-
sion weightings to enable accurate quantification of the ADC. The total scan time was
just under 27 minutes. After acquisition regions of interest were drawn on areas of
PCa, BPH, and normal peripheral zone (PZ) tissue where available. Calculated ADC
values were then compared across tissue types. 
Results Significant differences were noted between all tissue types in the x- and
y-directions (P < 0.001 for all comparisons). In the z-direction a significant difference
was noted between PCa and PZ (P < 0.0001). The results are presented in the accom-
panying table. 
Tissue ADCx ADCy ADCz
PCa 2.23±1.05 2.32±0.91 4.16±1.63 
BPH 2.39±0.81 2.65±0.91 4.33±1.59 
PZ 2.95±1.09 3.02±1.16 4.84±1.78 
ADC values were noted to be significantly higher in the z-direction for all tissue
types indicating that diffusion anisotropy may be important in the prostate. 
Conclusions Diffusion weighted imaging of the prostate may offer improved
diagnostic accuracy compared to conventional MR imaging. 
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ROLE OF MR IMAGING IN PROSTATE CANCER: 
CORRELATION  WITH PSA AND GLEASON GRADE.
B Wang, M Lowry & L W Turnbull, Centre for MR Investigations, Hull Royal
Infirmary, Anlaby Road, Hull HU3 2JZ 
Introduction Prostate cancer is the second most common cause of cancer-related death
in the UK. Although up to 40% of men will have prostate cancer by the age of 60 years,
not all will develop progressive or metastatic disease. The characteristics of lesions
associated with a poor prognosis are urgently being sought with a view to optimising
patient management. Tumours grow by induction of neoangiogenesis. Pharmacokinetic
modelling of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
allows analysis of amplitude of contrast uptake, estimation of permeability (ER) and
the distribution volume (DV). Empirical techniques provide a measurement of
maximum enhancement index (EI), a parameter related to blood flow. The objective
of this study is to determine if a relationship exists between MR-determined parame-
ters of neoangiogenesis and tumour stage (T-stage), size, Gleason grade, PSA level
and presence of bone metastases at initial presentation. 
Methods 78 patients (aged 48–82 yrs; mean 65) underwent MRI at 1.5T using a
pelvic phased array coil for signal reception. Thin-slice T2-weighted fast-spin echo
images were acquired for T-staging and tumour localisation, estimation of maximum
tumour diameter and volume. DCE-MRI was carried out at four slice locations using
an FSPGR sequence (temporal resolution 11.2 secs) and Gd-DTPA administered 
at 0.1 mmol/kg body weight. Regions-of-interest were drawn manually on a Sun
Workstation to encompass tumour, whilst excluding areas of benign prostatic hyper-
plasia and venous plexus. Data analysis was performed using a 2-compartment phar-
macokinetic model. Maximum EI was obtained empirically. Gleason grade (GG),
prostate specific antigen (PSA) level and radionuclide bone scanning were obtained
2–5 weeks prior to MRI. 
Results PSA values ranged from 0.6–292 ng/ml (mean 42) and GG from 2–10
(mean 6). Strong correlations were obtained between T-stage and both GG and PSA
(P < 0.000 and 0.002) and between tumour diameter/ volume and GG and PSA (P <
0.000 & 0.002; 0.028 & 0.037 respectively). No significant correlations were demon-
strated between GG, PSA or T-staging and MR parameters of angiogenesis. Moderate
correlations were obtained between maximum tumour diameter and EI and DV 
(P = 0.05 and 0.03 respectively) for patients with no bone metastases, but no correla-
tion found for those with bone metastases. 
Conclusions Strong correlations have been demonstrated between MR-defined
tumour size, T-stage, GG and PSA at presentation, but MR-defined parameters of
neoangiogenesis do not appear to be useful determinants of future potential for
progressive disease. 
P225
MONITORING CHEMOTHERAPY IN BREAST CANCER
USING QUANTITATIVE MR IMAGING DJ Manton1, D Tozer1, A
Maraveyas1, A Chaturvedi2, J Greenman1, L Cawkwell1, A Hubbard3, 
A Modi4, M Lind1, & LW Turnbull1, 1Faculty of Health, University of Hull, East
Riding Campus, Willerby, HU10 6NS;2Oncology Dept., Princess Royal
Hospital, Salthouse Rd., Hull, HU8 9HE, 3Breast Screening Unit, Castle Hill
Hospital, Castle Rd., Cottingham, HU16 5JQ,4Consultant breast surgeon,
Castle Hill Hospital, Castle Rd., Cottingham, HU16 5JQ 
Change in tumour volume may be a relatively late manifestation of response to
chemotherapy in patients with inoperable primary breast cancer. Recent studies1,2
have suggested that using MRI to quantify water apparent diffusion coefficient (ADC)
or microvessel permeability, or alternatively using proton MR spectroscopy (MRS) to
quantify the relative water and fat signal magnitudes may be able to provide an early
indication of ultimate treatment response. Therefore a study was designed to compare
the reliability of these three methods in women undergoing neoadjuvant chemo-
therapy for inoperable breast cancer. 
Five women have so far been recruited into the study who have fully completed
their course of treatment. All women received a standard dosage chemotherapy
regime involving intravenous administration of 5-Fluorouracil, Epirubicin and
Cyclophosphamide. MRI and MRS was carried out prior to chemotherapy, between
the second and third courses (TP2) and shortly after the final (fourth) course. ADC
was measured using an EPI sequence producing eight images with diffusion gradient
weightings up to 680 s/mm2. Microvessel permeability was measured using a 7.5
minute long T1-weighted fast spoiled gradient echo (FSPGR) sequence (temporal
resolution of 13 s) combined with a 3 compartment pharmacokinetic model. The
proportion of MRS signal arising from water (i.e. PW = water / {water+ fat}) was
measured using a single voxel STEAM sequence (TE 135 ms) combined with phase
encoding to give seven 0.25 ml voxels in a column through each tumour. Tumour
volume was measured using manually traced regions of interest drawn on high resolu-
tion 3D, post-contrast, fat-suppressed FSPGR images. 
Preliminary results demonstrated that all 5 tumours responded (median final:base-
line volume ratio = 12%; range = 5% to 32%). Both the TP2:baseline volume ratio
(44%; 9% to 64%) and the corresponding permeability ratio (25%; 5% to 56%) accu-
rately predicted response (by being less than 100%) in all 5 cases. The corresponding
ADC (115%; 49% to 147%) and PW (97%; 89% to 110%) ratios predicted response
(by being > 100% and < 100% respectively) in only 3/5 and 4/5 cases suggesting that
they may be less reliable indicators of final treatment efficacy. 
1. M Zhao, et al (1996) Br. J. Cancer 73: 61 
2. N Tsuboi, et al (1999) Oncology Reports 6: 727 
3. NR Jagannathan, et al. (1998) NMR in Biomedicine 11: 414 
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THE ROLE OF FDG WHOLE BODY POSITRON EMISSION
TOMOGRAPHY IN METASTATIC CARCINOMA OF
UNKNOWN PRIMARY SITE M Osborne, A Makris, PJ Hoskin, J Lowe, 
J Emmott, WL Wong, Mount Vernon Hospital, Northwood HA6 2RN, UK 
Aim 5–6% of new cancer cases present as cancer of unknown primary site. They
represent a heterogeneous group of tumours, often requiring extensive investigation.
The subgroup of patients presenting with extracervical metastases tend to have a
worse prognosis and whole body imaging with a non-invasive modality in this group
is appealing. The aim of this study was to evaluate the role of FDG PET in estab-
lishing a primary tumour in this group and assess its influence on their management. 
Patients and Methods 25 patients (13 male, 12 female), mean age 58 years
(range 35–86), with histologically (17) or cytologically (8) confirmed metastatic
carcinoma were imaged with whole body PET following conventional work up which
failed to reveal the primary origin. Sites of presenting metastases were liver (8
patients), bone (5), nodes (4), ascites (2), and mediastinum, scalp, brain, pelvis, chest
wall, abdominal wall (1 each). Investigations prior to PET scanning included CT scan-
ning in all cases and mammography, endoscopy, MRI, serum tumour markers and
immunohistochemistry according to clinical suspicion of primary tumour site. Whole
body scan was performed at one-hour post injection of 350MBq of FDG. 
Results In all cases the known sites of metastases were confirmed on PET and in
68% patients other metastatic sites were also identified. 14/25 (56%) PET scans
suggested a possible primary site – lung (4), pancreas (3), breast (1), renal (1), oesoph-
agus (1), caecum (1), colon (2), stomach (1). Of these, 1 primary was subsequently
confirmed. In one case a primary not visible on the original PET scan was subse-
quently identified and confirmed on biopsy in the pancreas. 9/25 (36%) PET scans
had some influence on management-8/25 (32%) supported planned treatment, but
only 1/25 (4%) actually altered planned treatment. 
Conclusion In this group of patients with metastatic carcinoma of unknown
primary origin PET identified the known metastases in all cases. Although a possible
primary was suggested in 56%, this could not be confirmed in the majority of cases.
The influence on patient management was limited. Poster presentations 91
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COBALT COMPLEXES WITH A TETRADENTATE SCHIFF 
BASE AS PERSPECTIVE ANTICANCER AGENTS 
S Osinsky1, I Levitin2, L Bubnovskaya1, A Sigan2 and I Ganusevich1, 1Inst.
exp. Pathol. Oncol., Kiev-03022, Ukraine, 2Inst. Organoelement Compounds,
Moscow, Russia 
Aims examination of antitumor activity of Co(III) complexes with both a tetradentate
Schiff base and a few native nitrogenous ligands in experiments in vivo. 
Introduction It is known that biogeneous ligands (amino acids, nucleic bases, etc.)
may substantially enhance or modify physiological activity of metal complexes. We
have been studying the influence of extra biogeneous ligands and their close synthetic
analogs on the anticancer activity of Co(III) chelates with tetradentate Schiff bases. A
moderate anitumor effect of parent compounds lacking such extra ligands was reported
earlier (Dori & Gershon, US-Patent, Pat. No5258403; Date of Pat. Nov. 2, 1993). 
Materials & Method Novel complexes of the common formula [Co(acac2en)L2]X
(1) where acac2en, L and X are (i) dianion residue of the Schiff base from acethylacetone
and ethylenediamine, (ii) nicotinamide (nic), isonicotinamide (i-nic), or histidine, and
(iii) counter-ion, respectively were synthesized and thoroughly characterized. Such
complexes may be reversibly reduced under hypoxia, giving rise to a catalytic autooxi-
dation process involving generation of reactive oxygen species (ROS). The biomedical
examinations were carried out using both rat (Guerin carcinoma) and mice [Lewis lung
carcinoma (3LL), melanoma B16, adenocarcinoma Ca755] tumors, and 1a (NH3), 
1b (nic) and 1c (i-nic) complexes. Level of lipid peroxidation and activity of glutathione
system was estimated by biochemical techniques. 31P NMR spectra of tissue perchloric
extracts were obtained using a Mercury 300 BB Varian spectrometer. All experiments
has been approved by the regional animal ethics committee. 
Results The inhibition of primary tumor growth ranged from 50 to 80%. Anticancer
effects generally increased along the series 1a < 1c < 1b. 1b and 1c displayed very high
antimetastatic effect. Namely, inhibition of metastases (IM) by their number (n) and
volume (v) was as follows: in the case of 3LL, IM was 67, 84 and 84% (n), and 80, 99
and 95% (v), and in the case of B16, 75, 71 and 65% (n) and 76, 99 and 85% (v) on
treatment with 1a, 1b and 1c, respectively. Malonyldialdehyde concentration rose by a
factor of 3.5 in tumor after 1b injection, while the increase in liver and kidney was only
1.2- and 2-fold, respectively. Activity of glutathione system decreased by a factor of 2 in
tumor without significant changes in normal tissues. It was also shown that 1b selectively
and significantly decreased the bioenergetic status of the tumor. 
Conclusions (1) selective effects of the complexes on lipid peroxidation and
bioenergetic status of tumor support our assumption that they are reduced in tumors
containing significant hypoxic regions, which leads to formation of ROS; (2) tested
complexes can be regarded as prospective selective anticancer agents; (3) anti-
metastatic activity of complexes may be also explained by complexes affecting factors 
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controlling metastases, in particular matrix mettaloproteinases and some other ones
associated with the tumor microphysiology which is modifyied by complexes as
shown earlier. 
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17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN (17-AAG)
DECREASES NPM-ALK STEADY-STATE AND PERTURBS
NPM-ALK-DEPENDENT TYROSINE PHOSPHORYLATION BY INHIBITING
NPM-ALK/HSP90 COMPLEX P Bonvini, T Gastaldi & A Rosolen. Clinica di
Oncologia Pediatrica, Azienda Ospedaliera di Padova, Padova, 35128, Italy 
Anaplastic Large Cell Lymphoma (ALCL) represent a well recognized subgroup of
non-Hodgkin Lymphomas, characterized by the expression of the membrane receptor
Ki-1/CD30, a member of the tumor necrosis factor (TNF) ligand family. About 40 to
50% of ALCLs posses a specific chromosomal translocation, t(2;5)(p23;q35), that
fuses the N-terminal portion of the NPM (or nucleophosmin) gene to the C-terminal
portion of the ALK (Anaplastic Lymphoma Kinase) gene, a novel orphan receptor of
the insulin tyrosine kinase receptor subfamily. This translocation originates the
soluble chimeric protein NPM-ALK, or p80, localized both in the nucleus and in the
cytoplasm. NPM-ALK shows a constitutive tyrosine kinase activity, which can
induce malignant transformation both in vitro and in vivo. However, little is known
about the NPM-ALK transduction pathway. In this study, we analyzed the stability
and tyrosine phosphorylation state of NPM-ALK, as well as NPM-ALK-dependent
tyrosine phosphorylation, in ALCL cell lines treated with the novel hsp90 antagonist 17-
AAG. We found that 17-AAG causes NPM-ALK depletion in a dose-and time-depen-
dent manner, but it does not affect the steady-state level of the NPM-ALK-associated
proteins Shc, IRS-1, Grb2 or PLCgl. Exposure to 0.5 mM 17-AAG for 24 hours,
decreases NPM-ALK steady-state level up to 10–15% of the control level, both in the
cytosolic and nuclear compartment, and the protein becomes undetectable with longer
exposure to the drug. Furthermore, 17-AAG stimulates NPM-ALK tyrosine dephospho-
rylation and inhibits NPM-ALK-dependent Shc and PLCg1 phosphorylation, by
inducing loss of NPM-ALK/Shc or NPM-ALK/PLCg1 association. Interestingly,
time-course experiments have shown that the tyrosine phosphorylation level of NPM-
ALK declines more rapidly than its total amount, suggesting that NPM-ALK regula-
tion occurs at a postranscriptional level. To further confirm that 17-AAG specifically
causes NPM-ALK destabilization, we found that NPM-ALK associates with the
molecular chaperone hsp90, and 17-AAG treatment completely down-regulates
NPM-ALK/hsp90 complex, as shown by co-immunoprecipitation experiments.
Finally, we found that NPM-ALK complexes with the co-chaperone hsc70 as well.
However, differently from the NPM-ALK/hsp90 association, the level of hsc70-asso-
ciated NPM-ALK increases markedly right after 4 hours of AAG treatment,
suggesting an hsc70 involvement in NPM-ALK degradation Thus, our findings
reveals NPM-ALK as a novel hsp90 client protein and underline the role of this
benzoquinone anasamycin in regulating NPM-ALK activity. 
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COMPARISON OF THE PLASMA PHARMACOKINETICS OF
17-ALLYLAMINO-17-DEMETHOXYGELDAMYCIN
ANALOGUES FOLLOWING CASSETTE AND SINGLE DOSING NF Smith,
FL Raynaud, PM Goddard and P Workman, CRC Centre for Cancer
Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Sutton,
Surrey, SM2 5NG, UK 
17AAG is a benzoquinone ansamycin which binds to and inhibits the molecular
chaperone heat shock protein 90, leading to depletion of several oncogenic proteins.
Phase I clinical trials of 17AAG as an anticancer agent are currently ongoing. In vitro
studies have shown that the growth inhibition properties of 17AAG depend upon
length of exposure. The aim of this study was to evaluate cassette dosing, the admin-
istration of several compounds as a mixture to a single animal, in a series of deriva-
tives of 17AAG by comparing the pharmacokinetic parameters of the same
compounds dosed both alone and in combination. 17AAG and four structural
analogues differing at positions 11, 17 and 19 of the ansamycin ring (NSC 255110;
NSC D682300; NSC D683661; NSC D683663) were administered intravenously to
Balb C- mice as single agents at the maximum tolerated doses and at 5 mg/kg, and as
a mixture at 5 mg/kg each. Plasma concentrations were determined by HPLC-MS/MS
with multiple reaction monitoring. Pharmacokinetic parameters were evaluated by
non-compartmental analysis. 17AAG displayed non-linear pharmacokinetics, with the
area under curve (AUC) increasing from 1.2 to 33.1 hr*nmol/mL with a 10-fold
increase in dose from 5 to 50 mg/kg. The AUCs were up to 5-fold higher following
cassette administration compared to single administration for 17AAG, NSC 255110
and NSC D683661. When administered in combination, none of the analogues
displayed a higher AUC than 17AAG (4.9 hr*nmol/mL). However, following admin-
istration at the maximum tolerated doses NSC D683663 displayed the highest AUC
(44.6 hr*mmol/mL) of the five compounds. The half life and AUC of NSC D683663
were 10-fold higher following single dosing compared to cassette dosing. With the
exception of NSC D683663, the ranking of four of the compounds from highest to
lowest AUC remained similar whether they were given alone at the maximum toler-
ated doses or in combination as a cassette (17AAG > NSC 255110 > NSC D683661 >
NSC D682300). The observed differences between cassette and single dosing could
be due to non-linear pharmacokinetics and/or drug-drug interaction. These issues will
be investigated in further studies. In conclusion, cassette dosing has a number of
advantages for use in drug development, ie. it increases sample throughput whilst
reducing animal usage, but is probably unsuitable for this compound series. 
This work was supported by the Cancer Research Campaign 92 Poster presentations
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SYNTHESIS OF MOLECULAR TWIST COMPOUNDS AND
EVALUATION OF THEIR INTERACTIONS WITH HIGHER-
ORDER DNA STRUCTURES PM Murphy1, TC Jenkins2, RT Wheelhouse1,
1School of Pharmacy and 2YCR Laboratory of Drug Design, University of
Bradford, BRADFORD, BD7 1DP, UK 
Compounds based on un-fused polyaromatic ring systems (e.g. 1) have been shown to
intercalate double stranded DNA. Normally bi-phenyl ring systems cannot adopt a
planar conformation; however, when N was substituted for methine in the central ring,
the diphenylpyrimidine, 1, was found to be able to overcome the small steric interac-
tions involved to become planar when an external stacking constraint (crystal packing
or DNA intercalation) was applied.1 The threading distance of the intercalator, esti-
mated from a model built using the crystal structure to be 13.2 Å, is comparable with
ethidium, anthraquinones and porphyrins, and is therefore predicted to be a closer
match to the larger cross-sections of triplex and tetraplex DNAs than to duplex DNA.
Tetraplex structures formed in G-rich DNA by guanine tetrads have been shown to be
important in the regulation of cellular replication, whilst triplex DNA formation has
been postulated as a specific means to target and thereby inhibit gene expression. 
A novel and versatile synthesis utilising a Suzuki coupling reaction has been
developed to prepare this class of compounds in greatly improved yields (Scheme).
Investigations of their binding interactions with several DNA types will be reported.
Structural preferences for DNA binding have been established using equilibrium
competition dialysis; binding stoichiometries and thermodynamic parameters have
been determined using isothermal titration calorimetry and UV spectrophotometry.
These data have been used to inform molecular modelling of the complexes between
the ligands and duplex, triplex and tetraplex DNA which may be used as the basis for
the design of potential drug compounds to target higher-order DNA structures. 
1. W.D Wilson, et al, (1988) J. Am. Chem. Soc. 110, 8292. 
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DESIGN OF NEW TOPOISOMERASE I INHIBITORS:
SYNTHESIS AND IN VITRO ACTIVITY. DJ Minchera, G Kaya,
S Petterssona, A Turnbulla and MC Bibbyb, aSchool of Life Sciences, Napier
University, Edinburgh, EH10 5DT, UK, bCancer Research Unit, University of
Bradford, Bradford BD7 1DP, UK 
We have shown that anthraquinone-amino acid conjugates afford a library of novel
topoisomerase inhibitors with broad spectrum anti-tumour activity both in vitro and in
vivo. [D.J. Mincher, G. Kay, J.E.L. McDonald, A. Turnbull, M.C. Bibby, J.A. Double,
(2000), Clin. Cancer Res., 6, 11:70]. The type and conformation of a spacer group
separating the anthraquinone chromophore from the amino acid/peptide motif modu-
lates relative inhibition of topo I versus the individual a and b isoforms of topo II. We
now demonstrate that topo I-selective agents can be produced by insertion of confor-
mationally rigid 1,4-diaminocyclohexane or piperizinyl spacer groups. In common
with the comparator compound, camptothecin, an L-phenylalanine conjugate and its
2- and 4- chloro derivatives constrained by rigid spacer groups, failed to inhibit topo I
mediated relaxation at concentrations up to 100 mM. Like camptothecin these conju-
gates stabilised topo I cleavable complexes resulting in 40–50% nicked pBR322
plasmid DNA in vitro. The conjugates were actively cytotoxic towards the refractory
MAC15A tumour cell line with IC50 values of 3.5, 3.0 and 1.0 mM respectively
(camptothecin 1.7 mM). Molecular modeling studies show that the novel conju-
gates can mimic the angular structure of camptothecin and account for the reduced
DNA-binding affinity compared to conformationally unrestrained analogues
possessing identical peptide motifs. 
Evidence for the involvement of drug-stabilised topo I cleavable complexes in the
mechanism of cell kill by the conjugates is given by the observed immunoband deple-
tion of topo I in human HL60 cells. For example, the extent of immunoband depletion
by the L-phe conjugate at 100 mM was comparable to that observed for camptothecin
at 50 mM. 
The conjugates constitute a new structural class of topo I inhibitor and exhibit
mechanisms of inhibition analogous to the structurally labile camptothecins and merit
further pre-clinical evaluation. 
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IN VITRO AND IN VIVO-ACTIVE ANTHRAQUINONE
PEPTIDE CONJUGATES: A PUTATIVE PHARMACOPHORE
FOR COLON TUMOUR SPECIFICITY S Petterssona, A Turnbulla, G Kaya,
MC Bibbyb JA Doubleb and DJ Minchera*. aSchool of Life Sciences, Napier
University, Edinburgh, EH10 5DT, UK. bCancer Research Unit, University of
Bradford, Bradford BD7 1DP, UK 
The novel anthraquinonyl L-proline conjugate NU:UK 31, active against the refrac-
tory murine MAC15A adenocarcinoma of the colon in vivo [S. Jackson, J.A. Double,
D.J. Mincher, A. Turnbull, M.C. Bibby, (2000), Clin. Cancer Res., 6, 11:93] has been
shown to inhibit both DNA topoisomerase I and topoisomerase II (a and b isoforms).
This dual inhibitory activity may permit circumvention of resistance mechanisms
arising from altered expression of an individual enzyme. We now report that
analogues of NU:UB 31 have been synthesised and evaluated against a broad panel of
human colon cancer cell lines in an attempt to define the structural requirements for
aliphatic hydrophobic a-side chains including Val, D-Val, Leu and the non-proteino-
genic amino acids Abu and Cha that show high sensitivity to all cell lines in the colon
sub-panel of the NCI 60 cell line screen as measured by GI50, TGI and LC50 parame-
ters. The pattern of sensitivity/resistance for these conjugates is in stark contrast to
those of the established topo II inhibitors, doxorubicin, mitoxantrone and etoposide or
the topo I inhibitor camptothecin. Colon selectivity is optimum when a three carbon or
four carbon spacer moiety separates the peptide motif from the anthraquinone; colon
selectivity is clearly abolished if the hydrophobic side chain is substituted by a polar
group. Extending the length of the contiguous peptide motif to a tripeptide addition-
ally confers colon resistance. Cyclic hydrophobic residues, notably proline and cyclo-
hexylalanine (Cha) show the greatest colon selectivity. We now show that the
proposed putative pharmacophore for colon selectivity also modulates the ability of
the conjugates to circumvent resistance mechanisms in a panel of human and animal
cell lines of well defined topoisomerase status. Evidence for the involvement of drug
stablised topoisomerase cleavable complex formation in intact cells by L-Pro and 
L-Cha conjugates is given by immunoband depletion experiments in human HCT116
colon cells and is correlated to increased expression of p21. 
A putative pharmacophore for colon selectivity in vitro is thus proposed for this
atypical class of novel dual topoisomerase inhibitor and merits validation in vivo. 
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USE OF A NOVEL DNA MICROARRAY APPROACH TO
IDENTIFY THE LOCUS OF ACTION OF A CLASS OF
QUINAZOLINE-BASED ANTI-TUMOUR AGENTS B Allan1, LA Skelton1, 
JP Clark2, F Yafai1, S Edwards2, CS Cooper2, AL Jackman12, 1CRC Centre for
Cancer Therapeutics and 2Molecular Carcinogenesis, The Institute of Cancer
Research, Sutton, Surrey SM2 5NG 
A compound development programme serendipitiously identified a class of highly
potent (growth inhibitory IC50 ~ 1nM) quinazoline-based analogues of folic acid with
an unknown mechanism of action. They induce a delayed, non-phase specific cell-
cycle arrest and are COMPARE negative in the NCI anti-tumour cell line screen. An
~300 fold resistant cell line (W1L2:R865) was raised by stepwise selection with one
analogue, CB30865. This cell line is cross-resistant to all analogues in the class but
not to other known anti-tumour agents. In an attempt to identify the in vitro target a
novel DNA microarray approach was employed. 
A cDNA library of ~7000 clones was generated with RNA from the W1L2:R865
line and used to produce microarray slides. These were probed with differentially
labelled reverse-transcribed RNA extracted from W1L2:R865 cells and the parent line
W1L2 cells. 26 distinct cDNAs were identified as over-expressed by a factor of three
or more in the resistant cell line. Sequencing and BLAST database analysis of these
clones revealed 50% map to chromosome 7, previously found by CGH to contain a
large amplicon. Eight of the cDNAs from chromosome 7 represent known genes and
the rest are of unknown function. Of particular interest are 9 genes (6 known, 3
unknown) located in 7q22, the region of maximum amplification. 
Microarray amplification was confirmed by northern blot analysis of RNA from a
panel of W1L2-derived cell lines with varying resistance levels to CB30865 or one of
its more water soluble analogues. Primary candidates for further investigation were
selected based on appropriate variation in the expression. There are six genes on the
primary candidate list, four of which are from chromosome 7q22 and as such have
been prioritised for further investigation. Preparations are underway to transfect these
genes into the susceptible parent cell line in an attempt to confer resistance. 
Tandem investigative approaches were also employed based on the microarray
results. One gene identified is a component of the 26S proteasome, the multi-catalytic
protease responsible for ~85% of all non-lysosomal protein degradation in cells,
including many key cell cycle regulatory proteins. The W1L2:R865 cell line was
shown to exhibit a low level of cross-resistance to the proteasome inhibitor,
Lovastatin pro-drug. Furthermore, example compounds from the quinazoline series
were shown to this is the growth rate limiting locus for these compounds. 
Sponsored by the Cancer Research Campaign. 
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THE SINGLE LXXLL MOTIF IN TIP60 MEDIATES
INTERACTION WITH CLASS I NUCLEAR HORMONE
RECEPTORS L Gaughan, ME Brady, DE Neal and CN Robson, Prostate
Research Group, School of Surgical Sciences, University of Newcastle upon
Tyne, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH 
The androgen receptor (AR), a member of the nuclear hormone receptor superfamily,
plays a prominent role in prostate development and malignant transformation of
prostate cells. Upon binding to androgen, the androgen receptor functions as a tran-
scription factor, enhancing expression of target genes. A pre-requisite for nuclear
hormone receptor activity is the binding of co-activator molecules to the activation
function-2 (AF-2) domain of the receptor. The LXXLL motif/ NR-box, contained
within a number of co-activator molecules, mediates the protein-protein interaction
with nuclear hormone receptors. 
We have previously demonstrated that Tip60 (Tat-interactive  protein-60kDa)
enhances the transcriptional activity of the AR in LnCaP cells in a hormone-dependent
manner. Tip60 contains one NR-box at its extreme C-terminus, which we hypothesised
to mediate the interaction with the AR. 
We show that interaction between the AR and Tip60 is hormone-dependent and
requires the single NR-box of Tip60. Removal of the C-terminal fragment of Tip60,
containing the LXXLL motif, abolishes AR-binding. We demonstrate that substitution
of individual leucine residues of the LXXLL motif prevent AR interaction and also
abolishes Tip60-mediated enhancement of AR activity, suggesting that inhibiting the
formation of the Tip60-AR complex may be a possible target for reducing AR activity
in the physiological context. We also demonstrate that Tip60 interacts in a hormone-
dependent manner with AR, estrogen receptor-a, estrogen receptor-b and glucocorti-
coid receptor, but fails to bind to thyroid hormone receptor, vitamin-D receptor and
retinoid-x-receptor implying that Tip60 may be principally involved in regulating
class I nuclear hormone receptors, giving an indication as to how specific receptor
activation can be achieved. 
P235
INFLUENCE OF RETINOID ISOMERISATION ON THE
CELLULAR ACTIVITY OF 13-CIS RETINOIC ACID IN
NEUROBLASTOMA GJ Veal1, J Errington1, CPF Redfern2, ADJ Pearson3
and AV Boddy1. 1Cancer Research Unit and Departments of 2Medicine and
3Child Health, University of Newcastle upon Tyne, Newcastle upon Tyne NE2
4HH 
Retinoids can inhibit cell proliferation and induce differentiation and apoptosis in
many cell types during normal development as well as in cancer cells propagated in
tissue culture. Two of the most clinically useful retinoids in oncology are 13-cis
retinoic acid (13-cis RA) and all-trans retinoic acid (ATRA). These isomers exhibit
contrasting efficacy, toxicity and pharmacokinetics in clinical studies and have both
been used in clinical trials for the treatment of neuroblastoma (NB). Recently
published data have shown a significant clinical benefit of 13-cis RA in high-risk NB
patients. Experiments were carried out to determine the extent of extra-and intracel-
lular isomerisation of 13-cis RA and all-trans retinoic acid (ATRA) in neuroblastoma
cell lines and to investigate the influence of isomerisation on the growth inhibitory
effects of 13-cis RA and ATRA and on the regulation of expression of CRABP II and
RAR-b, commonly used markers of retinoid activity. 
We have quantified extra- and intracellular levels of RA isomers after incubation
of a panel of NB cell lines with 13-cis RA or ATRA (10 mM) in vitro. Limited isomeri-
sation of 13-cis RA or ATRA was observed in the extracellular medium, with less than
20% conversion measured over a 72 h period after retinoid incubation. By contrast,
intracellular levels of ATRA determined over a 72 h period after incubation with 13-cis
RA, accounted for up to 45% of the total intracellular retinoids and levels of ATRA
actually exceeded those of 13-cis RA at 48 and 72 h in IMR32 cells, despite extracel-
lular levels of 13-cis RA being 4-fold greater than those of ATRA. Comparable levels
of intracellular isomerisation were not observed after ATRA incubations. Parallel cyto-
toxicity studies showed no differences in the sensitivity of three N-type NB cell lines to
either 13-cis RA (IC50: 11.2–13.9 mM) or ATRA (IC50:12.9–14.4mM), despite signifi-
cant differences in intracellular retinoid levels. However, a significant decrease in
sensitivity to 13-cis RA (IC50 = 137 mM), as compared to ATRA (IC50 = 41 mM), was
observed in the S-type cell line SH-S-EP. RAR-b was induced in a dose-dependent
manner in SH SY 5Y cells with ATRA resulted in a greater induction of CRABP II
than incubation with 13-cis RA. These results indicate either an intracellular conver-
sion of 13-cis RA to ATRA or a selective uptake of ATRA in neuroblastoma cells and
suggest that this may mediate the differential activity of 13-cis RA in neuroblastoma
cell subtypes. 
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THE ROLE OF b3-ADRENERGIC RECEPTORS IN CANCER 
CACHEXIA ST Russell1, K Hirai2 and MJ Tidale1,
1Pharmaceutical Sciences Research Institute, Aston University, Birmingham,
B4 7ET, 2Department of Obstetrics and Gynaecology, Osaka City University
Medical School, Osaka 545–8585, Japan 
A major contributor to the weight loss observed in cancer cachexia is the production
of alipid mobilizing factor (LMF) a 43KDa glycoprotein, which has been shown to be
excreted in the urine of cachectic cancer patients and induce lipolysis in isolated
murine adipocytes membranes. This lipolytic activity was attenuated by low concen-
trations (10–9–10–7M) of the specific b3-adrenoceptor (b3-AR) antagonist SR59230A.
LMF (250nM) was shown to produce comparable increases in intracellular cyclic
AMP in CHOK1 cells transfected with the human b3-AR to that obtained with isopre-
naline (1 nM). Also non-linear regression analysis of the binding of LMF to the b3-AR
showed a high affinity binding site with a Kd value 78 ± 45 nM and a Bmax value
(282±1 fmole mg protein–1) comparable with other b3-AR agonists. These results
suggest that LMF induces lipolysis through the b3-AR. LMF does not only induce
lipolysis in white adipose tissue, but also causes the up regulation of uncoupling
proteins-1 and -2 in brown adipose tissue, which have been shown to be induced by
b3-AR agonists. This suggests that LMF possibly plays a role in the increased energy
expenditure in cachectic cancer patients. 
P237
A COMPARISON OF THE EFFECTS OF THE ANTI-TUMOUR 
AND ANTI-CACHECTIC AGENT EICOSAPENTAENOIC ACID
IN CANCER CACHEXIA AND ACUTE STARVATION. AS Whitehouse and
MJ Tisdale, Pharmaceutical Sciences Research Institute, Aston University,
Birmingham, B4 7ET, United Kingdom
Cancer cachexia is the major cause of death in cancer patients. Muscle wasting is
associated with an upregulation of the ubiquitin-proteasome system in skeletal
muscle, as occurs in acute starvation The polyunsaturated fatty acid Eicosapentaenoic
Acid (EPA) is effective in attenuating the increased protein degradation seen 
in skeletal muscle during cancer cachexia, possibly by inhibiting formation of 
15-hydroxyeicosatetraenoic acid (15-HETE). To determine if similar pathways are
involved in different catabolic conditions, the effect of EPA on muscle protein degra-
dation and activation of the ubiquitin-proteasome pathway has been examined during
cancer cachexia and acute fasting in mice. 
Daily oral administration of EPA (2.5 g/kg) to animals bearing an experimental model
of cachexia (MAC16 colon adenocarcinoma) inhibited weight loss (P = 0.0016), tumour
growth (P = 0.0056) and proteolysis in muscle. This was correlated to a preservation of
myosin (P = 0.0029), inhibition of both the ‘chymotrypsin like’ proteasome activity and
expression of several proteasomal subunits including 20s (P = 0.0001), 19s(P = 0.0099)
and P42 (P = 0.001), but not the ubiquitin conjugating enzyme-E214k (P = 0.4313). 
When non-tumour bearing, fasted animals receiving either nothing, vehicle (olive
oil) or EPA (2.5 g/kg) were compared to non-tumour bearing non fasted controls,
there was a significant reduction in total muscle breakdown as measured by tyrosine
release in the soleus muscle of mice treated with EPA compared with the other two
starvation groups (P > 0.02 from control). The predominant proteolytic (chymotrypsin-
like) activity of the b-subunits of the proteasome was elevated in gastrocnemius
muscles of fasted animals with or without olive oil, but was completely attenuated in
animals pretreated with EPA. Proteasome subunit expression was determined in
gastrocnemius muscle by Western blotting using MCP231 antibody, which detected
three a-type subunits of the 20S proteasome. There was an increase in expression of
all three subunits in starved non-treated and vehicle treated controls, but proteasome
expression was reduced down to that of non-fasted animals in starved animals pre-
treated with EPA. A similar effect was observed with anti-MSSI directed to the 19S
cap of the proteasome, and P42 an ATPase subunit of the 19S regulator. However
again, there was no change in expression of the ubiquitin-conjugating enzyme E214k
These results suggest that protein catabolism in cancer cachexia and starvation is
mediated by a common pathway which is inhibited by EPA. That EPA is an effective
anti-tumour and anti-cachectic agent has been shown. However these results further
suggest that EPA may also be effective in the attenuation of protein catabolism in
other catabolic conditions. 94 Poster presentations
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PHASE I STUDY OF THE L-STEREOISOMER NUCLEOSIDE 
ANALOGUE TROXACITABINE JS de Bono, SD Baker, 
J Stephenson Jnr, C Simmons, A Goetz, L Prouix, J Jolivet, M Hidalgo, 
DD Von Hoff, and EK Rowinsky, Institute For Drug Development, University
of Texas at San Antonio, BioChem Pharma Inc. Laval (Quebec), Canada
Purpose To investigate the safety, toxicity profile, pharmacokinetics and activity of
troxacitabine (BCH-4556), a unique L-stereoisomeric nucleoside analogue that is not
a candidate for the nucleoside catabolic enzyme deoxycytidine deaminase, on a 30
minute infusion daily for five days schedule, and to recommend a dose for subsequent
disease-directed studies in both minimally pretreated (MP) and heavily pretreated
(HP) patients with advanced solid malignancies. 
Patients and methods Troxacitabine was administered by the most active preclinical
schedule, daily for 5 consecutive days as a 30 minute intravenous (IV) infusion every 3–4
weeks. The starting dose was 0.12 mg/m2. Dose escalation with each consecutive cohort
to 0.24, 0.48, 0.72 and 0.96 mg/m2 was undertaken. Further dose escalation was under-
taken to 1.2 and 1.5 mg/m2 for HP patients and to 1.5 and 1.8 mg/m2 for MP patients.
Troxacitabine concentrations were analysed and pertinent pharmacokinetic (PK) parame-
ters were related to the principal toxicities in pharmacodynamic (PD) analyses. 
Results 39 patients received 123 courses of troxacitabine. Neutropenia and dermato-
logic toxicity characterised by pruritic, erythematous and generalised maculopapular-
rashes precluded dose escalation above 1.8 mg/m2. There was an unacceptably high 
incidence of cumulative severe myelosuppression at troxacitabine doses exceeding 
1.5 mg/m2in HP patients and 1.8 mg/m2in MP patients. Palmoplantar erythrodysesthesia,
distinct from the maculopapular rash, was observed in 4 patients. The PK behaviour of
troxacitabine was linear over the dose range tested. On day 1, the disposition of troxac-
itabine was characterized by mean (SD) values for Vss and Cls of 60 (32) L and 161 (33)
mL/min, respectively. Following the fifth day of treatment, the mean (SD) t1/2 value was
39 (63) hours and Cls was reduced by approximately 20% with a mean (SD) value of 
127 (27) mL/min. For all dose levels combined, the mean (SD) accumulation ratio was
1.29 (0.29). A mean of 50% and 61% of the administered troxacitabine dose was excreted
as unchanged drug in the urine during the first 24 hours following treatment on days 1 and
5, respectively. An additional 16% of troxacitabine was excreted between 24 to 48 hours
after administration of the fifth dose. A significant and linear correlation was observed
between estimated creatinine clearance and troxacitabine systemic clearance on day 1 
(R2 = 0.318, P = 0.0002) and day 5 (R2 = 0.3017, P = 0.0003). More severe myelosup-
pression and dermatologic toxicities were associated with higher troxacitabine exposure.
One partial remission was observed in a patient with metastatic choroidal melanoma. 
Conclusion Troxacitabine can be safely administered using this schedule.
Combination and phase II studies to evaluate this unique L-stereoisomeric nucleo-
side’s anti-tumor efficacy have been initiated. 
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PHASE I CLINICAL AND PHARMACOKINETIC TRIAL OF 
VINFLUNINE: A NOVEL FLUORINATED VINCA ALKALOID
GIVEN ON DAY 1 EVERY 21 DAYS. P Fumoleau1; J Bennouna1, 
J-P Armand2, G Blanchot3, F-M Delgado3, and M Marty4,1, René Gauducheau
Cancer Centre (Nantes-F)2; Institut Gustave Roussy (Villejuif-F), 3Pierre
Fabre Medicament (Boulogne-F), 4St Louis Hospital (Paris-F)
Vinflunine (VFL), is a novel vinca alkaloid obtained by semi-synthesis using
superacidic chemistry. The most important structural modification is the selective
introduction of two fluorine atoms at the 20¢ position of vinorelbine. In human
tumours xenografts, VFL showed definite antitumour activity (high/moderate) in 64%
(7/11) of xenografts tested versus moderate activity with vinorelbine in 27% (3/11).
This first phase 1 study was performed to determine the toxicity and PK of escalating
doses (accelerated method) of VFL administered intravenously as 10 minute infusion
once every 21 days. Between 12/98 and 03/2000, 31 patients with a variety of cancers
(6 renal carcinoma (ca), 6 colorectal ca, 4 other gastro-intestinal ca, 4 unknown
primary ca, 4 sarcoma, 3 advanced breast ca, 2 gynaecological ca, 2 NSCLC) were
treated at 9 different dose levels from 30 to 400 mg/m2. 3/5 patients experienced dose
limiting toxicity (DLT) at 400 mg / m2 (at cycle 1): 1 patient with grade (G) 4 abdom-
inal pain, 1 patient G3 constipation and 1 transient and reversible G3 heart-failure.
Other G-3–4 non-DLT were: grade 4 neutropenia (3 patients). The maximal tolerated
dose was achieved at 400 mg/m2 every 3 weeks. A new dose level was tested at 
350 mg/m2 in which I heavily pre-treated pt developed febrile neutropenia and sepsis.
At the same level another patient experienced G3 dyspnoea and hypertension 5 days
after the drug administration. 
Pharmacokinetics was available in 30 patients. A dose proportional increase in
VFL AUC was observed. Apparent elimination half life was 25.5 ± 3.9 h. Inter-
individual variability was moderate (< 35%). Pharmacokinetic comparison at different
cycles supported a good reproducibility on blood exposure. Pharmacokinetic-
pharmacodynamic relationship was demonstrated on WBC and neutrophils. Therefore
the recommended dose for further phase II development of VFL is established at 
350 mg/m2 every 3 weeks. VFL is a promising new agent, 3 partial responses were
observed: 2 patients with advanced breast cancer (1 pt with liver involvement) and 
1 pt with renal cell carcinoma. Phase II trials are already ongoing. 
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A PHASE I AND PHARMACOKINETIC STUDY OF 
VINFLUNINE GIVEN ON A WEEKLY SCHEDULE 
J-B Vermorken1, R Stupp2, M-C Pinel3, R Bugat4, J-P Delord4 and P Variol3,
1University Hospital, Antwerpen, Belgium, 2Centre Pluridisciplinaire
d’Oncologie, Lausanne, Switzerland, 3Institute de Recherche Pierre Fabre,
Boulogne-Billancourt, France, 4Institut Claudius Regaud, Toulouse, France
Vinflunine (VFL) is derived from vinorebine (VRL) by novel semi-synthetic technic
which result in the insertion of two fluorine atomes. Pre-clinical activity in human
xenograft models has shown potential for efficacy in a panel of eleven human
tumours. The current phase I study was aimed at determining the tolerability and 
the pharmacokinetics of a weekly dose regimen of VFL. VFL was administered as a
10 minutes infusion every week for at least 4 weeks. 
A pharmacokinetic study of VFL administered on a weekly schedule was under-
taken in 14 previously treated patients (melanoma: 3, mesothelioma: 2, digestive tract
cancer: 3, other tumours: 6). 
The MTD was reached at the entry dose level (190 mg/m2) with 2/3 patients expe-
riencing dose limiting infection (grade 4) or raised transaminases: (grade 3); an initial
reduction to 150 mg/m2 was still associated with dose-limiting toxicity: in 3/5 patients
(neutropenia: grade 4, febrile neutropenia). At 120 mg/m2, 0/6 patients experienced
severe toxicity. One patient (renal cell carcinoma) entered at the second dose level
achieved a minor response. 
Dose proportional increases in blood concentration of VFL and its 3 metabolite peaks
were seen over the range of 120–190 mg/m2. While two of these metabolite 
peaks were eliminated between each weekly administration, P9VFL (4-O-
deacetyl-vinflunine) was measurable at pre-dose sampling and accumulated over
courses. A moderate accumulation was also observed for parent compound. 
In conclusion, the MTD in previously heavily treated patients was 150 mg/m2.
DLT were haematological toxicities. Pharmacokinetic behaviour of parent compound
and the P9VFL active metabolite might contribute to toxicities through its accumulation
on this weekly VFL dose regimen. 
The study is still ongoing in chemonaive patients in order to determine the MTD of
weekly vinflunine in this sub-set of patients. 
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A PHASE I AND PHARMACOKINETIC STUDY OF 
VINFLUNINE GIVEN ON DAYS 1 AND 8 EVERY 3 WEEKS 
P Johnson1, I Judson2, C Ottensmeier1, A O’Donnell2, M-C Pinel3, C. Puozzo3
and P Fumoleau4, 1Cancer Sciences Division, Southampton University
School of Medicine, United-Kingdom, 2Royal Marsden Hospital, Sutton,
United-Kingdom, 3Institute de Recherche Pierre Fabre, Boulogne-Billancourt,
France, 4Centre René Gauducheau, Nantes, France
Vinflunine (VFL) is a novel vinca alkaloïd produced by semi-synthetic insertion of
two fluorine atoms into vinorelbine (VRL); it shows significant evidence of pre-clin-
ical activity in human tumour xenografts. 
A phase I study using treatment on D1+D8 q 3 weeks was conducted in order to
evaluate the tolerability and pharmacokinetics of this dose regimen of Vinflunine. 
A starting dose of 210 mg/m2 was chosen on the basis of the first phase I study of
a 21 day regimen, and previous experience with VRL. Sixteen patients were treated at
dose levels of VFL of 210 mg/m2, 190 mg/m2 and 170 mg/m2. The clinical results 
of treatment in this typical phase I patient population (primary sites: colorectal: 4,
mesothelioma: 3, cervix: 2, sarcoma: 2, melanoma: 2, other tumours: 3) showed that
the MTD was reached with grade 3/4 toxicity in 3/6 patients at the starting dose-level
(210 mg/m2) necessitating two successive dose-reductions. Dose-limiting toxicity
consisted of severe constipation and myalgia, and at the first dose reduction
(190 mg/m2) febrile neutropenia and constipation were recorded. At 170 mg/m2, the
same effects were still seen grade 3/4 in 1 of 6 patients and another patient experi-
enced grade 3 chest pain. 
The pharmacokinetics observed during this study were very similar to those seen
with the 21 day regimen, except for the VFL elimination half-life. With pre-dose
sampling on D8 (i.e. T0 + 168 h from D1) a more accurate half-life of 39 ± 6 h was
obtained. Several peaks of metabolites were observed which were rapidly cleared
except P9VFL, with a half-life estimated between 3 and 8 days. 
In conclusion, DLT were neutropenia, constipation and myalgia. A dose level of
170 mg/m2 D1–D8 may be deliverable, but even at this level there is appreciable toxi-
city, and the D1–D21 schedule may be preferable for phase II trials. Poster presentations 95
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VINORELBINE AND OXALIPLATIN: A NEW SCHEDULE FOR 
MESOTHELIOMA AND OTHER SOLID TUMOURS PC Jeremy
Steele, Jonathan Shamash, Marie T Evans, Maria L Nystrom, Nicole H
Gower, Robin M Rudd, Lung and Mesothelioma Unit, Department of Medical
Oncology, St Bartholomew’s Hospital, London EC1
Introduction The incidence of malignant mesothelioma (MM) is increasing.
Treatment options are limited, though recent data suggest that chemotherapy can
provide effective palliation. We reported a response rate of 24% for vinorelbine 30
mg/m2 weekly (J Clin Oncol 18:3912–17, 2000). Oxaliplatin has not been evaluated in
MM or in combination with vinorelbine in other tumour groups. We conducted a
phase II trial of vinorelbine 30 mg/m2 days 1 and 8 and oxaliplatin 130 mg/m2 on day
1 each 21 days in patients (pts) with MM. The major endpoint was response with
secondary endpoints of toxicity, quality of life and survival. 
Results From November 1999, 26 pts with histologically-proven MM have been
treated. Pt characteristics: male 21 pts, female 5; median age 60 y (range 44–72); 13
epithelioid, 5 sarcomatous, 7 mixed, one pt awaiting subtype review. There were 6
PRs; 17 pts with SD; 3 pts progressed through therapy: response rate = 23% [95% CI
= 9% to 44%]. The median number of cycles delivered = 3 (range 1–6). Grade 3/4
toxicities: neutropenia 18%; phlebitis 12%; malaise 12%; anorexia 12%; nausea and
vomiting 12%; constipation 6%. Median survival has not yet been reached. 
Summary The combination of vinorelbine and oxaliplatin has activity in MM. The
toxicity is greater than that with single-agent vinorelbine. Survival data will indicate
whether this combination is worth evaluating in phase III trials in MM. The doses and
schedule of vinorelbine and oxaliplatin described here appears maximal and could be
tested in other tumour groups. 
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SAFETY PROFILE OF ZD0473 IN PHASE II TRIALS OF 
PATIENTS WITH ADVANCED CANCERS G Hoctin-Boes1, 
J Cosaert1, M Koehler2, M Smith1, 1AstraZeneca, Alderley Park, Cheshire,
UK, 2AstraZeneca, Wilmington, DE, USA
Current platinum anticancer drug development is principally focused on circum-
venting tumour resistance to cisplatin/carboplatin while optimising tolerability.
ZD0473 (cis-amminedichloro [2-methylpyridine] platinum [II]) is a new generation
platinum drug that shows evidence of an extended spectrum of antitumour activity and
overcomes platinum resistance mechanisms. After modification of the starting dose
from 120 mg/m2 to 150 mg/m2, every 3 weeks in the Phase II clinical trial programme,
a dose, safety and efficacy review was performed on 99 patients in 5 Phase II trials.
Patients with a range of tumours were included (previously treated ovarian cancer
[29], NSCLC [29], SCLC [25], or mesothelioma [10], and untreated NSCLC [6]).
Overall, 278 cycles of treatment were given and 28 patients received ³4 cycles.
ZD0473 had a manageable safety profile. Consistent with Phase II data, haemato-
logical toxicity was dose limiting. Grade 3/4 haematological toxicity consisted of:
thrombocytopenia (40% of patients), neutropenia (28%) and anaemia (19%).
Haematological toxicity was generally more frequent and of a higher grade in ovarian
cancer patients. ZD0473 had an acceptable non-haematological toxicity profile. There
was no evidence of clinically relevant neuro- nephro- or ototoxicity, and no drug
related deaths have occurred. Overall, this safety review demonstrates that ZD0473
has a manageable toxicity profile. 
AstraZeneca acknowledges the contribution of the investigators to the Phase II
clinical trial programme. 
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THE HUMAN UROPLAKIN IB GENE PROMOTER 
J Olsburgh1, P Selby1, J Southgate2, 1ICRF Clinical Cancer
Centre, Leeds LS9 7TF, 2Dept of Biology, University of York, York YO10 5YW
The uroplakins (UP) are 4 distinct genes whose products form plaques that are unique
to the luminal membrane of terminally-differentiated bladder epithelial (urothelial)
cells. The UPIb gene is highly expressed in around 50% of muscle-invasive bladder
cancer primaries and lymph node metastases1. Thus, the UPIb promoter could provide
a means to target therapeutic gene expression in bladder cancer and the aim of this
study was to characterise the promoter of the human UPIb gene. 
A human PAC library was screened for the UPIb coding sequence. The full-length
5´UTR and the transcription start site were mapped using 5’RACE and ribonuclease
protection assays. Functional characterisation of 5’flanking genomic DNA was
performed by transient transfection of UPIb-luciferase reporter constructs into UPIb-
expressing and non-expressing urothelial and non-urothelial cell lines of normal and
tumour derivation. Co-transfection with an HSV-tk promoter construct was used in a
dual luciferase assay to correct for transfection efficiencies. 
Results showed that the UPIb proximal promoter is TATA-less, with multiple tran-
scription initiation sites lying within a short (69 bp) non-coding exon 1. A short region
(150 bp), located 200 bp upstream of UPIb exon 1, conferred strong transcriptional
activity in a range of bladder cancer-derived cell lines. This activity was of compa-
rable intensity to the control SV40 promoter. The same UPIb construct had weaker
transcriptional activity in cultured primary human skin fibroblasts. Both longer and
shorter UPIb constructs generated lower luciferase activity in all cell types. 
This work suggests that a strong functional human UPIb proximal promoter has
been identified that shows differential transcriptional activity in urothelial and fibrob-
last cell types. The definition of urothelium-specific transcription regulatory elements
should find application in targeting gene therapy strategies for bladder cancer. 
1. Lobban ED, Smith BA, Hall GD, Harnden P, Roberts P, Selby PJ, Trejdosiewicz
LK, Southgate J. Uroplakin gene expression by normal and neoplastic human
urothelium. Am J Pathol 1998; 153: 1957–1967 
P245
CYTOTOXIC DRUGS COMBINED WITH ADENOVIRAL-
MEDIATED INTRODUCTION OF TUMOUR SUPPRESSOR
GENES ACT SYNERGISTICALLY TO DECREASE PANCREATIC CANCER
CELL VIABILITY CM Halloran, P Ghaneh, JP Neoptolemos and E Costello,
Department of Surgery, Royal Liverpool University Hospital, 5th floor UCD
Building, L69 3GA, Liverpool, UK
Pancreatic ductal adenocarcinoma has become a common cause of cancer related
deaths in Europe and the USA. The illness has a relatively symptom free progression
and by diagnosis the majority of patients have advanced incurable disease. At present
surgery offers the only prospect of a long-term survival, but is feasible in few patients
(around 20%). Chemotherapy increases survival for a few months only and recent trials
have shown radiotherapy may be deterimental to survival in the medium term. As
pancreatic cancer has a typical footprint of genetic mutations, including loss of func-
tion of the tumour suppressor genes p53 and p16INK4a, gene therapy has been suggested
as an additional treatment option. It has been demonstrated previously, by our group,
that adenoviral re-introduction of wild type p53 and p16INK4a into pancreatic adenocar-
cinoma cell lines caused growth arrest and apoptosis, and reduction in tumour growth
in subcutaneous tumours in nude mice. In this study we have investigated the results of
combining standard chemotherapeutic drugs used for pancreatic cancer, 5-flurouracil
(5-FU) and gemcitabine, with adenoviral introduction of p53 (Adp53) and p16INK4a
(Adp16). Pancreatic cancer cell lines, mutant for p53 and p16INK4a, were treated with
either drug followed by vector or vector followed by drug. In all cases, the doses of 5-
FU and gemcitabine used were singularly ineffective at reducing cancer cell number.
Likewise, Adp53 or Adp16, at the multiplicities of infection (MOIs) used had sub-
optimal effects. Cell viability was assessed by MTT assay. 5-FU and gemcitabine are
both agents that predominantly affect ‘S’ phase of the cell cycle. Hence any pre-treat-
ment of cancer cells with Adp53 or Adp16 which prematurely arrest the cell cycle in
‘G1’ might be expected to prevent co-operative action. Interestingly we have demon-
strated that pancreatic cancer cells treated with either Adp53 or Adp16 followed by
either 5-FU or gemcitabine showed a reduction in cell viability in keeping with an
additive effect from the vector and drug combination. When pancreatic cancer cells
were treated with 5-FU or gemcitabine and followed by Adp53 a similar additive effect
was seen between the combinations. Surprisingly, when cells were treated with 5-FU or
gemcitabine and subsequently treated with Adp16, there was an enhanced reduction in
cell number suggesting that a synergistic action exists between these combinations.
This was statistically significant (P = 0.04 for 5-FU/Adp16 and P = 0.02 for gemc-
itabine/Adp16). In addition, pancreatic cancer cells were treated with drug and vector
combinations simultaneously: Adp16 plus 5-FU, Adp53 plus 5-FU and Adp16 plus
gemcitabine all showed synergistic reduction in cell number after 5 days treatment (P <
0.05). We have shown that all combinations of 5-FU or gemcitabine with Adp53 or
Adp16 are beneficial in terms of reducing pancreatic cancer cell viability. The most
crucially beneficial combinations showed synergistic co-operation in reducing cancer
cell viability. It is envisaged that such use of combining standard chemotherapy with
adenoviral re-introduction of wild type copies of mutated genes may become an impor-
tant adjuvant treatment for pancreatic adenocarcinoma. 96 Poster presentations
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ISOLATION OF PEPTIDES RELATED TO CLASS I FROM 
TUMOUR CELL LINE WHICH HAS BEEN CORRECTED FOR
MISSING CLASS I ANTIGENS VIA b2-M GENE TRANSFACTION 
N Torabi-Pour, AME Nouri, R Saffie and RTD Oliver, Department of Medical
Oncology, The Bart’s and London Trust, London, UK
Given the difficulties of isolating tumour cytolytic T cells (CTL), and the fact that
tumour specific peptide(s) may prove to be critical for enhancing anti-tumour immu-
nity in some cancer patients we used immuno-bead purification technique in combi-
nation with high performance liquid chromatography (HPLC) approach to isolate
peptide(s) from the groove of class I antigens from various biological specimens. 
The results showed that: 
1. Pure class I complex molecules could be prepared from extract of tumour cell
lines, peripheral mononuclear cells as well as kidney and bladder tumour tissue
biopsies. 
2. The HPLC peptide profile differed for different specimens. 
3. In the case of a bladder tumour cell line which lacked class I antigens because of
a defective b2-m molecule, fully assembled class I antigens were re-expressed
following the insertion of cells with the normal b2-m gene. At least 22 different
peptides were isolated from the class I antigens of these cells. Tandem mass spec-
trometry analysis of HPLC purified peptides of these cells showed at least three
identifiable peptides one octomer and two nanomers with the following amino
acid sequences; L,T,P’, H,L,L,S,Y and V,T,D,P,G,N,L,L,Y and L,T,D,L,G,F,L,V,Y.
Prediction of class I alleles, showed that the eluted peptides had motifs of HLA-
A1 and resembled the MAGE1 HLA-A1 peptide EADPTGHSY in having a D at
position 3 and/or a P at position 4 and a Y at the C-terminus of the sequence. The
first peptide (being an 8-mer) may have been trimmed in the preparative portion
of the purification protocol (and could have started life as a 9-mer) whose putative
source peptides are unknown. 
These data demonstrated the feasibility of isolating and identifying class I-
associated peptides from tumour specimens. Further simplification of these approaches
will prove to be helpful for the future of tumour vaccine therapy for induction of anti-
tumour immunity post de-bulking of accessible tumour in cancer patients following
surgery. 
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BEHAVIOUR OF HLA RELATED PEPTIDES ISOLATED 
FROM A BLADDER TUMOUR CELL LINE: A FURTHER STEP
TOWARD THE FUTURE OF PEPTIDE VACCINE THERAPY IN BLADDER
CANCER PATIENTS N Torabi-Pour, R Saffie and RTD Oliver, Departments of
Medical Oncology, Bart’s and London NHS Trust, London. UK
Results from the use of BCG for treatment of superficial bladder cancer suggest that
this tumour is one of the most immunogenic tumours in man, though little is known
about the antigenic determinants responsible for immune rejection. Part of the
problem in identifying these determinants is the lack of T cell cellular immunoassay. 
The research goal of this study is to define the biochemical and functional nature of
antigenic peptides presented in the context of HLA (human leukocyte antigen) class I
antigens. 
The HPLC profile of nano peptides was eluted from purified HLA molecules from
an in house bladder tumour cell line. Chemical sequencing of eluted nanopeptides was
performed by Tandem mass spectrometry and the nanopeptides were characterised as
follows: NAT 1 (VTDPGNLLY), NAT2 (LTDLGFLVY) and NAT 3 (LTDPHLLSY). 
Predictions of class I alleles based on the NCBI GenBank show that eluted
peptides are all motif peptides of HLA-A1. NAT 2 and NAT 3 resemble the MAGE-
1A1 and human Herpes simplex virus 1 presented peptides. The putative source
peptide of the first peptide (NAT 1) is the Hepatitis B virus. By monitoring the incor-
poration of 125I b2-m into the class I complex, it was found that the percent specific
binding for dissociation of b2-m at 37˚C was more than 40 h for HLA-A1 complexes
containing the peptides NAT 1 & 3, whereas it was less than 40 h for the NAT 2. 
Experimental measuring half-life (t1/2) of b2-m dissociation at 37˚C was about
3140/720 min for the corresponding complexes containing NAT 3 and NAT 1 respec-
tively and about 173 min for NAT 2. These results resembled the theoretical t1/2
measurement (Fortan program) predicting that both NAT 3 and NAT 1 should disso-
ciate from HLA-A1 with a half-life (t1/2) of 3125 and 810 min respectively, versus 312
min for NAT 2. Since MAGE 3 peptide (was used as a negative control) did not display
enhanced binding affinity for HLA-A1 suggest that the importance role play with the
specific peptides to increase the relative binding strengths of HLA-A complexes. 
The data presented in this investigation demonstrate the feasibility of isolating and
identifying peptides from class I antigens of a bladder tumour cell line. Although we
have applied this approach on a relatively small scale in this study, broader applica-
tions can be foreseen. 
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A HETEROLOGOUS VACCINATION PROTOCOL 
STIMULATES BOTH HUMORAL AND CELL MEDIATED
IMMUNE RESPONSES, A Conn, V Potter, I Spendlove, J Ramage, 
L Durrant and Professor J Carmichael, CRC Academic Unit of Clinical
Oncology, Nottingham City Hospital, Nottingham NG5 2PB
Aims 105AD7 is a human anti-idiotypic antibody that mimics the tumour associated
antigen CD55, which is over-expressed on colorectal carcinoma. 105AD7 has been
constructed as a DNA vaccine in the form of a dimeric single chain Fv (scFv).
Immune responses generated by a DNA prime and protein boost vaccination protocol
have been studied in a mouse model. 
Procedures Three 6–8 week old female balb/c mice were immunised in the
quadriceps muscle with 100 mg of 105AD7 scFv DNA and CpG at weeks 0 and 2.
Antisera were obtained at week 4 from tailbleeds. At week 5 mice were immunised
subcutaneously with 100 mg of 105AD7 protein in incomplete freunds adjuvant. Five
days later spleens were harvested and antisera obtained. Antisera were assessed by
ELISA for the production of anti-anti-idiotypic antibodies against 105AD7 scFv.
Splenocyte cultures were assessed for the presence of cytotoxic T cells, and CD8 posi-
tive cells were quantified by flow cytometry. 
Major Findings There was a significant increase in anti-anti-idiotype antibody
production at a 1:100 dilution for all three mice when compared to un-immunised
controls. The cytotoxic T cell assay for one of the three mice showed a 30% increase
in the specific lysis of P815 target cells pulsed with the H2Kd and the CDRH3 of
105AD7. Flow cytometric analysis showed there to be at least 19% CD8 positive T
cells in splenocyte cultures, and this was increased by 8% in one mouse following
culture with the H2Kd. 
Conclusion Stimulation of both humoral and cell mediated immune responses
have been shown by a 105AD7 scFv DNA prime and protein boost vaccination
protocol in balb/c mice. This heterologous vaccination protocol could be translated
into a clinical trial in the therapy of advanced or primary colorectal carcinoma. 
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MUCI-BASED cDNA VACCINES IN MURINE TUMOUR 
MODEL SYSTEMS TA Plunkett, I Correa, RA Graham, 
J Taylor-Papadimitriou & DW Miles, ICRF Breast Cancer Biology Group,
Guy’s Hospital, London SE1 9RT
MUCI has been proposed as a target for tumour immunotherapy. We have developed
murine tumour models to assess the potential usefulness of MUCI-based vaccines. In
addition, both C57B16 and BalbC mice transgenic for human MUCI have been devel-
oped. In transgenic mice human MUCI is a self-antigen, allowing the study of 
both immunological tolerance and auto-immunity. Three intramuscular injections at 
3 week intervals with at least 50mcg of MUCIcDNA resulted in partial protection
against subsequent challenge with MUCI-expressing tumour cells in both wild type
C57B16 (80% of mice alive and tumour-free at 6 weeks vs 0% controls) and BalbC
mice (25% of mice alive at 6 weeks vs 0% controls). Cellular depletion studies
following cDNA immunisation demonstrated that the tumour protection was depen-
dent upon both CD4+ and CD8+ T cells. However, no MUC1-specific cytotoxic 
T cells (CTL) could be demonstrated prior to tumour challenge. These results
suggested that CTL activation was sub-optimal following cDNA immunisation with
MUCI cDNA. Recent work has demonstrated the primacy of CD4 T cells in effective
tumour-specific CTL activation. We reasoned that increasing MHC class II presenta-
tion of MUCI-derived epitopes might translate into more effective MUCI-specific
CTL activation and thereby more effective tumour protection. We developed a
chimeric construct encoding the extracellular domain of MUCI and the transmem-
brane and cytoplasmic tail of Lamp1. Lamp1 is found in the MIIC, the putative site of
MHC class II-loading. The MUC1/Lamp1 chimeric construct localised to vesicular
intracellular compartments that also expressed wild type Lamp1. In proliferation
studies using antigen-presenting cells transfected with either wild type MUCI or the
MUC1/Lamp1 construct, the MUC1/Lamp1 construct generated significantly greater
responses suggesting more effective MHC class II processing and presentation.
However, MUCI-specific CTL could not be demonstrated in mice immunised with the
MUC1/Lamp1 construct. In tumour protection studies, the MUC1/Lamp1 construct
was not more effective than the wild type MUC1 cDNA. Studies were also performed
in mice transgenic for human MUC1; injection with up to 100mcg cDNA at 3 week
intervals did not result in tumour protection. In this study the chimeric MUC1/Lamp1
construct was not more effective than the wild type cDNA. These studies also demon-
strate that although MUC1-based cDNA vaccines can protect against tumour chal-
lenge in wild type mice, they do not elicit a protective immune response in mice
transgenic for human MUC1. These data suggest that alternative immunisation strate-
gies are required to overcome immunological tolerance to MUC1. Poster presentations 97
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GENETIC MODIFICATION OF HUMAN NATURAL KILLER 
CELLS: IMPLICATIONS FOR CANCER IMMUNOTHERAPY
CS Naylor, DE Gilham, RE Hawkins, CRC Department of Medical Oncology,
University of Manchester, Paterson Institute for Cancer Research,
Manchester M20 4BX 
Natural Killer (NK) cells provide a cellular defence which compliments that of T-cells
in so much as NK cells are activated in the absence of MHC Class I molecules on the
surface of target cells. As many tumour cells down regulate MHC Class I in order to
avoid T-cell immune surveillance it would be expected that these cells become targets
for NK activity. Indeed, there is a growing body of evidence that supports the view that
NK cells play a critical role in controlling the growth and metastatic spread of a variety
of tumours. It could be predicted therefore that enhancing NK activity would be advan-
tageous to the patient. One strategy that may maintain or enhance NK activity in vivo,
is to use them as targets for gene therapy. Many immune effector cells have been targets
for retroviral gene transfer and expression of transgenes such as cytokines and chimeric
immune receptors have shown to be effective in tumour targeting experiments.
However, for reasons unknown, NK cells appear refractory to retroviral uptake. 
In this study we report the optimisation of retroviral transduction in freshly
isolated human Natural Killer cells. Transduction efficiency was based on EGFP
transgene expression and NK cell viability post-transduction. An optimised spin
infection and a retronectin-aided supernatant infection were demonstrated to be more
efficient at transducing isolated NK cells, whilst maintaining optimal viability. GFP
expression in viable CD56+, CD3- NK cells was routinely over 20%, with individual
donors ranging from 6–40%. The manipulation of primary NK cells in vitro is
hampered by difficulties encountered in their long-term culture. NK cell proliferation
peaked between 11 and 14 days with viability declining considerably by 3 weeks post-
harvest. We therefore studied mechanisms of maintaining the survival of transduced
NK cells in vitro. Reintroduction of transduced cells into an NK-depleted autologous
feeder population allowed the survival of the NK cells to be extended for a further 2–3
weeks. Upon re-isolation, their cell surface phenotype and transgene expression
remains largely unchanged. Although their viability can be extended, the NK popula-
tion were not found to proliferate whilst being maintained in the feeder cells. 
Subsequently NK cells have been transduced with a retrovirus containing a chimeric
immune receptor consisting of a ScFv for a specific Tumour Associated Antigen, fused
to the CD3z domain. FACs analysis and Western Blotting confirm successful transduc-
tion of NK cells with the chimeric immune-receptor. By reintroduction into a feeder
population, viability of transduced cells can, again, be prolonged. Work is continuing to
assess the functionality of the transduced cells in redirected killing assays. 
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Although it has been demonstrated here that NK cells can be transduced and main-
tained for up to 6 weeks, additional factors other than cytokines, such as IL-2, and
feeder cells may be required to enhance NK cells expansion in vitro. The lack of
proliferation in isolated NK populations will have serious implications for their poten-
tial as targets for cancer immunotherapy. These difficulties must be overcome before
NK cells, and their properties can be exploited for clinical therapies.
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IMPROVING THE SURVIVAL OF GENE MODIFIED 
LYMPHOCYTES FOR ADOPTIVE CELLULAR THERAPY
USING ANTI-APOPTOSIS GENES JD Eaton, DE Gilham, A O’Neil & 
RE Hawkins. CRC Department of Medical Oncology, Paterson Institute for
Cancer Research, University of Manchester
For a gene-modified adoptive cellular immunotherapy approach to be successful the
prolonged in vivo survival of genetically modified effector cells is crucial. Detection
of circulating gene-modified T cells following re-infusion into patients has so far
required highly sensitive techniques. Whilst the exact fate of these T cells is not
known, the genetic modification process, or the local tumour environment in vivo
could be expected to lead to activation-induced apoptosis. 
In vitro studies of CD 28 co-stimulation have shown that up-regulation of certain
anti-apoptosis genes, in particular Bcl-xL, promote T cell survival. We have attempted
to modulate this resistance to apoptosis and improve cell survival by using retroviral
genetic modification to increase expression of Bcl-xL in human peripheral blood
lymphocytes. Modified cells have been identified by linking Bcl-xL expression via an
internal ribosome entry site to the marker green fluorescent protein. 
Jurkat cells transduced with Bcl-xL were partially resistant to Fas (CD95) antibody
induced apoptosis. Subsequent in vitro assays with transduced primary human
lymphocytes demonstrated that over-expression of Bcl-xL promoted the survival of
lymphocytes cultured in the absence of interleukin-2, either with or without the anti-
CD3. antibody, OKT3. 
Furthermore, Bcl-xL over-expression in human lymphocytes delayed the onset of
apoptosis induced by long-term co-culture with the HeLa and 293T tumour cell lines.
These results indicate that co-expression of Bcl-xL in donor lymphocyte infusions or
in conjunction with a therapeutic gene might enable the long-term survival and persis-
tence of transduced cells in vivo thereby potentially enhancing the clinical outcome of
gene-modified adoptive cellular therapy. 
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THE MODIFICATION OF T LYMPHOCYTES FOR THE GENE 
THERAPY OF CANCER DE Gilham, A O’Neill, C Hughes, 
R Guest, M Lehane, N Kirillova, RE Hawkins, CRC Department of Medical
Oncology, Paterson Institute, Christie Hospital, Manchester M20 9BX
The aim of this project is to produce large numbers of tumour specific lymphocytes
through the introduction of constructs encoding chimeric immune receptors into
primary human T lymphocytes. These receptors consist of the CD3z protein fused to
an antigen binding domain consisting of single chain antibody fragments (scFv)
specific for tumour associated antigens (TAA’s). The scFv’s used were specific for the
carcino-embryonic antigen (CEA) and neuro-cell adhesion molecule (NCAM).
Ligation of the scFv by antigen results in the clustering of the CD3z signalling
domains resulting in downstream activation of the modified lymphocyte. In this
manner, it is anticipated that the gene modified lymphocytes will target and be acti-
vated by tumours expressing the relevant TAA in the absence of the usual T cell
requirement for peptide-MHC presentation on the target cell 
Retroviral gene transfer methods have been used to transduce primary activated
polyclonal T lymphocytes from normal donors. High level transduction was identified
by the use of an EGFP marker gene expressed under the control of an IRES element
downstream of the scFv:CD3z construct. These cells were expanded in the presence
of IL-2 and the expression of the recombinant receptors confirmed by western blot.
The chimeric receptors were found to homodimerise and also to heterodimerise with
wild-type CD3z protein. 
The modified lymphocytes were induced to produce interferon g (IFNg) when
cultured in the presence of the correct protein antigen either on target cells or on puri-
fied protein. However, no IFNg was detected when control or modified lymphocytes
were cultured on target cells or antigen not recognised by the individual scFv.
Furthermore, specific proliferation was observed when the anti-CEA:CD3z modified
lymphocytes, but not the anti-NCAM:CD3z modified cells, were cultured on immo-
bilised purified CEA. 
Encouragingly, these modified cells also displayed specific cytotoxicity against
cell lines expressing the relevant target antigen. Anti-CEA:CD3z expressing lympho-
cytes killed CEA-positive colo-rectal lines including MKN45K while the anti-
NCAM:CD3z lymphocytes killed the neuroblastoma line SK-N-BE in a
dose-dependent manner. However, further studies have suggested that signalling
through the scFv:CD3z receptor may result in activation-induced cell death (AICD)
and that the modified effectors themselves may be subject to target cell induced death.
AICD can be avoided to some extent by the inclusion of anti-CD28 Mabs. These
studies indicate that gene modified T lymphocytes can successfully target and elimi-
nate tumour cells. However, further critical issues, including the survival of modified
cell during activity, need to be addressed for this therapy to approach a clinical setting. 98 Poster presentations
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DNA TRANSFER TO TUMOUR CELLS IN VITRO AND IN 
VIVO FOR GENE DIRECTED ENZYME PRODRUG
THERAPY. J Tupper, O Greco, M Cemazar, GM Tozer, GU Dachs, Tumour
Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount
Vernon Hospital, Middlesex, HA6 2JR, UK
Cancer treatment is the main application of gene therapy, initially devised to correct
inherited monogenic disorders. Gene directed enzyme prodrug therapy (GDEPT)
involves the transfer of a gene encoding an enzyme to cells, and the subsequent
administration of a prodrug, which is converted to a cytotoxin by the enzyme. Several
GDEPT systems have been devised, including the novel horseradish peroxidase/
indole-3-acetic acid (HRP/IAA) combination (Greco et al., 2000, Cancer Gene Ther.
7, 1414). When expressed in mammalian cells, the plant enzyme HRP is able to
convert IAA, a plant hormone, to a cytotoxin. 
One of the main limitations of gene therapy is the efficient delivery of the DNA to
target cells. Viral vectors are currently the most efficient transfection method,
however they may activate oncogenes and elicit immune responses often preventing
repeat administration. 
The aim of this study was to assess transfection of FaDu – human nasopharyngeal
squamous carcinoma – cells in vitro and in vivo with relation to the HRP/IAA GDEPT
system. The marker green fluorescent protein (GFP) was encapsulated in lipofectin
vesicles targeted with integrin binding peptide, and incubated with cell monolayers
(Hart et al., 1998, Human Gene Ther. 9, 575). This gave a transient transfection effi-
ciency of 36–40%. Application of high voltage direct current pulses to cells and
tissues can be used to facilitate DNA entry. In this case percutaneous square wave
pulses significantly increased transfection efficiency in subcutaneous tumours when
compared with DNA alone or in lipofectin vesicles. However, transfection levels were
still below 1%. 
Transfection of cell cultures with plasmid containing the HRP gene resulted in
10–14% of cells expressing the enzyme. This level of expression was sufficient to
result in significant cell kill after exposure to IAA, and increased sensitivity 55-fold
compared to GFP transfectants. 
The HRP/IAA combination is a potentially efficient GDEPT strategy. Whilst elec-
troporation significantly increases in vivo DNA delivery, the levels of expression
obtained need to be optimised for therapeutic use. 
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PHYSIOLOGICALLY REGULATED GENE THERAPY FOR 
THE TREATMENT OF CANCER K Binley, L Griffiths, O Kan, S
Iqball, H Spearman, S Kingsman, S Naylor. Oxford BioMedica, Oxford
Science Park, Oxford, OX4 4GA
Targeted transgene expression is an important feature for gene-based therapies.
Although tissue-specific regulatory elements have been used for transcriptional
targeting often the level of transgene expression is relatively low. Hypoxia is a
common feature of solid tumours and triggers a cascade that is mediated by transcrip-
tion factors binding to the Hypoxia Response Element (HRE). We have developed a
novel adenoviral vector (AdOBHRE) that targets gene expression to areas of low
oxygen tension (hypoxia) through an optimised HRE. 
We have previously shown AdOBHRE displays hypoxia regulated reporter gene
expression in a range of tumour cell lines1 and primary cell types including macro-
phages2. The reporter gene was replaced with a therapeutic gene encoding human
cytochrome P4502B6 (CYP2B6) to generate Ad.OBHREP450. Macrophages trans-
duced with Ad.OBHREP450 demonstrate induced gene expression when infiltrated
into a tumour spheroid and a significant reduction in tumour spheroid volume upon
exposure to the prodrug cyclophosphamide2. 
We have assessed the potency of AdOBHREP450 by direct injection into estab-
lished MDA231 human tumour xenografts on nude mice. We demonstrate significant
tumour growth delay only in the presence of cyclophosphamide via activation of
P4502B6 in the hypoxic tumour environment. The work presented will demonstrate
the potential of targeting gene expression to ischemia/hypoxic regions using the
OBHRE promoter in the context of an adenoviral vector. 
1. Binley K et al., Gene Therapy (1999) 6: 1721–1727 
2. Griffiths et al., Gene Therapy (2000) 7: 255–262 
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NITROREDUCTASES FROM Bacillus subtilis FOR PRODRUG 
ACTIVATION IN CANCER GENE THERAPY GM Anlezark1, 
T Vaughan2, NP Michael3, H Murdoch1, MA Sims1, E Fashola-Stone1, 
NP Minton.11 Centre for Applied Microbiology and Research, Porton Down,
Salisbury SP4 0JG; Present addresses: 2Dept of Biology, Univ of York YO10
5YW, 3Nycomed-Amersham, Cardiff Laboratories CF4 7YT 
Nitroreductases activate diphenylcarboxamide prodrugs to form alkylating agents
which crosslink DNA and kill tumour cells. This property was first demonstrated for a
rat DT diaphorase with the prodrug CB 1954, and subsequently, cytotoxicity has been
demonstrated in vitro and in vivo using transfected cells expressing E. coli B nitro-
reductase (NfnB) when CB 1954 and its analogues are administered. Using the
sequences of NfnB and YwrO of Bacillus amyloliquefaciens (YwrO BAM), a novel
protein that reduces CB 1954, we have identified 5 sequences encoding novel putative
nitroreductases in the B. subtilis genome. The genes were obtained as PCR products
by reverse genetics, cloned and the proteins expressed in an E. coli host. The recom-
binant proteins were purified to homogeneity by ion exchange chromatography and
characterised. The proteins more highly related in sequence to YwrO BAM (YrkL,
YdeQ and YwrO BS) were either inactive or very slowly active with CB 1954 and
showed no activity with its mustard analogue SN 23862. However they used flavins,
menadione and azodyes as substrates. In contrast, the two proteins related in sequence
to NfnB (YodC and YdgI) rapidly reduced both CB 1954 and SN 23862. HPLC
analysis of the reduction products of CB 1954 showed that both enzymes form the 
4-hydroxylamine cytotoxic product only. Both YodC and YdgI are flavoproteins and
are flavin, menadione and azoreductases, although they differ in kinetic parameters
and cofactor specificity. In in vitro cytotoxicity tests enhanced cytotoxicity of CB
1954 and SN 23862 was demonstrated when V79 cells were incubated with prodrug,
NAD(P)H and YodC or YdgI. The NfnB family of bacterial proteins is likely to
provide further new candidates for effective nitroreductive prodrug activation by
transfected tumour cells for DEPT (Directed Enzyme Prodrug Therapy) applications. 
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IMMUNOGENICITY OF CARBOXYPEPTIDASE G2 (CPG2) 
ENZYME IN ADEPT SK Sharma, J Bhatia, RB Pedley, 
DIR Spencer, 1N Minton, KA Chester, and RHJ Begent, CRC Targeting &
Imaging Group, Dept. of Oncology, RF & UCMS, UCL, Royal Free Campus,
Rowland Hill Street, London NW3 2PF.1 CAMR, Porton Down, Salisbury
Pilot clinical trials with chemical conjugates of carboxypeptidase G2 (CPG2) and
anti-CEA F(ab¢)2 have shown that CPG2 mediated Antibody Directed Enzyme
Prodrug Therapy (ADEPT) is effective, but limited by formation of human antibodies
to CPG2 (HACA). 
We have engineered a recombinant fusion protein of anti-CEA single chain Fv
(MFE-23) fused to CPG2. This fusion protein (MFE-CP) has been expressed in
bacteria (E. coli) and yeast (Pichia pastoris) with C-terminal hexa-histidine (his) or
myc-his tags. Both expression systems resulted in production of stable and biologi-
cally active molecules but the Pichia product gave 100-fold greater yields and was
glycosylated. Immunogenicity of these molecules was studied by injecting Balb/c
mice with MFE-CP protein (50–100 ug/mouse, ip.) at 14–28 day intervals. Mouse
anti-CPG2 antibodies (MACA) in serum were measured, by ELISA, 10 days after
each immunisation. Results showed that the presence of the C-terminal tags appeared
to reduce MACA but glycosylation did not. In addition, a functional mutant of MFE-
CP1 has shown a significant reduction (range 10.2–65.3%, median 45.1%) in reac-
tivity with sera of 15 patients with post-therapy HACA. 
These studies demonstrate how molecular and structural biology may be applied to
reduce immunogenicity of protein therapeutics for cancer. 
1. Spencer DIR, Purdy D, Minton N, Whitelegg NR, Rees AR, Begent RHJ, Chester
KA (2000) Mutating ADEPT enzyme CPG2 to reduce its immunogenicity. British
Journal of Cancer 83: 71 
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BIODISTRIBUTION OF 123I-LABELLED MFE-CP FUSION 
PROTEIN IN LS174T XENOGRAFTED NUDE MICE
SK Sharma, H Irwin, RB Pedley, J Bhatia, J Dearling, A Flynn, KA Chester
and RHJ Begent, CRC Targeting & Imaging Group, Dept. of Oncology, RF &
UCMS, UCL, Royal Free Campus, Rowland Hill Street, London NW3 2PF
A biologically active recombinant fusion protein, comprising an anti-CEA single
chain Fv (MFE-23) fused to the bacterial enzyme carboxypeptidase G2 (CPG2), 
has been constructed for use in ADEPT. This fusion protein (MFE-CP) has been
expressed in Pichia pastoris to give high yields of a stable glycosylated product.
Biodistribution studies of functional enzyme activity in nude mice bearing LS174T
xenografts showed localisation of MFE-CP in tumours and rapid clearance from
plasma at 6 hours (6.7% ID/g tumour and 0.0065% ID/ml plasma), resulting in tumour
to plasma ratio of 1030:1. MFE-CP, in combination with prodrug gave reproducible
growth delay of the xenografts, with no systemic toxicity. 
MFE-CP is currently being manufactured for a clinical trial of ADEPT and it is
desirable to develop a radiolabelling method to provide estimates of enzyme activity
in tumour and normal tissues prior to prodrug administration. 123Iodine was selected
for radiolabelling because of the favourable energy of its gamma emission for imaging
patients and its comparable half-life (13.27 h) with the fusion protein clearance. 
MFE-CP was radiolabelled with 123iodine by either the chloramine T or iodogen
method. Free and protein-bound 123iodine were separated using a PD10 column.
Results showed that both iodination methods gave >90% incorporation of 123Iodine
and retained CEA binding and functional enzyme activity of MFE-CP. 123I-MFE-CP
was injected into nude mice bearing LS174T xenografts and biodistribution was
investigated by gamma counting and by phosphor imaging. Results demonstrate the
potential of 123I labelling of MFE-CP for assessing fusion protein distribution in future
clinical trials of ADEPT. 
Supported by the Cancer Research Campaign and the Association For
International Cancer Research. 
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RELATIONSHIP BETWEEN MLH1 EXPRESSION AND 
CISPLATIN SENSITIVITY IN SMALL CELL LUNG CANCER 
S Davidson1, J Plumb1, G Strathdee1, R Milroy2, R Brown1, 1CRC Department
of Medical Oncology, University of Glasgow, Glasgow G61 1BD, 2Department
of Respiratory Medicine, Stobhill Hospital, Glasgow, G21 3UW 
Deletion of chromosome 3p is common in both Small Cell (SCLC) and Non-Small
Cell (NSCLC) lung cancer. The mismatch repair (MMR) protein MLH1 maps within
the chromosomal region commonly deleted (3p21). Loss of MLH1 expression, and
thus MMR activity, is associated with drug resistance in various tumour cell lines 
in vitro. We therefore wish to ask the question; does loss of MMR activity play a role
in the drug resistance seen in lung cancer? 
MLH1 expression has been measured by Western analysis and correlates with
cisplatin sensitivity (IC50) in a panel of seven SCLC call lines (r2 = 0.83). Two related
lines LS274 & LS310 have been derived from the same patient pre- and post-
chemotherapy. The post treatment LS310 line is more resistant to cisplatin (IC50: 10.6
± 0.3 mM) than the LS274 line (IC50: 4.5 ± 0.6 mM) and has reduced level of MLH1
protein. LS310 has the lowest MLH1 expression in the panel of SCLC lines and is the
only cell line shown to have a methylated MLH1 promoter, as measured by methyla-
tion-specific PCR (MSP). However, MSP evaluates only the presence of methylation
within one primer region. In order to determine whether the level of expression of
MLH1 in the cell lines relates to methylation at specific sites within the gene
promoter, we are sequencing the MSP amplified region to determine the precise
methylation pattern. 
Treatment of LS310 with the DNA demethylating agent Decitabine (2¢-deoxy-5-
azacytidine, 0.2 mM, 48 h) increased the cisplatin sensitivity (IC50: 7.8 ± 1.0 mM) 
of this cell line. Treatment with Decitabine and a histone deacetylase inhibitor
(Trichostatin A: TSA) together further increased the cisplatin sensitivity (IC50: 5.6 ±
0.6 mM). Increased sensitivities correlate with an increase in MLH1 protein expres-
sion induced by these treatments. Decitabine and TSA appear to act synergistically
since treatment of LS310 with TSA alone did not affect either cisplatin sensitivity or
MLH1 expression. Treatment of LS274 with Decitabine, TSA or Decitabine + TSA
had no effect on the cisplatin sensitivity or MLH1 expression level. 
Our results demonstrate a spectrum of MLH1 expression within the SCLC cell line
panel and that MLH1 expression correlates with cisplatin sensitivity. This mechanism
of drug resistance is now being investigated in a clinical study of lung cancer patients
receiving cisplatin-based chemotherapy. Furthermore our results suggest that there
may be a role for the use of both a demethylating and histone deacetylase inhibitor in
the reversal of acquired drug resistance of SCLC. 
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TAMOXIFEN-RESISTANT GROWTH IS ASSOCIATED WITH 
INCREASED EGFR/MAP KINASE SIGNALLING ACTIVITY IN
MCF-7 BREAST CANCER CELLS IR Hutcheson, JM Knowlden, D Barrow,
CM Dutkowski, and RI Nicholson, Tenovus Centre for Cancer Research,
Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, UK
The development of “acquired resistance” to anti-hormonal agents in breast cancer is
a major therapeutic problem and major efforts are now being made to understand the
mechanisms responsible for this condition. A significant inverse relationship between
epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK)
signalling activity and endocrine sensitivity has been reported in breast cancer. We
have attempted to mimic the clinical situation by developing an antihormone-resistant
cell line through long term exposure of endocrine-sensitive MCF-7 breast cancer cells
to tamoxifen. In the present study we have characterised the expression and activation
levels of EGFR/MAPK signalling components in both tamoxifen-sensitive (wild-
type) and -resistant (TAM-R) cell lines. The role played by the EGFR/MAPK
signalling pathway in the growth of these cell lines was assessed using an EGFR-
selective tyrosine kinase inhibitor, ZD1839 ‘Iressa’ 1 mM), and a selective MEK
inhibitor, PD098059 (50 mM). Under basal conditions there was a 2–3 fold increase in
both EGFR and c-erbB2 mRNA and protein expression in TAM-R compared to wild-
type MCF-7 cells, whereas, comparable levels of c-erbB3 and c-erbB4 mRNA and
protein were expressed in both cell lines. Immunoprecipitation/WB studies demon-
strated that, under basal conditions, all four c-erbB receptor types were found to exist
as pre-formed heterodimers in both cell lines. However, only TAM-R cells demon-
strated measurable levels of basal activation of EGFR/c-erbB2 and EGFR/c-erbB3
receptor dimers. There was no expression of phosphorylated c-erbB2/c-erbB3 dimers
in either cell line suggesting that an EGFR-selective ligand was responsible for the
activation of TAM-R cell c-erbB receptors. Activation levels of MAPK/extracellular-
regulated kinase1/2 (ERK1/2) were also found to be higher in TAM-R compared 
to wild-type MCF-7 cells with immunocytochemical staining showing localisation
within the nucleii. Treatment of TAM-R cells with ZD1839 prevented both receptor
heterodimer and ERK1/2 activation and strongly inhibited cell growth. PD098059 had
no effect on levels of phosphorylated EGFR and c-erbB2 but greatly attenuated acti-
vation of ERK1/2 and inhibited TAM-R growth to a similar degree to ZD1839.
Although both agents abolished ERK1/2 activity in wild-type MCF-7 cells they had
little effect on cell proliferation. These results demonstrate that our tamoxifen-
resistant MCF-7 breast cancer cell line basally expresses increased total and activated
levels of EGFR, c-erbB2 and ERK1/2 and that signalling via this EGFR/MAPK
pathway is responsible for the growth of TAM-R but not wild-type MCF-7 cells. 
‘Iressa’ is a trademark of the AstraZeneca Group of companies 
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CAVEOLIN EXPRESSION IN TAMOXIFEN-SENSITIVE MCF-7 
BREAST CANCER CELL LINES NPB Thomas1,2, IR Hutcheson1,
D Barrow1, CM Dutkowski1, L Campbell2, M Gumbleton2 and RI Nicholson1,
1Tenovus Centre for Cancer Research and 2Pharmaceutical Cell Biology Group,
Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, UK
Use of the antihormone tamoxifen has proved to be an effective treatment for breast
cancer, however, initially-responsive tumours eventually relapse due to the develop-
ment of antihormone resistance. Tamoxifen-resistant tumour growth has been shown
to be associated with elevated levels of epidermal growth factor receptor (EGFR) and
activation of the associated mitogen activated protein kinase (MAPK) signalling
pathway. The components of this signalling cascade are believed to be localised
within caveolae and may be negatively regulated by the principal component of
caveolae membranes, caveolin-1. It has recently been proposed that hyper-activation
of the MAPK cascade, as a consequence of caveolin-1 down-regulation, may be a crit-
ical event in the oncogenic transformation of some cell lines. To investigate the poten-
tial role of caveolin-1 in the development of tamoxifen resistance we have studied the
relationship between caveolin-1 and the EGFR/MAPK signalling pathway in tamox-
ifen-sensitive (wild-type) and -resistant (TAM-R) MCF-7 breast cancer cell lines.
Caveolin-1 and EGFR mRNA and protein expression was measured at four time
points: day 1, 4, 7 and 10 in the absence or presence of either epidermal growth factor
(EGF, 10 ng/ml) and/or the specific EGFR tyrosine kinase inhibitor, ZD1839 (‘Iressa’
1 mM). EGFR/MAPK signalling activity was assessed by measurement of phosphory-
lated MAPK/extracellular-regulated kinase 1/2 (ERK1/2). An inverse relationship
between the basal expression of caveolin-1 and EGFR was observed in the two cell
lines. Wild-type MCF-7 cells exhibited high caveolin-1 and low EGFR mRNA and
protein levels, whereas, in TAM-R cells the reverse was evident. A direct correlation
between EGFR expression and ERK1/2 activity was also apparent in both cell lines.
Stimulation of wild-type MCF-7 cells with EGF had no effect on caveolin-1 mRNA
expression but caused a small reduction in protein levels. There was no observable
effect of EGF stimulation in TAM-R cells due to the low expression of caveolin-1 in
this cell line. Treatment with ZD1839 significantly increased expression of caveolin-1
mRNA and protein levels in both cell lines, with the effect being far greater in 
TAM-R cells. These results indicate that the elevation of EGFR and activation of the
MAPK pathway in TAM-R cells is associated with a decrease in basal caveolin-1
expression. Our data also suggests a negative regulatory role for the EGFR/MARK
signalling pathway on caveolin-1 expression. It remains to be determined whether the
increased EGFR/MAPK activity observed in TAM-R cells is the cause or the conse-
quence of caveolin-1 down-regulation and whether the potentially beneficial effect of
ZD1839 on caveolin-1 expression in these cells has a possible clinical correlate.
‘Iressa’ is a trademark of the AstraZeneca Group of companies.100 Poster presentations
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ANDROGEN RECEPTOR TRANSCRIPTIONAL ACTIVITY IS 
DOWN-REGULATED BY HISTONE DEACETYLASE 1 AND 2
L Gaughan, DE Neal and CN Robson, Prostate Research Group, School of
Surgical Sciences, University of Newcastle upon Tyne, The Medical School,
Framlington Place, Newcastle upon Tyne, NE2 4HH
The mechanisms involved in the transition from androgen-dependent to androgen-
independent prostate cancer remains largely undefined. The androgen receptor, a
member of the steroid hormone receptor family, is thought to play an important role in
the development of both androgen-dependent and -independent prostatic malignancy.
The androgen receptor is an androgen-dependent transcription factor which activates
expression of numerous androgen-responsive genes. Histone acetyltransferase 
(HAT)-containing proteins have been shown to increase activity of nuclear hormone
receptors by eliciting histone acetylation, which facilitates promoter access to the
transcriptional machinery. Conversely, histone deacetylases (HDACs) have been
identified which reduce levels of histone acetylation, thereby returning active genes to
a quiescent state. 
It has recently been demonstrated that the AR is directly acetylated resulting in
increased transcriptional activity. We have recently shown that Tip60 (Tat-interactive
protein-60 kDa), a MYST protein-family member, is a bona fide co-activator protein
for the AR. Here we show that Tip60 mediates direct acetylation of the AR. Using an
AR mutant lacking this acetylation site, we demonstrate, in transient transfection
studies, that Tip60 is incapable of enhancing AR-mediated transcriptional activity
suggesting that direct Tip60-mediated acetylation of the AR is a requisite for 
AR-associated gene expression. 
Both HDAC1 and HDAC2 specifically reduced transcriptional activity of wild-
type AR, and in immunoprecipitation experiments, the AR was shown to interact with
both HDAC1 and HDAC2. We also show in transfection experiments that Tip60
mediates reversal of HDAC-mediated effects, facilitating AR activity. These results
suggest that the cellular status of HDAC and HAT proteins may influence physiolog-
ical activity of the AR; an imbalance of which may lead to dysregulated AR function
and cellular transformation. 
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ENHANCEMENT OF DOXORUBICIN INDUCED G2 ARREST 
AND APOPTOSIS BY AN INHIBITOR OF THE PI3K
SURVIVAL PATHWAY LSM McCarragher1, BL Brown1 & PRM Dobson2,
Institute of Endocrinology, 2Institute for Cancer Studies, Division of Genomic
Medicine, Sheffield University Medical School, Sheffield, UK
Doxorubicin (DOX) is an effective anticancer agent, used in the treatment of many
cancers including those of the breast. However, current use of this drug manifests a
wide range of serious side effects. The PI3 kinase-signalling pathway is a major
survival pathway having a role in cellular survival and proliferation. Our aim was to
investigate whether the inhibition of the PI3 kinase pathway could sensitise the human
breast cancer cell line, MDA-MB-231, to the effects of DOX. Cells were treated with
the specific PI3 kinase inhibitor, LY294002 at a dose (1 mg/ml) which had minimal
effects on cellular growth (5–20% inhibition at 48 hours). After 45 minutes DOX
(6–1000 ng/ml) was added for a further 24–96 hours. In Situ Nick Translation assay
and Annexin-V-FITC binding were used as measures of apoptosis. We have previ-
ously shown that synergistic growth inhibition was observed at 48 hours, with lower
dose of DOX (10 ng/ml) in the presence of LY294002. The present study was under-
taken to analyse effects on the cell cycle and the expression of Akt, and cyclin B1 was
investigated using western blotting. Cell cycle analysis showed G2 arrest from 24
hours in cells treated with doxorubicin alone and in combination with LY294002, but
a synergistic enhancement of this G2 population was observed from 48 hours with the
combination. In situ Nick Translation assay at 48 hours showed G2 cell cycle arrest,
but no apoptosis. Cell cycle studies at 96 hours revealed a high sub-G0 population in
cells treated with the combination and this was supported by the Annexin-V-FITC
binding assay, which revealed a synergistic induction of apoptosis (>50%). Cyclin B1
was observed to be upregulated from 72 hours with the combined treatments only,
with a more pronounced increase at 96 hours. There appeared to be no change in the
PI3 kinase downstream effector, Akt, at 48 hours suggesting that PI3 kinase may not
be fully inhibited with this low dose of LY294002. In conclusion, LY294002 appears
to sensitise the breast cancer cell line MDA-MB-231 to the effects of DOX through an
initial synergistic induction of a G2 cell cycle arrest at 48 hours, followed by a syner-
gistic induction of apoptosis seen at 96 hours. These results support the use of survival
signalling pathways as targets for anti-cancer treatment. 
We are grateful to Yorkshire Cancer Research for funding.
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THE EFFECT OF OVEREXPRESSION OF C-ERBB2 ON THE 
CHEMOSENSITIVITY OF A HUMAN OVARIAN CARCINOMA
CELL LINE V Smith, S Hobbs, P Workman and LR Kelland, CRC Centre for
Cancer Therapeutics, Institute of Cancer Research, Sutton Surrey SM2 5NG 
c-erbB2 (also known as HER2) is a 185 kDa transmembrane receptor of the EGF
receptor family. It is overexpressed in about 30% of breast and ovarian cancer.
Furthermore, overexpression of the protein is associated with poor prognosis and
some preclinical studies have shown a correlation between high levels and resistance
to chemotherapeutic drugs such as cisplatin and taxol. 
The aim of this study was to investigate the possible role of c-erbB2 in mediating
drug resistance in ovarian cancer. An isogenic human ovarian carcinoma cell line
model (CH1) differing only in c-erbB2 status has been established by stable transfec-
tion of the gene encoding c-erbB2 status has been established by stable transfection of
the gene encoding c-erbB2 and selection using puromycin. Immunoblotting studies
revealed that the transfected line over-expressed c-erbB2 in comparison to empty
vector controls. The sensitivity of the transfected line CH1/F405 compared its vector
control (CH1/F373) – which does not express any detectable levels of c-erbB2 – was
then determined to a variety of cytotoxic drugs and signal transduction inhibitors
using 96 hour drug exposure and the sulforhodamine B (SRB) growth inhibition
assay. 
Results showed that overexpression of c-erbB2 caused an increase in sensitivity
(5-fold; IC50 in mM of 0.24 in CH1/F405 versus 1.36 in CH1/F373) to the heat shock
protein (Hsp) 90 inhibitor, geldanamycin. Similarly, there was a trend towards
increased sensitivity to another structurally unrelated Hsp 90 inhibitor, radicicol 
(IC50 in mM of 0.23 in CH1/F405 versus 0.57 in CH1/F373). However, both lines
showed similar sensitivity to the analogue of geldanamycin, 17-allyl-aminogel-
danamyicin (17AAG) which is currently undergoing clinical trials (IC50 in mM of 0.58
for CH1/F405 and 0.65 for CH1/373). Western blot analysis after exposure to 5 mM
17AAG for 24 hrs showed a decrease in c-erbB2 protein levels in the transfected line. 
In contrast, the overexpression of c-erbB2 conferred resistance to some agents.
2.5-fold resistance was observed to emodin (a tyrosine kinase inhibitor which blocks
c-erbB2 tyrosine kinase activity), 4-fold resistance to a PI3 kinase inhibitor,
LY294002 and 2-fold resistance to cisplatin. No difference in IC50 was observed after
exposure to taxol, the cyclin dependent kinase inhibitor flavopiridol, a tyrosine kinase
inhibitor of the epidermal growth factor receptor, PD153035, a MEK inhibitor,
UO126 and a farnesyl transferase inhibitor, R115777. 
These results show that high levels of c-erbB2 induced resistance to the PI3 kinase
inhibitor LY294002 and cisplatin. In contrast, overexpression led to increased sensi-
tivity to the Hsp90 inhibitor geldanamycin. 
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THE GROWTH INHIBITORY EFFECT OF ZD0473, A NEW 
GENERATION PLATINUM DRUG, IS NOT INFLUENCED BY
MISMATCH REPAIR PROFICIENCY RJ Sun1, M Edelman1, TC Stephens2,
PF Hausner1, 1University of Maryland Greenbaum Cancer Center, Baltimore,
MD, USA, 2AstraZeneca, Alderley House, Cheshire, UK 
A significant fraction of primary cancers are functionally mismatch repair deficient.
Additional cancers acquire mismatch repair deficiency in the course of chemotherapy
and/or radiation usually due to selection of cancer cell clones with a methylated
promoter of hMLH1. Mismatch repair deficiency provides cancers not only with a
low grade resistance against cisplatin, methylating agents, and some other chemother-
apeutic agents and radiation, but with an increased genomic instability as well. Thus,
cytotoxic agents, which do not select for mismatch repair deficiency are preferable.
We tested a new generation platinum derivative, ZD0473 developed to overcome plat-
inum resistance, for differential growth inhibitory activity against mismatch repair
deficient and proficient cells using the comparative growth assay. This assay is based
on co-culture of two HCT116 colon cancer cell line derivatives, one mismatch repair
deficient and permanently labelled with the green fluorescent protein and the other
mismatch repair proficient and labelled with the yellow fluorescent protein. Co-
cultures were exposed to the studied drugs for 72 hours and the relative growth
suppression was evaluated. Similarly to oxaliplatin, and contrary to cisplatin, ZD0473
showed no significant preferential toxicity against mismatch repair proficient 
cells. ZD0473 inhibits in vitro the growth of mismatch proficient and deficient cells
similarly. Poster presentations 101
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ROLE OF MULTI-DRUG RESISTANCE (MDR) PHENOTYPE AS 
A PREDICTIVE MARKER OF RESPONSE TO
CHEMOTHERAPY AND AS A PROGNOSTIC MARKER IN CARCINOMA
BREAST A Srivastava1, SR Chaudhary1, MC Mishra1, O Coshic1, SN Das2 and
A Goyal1, 1Dept. of Surgery, 2Dept of Biotechnology, All India Institute of Medical
Sciences, New Delhi-110029, India
Development of tests to predict response to chemotherapy will help to accurately
select patients who may or may not benefit from such therapy. P-glycoprotein(Pgp)
expression has been strongly associated with aggressive biologic behaviour, poor
treatment response and poor outcome in many tumors. 
Objectives a) To carry out sequential assessment of MDR gene expression before
and after first cycle of neoadjuvant chemotherapy and to evaluate its role as a predic-
tive marker for breast cancer response. b) To evaluate the role of MDR gene expres-
sion as a prognostic marker for local and systemic recurrences in patients undergoing
post-operative adjuvant chemotherapy for breast cancer. 
Methodology Group A included 26 patients of biopsy/FNAC proven breast cancer
with locally advanced stage(IIIA, IIIB). They were studied for the multidrug resistant
gene/Pgp expression before neoadjuvant chemotherapy (day 0) and after one cycle of
chemotherapy (day 21). Chemotherapy responses were clinically assessed after three
cycles of chemotherapy using the UICC criteria. Group B included 21 patients of
early breast cancer(stage I,II) undergoing modified radical mastectomy/conservative
surgery followed by adjuvant chemotherapy with CAF/CMF. Tumor tissues taken
from the specimen after surgery was analysed for Pgp expression. Follow up informa-
tion on local and systemic recurrence was recorded. We tried to evaluate the role of
Pgp expression as a prognostic marker for local and systemic recurrence in these
patients. Flowcytometric analysis of Pgp was done by fluoroscence activated cell
staining, (FAC-SCAN) from the tissues taken by FNAC/operative specimen. Relation
of MDR protein to known prognostic factors e.g lymph node status, menopausal
status was assessed in both groups. 
Results Group A:-Clinically after three cycles of chemotherapy 10 patients (38.5%)
had complete response (CR), 9(34.6%) had partial response (PR) and 7 patients (26.2%)
had no response (NR). The mean Pgp expression on day 0 (before chemotherapy) and
day 21 (after one cycle of chemotherapy) in patients with CR were 18.73%(SD-19.9) and
10.97%(SD-18.52) respectively (difference not statistically significant on Kruskal-Walls
H test). The mean expression on day 0 and day 21 in patients with PR were 34.38%(SD-
30.5) and 27.2%(SD-38.4) respectively (difference not statistically significant). The
mean expression on day 0 and day 21 in patients with NR were 45.82%(SD-19.8) and
45.94%(SD-35.94) respectively (difference not statistically significant). 
Group B:-Mean Pgp expression in T1, T2, and T3 were 6.2%, 33.8% and 19.2%
respectively. In 1 year follow up, only 1 patient developed systemic recurrence. There
was no significant correlation between Pgp expression on both the days with systemic
metastasis, lymphnode status and menopausal status in patients of both groups. 
Conclusions Pgp may be a useful marker in predicting the response to neoadjuvant
chemotherapy for breast cancer. No comment is possible on the association of Pgp
expression and local and systemic recurrence due to the short followup. 
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RM175, A NOVEL RUTHENIUM (RU11) ORGANO-METALLIC 
COMPLEX: PATTERNS OF RESISTANCE IN VITRO AND IN
VIVO RE Aird1, J Cummings1, R Morris2, AA Ritchie1, PJ Sadler2, 
DI Jodrell1, 1ICRF Medical Oncology Unit, Western General Hospital,
Edinburgh, EH4 2XU, UK, 2Department of Chemistry, University of
Edinburgh, Edinburgh, EH9 3JJ, UK 
RM175, [(h6C6H5C6H5)RuCl(H2NCH2CH2NH2-N,N)]+PF6, is a lead compound in a
series of novel ruthenium (Ru11) organo-metallic complexes which show activity 
in the human ovarian cancer cell line A2780. RM175 has an IC50 value of 6mM
compared to 0.5mM for cisplatin and 6mM for carboplatin. (Cummings et al, 2000,
Clin Cancer Res, 6, 4494s). In the present study the activity of RM175 was evaluated
in drug-resistant sub-clones of A2780: cisplatin resistant A2780cis cells (obtained
from ECACC) and multidrug resistant 2780AD cells (gifted by Prof. Ozols, USA).
2780AD cells exhibit a classic multidrug resistant phenotype due to over expression of
mdrl and to a lesser extent mrp. Cross-resistance was observed in 2780AD (38-fold) but
co-incubation in these cells with verapamil (50mM) reduced the degree of resistance
to only 3-fold, strongly suggesting active efflux of the compound by P170. A2780cis
cells are 10-fold resistant to cisplatin but no cross resistance was observed in
A2780cis when treated with RM175. A2780cis cells do not over express mdrl or mrp.
In the absence of increased expression of drug transporters, we looked at the level of
expression of the mismatch repair protein, hMLH1 as a possible mechanism of resis-
tance to cisplatin in these cells. Western blotting showed that hMLH1 is expressed in
the parental line, but not in the A2780cis cells suggesting that damage caused 
by RM175 is not recognised by mismatch repair. When tested against A2780
xenograft RM175 (25 mg/kg i.p., days 1 & 5) showed statistically significant antitu-
mour activity vs. control tumour on days 4, 7 and 9 (P = 0.003). The compound was
also evaluated against the cisplatin-resistant A2780cis xenograft, in parallel with
cisplatin. RM175 showed significant activity in this xenograft (days 6, 8, 11 & 13)
compared to both the control (P = 0.02) and the cisplatin treated group (P = 0.03).
Cisplatin showed no significant activity against the A2780cis xenograft. 
Therefore RM175 has demonstrated activity in a platinum resistant human ovarian
cancer model both in vitro and in vivo. 
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IDENTIFICATION OF GENES ASSOCIATED WITH 
INTERFERON RESISTANCE IN MALIGNANT MELANOMA 
DP Jackson1, R Drake1, TJ Hay1, JM Smith1, PJ Selby1, PM Patel1, 1ICRF
Clinical Cancer Centre, St James’s University Hospital, Leeds, LS9 7TF
Interferon a is used in the treatment of malignant melanoma, but is of benefit in only
a limited proportion of patients. In addition to the clinical variation in response, there
is heterogeneity in the response of melanoma cell lines to the anti-proliferative effects
of interferon a in vitro. The mechanism of interferon resistance in melanoma is
unknown, and currently there is no reliable method of predicting response either clin-
ically or in vitro. 
The aim of this work is to identify genes associated with interferon resistance that
may provide information as to the mechanism of resistance, and act as markers of
potential utility in predicting interferon response and directing therapy. 
We have shown that two melanoma cell lines, characterised as sensitive and resis-
tant to the anti-proliferative effects of IFN-a have intact and functional interferon
signalling via the JAK/STAT pathway, suggesting that resistance must be mediated
through components either downstream or additional to this pathway. 
We have used a method of cDNA subtractive hybridisation to identify differences
in interferon regulated gene expression between these two cell lines. 
A number of genes were identified that showed differential regulation by inter-
feron. These included a protein tyrosine phosphatase, previously associated with
cellular transformation, that was expressed constitutively at a higher level in the resis-
tant cell line relative to the sensitive cell line, and which was down regulated by inter-
feron a in both cell lines. This pattern of expression is consistent with a role for this
gene in negative regulation of the interferon anti-proliferative response. The regula-
tion of this phosphatase by interferon a is a novel observation. 
Further analysis of differential gene expression between these cell lines has been
performed using cDNA microarray technology. This has yielded a wealth of informa-
tion, and has identified a number of genes that are up or down regulated by interferon
a specifically in either the sensitive or resistant cell line. 
Genes identified by these techniques will be put forward as candidate markers of
interferon response and screened in a panel of established and primary melanoma cell
lines. 
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BUTYRATE INDUCES TERMINAL DIFFERENTIATION AND 
APOPTOSIS IN CELL LINES DERIVED FROM ORAL
SQUAMOUS CELL CARCINOMAS A Hague, KE Shefford, DM Marland and
SJ Thavaraj, Dept of Oral & Dental Science, University of Bristol, Lower
Maudlin Street, Bristol, BS1 2LY, UK
Since malignant keratinocytes can be defective in terminal differentiation, agents that
can reactivate terminal differentiation pathways and/or induce apoptosis would be
valuable therapeutic tools for oral cancer. Sodium butyrate is a potent differentiation
agent that induces terminal differentiation in normal skin keratinocytes. In this study,
we questioned whether malignant oral keratinocytes would be induced to undergo
differentiation or apoptosis in response to butyrate. In keratinocytes, terminal differ-
entiation is thought to be distinct from apoptosis, and defects in terminal differentia-
tion pathways could result in the induction of apoptosis by butyrate as a result of
conflicting signals. In two cell lines derived from oral squamous cell carcinomas,
butyrate inhibited cellular proliferation and induced both apoptosis and terminal
differentiation. Butyrate treated cells had increased numbers of cells with G2 DNA
content. Consistent with cell cycle arrest, the mitotic index decreased and p21 Waf-1
was induced (0.5 mM to 6 mM). By contrast, levels of p53 were reduced.
Concentrations of 2 mM and above induced cellular flattening and increased cell size
and expression of the cornified envelope protein, involucrin. This was accompanied
by a reduction in colony forming efficiency after 72 hours of treatment, even if the
cells were subsequently allowed to recover for 24 hours in butyrate-free medium.
These results suggest that at least some of the tumour cells retain the ability to
undergo terminal differentiation in response to butyrate. However, lower concentra-
tions of sodium butyrate (0.5 and 1 mM) induced primarily growth inhibition and
apoptosis. Furthermore, using concentrations that induced involucrin, apoptosis was
also induced, particularly during the first 24 hours of treatment. Cells shed into the
medium had apoptotic morphology and alterations in the balance of pro-apoptotic to
anti-apoptotic members of the Bcl-2 family were detected, including a marked
decrease in Bcl-xL. The potent growth inhibitory effects of butyrate and loss of cell
viability subsequent to treatment highlight the potential of butyrate analogues as ther-
apeutic tools for oral cancer. 102 Poster presentations
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A PHASE II STUDY USING RETINOIDS AS 
REDIFFERENTIATION AGENTS TO INCREASE IODINE
UPTAKE IN METASTATIC THYROID CANCERS SC Short1, G Cook2, 
G Flux2 L Vini1 and CL Harmer1, 1Dept. Clinical Oncology, The Royal
Marsden Hospital, Sutton, Surrey, 2Dept. Nuclear Medicine, The Royal
Marsden Hospital, Sutton, Surrey SM25PT
Radio-iodine is the most effective treatment for metastatic differentiated thyroid
cancers. In some cases however, these tumours fail to take up radio-iodine and for
these patients treatment options are very limited. Failure of iodine uptake is thought to
occur because of de-differentiation of tumour cells, which might be reversible using
re-differentiating agents. Retinoids demonstrate re-differentiating effects in a variety
of cell types and increase iodine uptake in thyroid tumour cells in vitro. The aim of
this study is to assess whether oral iso-tretinoin can increase radio-iodine uptake in
patients with iodine uptake negative metastatic follicular and papillary thyroid
cancers. 
Patients who had iodine negative metastatic papillary or follicular thyroid cancers
were selected from the thyroid database at The Royal Marsden Hospital and enrolled
to an open, non-randomised phase II trial. Sites of metastatic disease were assessed
using CT or MRI and lack of iodine uptake was confirmed using a diagnostic radio-
iodine scan prior to study entry. In eligible patients iso-tretinoin was prescribed at 
1.5 mg/kg/day orally for 6 weeks. Response was assessed within 2 weeks of completing
treatment with repeat radio-iodine scan. In patients who showed iodine uptake after
treatment dosimetric data were collected using SPECT scanning. All patients were
reviewed 2-weekly during treatment for assessment of toxicity and side effects. 
The results of the first cohort of patients entered to this study between December
2000 and June 2001 will be presented. These will represent the first data showing the
effect of retinoids in this patient population in the UK. 
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CHARACTERISATION OF THE DNA DAMAGE 
RECOGNISED BY A MONOCLONAL ANTIBODY RAISED
AGAINST CISPLATIN-MODIFIED DNA EL Meczes1, ADJ Pearson2 and 
MJ Tilby1, 1Cancer Research Unit and 2Dept. Child Health, University of
Newcastle Upon Tyne, Newcastle Upon Tyne, NE2 4HH
Background The widely used cancer chemotherapy drug cisplatin, is thought to exert
its cytotoxic action as a result of the formation of cisplatin-DNA adducts. Cross-links
between two adjacent guanines and between adjacent guanine and adenine, amount to
approximately 60% and 20% respectively of all the adducts formed by cisplatin on
DNA. Other types of adducts involve reaction with a single guanine or cross-linkage
between two non-adjacent purines, either in the same or opposite DNA strands. To
quantify the these adducts we have developed effective immunological techniques
based on a monoclonal antibody (Tilby et al. 1991 Cancer Research 51, 123). This
antibody is being used in a widening range of clinical and experimental studies here
and in other centres. 
Aims The present study aims to confirm the hypothesis that antibody, CP9/19/1i,
recognises the major cisplatin-DNA adducts. 
Methods A series of appropriately designed oligodeoxynucleotides (oligos) and
polydeoxynucleotides (polymers) were first reacted with cisplatin. The amount of
bound platinum, following dialysis to remove unreacted drug, was determined by
atomic absorption spectrophotometry. The ability of platinum-DNA adducts to be
recognised by the antibody was determined by competitive ELISA. The concentration
of competing adducts required to cause 50% inhibition (the K value), is inversely
proportional to the immunoreactivity of the particular adduct(s) formed. 
Results and Conclusions Adducts on oligos lacking guanines were, at most, very
weakly immunoreactive (e.g. mean K values on oligo dT = 2.7 pmol/well, oligo dA 
> 200 pmol/well). Adducts on oligos containing single guanine residues were also
very weakly immunoreactive (median K value = 3.3 pmol/well). Highest levels of
immunoreactivity, comparable to that observed with high molecular weight DNA 
(K = 0.002–0.006 pmol/well), required at least two adjacent guanines interspersed by
pyrimidines. However, adducts on oligo dG or poly dG were recognised less well
(median K = 0.13 pmol/well). Levels of immunoreactivity were detected on platinated
oligos upon which only cross-links between a guanine residue and an adenine residue
could form (median K = 0.47 pmol/well), i.e. up to five hundred fold less immunore-
active than on equivalent oligos containing adjacent guanines. These results show that
antibody CP9/19/1i preferentially recognises platinum-DNA cross-links formed
between adjacent guanines. The data also suggest that antibody recognition is depen-
dent not only on the platinum adduct itself, but also on the nature of the surrounding
sequence. This information will be important for the interpretation of clinical and
experimental data from several studies both in Newcastle and other research centres. 
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MECHANISMS UNDERLYING DIFFERENCES IN 
IMMUNOREACTIVITY OF CISPLATIN DNA ADDUCTS
FORMED IN CERTAIN CANCER CELLS A Azim-Araghi*1, CJ Ottley2, 
DG Pearson2, and MJ Tilby1, 1Cancer Research Unit, University of
Newcastle, NE2 4HH, 2Department of Geological Sciences, Durham
University
Aims To investigate the basis of differences in immunoreactivity of cisplatin-DNA
adducts, previously seen in two cell lines. 
Methods The two cell lines used were the drug sensitive small cell lung cancer
line, H69, and the inherently drug resistant adenocarcinoma lung cancer line, Mor.
The two lines were exposed to a range of concentrations of cisplatin (2 h), DNA
extracted and adduct levels determined using a competitive ELISA technique based
on a monoclonal antibody (1). The total amount of cisplatin bound to DNA was quan-
tified by inductively coupled plasma mass spectrometry (ICP-MS). In contrast to the
total Pt measured by ICP-MS, the ELISA method determined only immunoreactive
adducts. 
Results Platinum associated with protein contaminating the purified DNA could
have caused a trivial explanation of previously seen differences in apparent adduct
immunoreactivity (Table). This hypothesis was excluded by analyses in which 
ICP-MS, ELISA and protein assay were carried out on the same DNA samples. The
amount of adducts needed to cause 50% reduction in immunoassay signal (K value)
was independent of protein level in the DNA samples. Protein levels were mostly in
the range of 1–5% of the total DNA. Also the level of protein contamination was not
significantly different between the DNA from the two cell lines. The difference in
immunoreactivity was also independent of the adduct level. 
Cisplatin Dose (mM) K Value (fmole per well) ±SD 
H69 Mor 
25 2.0 ± 0.5 3.5 ± 0.4 
50 1.8 ± 0.4 3.5 ± 0.8 
100 1.1 ± 0.2 3.4 ± 1.1 
Each value represents the mean of 2–4 replicates of 8 different experiments. 
Conclusion A 2-fold change in the overall immunoreactivity indicates a consider-
able difference in some aspect of platinum DNA adduct structure in the Mor cells.
This was due to differences in the nature of the DNA adducts, and not the different 
P271 Cont’d
protein levels in the DNA of the two cell lines. To establish the exact nature of this
difference, ion exchange chromatography (FPLC) is currently being carried out to
further analyse the DNA of each line, and to determine if there are differences in the
nature or relative frequencies of individual adduct structures (e.g. GG and AG intra-
strand cross-links). 
1. Tilby et al 1991. Cancer Res. 51: 123. 
This work is supported by the Cancer Research Campaign. Poster presentations 103
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MECHANISTIC STUDIES AND EVALUATION OF CLINICAL 
MARKERS FOR PHORTRESS, A NEW AGENT FOR
CLINICAL TRIALS TD Bradshaw, HL Browne, I Hutchinson, CA Laughton,
CO Leong, S O’Brien, MFG Stevens, V Trapani, AD Westwell*, Cancer
Research Laboratories, School of Pharmaceutical Sciences, University of
Nottingham, NG7 2RD 
The lysyl amide prodrug of 2-(4-amino-3-methylphenyl)-5-fluoro-benzothiazole,
Phortress, has been selected for Phase I clinical evaluation (Cancer Research
Campaign). The 2-(4-aminophenyl)benzothiazole series is characterised by a number
of unique antitumour properties: rapid conversion of the active species 2-(4-amino-3-
methylphenyl)-5-fluoro-benzothiazole (5F 203) from the parent prodrug in vivo
(18 mg/Kg iv, efficacious plasma levels of active drug >6 h in mice); extremely potent
in vitro and in vivo activity in certain human cancer cell lines only (e.g. breast, ovarian
and colon xenografts); a unique (NCI COMPARE -ve) mechanism of action involving
selective uptake into sensitive cells only, binding to the Aryl hydrocarbon Receptor
(AhR) followed by nuclear translocation, induction of the P450 isoform CYP1A1
leading to generation of an (as yet unidentified) reactive intermediate and formation of
DNA adducts leading to cell death. 
The aforementioned mechanistic scenario provides several opportunities for the
development of novel biological markers for clinical trials due to begin in early 2002.
In order to probe drug distribution in vivo (PET scanning), the synthesis of the 18F
radiolabelled version of 5F 203 has been accomplished. Key features of this route
include the regiospecific synthesis of 2-(4-amino-3-methylphenyl)-5-bromo-benzoth-
iazole, its conversion to a 5-trimethylstannyl analogue via palladium-catalysed
coupling and reaction with [18F]fluorine (P.M. Price, F. Brady and colleagues,
Hammersmith Hospital, London). Detection of drug-DNA adducts through analysis
of DNA extracted from treated cells by the 32P postlabelling assay (P.B. Farmer, E.A.
Martin, MRC Toxicology Unit, University of Leicester) has led to the hypothesis that
the number of DNA adducts formed on dose escalation may correlate with tumour
response in the clinic. In addition, AhR nuclear translocation, evident in sensitive cells
only, may provide a means of measuring tumour response. 
Recent efforts to understand the nature of the critical drug interaction with
CYP1A1 and the identity of the resulting reactive intermediate have been undertaken
since the original lead compound 2-(4-amino-3-methylphenyl)benzothiazole (DF 203)
was found to undergo deactivating hydroxylative metabolism in addition to its cyto-
toxic effect. In the case of the fluorinated substrates, only the 5-fluoro-and 7-fluoro-
DF 203 analogues appeared to thwart this deactivating hydroxylation. Frontier
molecular orbital calculations on this series have been used to predict potential sites of
metabolic hydroxylation and also to predict the likely nature of the electrophilic reac-
tive intermediate. 
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BIOCHEMOTHERAPY FOR METASTATIC KIDNEY CANCER: 
THE NEED FOR RANDOMISED TRIALS JPC Steele and
RTD Oliver, Department of Medical Oncology, St Bartholomew’s Hospital/The
Royal London Hospital, London 
Introduction The combination of interleukin-2 (IL-2), interferon-alpha (IFN-a), and
5-fluorouracil (5-FU) for metastatic renal cancer as originally described by Atzpodien
in Hannover, Germany (Eur J Cancer 1993; 29 suppl 5:S6–8) has proved controver-
sial. Other centres have had difficulty in reproducing results equivalent to Atzpodien’s
– though the combination appears to have clinical activity. Since 1993, 46 patients
have been treated with biochemotherapy at St Bartholomew’s Hospital and the
London Hospital. We present the results from these patients. 
Patients and Methods From 1993, 46 patients (pts) with advanced metastatic
kidney cancer have been treated with subcutaneous IL-2 and IFN-a, and intravenous
5-FU. Eleven pts had lung metastases only; 34 pts had had a nephrectomy.
Histological subtypes were available for 32 pts: 22 clear-cell adenocarcinoma, 
7 papillary carcinoma, two clear-cell/sarcomatoid, and one had papillary/sarcomatoid. 
Results There was one (2%) complete response; six (13%) partial responses; eight
(17%) minor responses; seven (15%) pts had stable disease on therapy. Twenty-one
(46%) pts progressed on therapy. Three patients were inevaluable for response but
were included in survival analyses. Two patients with papillary carcinoma had PRs.
All three pts with sarcomatoid histology progressed on therapy. All but one pt
responding had previously had a nephrectomy. Intention-to-treat analysis showed a
median progression-free survival of 4.7 months and an overall survival of 11.4
months. The median overall survival of pts with PR or CR was 22.8 months. 
Summary These data confirm results from other phase II trials of IL-2/IFN-
a/5FU: the overall response rate is low but a small number of pts experience
prolonged progression-free survival. We still do not know whether the effect of
biochemotherapy is real or reflects patient selection bias. Randomised phase III trials
comparing biochemotherapy with single-agent interferon, chemotherapy or novel
agents are required. 
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IPM CHEMOTHERAPY IN CYTOKINE-REFRACTORY RENAL
CELL CARCINOMA (RCC) J Shamash, JPC Steele, P Wilson,
M Nystrom, W Ansell, RTD Oliver, Department of Medical Oncology, 
St Bartholomew’s Hospital, London
Introduction Irinotecan has documented activity in renal cell lines in vivo. In several
malignancies synergy has been demonstrated with either cisplatin or mitomycin. The
regimen IPM (irinotecan 100 mg/m2 d1 + d15, cisplatin 40 mg/m2 d1 + d15 and mito-
mycin 6 mg/m2 d1 repeated every 28 days) was given to 27 patients with RCC who
had progressive disease despite interferon based cytokine therapy. 
Results Patient characteristics were: performance status 1 (range 0–3), metastatic
sites 2 (range 1–3). Patients received a median of 3.5 courses of IPM. Twenty-four
patients were evaluable for response:-PR 4%, MR 29%, SD 21%, PD 46%. Thirteen
out of 24 (58%) who were symptomatic improved. Median progression free interval
(PFI) was 4.8 months (0.4–15.5); the median PFI for the same patients on initial
cytokine therapy had been 3.8 months (0.4–21). Median overall survival following
IPM was 8.0 months (0.5–19). Grade 3/4 toxicities:-neutropenia 14% thrombocy-
topenia 0%, diarrhoea 2%, vomiting 1%, alopecia 31% and renal dysfunction 0%.
Five out of 14 patients (35%) who had progressed during cytokine therapy had
measurable responses to IPM. 
Conclusions In this cohort the response rate and PFI was comparable to that of
cytokine therapy despite being used following its failure. 
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RADICAL CHEMORADIATION FOR SQUAMOUS CELL 
CARCINOMA OF THE ANUS USING A TWO PHASE
TECHNIQUE WITH NO BOOST A Melcher, C Brammer, D Sebag-
Montefiore, Cookridge Hospital, Leeds, UK
Purpose To assess the toxicity and outcome of radical chemoradiation (CRT) for
squamous cell carcinoma of the anus using a simplified radiation technique with no
boost. 
Methods between 1996 and 1999 50 patients with histologically proven squamous
cell carinoma of the anus were treated. Median age was 62 (range 35–85). Staging was
T1 in 2 patients, T2 in 13, T3 in 31, and T4 in 4. 38 patients were N0/1, and 12 N2/3.
Radiotherapy was delivered by a 2 phase technique. Phase 1 was 30 Gy in 15 fractions
to wide fields, to include primary and nodal disease and both inguinofemoral regions.
Phase 2 was 20 Gy in 10 fractions, treating presenting macroscopic disease with a 2–3
cm margin, by i) parallel opposed fields if nodes involved, ii) a planned volume if anal
canal involved, or iii) a direct field for disease restricted to the anal margin only. Anal
bolus was used throughout, and no boost radiotherapy was given. Chemotherapy was
Mitomycin C 8–12 mg/m2 day 1, and 5FU 750–1000 mg/m2 days 1–4 and 29–32. 
Results Other than the anticipated severe skin reaction, grade 3/4 toxicity was
diarrhoea in 14% and myelosuppression in 10%. 47 patients received 50 Gy as
planned, whilst 18 required modification of the planned chemotherapy regime.
Overall treatment time was extended to 40 or more days in only 6 patients, and 38 had
no treatment interruptions for toxicity. After a median follow-up of 24 months, local
control has been achieved in 80% of patients overall (93% of T1/2 tumours, and 74%
of T3/4 tumours). 9 patients have died from anal cancer, 1 remains alive with disease,
and 38 are currently disease free. 8 have required salvage surgery following CRT. 
Conclusion This CRT protocol has acceptable local control and acute toxicity. It
has the advantage of a continuous schedule and the use of a two phase technique
reduces skin morbidity. The lower total dose of irradiation used may reduce late
morbidity. This schedule appears suitable for testing within the ACT2 trial, comparing
cisplatin against mitomycin C during concurrent CRT, and adjuvant cisplatin/5FU
versus no further treatment following CRT. 104 Poster presentations
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CHEMORADIOTHERAPY FOR CARCINOMA OF THE 
OESOPHAGUS: EXPERIENCE OF A SINGLE INSTITUTION
E Toy, J Abraham, T Crosby, A Brewster, D Mort, T Maughan, Velindre
Hospital, Whitchurch, Cardiff, CF14 2TL, UK 
Background Over the last ten years there has been interest in the use of combined
modality therapy for locally advanced oesophageal cancer. 
Methods Since 1995, 86 non-randomised patients at Velindre Hospital have
received Chemoradiotherapy (CRT) using a variety of Cisplatin based regimens:
[2 cycles of Cisplatin d1 5-FU d1-4 ´ 2 (32 patients), 4 cycles of Cisplatin d1 + PVI 5-
FU q 21 (38 patients), other Platinum regimens (16 patients) ] and radiation schedules
(90% received 40–50 Gy in 15–25F) as either neo-adjuvant (CRT+S) or bi-modality
(CRT) treatment outside a clinical trial. Patients selected for CRT alone included those
unfit for or refusing surgery, T4 N1 or heavy nodal positivity on EUS criteria. 
Results 86 patients, mean age 61, 48% squamous, 2% anaplastic, 50% adenocarci-
nomas were treated. 
Number Median Survival 2 year Survival  3 year Survival 
CRT+S 37 765 days 54% 43% 
CRT 49 363 days 42% 30% 
Overall 86 593 days 48% 36% 
60% of patients experienced at least one Grade 3 or 4 toxicity, including throm-
boembolism, myelosuppression, vomiting and dysphagia however only 30% required
chemotherapy dose reduction. Initial experience was that the regimen described by
Walsh et al. (1996) gave unacceptable morbidity and mortality (30% peri-operative
mortality) and led to a change in clinical practice. Subsequent peri-operative mortality
has been 6%. Of those in whom resection was performed pathological CR rate was
39%. 
Conclusions Chemoradiation has considerable activity in oesophageal cancer, is
well tolerated, and produces long term control comparable with surgical series.
Further research is needed to determine the optimal regimen and the additional value
of surgery. 
Walsh T, Noonan N, Hollywood D, et al (1996) A comparison of multimodal therapy
and surgery for oesophageal adenocarcinoma. NEJM: 335: p. 462 
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A PILOT STUDY OF PREOPERATIVE COMBINED MODALITY
THERAPY USING PACLITAXEL, CISPLATIN,5FU AND
RADIOTHERAPY IN LOCALLY ADVANCED OPERABLE OESOPHAGEAL
CARCINOMA J Abraham, T Crosby, E Toy, A Brewster, C Askill, J Manson,
G Williams, R Hardwick, T Havard, W Lewis, South Wales Upper GI Group
Background In patients with resectable oesophageal cancer, there is some evidence
that combined modality therapy is superior to surgery alone. However the toxicity and
duration of therapy are increased and the optimum regimen is yet to be established.
Most previous studies have combined 5FU, cisplatin (C) and radiotherapy (RT).
Paclitaxel (T), a radiation sensitiser, when used as a single agent and in combination
has significant activity in the treatment of oesophageal cancer. 
Aim To test the feasibility, efficacy and tolerability of this regimen. 
Method From Aug. 1999-Oct. 2000, 16 patients, WHO PS 0–1, median age 49
(31–73) with T3 and/or N1 carcinoma of the middle/lower oesophagus were recruited.
Patients were staged by EUS, CT and laparoscopy as 13(81%) lower oesophageal
tumours, 14(88%) Adenocarcinomas and 11(69%) T3N1M0. 
Regimen Weeks 0 – 6; 2 cycles induction chemotherapy (Cx) at 3 weekly intervals,
T 125 mg/m2, C 60 mg/m2 and continuous infusional(CI)5FU 200 mg/m2. Weeks
7–11; Concurrent chemoradiation (Cx/RT) with daily RT at 45Gy in 25#, weekly T 40
mg/m2, C 30 mg/m2 and CI5FU 200 mg/m2. Weeks 17–21; Planned radical 2–3 stage
oesophagectomy. 
Results 16 patients have completed Cx/RT and to date 9 have had surgery. (3
awaited, 1 progressive disease, 1 cardiac deterioration, 1 declined, 1 pre-operative
death). Specific pathological criteria were defined and applied to assess response.
There have been 3(33%) complete pathological responses, 2(22%) minimal residual
disease, 2(22%) partial responses and 2(22%) with no definite response (CR/MRD =
55%). The median survival is not yet reached. 
A dose reduction of T from 175 mg/m2 to 125 mg/m2, in the induction phase was
made after the first 4 patients were recruited, due to unacceptable Grade 3/4 diarrhoea
and stomatitis. Since this dose modification, the incidence of Grade 3/4 toxicities are;
diarrhoea 12%, stomatitis 0%, asthenia 37%, oesophagitis 37%, neutropenia 12%.
4(25%) thrombotic events have occurred, 1 resulting in a preoperative death. There
have been 2(22%) post-operative deaths. 1 patient bled from the gastric conduit
outside the radiation field on day 21.1 developed ARDS and subsequent multi-organ
failure on day 11. 
Conclusion This regimen is highly active in the treatment of locally advanced
oesophageal carcinoma. The toxicity and duration of therapy are a concern and
analysis of the quality of life data will be instructive. Comparative trials are needed to
ascertain the role of combined modality therapy and define the optimum regimen.
Treatment costs were supported by Bristol Myers Squibb. 
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A RANDOMISED PLACEBO-CONTROLLED TRIAL OF 
DEXAMETHASONE IN THE TREATMENT OF THE
IMMEDIATE SIDE EFFECTS FROM CHEST RADIOTHERAPY FOR LUNG
CARCINOMA DLS Furniss1, RD Jones2, MQ Hatton1, 1Weston Park Hospital,
Whittam Road, Sheffield. 2Beatson Oncology Centre, Dumbouton Road,
Glasgow
Introduction Palliative radiotherapy using hypofractionation is commonly used by
clinical oncologists in the United Kingdom. Large doses per fraction however are
associated with immediate side effects and have also been shown to reduce peak expi-
ratory flow rate (PEFR) 6 hours following treatment. This study looks to see if a single
dose of dexamethasone can reduce these immediate side effects and prevent the reduc-
tion in PEFR. 
Methods Patients treated with palliative radiotherapy 17 Gy in 2 weekly fractions
were randomised to receive dexamethasone, single dose 4 mg 1 hour before treatment,
with their first or second radiotherapy fraction and placebo with the remaining frac-
tion. Patients were asked to complete a questionnaire 24 hours post treatment and
perform home PEFR monitoring for 72 hours post treatment. Baseline PEFR’s for the
patients were obtained in the 2–3 weeks prior to radiotherapy. The frequency of symp-
toms reported with the 2 fractions were compared using McNemars test. The PEFR’s
were calculated as percentages of their baseline and compared using a paired t-test. 
Results 54 patients were recruited. 76% of patients reported one or more symp-
toms with their treatment. There was a statistically significant difference between the
incidence of chest pain reported between the 2 fractions, with less chest pain reported
in the dexamethasone fraction alone 22% vs 2% P = < 0.01. There was also a statisti-
cally significant difference between the incidence of rigors between the 2 fractions,
10% in the placebo fraction only vs 0% in the dexamethasone fraction only P = <0.05.
No difference was found between the incidence of flu-like symptoms or sweating. A
fall in PEFR at 4 – 6 hours post treatment was demonstrated in the placebo arm only,
but the difference between the 2 groups did not reach statistical significance. 
Conclusion Dexamethasone can reduce some of the immediate side effects of
hypofractionated palliative radiotherapy for lung cancer. However we did not measure
any significant difference in the fall of PEFR following treatment, leaving some
concern about large fraction radiotherapy in patients whose airway patency is signifi-
cantly compromised. 
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THE ROLE OF INTENSITY-MODULATED RADIOTHERAPY IN 
THE TREATMENT OF PAROTID TUMOURS CM Bragg1, 
J Conway2 and MH Robinson1, 1YCR Department of Clinical Oncology and
2Department of Radiotherapy Physics, Weston Park Hospital, Whitham
Road, Sheffield, S10 2SJ
The introduction of multi-leaf collimators as a means of shaping radiotherapy treat-
ment beams enabled a reduction in the volumes of normal tissue receiving high doses.
Intensity-modulated radiotherapy (IMRT) has shown potential as a means of
improving the quality of treatments by shaping the dose distribution more closely to
the tumour, further sparing normal tissue compared to conventional radiotherapy
treatments. In this study we investigate the ability of IMRT to improve treatment of
cancer of the parotid gland. 
Nine patients previously treated at Weston Park Hospital were considered in this
planning study. Treatment plans were produced for each patient using 3D conformal
radiotherapy (3D-CRT) and ten IMRT beam arrangements. Between 3 and 9 fields
were used in the IMRT plans, which were produced using the Helios inverse planning
system (Varian Oncology Systems). The IMRT plans were compared to the 3D-CRT
plans in terms of dose statistics, regret scores and uncomplicated tumour control prob-
ability (UTCP). 
3D-CRT and the three-four-and five-field IMRT arrangements produced similar
dose distributions to the target in terms of underdosing, overdosing, dose homogeneity
and conformation of the 95% isodose to the planning target volume (PTV). The seven-
and nine-field IMRT plans produced significantly (P < 0.05) better target dose homo-
geneity and conformation, as well as reducing the underdosing of the target. All IMRT
arrangements significantly reduced the maximum dose to critical structures, reduc-
tions of 50% (approximately 20 Gy) being achieved in the spinal cord and smaller
reductions in both the contralateral parotid gland (up to 16.9 Gy) and the brain (up to
7.9 Gy). The doses to the contralateral lens were equivalent from the different treat-
ment techniques, although small increases in the maximum doses to the ipsilateral
lens (up to 3.1 Gy) were seen in six IMRT beam arrangements. The IMRT arrange-
ments with 4,5,7, and 9 beams produced higher UTCP values than did the 3D-CRT
plans, the largest absolute improvement being 9.6%. 
IMRT produced better dose distributions than the 3D-CRT plans, sparing greater
amounts of normal tissue while treating the tumour to the same or a better extent and
therefore is a suitable technique for the treatment of parotid tumours. The best distrib-
utions were obtained from a 7-field IMRT plan, although clinically acceptable results
were obtained with a 5-field plan, which is proposed as a class solution for the treat-
ment of parotid tumours. Poster presentations 105
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MINIMAL DISEASE STUDY IN RHABDOMYOSARCOMA 
USING REVERSE TRANSCRIPTASE-POLYMERASE CHAIN
REACTION FOR THREE DIFFERENT TARGET GENES F Sartori, M Carli, A
Rosolen, Clinica di Oncoematologia Pediatrica, azienda Ospedaliera di
Padova, Via Giustiniani 3, 35128 Padova, Italy 
Rhabdomyosarcoma (RMS) is a soft tissue tumour of childhood that arises from cells
of skeletal muscle lineage. It is a tumour whose differential diagnosis might be diffi-
cult within the group of small round blue cell tumours. 
Some immunohistochemical and molecular features, including MyoD1 and
myogenin are useful markers in the diagnosis of RMS. Furthermore, the alveolar
subtype is often associated to the reciprocal chromosomal translocations t(2;13)
(q35;q14) or t(1;13)(p36;q14), involving PAX3 and FKHR or PAX7 and FKHR
genes, respectively. 
We established RT-PCR protocols to specifically detect MyoD1, myogenin and
PAX/FKHR transcripts in tumour tissue and bone marrow aspirates in order to define
the feasibility of this approach to study minimal disseminated disease in children with
RMS. 
We first determined the sensitivity of the method by limiting dilutions of alveolar
RMS tumour cells RH30, which tested positive for MyoD1, myogenin and PAX3-
FKHR transcripts in haematopoietic cells, in vitro. Then we studied 30 tumour biop-
sies and bone marrow aspirates obtained at diagnosis from patients affected by RMS,
mostly with advanced-stage disease, in whom at least one of the markers was
expressed. 
Depending on the molecular target, we found that RT-PCR analysis can detect 10–4
to 10–6 RMS tumour cells in vitro. MyoD1 RT-PCR was more sensitive than myogenin
and PAX3-FKHR assays, although sensitivity varies depending on reaction condi-
tions. Preliminary data from 20 of the 30 patients indicate a low prevalence of bone
marrow involvement at diagnosis: 2 positive cases out of 20, 1 of whom was detected
by microscopic analysis, as well. 
In these 2 patients we determined the response kinetics of bone marrow to first line
chemotherapy, with subsequent RT-PCR analyses performed at different time points.
Relative sensitivity of the molecular markers studied and prevalence of minimal
disseminated disease in relationship with histologic and clinical characteristics will be
discussed. 
This study suggests that RT-PCR assays can be useful in the staging work-up of
children with RMS, for monitoring response to treatment and to detect minimal
tumour contamination of bone marrow or PBSC harvests in patients undergoing
intensification treatment. 
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DOES LONGER BREAST-FEEDING PROTECT AGAINST 
CHILDHOOD LEUKAEMIA AND LYMPHOMAS Abdulbari
Bener1, Srdjan Denic2, Sehamuddin Galadari3, Depts. of Community
Medicine1, Internal Medicine2 and Biochemistry3, Faculty of Medicine, 
UAE University, PO Box 17666, Al Ain, United Arab Emirates. 
e-mail: abener@uaeu.ac.ae 
Background and aim The protective role of breastfeeding against childhood acute
leukemia and lymphomas in uncertain. We investigated this issue in a case-controlled
study. 
Methods 117 patients with acute lymphocytic leukemia (ALL), Hodgkin’s (HL)
and non-Hodgkin’s lymphoma (NHL), age 2–14, were retrospectively collected (15
year-period) in the United Arab Emirates. 117 controls were matched to patients for
age, sex and ethnicity. The primary variable was duration of breastfeeding, and the
secondary variables were environmental proxies for increased infection transmission
or suspected confounders. Information was collected by telephone interview of
mothers. 
Findings Median duration of breastfeeding in patients was significantly shorter
than in controls, 7 and 10 months respectively (P < 0.0001). Breastfeeding of 0 to 6
months duration, when compared with feeding longer than 6 months, was associated
with increased odds of ALL (OR = 2.5, CI 1.2–5.3), HL (OR = 3.8, CI 0.80–18.7),
NHL (OR = 4.18, CI 0.8–22.6) and overall (OR = 2.8, CI 1.5–5.1). In the patient
group, there were significantly higher number of children and people per family, and
patients were of a higher birth order than controls. In multivariate analysis, breast-
feeding duration continues to be an independent predictor of lymphoid malignancies. 
Conclusion Breastfeeding longer than 6 months may protect against childhood
acute leukemia and lymphomas. 
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CONSANGUINITY AND FAMILY HISTORY OF CANCER IN 
CHILDREN WITH LEUKEMIA AND LYMPHOMAS Abdulbari
Bener1, Srdjan Denic2, Mariam Al-Mazrouei1, Depart. of Community
Medicine1, Dept. of Internal Medicine2, Faculty of Medicine & Health
Sciences, UAE University, PO Box 17666, Al Ain, United Arab Emirates. 
e-mail: abener@uaeu.ac.ae
Background The consanguinity rate among the nationals of the United Arab Emirates
(UAE) is 50.5%. This study was designed to determine whether the rates of consan-
guinity and family history of cancer are higher among the families of children with
lymphoid malignancy than the rates in the general population of UAE nationals. 
Methods This case-control study comprised 117 patients with acute lymphocytic
leukemia (ALL) and Hodgkin’s (HL) and non-Hodgkin’s lymphoma (NHL), ranging
in age from 1 to 15 years, and 117 matched controls. In a telephone interview, each
mother was asked to provide data regarding the biological relationship between her
and her husband as well as that between both sets of grandparents; each was also
asked whether any family relative had cancer and if so, of what type. 
Results Among the 69 ALL cases, 80% of families were consanguineous and 20%
were nonconsanguineous. Among the 26 NHL and 22 HL cases, each group included
3 consanguineous families, 12% and 14%, respectively. The consanguinity rates for
ALL, NHL, and HL were all significantly different from the 50.5% consanguinity rate
in the UAE population (all three P values <0.0001). The family history of cancer was
more often positive in ALL patients than in controls (odds ratio 2.30; confidence
interval 1.12–4.80). Overall and for each malignancy, there was no difference in
family history of cancer between consanguineous and nonconsanguineous groups of
cases. 
Conclusion The consanguinity rate in the families of patients with ALL is signifi-
cantly higher and in those with NHL and HL significantly lower than that in the UAE
population. The family history of cancer is more often positive among ALL cases than
controls – consanguinity having no effect. 
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EXPRESSION OF TRUNCATED ENDOTHELIN-A RECEPTOR 
IS ASSOCIATED WITH MALIGNANCY PA Berry & 
SA Burchill, Candlelighter’s Children’s Cancer Research Laboratory, ICRF
Cancer Medicine Research Unit, SJUH, Leeds LS9 7TF
Endothelins (ET-1, ET-2 and ET-3) are small 21 residue peptides that activate one or
both of the G-protein coupled endothelin receptors, ET-A and ET-B. ET-A preferen-
tially binds ET-1, and ET-B binds each ligand with similar affinity. These proteins
have been implicated in the regulation of proliferation, migration, differentiation and
angiogenesis in a number of different cell types. We have previously reported expres-
sion of a truncated ET-A receptor missing exons three and four, the binding region for
ET ligands. This receptor does not bind ET-1. 
The aim of this study was to examine the expression and potential role of this trun-
cated ET-A receptor in malignancy. 
A panel of 41 tumours, 25 tumour derived cell lines, and 12 normal tissues were
examined by RT-PCR for ET-A and truncated ET-A receptor expression. The tumours
included 14 neuroblastomas (NBL), 9 Ewing’s sarcomas (ES), and 12 additional
paediatric tumours. 
In 35/41 (85%) tumours full length wild-type (FLWT) ET-A receptors were
expressed and 17/41 (41%) tumours expressed the truncated ET-A receptor. In 12/14
(86%) NBL FLWT ET-A was present, but only 3/12 (21%) expressed truncated ET-A
receptors. All 9 ES expressed FLWT ET-A and 6/9 (67%) expressed truncated 
ET-A receptors. Of the other paediatric tumours examined, 9/12 (75%) expressed
FLWT ET-A and 5/12 (42%) also expressed truncated ET-A receptors. 
Six ES and 4 NBL cell lines expressed both FLWT ET-A and truncated ET-A
receptors, and 10/15 (67%) of the other cell lines expressed FLWT ET-A and 9/15
(60%) expressed truncated ET-A receptors. All 12 normal tissues expressed FLWT
ET-A, where as the truncated ET-A receptor was restricted to only 2/12 (17%) tissues
(bladder and gut). 
Expression of the truncated ET-A receptor appears to be up regulated in estab-
lished tumour cell lines, compared to primary tumour. 
In conclusion these results show the truncated ET-A receptor is more frequently
expressed in tumours than in normal tissues. This suggests the ET-A receptor splice
variant may play a role in the development or progression of malignancy. This may be
particularly important in ES as 67% expressed the truncated ET-A receptor. 106 Poster presentations
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THE RELATIONSHIP BETWEEN EWS-ETS GENE 
REARRANGEMENTS, PROLIFERATION INDEX AND
SURVIVAL IN THE EWING’S SARCOMA FAMILY OF TUMOURS
S Brownhill*1, C Mangham2, R Grimer3, IJ Lewis4 and SA Burchill1,
1Candlelighter’s Children’s Cancer Research Laboratory, and 4Paediatric
Oncology, St. James’s University Hospital, Leeds, 2Department of
musculoskeletal Pathology and 3Royal Orthopaedic Hospital, Birmingham
EWS gene rearrangements, involving the EWS gene on chromosome 22q and one of
several ETS transcription factor genes have been described in over 95% of Ewing’s
sarcoma family of tumours (ESFT). Recent studies have suggested the fusion tran-
script type may be related to proliferation index and be of prognostic significance. The
aims of this study were to examine ESFT for EWS-ETS gene rearrangements by 
RT-PCR and in situ RT-PCR, and to correlate these findings with proliferation index
and clinical outcome. RNA from primary tumours of the Ewing’s sarcoma family was
amplified by RT-PCR for EWS-FLII and EWS-ERG fusion transcripts. In situ
RT-PCR was performed on 7mm tumour sections. Proliferation was measured by
immunohistochemistry for Ki67; cells with nuclear staining for Ki67 were scored as
proliferating and proliferation index scored. Proliferation index (PI)=[number of Ki67
positive nuclei÷number of nuclei scored] ´ 100. EWS-FLII type 1 fusion types were
detected in 21/27 (78%) of ESFT analysed. The presence of EWS-FLI1 type 1 fusion
transcripts did not predict survival (Log Rank test P = 0.87) or low PI (Fisher’s exact
test P = 0.385). However, there was a significant correlation between PI and survival
(Log Rank test P = 0.03), tumours with a high PI (>10% cells proliferating) corre-
lating with a poor outcome. In one ESFT both EWS-FLI1 and EWS-ERG fusion types
were detected by RT-PCR, the expression pattern of the fusion types within this
tumour was investigated by in situ RT-PCR. In conclusion, tumours with a prolifera-
tion index greater than 10 predict poor survival for children and young adults with
ESFT. In this study no correlation between EWS-ETS fusion type and survival was
found, furthermore there was no association between fusion transcript type and
proliferation. 
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BASIC FIBROBLAST GROWTH FACTOR (bFGF) IS 
PRODUCED AND SECRETED BY TUMOURS OF THE
EWING’S SARCOMA FAMILY F Diaz-Mendez and SA Burchill,
Candlelighter’s Children’s Cancer Research Laboratory, ICRF Cancer
Medicine Research Unit, St James’s University Hospital, Leeds
bFGF and its receptors regulate cell growth. Their aberrant expression has been asso-
ciated with tumourigenesis, increasing tumour growth and angiogenesis. The aim of
this study is to examine the expression and potential role of bFGF and its receptors in
ESFT. 
The expression and localisation of bFGF and its receptors was examined by
immunohistochemistry and Western blot. RT-PCR was used to identify specific FGF
receptor subtypes. The levels of bFGF and FGF receptors in ESFT have been quanti-
fied by real-time RT-PCR. 
All ESFT examined expressed bFGF, as demonstrated by immunohistochemistry
and Western blotting. By immunohistochemistry, bFGF was localised in vesicles
within the ESFT cell. These vesicles were particularly abundant at the cell surface.
Furthermore, bFGF was detected in vesicles outside the cell body, attached to the
extracellular matrix. 
Expression of FGF receptors was also evident in all the Ewing’s sarcoma cell lines.
Immunofluorescence using an FGF receptor-1 antibody showed diffuse staining
throughout the cell. The same antibody used for Western blotting confirmed the pres-
ence of FGF receptor-1. Using RT-PCR it was possible to demonstrate the presence of
all four high affinity receptors in the Ewing’s sarcoma cell lines studied. Two variant
forms of FGF receptor-3 were detected; sequence analysis showed these variant forms
to be lacking the second half of the third immunoglobulin-like loop of the extracel-
lular domain and the transmembrane domain. In addition, the Ewing’s sarcoma cell
lines SK-N-MC and A673 expressed a truncated form of FGF receptor-2, missing the
first immunoglobulin-like loop of the extracellular domain. 
In summary, ESFT produce and secrete bFGF. bFGF associated with the extracel-
lular matrix may play a critical role regulating the growth and metastasis of ESFT.
This may in part be mediated by down-regulation of FGF receptor expression. 
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REAL TIME IMAGING OF APOPTOSIS IN 
NEUROBLASTOMA CELL LINES M Elliott1, B Nelson1, 
MRH White1 & HP McDowell2. 1School of Biological Sciences, University of
Liverpool, Life Sciences Building, Crown Street, Liverpool, L69 7ZB. 2Royal
Liverpool Children’s NHS Trust, Eaton Road, Liverpool, L12 2AP
Background Neuroblastoma often has a poor long-term response to cytotoxic
chemotherapy agents. The apoptotic response of cells to these agents is important in
their success as a treatment modality. p53 has long been recognised as being important
in the initiation of apoptosis in response to DNA damage. Apoptotic cells can be iden-
tified by changes in the cell membrane, mitochondria or nucleus. We have attempted
to determine apoptotic rates in neuroblastoma cells in real time rather than performing
assays at isolated time points. 
Methods Using Western Blotting technique, we characterised the p53 response of
neuroblastoma cell lines (SK-N-SH, SK-N-MC, IMR-32, SH-SY-5Y, SHEP and SK-
N-AS) to DNA damage by etoposide and ultra-violet (UV) light. The cell lines were
cultured on “Mattek” dishes and then treated with etoposide or uv light. After adding
fluorescently labelled annexin V and propidium iodide (PI) to the culture media, a
field of cells was then imaged for 48–72 h using a confocal laser-scanning micro-
scope, taking images at 6 min time intervals. The equipment allowed temperature,
humidity and carbon dioxide concentration to be kept constant over a long time
period, maintaining the cells in a physiological environment. The timing of annexin V
and PI binding was determined for each cell in the field (20–40). Apoptotic cells bind
annexin V prior to binding PI and this timing permitted us to clearly differentiate
apoptosis from necrosis. Using flow cytometry, large populations of cells were
analysed at given time points, to confirm the microscopy findings. 
Results A p53 response to both etoposide and UV light occurred in all cell lines
apart from SK-N-AS. The degree of p53 response was maximal by 4–6 h and the
maximum response was dose dependent in all cell lines. The SK-N-SH and SH-SY-
5Y cell lines became apoptotic within 4 h of exposure to a DNA damaging agent.
However, all of the other cell lines did not show evidence of apoptosis, but did demon-
strate necrosis if a sufficient level of DNA damaging agent was used. These results
were confirmed by flow cytometry analysis of the cell lines. 
Conclusions The cell lines are known to express wild type p53 apart from SK-N-
MC, which expresses mutant p53. Despite a p53 response to DNA damage, four of the
cell lines were unable to become apoptotic suggesting a defect in the p53 dependent
apoptotic pathway. This poor apoptotic response in cell lines may be relevant to the
often poor response of neuroblastoma to cytotoxic agents used ckinically. Using real
time imaging of living cells, it is possible to analyse more subtly the mechanism of
cell death and makes the differentiation of apoptosis and necrosis possible. 
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THERAPEUTIC RESPONSES IN NEUROBLASTOMA ARE 
CORRELATED TO PHENOTYPE: SK.N.SH IN VITRO
STUDIES S Hankin*, and J Lawry, Institute for Cancer Studies, University of
Sheffield Medical School, Sheffield, UK 
Human neuroblastoma is a clinically and biologically heterogeneous childhood
tumour. The selection of resistant sub-clones during chemotherapeutic treatment is the
central cause of failure in disease management. Two human neuroblastoma cell lines,
Kelly and SK.N.SH, have been used to monitor drug-induced cell cycle arrest and
apoptosis with cisplatin, etoposide and cyclophosphamide using flow cytometry.
SK.N.SH shows the coexistence of morphologically and biochemically distinctive
cell types; neuronal cells (N-cells) and substrate-adherent cells (S-cells). Kelly is
composed only of N-type cells. Cell cycle effects were examined by staining with the
DNA intercalating agent propidium iodide (PI) and kinetic data was obtained by
incorporating the thymidine analogue 5-Bromo-2-deoxyuridine (BrdU). 
Both dose and time dependent increases in the number of apoptotic cells were
observed with the Annexin-V assay and the terminal deoxynucleotide transferase
dUTP nick end labeling (TUNEL) technique. Each morphologically distinctive cell
phenotype of SK.N.SH had a specific response to the chemotherapeutic drugs. The 
N-phenotype cells showed classic apoptotic morphology and dose dependent cell
death. The S-phenotype appeared more refractory to cytotoxic insults, and displayed
morphological signs of differentiation. 
The Percentage of Apoptotic Cells at 72 Hours of Drug Incubation 
(TUNEL Assay) 
Cell Line Untreated 1 mg/ml 2 mg/ml 200 mg/ml
Control Cisplatin Etoposide Cyclophosphamide
Kelly 0.60 10.70 65.17 29.85
(N-cells)
SK.N.SH 0.10 0.40 0.14 0.21
(S-cells)
SK.N.SH 0.14 45.32 28.97 38.11 
(N-cells)
Current work includes evaluating drug-associated changes in both cell cycle and
apoptosis-related protein expression in these human neuroblastoma cell lines. The
coexistence of diverse cell phenotypes provides a unique model for preclinical studies
that may interpret the mixed clinical response associated with neuroblastoma. 
This work is funded by Yorkshire Cancer Research. Poster presentations 107
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IDENTIFICATION AND MOLECULAR CHARACTERISATION 
OF A CALM:AF10 FUSION IN ACUTE MEGAKARYOBLASTIC
LEUKAEMIA IDENTIFIES A NOVEL CALM VARIANT LK Jones1, B Linder1,
PJ Wu1, M Neat2, BD Young2 and V Saha1, 1ICRF Children’s Cancer Group
and 2Medical Oncology Unit, Charterhouse Square, London EC1M 6BQ
The t(10;11)(p13;q14) is a non-random translocation described in both adult and
paediatric acute lymphoblastic and myeloid leukaemias. It results in the fusion of the
gene CALM, which encodes a clathrin assembly protein, on 11q14 to the AF10 gene, a
putative transcription factor on 10p13. Here we describe for the first time, the occur-
rence of a CALM-AF10 fusion in a case of acute megakaryoblastic leukaemia (FAB
M7). Fluorescence in situ hybridisation and reverse transcriptase polymerase chain
reaction were used to confirm the presence of a CALM-AF10 fusion, together with the
reciprocal AF10:CALM fusion. Cloning and sequencing of the amplified PCR prod-
ucts revealed that fusion of the CALM:AF10 occurred at nucleotide position 1926 of
the CALM cDNA and position 424 of the AF10 sequence. The reciprocal transcript
fused AF10 423 to CALM 1987. All samples sequenced were found to contain a novel
splice variant of CALM, missing nucleotides 1927–2091. This new variant WT CALM
cDNA encodes a protein lacking amino acids 594–648. 
The breakpoints in CALM are located towards the carboxy terminal, resulting in
the majority of CALM fused to various lengths of AF10 in the CALM-AF10 fusion
products. CALM is a cytoplasmic protein, while AF10 can be detected in both the
cytoplasm and the nucleus. Sequence analysis of AF10 has identified three putative
bipartite Nuclear Localisation Signals (NLS). Using GFP-AF10 fusion constructs we
have shown that the most N-terminal NLS (aa232-247) alone mediates the nuclear
transport of AF10. These results were confirmed by site directed mutagenesis of the
NLS consensus sequence. The described breakpoints in AF10 in the CALM:AF10
fusion include nt 423/424, 589/560, 883/884 and 979/980. Depending on where the
breakpoints are in AF10, the fusion product will retain or loose some of the interactive
domains of AF10. The CALM:AF10 424 and 590, will retain the bipartite NLS, and so
localise to the nucleus. To support this data, we have confirmed by immunohisto-
chemistry that the CALM:AF10 product localises to both the nucleus and cytoplasm
in the U937 cell line. The CALM:AF10 883 and 979 will lack the NLS, and we there-
fore predict that these fusions will localise to the cytoplasm. However, as with all the
CALM:AF10 fusions, the AT-hook, Q-rich region and leucine zipper are retained. The
relatively even distribution of patients over the four described AF10 breakpoints
suggest that, irrespective of the positioning on the NLS the retention of the interactive
leucine zipper is critical for leukaemogenesis. 
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EXPRESSION OF PAX-3 ALTERNATIVELY SPLICED 
TRANSCRIPTS IN HUMAN TUMOURS OF NEURAL CREST
ORIGIN C Parker, SG Shawcross1, I Hart1, S Kumar2, R MacKie3, K Sisley4,5,
and P Kumar1, 1Manchester Metropolitan University M1 5GD, 2St Thomas’
Hospital, London SE1 7EH, 3Manchester University M13 9PT, 4Royal
Infirmary Glasgow G4 0SF, 5Royal Hallamshire Hospital, Sheffield S10 2JF
The developmental gene, PAX-3, is expressed in the early embryo in developing
muscle and elements of the nervous system, including the brain. Recent studies have
demonstrated PAX-3 over-expression in both embryonal and alveolar rhabdomyosar-
comas (ERMS and ARMS), while we have demonstrated its expression in melanomas
and small cell lung carcinomas (SCLCs). Alternative transcripts encoding two addi-
tional exons downstream of exon 8 have been identified. The original isoform has
been designated PAX-3c, the isoform which includes one additional exon, PAX-3d,
and that encoding two extra exons, PAX-3e. In the study here, RT-PCR was used to
screen for the alternative transcripts, PAX-3c, PAX-3d and PAX-3e, in human and
murine melanoma cell lines, primary human ocular melanomas, secondary human
cutaneous melanomas and human SCLC cell lines. Sets of primers for each of the
isoforms were designed and their specificity confirmed by sequence analysis of 
the products. 
All 8 primary human ocular melanomas expressed PAX-3c and 3d, and 7/8, PAX-3e.
Two human ocular melanoma cell lines expressed PAX-3d, 1/2 cell lines, PAX-3c, (in
both cases expression was barely detectable), but neither, PAX-3e. 
In the secondary human cutaneous melanomas, 14/17 showed PAX-3c expression,
16/17, PAX-3d and 15/17, PAX-3e. The 8 human cutaneous melanoma cell lines all
expressed PAX-3c, PAX-3d and PAX-3e. 
In the case of SCLC, 4/5 cell lines expressed PAX-3d, but none PAX-3c or 
PAX-3e.
In summary, we found all three transcripts expressed in every cutaneous melanoma
cell line and the majority (>80%) of cutaneous melanoma tumour tissues. All of 
the ocular melanomas expressed PAX-3c and PAX-3d, with over 80% expressing
PAX-3e. There was less predictable expression of the PAX isoforms in ocular
melanoma cell lines. SCLC cell lines appear to express only PAX-3d. In addition, a
comparison of the different amplicon staining intensities for any one sample, indi-
cated that PAX-3d was the predominant transcript, followed by PAX-3c. PAX-3e was
often barely detectable and may be expressed at very low levels. The role of the three
isoforms in tumourigenesis and cancer progression is currently under investigation. 
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THE GEOGRAPHICAL DISTRIBUTION OF CHILDHOOD 
LEUKAEMIA AND LYMPHOMA IN NORTH WEST ENGLAND
RJQ McNally1, DP Cairns1, OB Eden1, AM Kelsey1 & JM Birch1, 1Royal
Manchester Children’s Hospital, Manchester M27 4HA
The objective was to explore the geographical distribution of leukaemia and
lymphoma in cases included in the Manchester Children’s Tumour Registry, 1977 to
1996. Cases of acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia
(AML), Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL) were allocated
to the electoral ward in which they were resident at the time of diagnosis. Observed
(O) and expected (E) numbers of cases and standardised morbidity ratios were
obtained by electoral ward. Poisson regression was used to examine the relationship
between incidence rates and (i) population density; (ii) ethnic composition of the
ward; and (iii) deprivation index for the ward (Carstairs and Townsend), based on
decennial census data. ALL had a particularly heterogeneous distribution; higher rates
were associated with: (i) wards with high population density (O/E = 1.13 for highest
quintile; O/E = 0.87 for lowest quintile; P = 0.06); (ii) wards with a greater proportion
of Pakistanis (O/E = 1.12 for highest quintile; O/E = 0.87 for lowest quintile; 
P = 0.04); wards with a greater proportion of Indians (O/E = 1.09 for highest quintile;
O/E = 0.71 for lowest quintile; P = 0.07); and wards with a greater proportion of Afro-
Caribbeans (O/E = 1.09 for highest quintile; O/E = 0.81 for lowest quintile; P = 0.08).
Conversely, lower rates for ALL were associated with wards with a greater proportion
of white Europeans (O/E = 0.71 for highest quintile; O/E = 1.11 for lowest quintile; 
P = 0.04). (iii) There was no association between incidence of ALL and deprivation,
as measured by the Townsend and Carstairs indices. For AML, HD and NHL, no asso-
ciations were found between incidence and any of these factors. This may be due, at
least in part, to the small numbers of cases. Results differ from other recent findings,
linking higher incidence of ALL with increased affluence, but are consistent with a
role for infection in the aetiology of ALL. Increased opportunity for exposure is asso-
ciated with higher population density, which may also explain the differences in inci-
dence found by ethnic group stratification. 
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CLUSTERING IN NON-CENTRAL NERVOUS SYSTEM 
CHILDHOOD SOLID TUMOURS RJQ McNally1, AM Kelsey1,
FE Alexander2, OB Eden1, & JM Birch1, 1Royal Manchester Children’s
Hospital, Manchester M27 4HA, 2Dept of Public Health Sciences, University
of Edinburgh, Edinburgh EH8 9AG 
The objective was to analyse space-time clustering of non-central nervous system
solid tumours in children included in the Manchester Children’s Tumour Registry,
1954 to 1998. Knox tests for space-time interactions between cases were applied with
fixed thresholds of close in space, <5 km and close in time, <1 year apart, to determine
whether there are more pairs of cases occurring in close proximity than expected by
chance. Tests were repeated replacing geographical distance with distance to the Nth
nearest neighbour to adjust for population density. N was chosen such that the mean
distance was 5 km. Data were also examined by a second order procedure based on 
K-functions to allow for multiple testing and boundary effects. Reference points in
time and space were dates and addresses at birth and diagnosis respectively. The
methods showed statistically significant evidence of space-time clustering for
sarcomas and Wilms’ tumour, based on time and location at birth, but not time and
location at diagnosis. For sarcomas, P = 0.02 using the geographical distance version
of the Knox test and P = 0.004 using the nearest neighbour version. Using the
geographical distance version of the K-function method P = 0.006 and P < 0.001
using the nearest neighbour version. For Wilms’ tumour the clustering was particu-
larly apparent amongst children aged 0–4 years: P = 0.007 using the geographical
distance version of the Knox test and P = 0.006 using the nearest neighbour version.
Using the geographical distance version of the K-function method P = 0.004 and 
P = 0.01 using the nearest neighbour version. There was no evidence of space-time
clustering amongst cases of neuroblastoma, peripheral neuroectodermal tumours,
Hodgkin’s disease and non-Hodgkin’s lymphoma. These are the first results to
demonstrate the presence of space-time clustering for childhood sarcomas and Wilms’
tumours. Results are consistent with environmental exposure hypotheses relating to
locations pre-natally or peri-natally. 108 Poster presentations
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MLL CLEAVAGE AND REARRANGEMENT FOLLOWING 
TOPOISOMERASE 2 INHIBITOR THERAPY IN PAEDIATRIC 
t-AML A Ng1,2, GM Taylor1 & OB Eden2, Immunogenetics Laboratory, 
St. Mary’s Hospital1, Manchester M13 0JH, Academic Unit of Paediatric
Oncology, Royal Manchester Children’s Hospital2, Manchester M27 4HA, UK
Treatment related acute myeloid leukaemia (t-AML) is the most serious complication
of effective DNA topoisomerase 2 (topo 2) inhibitor therapy used for childhood
cancers and rarely, for non-malignant conditions. Most cases are characterised by
abnormalities involving the Mixed Lineage Leukaemia (MLL) gene on chromosome
11q23, and a poor outcome. Although frequent scheduling and high cumulative
dosage of topo 2 inhibitors have been shown to associate with the development of 
t-AML, individual risk prediction remains ill defined. Molecular analyses of MLL
abnormalities during topo 2 inhibitor treatment may improve our understanding on the
process of secondary leukaemogenesis and contribute to identifying patients at risk of
t-AML. 
Genomic DNA from serial blood and bone marrow samples were obtained from a
boy who received etoposide-based therapy for primary, non-familial haemophago-
cytic lymphohistiocytosis (HLH) but subsequently developed a t-AML 6 months post
treatment. Cleavage and rearrangement of the MLL gene were studied using Southern
blotting and hybridisation with a MLL cDNA probe and real-time autoradiography.
Panhandle PCR was also used to detect MLL rearrangement in bone marrow speci-
mens obtained during his primary therapy and at the onset of t-AML. MLL cleavage
was identified in the bone marrow 3 months after the start of etoposide treatment and
rearrangement of the gene was found at the time of t-AML diagnosis. The abnormali-
ties were not detected in his marrow at the presentation of HLH or in any of his serial
blood samples. 
These findings provide further support that the MLL gene is implicated in the
molecular pathogenesis of paediatric t-AML associated with epipodophyllotoxin
therapy. They also suggest the potential of MLL cleavage and rearrangement as
biomarkers for treatment-related leukaemogenesis, and that bone marrow is the most
informative material for such detection. The relationship between MLL cleavage and
rearrangement, their actual roles in leukaemogenesis and risk prediction for t-AML
warrant further investigations. 
P293
ANALYSIS OF EPENDYMOMAS USING COMPARATIVE 
GENOMIC HYBRIDISATION M Carter1, FM Ross1, 
JC Nicholson1,5, R Allibone4, V Balaji2, JA Crolla1, RJ Gilbertson3, RH Perry3,
DA Walker4, DW Ellison2,3, 1Wessex Regional Genetics Lab., Salisbury;
Universities of 2Southampton, 3Newcastle and 4Nottingham; 5Addenbrookes
Hospital, Cambridge
Background and objectives Ependymomas are the third most common CNS
tumours in childhood, and account for 9–12% of CNS neoplasms in all age groups.
However, the prognosis for cases not completely excised is poor and the underlying
biology of their development and progression is poorly understood. The few studies
published to date have suggested that specific chromosomal abnormalities may be
associated with the development of a significant proportion of these tumours. We set
out to screen a large series of intracranial and spinal ependymomas for genetic imbal-
ances, and to correlate these with histology and clinical behaviour. 
Methods Comparative genomic hybridisation (CGH) was used to detect chromo-
some imbalances on 86 ependymomas from 77 patients, of which 22 were children
under 16, treated at one of three UK centres (Newcastle, Nottingham, Southampton).
Cases were first analysed without reference to histology or clinical features, and were
then divided up according to anatomical location, histology and age at presentation. 
Results Chromosomal imbalances were detected in tumours from 63/77 patients
(82%). The majority involved entire chromosomes or chromosome arms, many
showing patterns of gains suggestive of intermediate ploidy. Of previously reported
abnormalities in ependymoma, the most frequent findings were gain of 1 q, seen in 13
cases (17%), and loss of 22 in 20 (26%). Whereas 1 q gain was seen mainly in poste-
rior fossa tumours and was restricted to those with classic and anaplastic histology,
loss of 22 was rarely observed in tumours from this location and their histology was
predominantly classic or myxopapillary. In contrast to previous studies, loss of 6q was
found in only 6 cases (8%) and in only one child. Out of 7 tumours biopsied at presen-
tation and relapse, 4 revealed imbalances and 3 of these demonstrated progression of
abnormalities at relapse. 
Conclusions Chromosomal imbalance is common in ependymoma and patterns of
abnormality are emerging that are associated with histology or location. Further
studies are needed to establish the prognostic significance of these abnormalities. 
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EWING’S TUMOUR: NOVEL RECURRENT CHROMOSOMAL 
ABNORMALITIES DEMONSTRATED BY MOLECULAR
CYTOGENETIC ANALYSIS OF SEVEN CELL LINES AND ONE PRIMARY
CULTURE Danielle C Shing1,2, Catherine A Morley-Jacob1,3, Ian Roberts2,
Elisabeth Nacheva4, and Nicholas Coleman2,5, 1Joint first authors,
2Department of Pathology, University of Cambridge, Tennis Court Road,
Cambridge, United Kingdom, 3Department of Paediatrics, Addenbrooke’s
Hospital, Hills Road, Cambridge, United Kingdom, 4Department of
Haematology, Cambridge Institute for Medical Research, Hills Road,
Cambridge, United Kingdom, 5Department of Histopathology, Addenbrooke’s
Hospital, Hills Road, Cambridge, UK 
Conventional cytogenetics has led to the identification of the primary t(11;22) (q24;
q12) translocation in the Ewing’s family of tumours, and to the demonstration of
certain recurring secondary aberrations that may contribute to neoplastic progression.
Other important cytogenetic abnormalities may previously have been overlooked due
to the limited resolution of chromosome banding. We have applied the molecular
cytogenetic techniques of SKY, M-FISH and CGH to the characterisation of seven
Ewing’s tumour cell lines and one primary culture. These complementary techniques
have enabled us to produce a detailed description of the karyotypes of the cell lines
and to demonstrate recurring numerical and structural abnormalities. In particular, we
have identified a novel, unbalanced translocation involving chromosomes 16 and 17
in three of eight samples, including the primary culture. The unbalanced translocation
was associated with CGH evidence of loss of 16 q and 17p, copy number imbalances
that were seen in five and four of the eight samples respectively. Recurrent break-
points at 16p11.2, 16q11.1, 17p11.2 and 17q11.2 were identified. Our findings indi-
cate that chromosomes 16 and 17 should be investigated further in the search for
genes involved in the development of Ewing’s family tumours. 
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THE EWINGS SARCOMA EWS/FLI-1 PROTEIN UP-
REGULATES THE STROMELYSIN AND PARP PROMOTERS
IN NIH-3T3 CELLS. BTS Ubhi, DR Rainey, AR Craig & DM Meredith.
Molecular Medicine Unit, University of Leeds, Beckett St, Leeds, LS9 7TF
Introduction The EWS/Fli-1 protein results from the translocation of the EWS gene
on chromosome 22 with the Fli1 gene on chromosome 11. This translocation is
present in 95% of cases of Ewings sarcoma and results in the production of a chimeric
transcription factor. Fli-1 is a member of the ETS family of transcription factors with
a DNA binding domain. The role of EWS/Fli-1 in the pathogenesis of Ewings
sarcoma is thought to involve the up regulation of specific target genes. These genes
are as yet unknown although several workers have proposed genes such as PARP,
WAF-1, PIM-1 and stromelysin. Since stromelysin (one of the matrix metallopro-
teinases) has a putative role in tissue invasion and metastases and since PARP (poly
ADP ribose polymerase) is expressed at very high levels in Ewings sarcoma cells we
sought to characterise these genes in terms of the responsiveness of their promoter
regions to both EWS/Fli-1 and Fli-1. In addition we investigated the effect of TEL, a
putative tumour suppressor gene on trans-activation of the Stromelysin promoter by
EWS/Fli-1 and Fli-1. 
Method The EWS/Fli-1 type 1, Fli1 and TEL genes were cloned into the
pcDNA3.1 mammalian expression vector. Similarly, two reporter plasmids were
constructed based on the pG1-3 firefly luciferase reporter system with the Stromelysin
promoter region and the PARP promoter region cloned in. The EWS/Fli1 and Fli-1
vectors were co-transfected with the reporter vector into NIH-3T3 cells using
Superfect, a liposomal transfection system. Cells were harvested at 24 hours and
assayed for luciferase activity. The study was repeated with the addition of the TEL
expression vector. All experiments were done in triplicate and repeated with similar
results. 
Results EWS/Fli-1 demonstrated a 2–3 fold increase in activity at the PARP
promoter in contrast to a 3–4 fold increase with Fli-1. EWS/Fli1 also showed up to a
10-fold increase in activity at the Stromelysin promoter in contrast to a 20-fold
increase in activity seen with Fli1 alone. TEL caused a 5% decrease in EWS/Fli-1
trans-activation and a 17% decrease in Fli-1 trans-activation. 
Conclusion The results suggest that both Stromelysin and PARP promoters are
direct targets of both EWS/Fli-1 and Fli1 with early up regulation of both promoters
after co-transfection. This supports previous data seen using RDA although a greater
response was seen with Fli-1 than in previous studies. TEL resulted in a decrease in
trans-activation particularly with Fli-1.Poster presentations 109
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EXPRESSION AND ASSOCIATION OF THE HUMAN 
TRITHORAX AND POLYCOMB GROUP OF PROTEINS 
Pei Jun Wu1, Julia I Bardos2, Denise Sheer3 Paul Freemont2, Vaskar Saha1,
1ICRF Children’s Cancer Group, St. Bartholomew’s and The Royal London
School of Medicine and Dentistry, London EC1M 6BQ, 2ICRF, Molecular
Structure and Function Laboratory, 3ICRF, Human Cytogenetics Laboratory,
PO Box 123, London WC2 3PX, UK
We recently proposed a hypothesis that genes disrupted by chromosomal transloca-
tions in acute leukaemia, may have a common mechanism for leukaemogenesis, by
acting on chromatin pathways regulating the HOX gene cascade via interactions of the
trithorax (TrG) and polycomb (PcG) proteins. 
The nuclear distribution of TrG (MLL) and PcG (RING1, BMI1 and HPC3) and
their co-localisations in different cell lines (HeLa, U937, HT1080 and U2OS) were
examined by immunofluorescent labelling with antibodies against MLL and RING1,
or BMI1, or HPC. Cells were fixed and permeabilized with formaldehyde and Triton
X-100, incubated with the antibody, mounted in Citifluor containing DAPI then visu-
alised and recorded on a Zeiss fluorescent microscope. Images were analysed and 3-D
reconstruction was carried out with the Zeiss LSM program. MLL displays a punctate
nuclear distribution, while polycomb proteins form discrete foci in a cell line specific
manner. Partial colocalisation of MLL and polycomb was evident in a small but
consistent number of foci in all cell lines tested and appeared to be peri-nucleolar or at
the rim of the nucleus. 
To test for physical interactions between the TrG and PcG proteins, immuno-
precipitations of MLL-HPC3/RING1 were carried out in U2OS cells, which were
transiently transfected with GFP-tagged HPC3 or RING1, using the SuperFect trans-
fection reagent (Qiagen). The cells were harvested after transfection and a cell extract
was pre-cleared with protein G Sepharose. anti-MLL antibody was added to the
extracts, and incubated with continuous mixing. Protein G Sepharose was added and
the immunoprecipitate washed. After heating and removal of the protein G beads, the
proteins were separated by SDS-PAGE and blotted onto nitrocellulose. The blots were
probed with a monoclonal anti-GFP antibody, and the ECL chemiluminescence
system (Amersham) was used for detection. However, to date we have not been able
to detect any bands. 
Our preliminary studies suggest that there are nuclear regions where TrG and PcG
complexes aggregate together. There appears to be no physical interaction between
the complexes, and the co-localisation may reflect the state of chromatin activation in
these regions. 
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RQ-PCR STRATEGIES TO DETECT MINIMAL RESIDUAL 
DISEASE IN CHILDHOOD ALL Maria Pitsiouni1, Naina Patel1,
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We present our experience in the use of real-time PCR to quantify genomic and RNA
targets for the detection of minimal residual disease in childhood acute lymphoblastic
leukaemia (ALL). The genomic strategy involves the detection of clone specific IgH
gene rearrangements and the RNA approach the detection of ETV6-CBFA2 transcript
detectable in approximately 25% of children with ALL. 
Methods Bone marrow samples from 23 ALL patients were analysed by end
point PCR using consensus primers to the FR1 region and a JH consensus primer,
allowing the design of allele specific oligonucleotides. This strategy was used to
underpin the design of a Real-Time PCR (RQ-PCR) using consensus probes to the
FRIII and JH regions. We have also extensively evaluated the methodology for
reverse-transcriptase RQ-PCR to detect ETV6-CBFA2 fusion in 6 patients. RQ-PCR
strategy employed a forward primer and probe on exon 5 of ETV6 and a reverse
primer on exon 2,3 or 4 of CBFA2. 
Results Using consensus probes to the FRIII region (as opposed to the JH region)
for the RQ-PCR quantification of the IgH region appears to be reliable and as sensi-
tive (10–4) as the end point PCR technique. With both techniques, it is possible to track
disease and the majority of standard risk patients do not have detectable disease at day
15. For the RNA based analyses, we found cDNA synthesis to be most reliable using
random hexamers and MMLV-RT, rTth giving occasionally skewed results and
B2microglobulin as the best internal control. In comparison to genomic detection,
transcripts are detectable in most patients at d30 and often upto 4 months. 
Conclusions RQ-PCR can be used reliably to monitor disease levels in childhood
ALL. It is fast, less prone to contamination and will provide a sensitivity of at least
10–4. Further analysis is required to determine whether this will be a useful tool to risk
stratify patients. 